Methods of using bispecific antigen-binding constructs targeting her2

ABSTRACT

Described herein methods of using antigen-binding constructs to treat HER2+ tumors in a subject such as breast, lung, or head and neck tumors. In some aspects, the tumor volume in the subject after receiving at least seven doses of the antigen binding construct is less than the tumor volume of a control subject receiving an equivalent amount of trastuzumab. In some aspects, the survival of the subject receiving the antigen binding construct is increased as compared to a control subject receiving an equivalent amount of a non-specific control antibody or as compared to a control subject not receiving treatment.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of PCT/CA2014/051140, filed Nov. 27,2014, and 62/166,844, filed May 27, 2015; each of which is hereinincorporated by reference, in its entirety, for all purposes.

SEQUENCE LISTING

The instant application contains a Sequence Listing which will besubmitted via EFS-Web and is hereby incorporated by reference in itsentirety. Said ASCII copy, created on Nov. 24, 2015, is named32565PCT_sequencelisting.txt, and is 275,091 bytes in size.

BACKGROUND

The majority of current marketed antibody therapeutics are bivalentmonospecific antibodies optimized and selected for high affinity bindingand avidity conferred by the two antigen-binding domains. Afucosylationor enhancement of FcgR binding by mutagenesis have been employed torender antibodies more efficacious via antibody Fc dependent cellcytotoxicity mechanisms. Afucyosylated antibodies or antibodies withenhanced FcgR binding still suffer from incomplete therapeutic efficacyin clinical testing and marketed drug status has yet to be achieved forany of these antibodies. Typical bivalent antibodies conjugated totoxins (antibody drug conjugates) are more efficacious but broaderclinical utility is limited by dose-limiting toxicity.

Therapeutic antibodies would ideally possess certain minimalcharacteristics, including target specificity, biostability,bioavailability and biodistribution following administration to asubject patient, and sufficient target binding affinity and high targetoccupancy to maximize antibody dependent therapeutic effects. Typicallytherapeutic antibodies are monospecific. Monospecific targeting howeverdoes not address other target epitopes that may be relevant in signalingand disease pathogenesis, allowing for drug resistance and escapemechanism. Some of the current therapeutic paradigms call for the use ofcombination of two therapeutic monospecific antibodies targeting twodifferent epitopes of the same target antigen. One example is the use ofa combination of Trastuzumab and Pertuzumab, both targeting the HER2receptor protein on the surface of some cancer cells, but patients stillprogress with disease while others with lower HER2 receptor levels (HER2<3+ by Hercept test) show no therapeutic benefit. Therapeutic antibodiestargeting HER2 are disclosed in WO 2012/143523 to GenMab and WO2009/154651 to Genentech. Antibodies are also described in WO2009/068625 and WO 2009/068631.

Co-owned patent application number PCT/CA2014/051140 describes HER2antibodies. Co-owned patent application number PCT/US2014/037401 (WO2014/182970) describes HER2 antibodies. Co-owned patent applicationnumber PCT/CA2013/050358 (WO 2013/166604) describes single armmonovalent antibodies. Co-owned patent applications PCT/CA2011/001238,filed Nov. 4, 2011, PCT/CA2012/050780, filed Nov. 2, 2012,PCT/CA2013/00471, filed May 10, 2013, and PCT/CA2013/050358, filed May8, 2013 describe therapeutic antibodies. Each is hereby incorporated byreference in their entirety for all purposes.

SUMMARY

Described herein are methods of using one or more antigen-bindingconstructs to treat tumors in a subject, e.g., such as gastric,pancreatic, breast, lung, or head and neck tumors. The one or moreantigen-binding constructs can comprise a first antigen-bindingpolypeptide construct which monovalently and specifically binds a HER2(human epidermal growth factor receptor 2) ECD2 (extracellular domain 2)antigen on a HER2-expressing cell and a second antigen-bindingpolypeptide construct which monovalently and specifically binds a HER2ECD4 (extracellular domain 4) antigen on a HER2-expressing cell, firstand second linker polypeptides, wherein the first linker polypeptide isoperably linked to the first antigen-binding polypeptide construct, andthe second linker polypeptide is operably linked to the secondantigen-binding polypeptide construct; wherein the linker polypeptidesare capable of forming a covalent linkage with each other, wherein atleast one of the ECD2- or the ECD4-binding polypeptide constructs is anscFv. In certain embodiments, the ECD2-binding polypeptide construct isan scFv, and the ECD2-binding polypeptide construct is a Fab. In certainembodiments, the ECD2-binding polypeptide construct is a Fab and theECD4 binding polypeptide construct is an scFv. In some embodiments, boththe ECD2- and ECD4-binding polypeptide constructs are scFvs. In someembodiments, the antigen-binding constructs have a dimeric Fc comprisinga CH3 sequence. In some embodiments, the Fc is a heterodimer having oneor more modifications in the CH3 sequence that promote the formation ofa heterodimer with stability comparable to a wild-type homodimeric Fc.In some embodiments, the heterodimeric CH3 sequence has a meltingtemperature (Tm) of 68° C. or higher.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A depicts the structure of a biparatopic antibody in a Fab-Fabformat. FIGS. 1B to 1E depict the structure of possible versions of abiparatopic antibody in an scFv-Fab format. In FIG. 1B, antigen-bindingdomain 1 is an scFv, fused to Chain A, while antigen-binding domain 2 isa Fab, fused to Chain B. In FIG. 1C, antigen-binding domain 1 is a Fab,fused to Chain A, while antigen-binding domain 2 is an scFv, fused toChain B. In FIG. 1D, antigen-binding domain 2 is a Fab, fused to ChainA, while antigen-binding domain 1 is an scFv, fused to Chain B. In FIG.1E, antigen-binding domain 2 is an scFv, fused to Chain A, whileantigen-binding domain 1 is a Fab, fused to Chain B. In FIG. 1F, bothantigen-binding domains are scFvs.

FIG. 2 depicts the characterization of expression and purification ofexemplary anti-HER2 biparatopic antibodies. FIG. 2A and FIG. 2B depictthe SEC chromatograph of the protein A purified antibody, andnon-reducing SDS-PAGE analysis of 10 L expression and purification ofv5019. FIG. 2C depicts the SDS-PAGE analysis of a 25 L expression andpurification of v10000.

FIG. 3 depicts the results of UPLC-SEC analysis of exemplary anti-HER2biparatopic antibodies purified by protein A and SEC. FIG. 3A shows theresults for v5019, where the upper panel shows the results of thepurification and the lower panel shows the same result with an expandedscale for the y-axis. A summary of the data obtained is provided belowthe UPLC-SEC results. FIG. 3B shows the results for v10000.

FIG. 4 depicts LCMS analysis of the heterodimer purity of exemplaryanti-HER2 biparatopic antibodies. FIG. 4A depicts results from LC-MSanalysis of the pooled SEC fractions of v5019. FIG. 4B depicts theresults from LC-MS analysis of the pooled protein A fractions of v10000.

FIG. 5 depicts analysis of a 25 L-scale preparation of an exemplaryanti-HER2 biparatopic antibody. FIG. 5A depicts the SDS-PAGE profile ofan exemplary anti-HER2 biparatopic following MabSelect™ and HiTrap™ SPFF purification. FIG. 5B depicts LCMS analysis of the purified antibody.

FIG. 6 compares the ability of an exemplary biparatopic anti-HER2antibodies to bind to HER2+ whole cells displaying different HER2receptor density compared to control antibodies, as measured by FACS.FIG. 6A and FIG. 6E depict binding to SKOV3 cells;

FIG. 6B depicts binding to JIMT1 cells; FIG. 6C and FIG. 6F depictbinding to MCF7 cells; FIG. 6D depicts binding to MDA-MB-231 cells; andFIG. 6G depicts binding to WI-38 cells.

FIG. 7 depicts the ability of exemplary anti-HER2 biparatopic antibodiesto inhibit the growth of HER2+ cells. FIG. 7A and FIG. 7D shows growthinhibition in SKOV3 cells; FIG. 7B shows growth inhibition in BT-474cells; FIG. 7C shows growth inhibition in SKBR3 cells, and FIG. 7E showsgrowth inhibition in JIMT-1 cells.

FIG. 8 depicts the SPR binding data relating to the paratopes of anexemplary anti-HER2 biparatopic antibodies. FIG. 8A illustrates theK_(D) values (nM) of a monovalent anti-Her2 antibody (v1040;representing the antigen-binding domain on CH—B of exemplary anti-Her2biparatopic antibody), for binding to immobilized Her2 ECD or dimericHer2-Fc. FIG. 8B illustrates the K_(D) values (nM) of a monovalentanti-Her2 antibody (v4182; representing the antigen-binding domain onCH-A of exemplary anti-Her2 biparatopic antibody) for binding toimmobilized Her2 ECD or dimeric Her2-Fc.

FIG. 9 depicts the ability of exemplary anti-HER2 biparatopic antibodyto internalize in HER2+ cells. FIG. 9A depicts internalization in BT-474cells, while FIG. 9b depicts internalization in JIMT-1 cells.

FIG. 10 depicts surface binding and internalization of exemplaryanti-HER2 biparatopic antibodies. FIG. 10A (v5019) depicts the result inBT-474 cells; FIG. 10B (v5019) and FIG. 10F (v5019 and v10000) depictthe result in JIMT1 cells; FIG. 10C (v5019) and FIG. 10E (v5019 andv10000) depict the result in SKOV3 cells, and FIG. 10D (v5019) depictsthe result in MCF7 cells.

FIG. 11 depicts the ability of an exemplary anti-HER2 biparatopicantibody to mediate ADCC in SKOV3 cells. In FIG. 11A, the assay wascarried out using an effector to target cell ratio of 5:1; in FIG. 11B,the assay was carried out using an effector to target cell ratio of 3:1;and in FIG. 11C, the assay was carried out using an effector to targetcell ratio of 1.1.

FIG. 12 depicts the characterization of affinity and binding kinetics ofmonovalent anti-HER2 (v630 and v4182) and an exemplary biparatopicanti-Her2 antibody (v5019) to recombinant human HER2. FIG. 12A shows themeasurement of ka (1/Ms). FIG. 12B shows the measurement of kd (1/s).FIG. 12C shows the measurement of K_(D) (M).

FIG. 13 depicts affinity and binding characteristics of an exemplarybiparatopic anti-HER2 antibody to recombinant human HER2 over a range ofantibody capture levels. FIG. 13A depicts the measurement of kd (1/s) toHER2 ECD determined over a range of antibody capture levels forexemplary biparatopic anti-Her2 antibody (v5019). FIG. 13B depicts themeasurement of kd (1/s) to HER2 ECD determined over a range of antibodycapture levels for monovalent anti-Her2 antibody (v4182). FIG. 13Cdepicts the measurement of kd (1/s) to HER2 ECD determined over a rangeof antibody capture levels for monovalent anti-Her2 antibody (v630).

FIG. 14 shows a comparison of the mechanism of binding of a monospecificanti-ECD4 HER2 antibody (left), and a Fab-scFv biparatopicanti-ECD2×ECD4 HER2 antibody (right). The monospecific anti-ECD4 HER2antibody is capable of binding one antibody molecule to two HER2molecules; whereas the biparatopic anti-ECD2×ECD4 HER2 antibody iscapable of binding one antibody to two HER2 molecule, as well as 2antibodies to one HER2 molecule and combinations therein which resultsin HER2 receptor cross-linking and lattice formation followed bydownstream biological effects such as internalization and/or growthinhibition as indicated by the arrows. IEC represents “immune effectorcells.” The four extracellular domains of HER2 are numbered as 1, 2, 3,or 4 where 1=ECD1, 2=ECD2, 3=ECD3, and 4=ECD4.

FIG. 15 depicts the effect of an exemplary anti-HER2 biparatopicantibody on AKT phosphorylation in BT-474 cells.

FIG. 16 depicts the effect of an exemplary anti-HER2 biparatopicantibody on cardiomyocyte viability. FIG. 16A depicts the effect ofv5019 and the corresponding ADC v6363 on cardiomyocyte viability; FIG.16B depicts the effect of v5019, v7091, and v10000 and correspondingADCs v6363, 7148, 10553 on cardiomyocyte viability, and FIG. 16C depictsthe effect of v5019, v7091, and v10000 and corresponding ADCs v6363,7148, 10553 on the viability of doxorubicin-pretreated cardiomyocytes.

FIG. 17 depicts the ability of exemplary anti-HER2 biparatopic antibodydrug conjugates to inhibit the growth of HER2+ cells. FIG. 17A shows theability of the ADC v6363 to inhibit the growth of JIMT1 cells. FIG. 17Bshows the ability of the ADC v6363 to inhibit the growth of SKOV3 cells.FIG. 17C shows the ability of the ADC v6363 to inhibit the growth ofMCF7 cells. FIG. 17D shows the ability of the ADC v6363 to inhibit thegrowth of MDA-MB-231 cells. FIG. 17E shows the ability of ADCs v6363,v10553, and v1748 to inhibit the growth of SKOV3 cells. FIG. 17F showsthe ability of ADCs v6363, v10553, and v1748 to inhibit the growth ofJIMT-1 cells. FIG. 17G shows the ability of ADCs v6363, v10553, andv1748 to inhibit the growth of NCI-N87 cells.

FIG. 18 depicts the effect of a biparatopic anti-HER2 antibody in ahuman ovarian cancer line xenograft model (SKOV3). FIG. 18A shows theeffect of the antibody on mean tumor volume. FIG. 18B shows the effectof the antibody on percent survival of the animals.

FIG. 19 depicts the effect of a biparatopic anti-HER2 antibody drugconjugate (ADC) in a human ovarian cancer line xenograft model (SKOV3).FIG. 19A shows the effect of the antibody on mean tumor volume. FIG. 19Bshows the effect of the antibody on percent survival of the animals.

FIG. 20 depicts the effect of a biparatopic anti-HER2 antibody drugconjugate (ADC) on mean tumour volume in a human breast primary cellxenograft model (HBCx-13b).

FIG. 21 depicts the effect of a biparatopic anti-HER2 antibody drugconjugate (ADC) on mean tumour volume in a human breast primary cellxenograft model (T226).

FIG. 22 depicts the effect of a biparatopic anti-HER2 antibody drugconjugate (ADC) on mean tumour volume in a human breast primary cellxenograft model (HBCx-5).

FIG. 23 depicts the effect of a biparatopic anti-HER2 antibody drugconjugate (ADC) on anti-HER2 treatment resistant tumors in a human cellline xenograft model (SKOV3).

FIG. 24 depicts the effect of a biparatopic anti-HER2 antibody drugconjugate (ADC) to anti-HER2 treatment resistant tumors in human primarycell xenograft model (HBCx-13b).

FIG. 25 depicts the thermal stability of exemplary anti-HER2 biparatopicantibodies. FIG. 25A depicts the thermal stability of v5019. FIG. 25Bdepicts the thermal stability of v10000. FIG. 25C depicts the thermalstability of v7091.

FIG. 26 depicts the thermal stability of exemplary anti-HER2 biparatopicantibody drug conjugates. FIG. 26A depicts the thermal stability ofv6363. FIG. 26B depicts the thermal stability of v10553. FIG. 26Cdepicts the thermal stability of v7148.

FIG. 27 depicts the ability of anti-HER2 biparatopic antibodies tomediate ADCC in HER2+ cells. The legend shown in FIG. 27C applies toFIG. 27A and FIG. 27B. FIG. 27A depicts this ability in SKBR3 cells;FIG. 27B depicts this ability in JIMT-1 cells; FIG. 27C depicts thisability in MDA-MB-231 cells; and FIG. 27D depicts this ability in WI-38cells.

FIG. 28 depicts the effect of afucosylation on the ability of anti-HER2biparatopic antibodies to mediate ADCC. The legend shown in FIG. 28Bapplies to FIG. 28A as well. FIG. 28A compares the ability of anafucosylated version of v5019 to mediate ADCC to that of Herceptin™ inSKOV3 cells. FIG. 28B compares the ability of an afucosylated version ofv5019 to mediate ADCC to that of Herceptin™ in MDA-MB-231 cells.

FIG. 28C compares the ability of v10000 and an afucosylated version ofv10000 to mediate ADCC against that of Herceptin™ in ZR-75-1 cells.

FIG. 29 depicts the ability of v5019 to inhibit growth of BT-474 cellsin the presence or absence of growth-stimulatory ligands.

FIG. 30 depicts the effect of an afucosylated version of v5019 (v7187)on tumor volume in a human breast cancer xenograft model (HBCx13B).

FIG. 31 depicts the ability of anti-HER2 biparatopic antibodies andanti-HER2 biparatopic-ADCs to bind to HER2+ tumor cells. FIG. 31Acompares the binding of v6363 to a T-DM1 analog, v6246, in SKOV3 cells.FIG. 31B compares the binding of v6363 to a T-DM1 analog, v6246, inJIMT-1 cells. FIG. 31C compares the binding of several exemplaryanti-HER2 biparatopic antibodies and anti-HER2 biparatopic-ADCs tocontrols, in SKOV3 cells. FIG. 31D compares the binding of severalexemplary anti-HER2 biparatopic antibodies and anti-HER2biparatopic-ADCs to controls, in JIMT-1 cells.

FIG. 32 depicts Dose-Dependent Tumour Growth Inhibition of an exemplaryanti-HER2 biparatopic-ADC in a HER2 3+ (ER-PR negative) patient derivedxenograft model (HBCx13b). FIG. 32A shows the effect of v6363 on tumorvolume, while FIG. 32B shows the effect on percent survival.

FIG. 33 depicts the effect of Biparatopic anti-HER2-ADC v6363 comparedto Standard of Care Combinations in a Trastuzumab Resistant PDX HBCx-13bxenograft model. FIG. 33A depicts the effect of treatment on tumorvolume, while FIG. 33B depicts the effect of treatment on survival.

FIG. 34 depicts the efficacy of a biparatopic anti-HER2-ADC in HER2+trastuzumab-resistant breast cancer cell derived tumour xenograft model(JIMT-1).

FIG. 35 depicts the efficacy of exemplary anti-HER2 biparatopicantibodies in vivo in a trastuzumab sensitive ovarian cancer cellderived tumour xenograft model (SKOV3). FIG. 35A depicts the effect oftreatment on tumor volume, while FIG. 35B depicts the effect oftreatment on survival.

FIG. 36 depicts the dose-dependent efficacy of exemplary anti-HER2biparatopic antibodies in vivo in a trastuzumab sensitive ovarian cancercell derived tumour xenograft model (SKOV3).

FIG. 37 depicts the ability of an anti-HER2 biparatopic antibody and ananti-HER2 biparatopic-ADC to inhibit growth of cell lines expressingHER2, and EGFR and/or HER3 at the 3+, 2+ or 1+ levels. FIG. 37A depictsthe ability of v10000 to inhibit growth selected cell lines. FIG. 37Bdepicts the ability of v10553 to inhibit growth of selected cell lines.

FIG. 38 depicts a summary of the ability of v10000 and v10553 to inhibitgrowth in a panel of cell lines. Hyphenated values (e.g. ½) indicatediscrepant erbb receptor levels as reported in the literature; Erbb IHCvalues were obtained internally or from the literature. Where no valueis reported the receptor quantities are unknown and/or not reported. *IHC level estimate based on erBb2 gene expression data (CrownBioSciences). Numbered references are described below.

FIG. 39 depicts the ability of v10000 to mediate ADCC in HER2+ cells.FIG. 39A depicts the results in FaDu cells. FIG. 39B depicts the resultsin A549 cells. FIG. 39C depicts the results in BxPC3 cells. FIG. 39Ddepicts the results in MiaPaca2 cells.

FIG. 40 depicts the ability of anti-HER2 biparatopic antibodies tomediate ADCC in HER2+ cells. FIG. 40A depicts the results in A549 cells.FIG. 40B depicts the results in NCI-N87 cells. FIG. 40C depicts theresults in HCT-116 cells.

FIG. 41 depicts the effect of anti-HER2 biparatopic antibody format onbinding HER2+ cells. FIG. 41A depicts the effect of format on binding toBT-474 cells. FIG. 41B depicts the effect of format on binding to JIMT-1cells. FIG. 41C depicts the effect of format on binding to MCF7 cells.FIG. 41D depicts the effect of format on binding to MDA-MB-231 cells.

FIG. 42 depicts the effect of anti-HER2 biparatopic antibody format oninternalization of antibody in HER2+ cells. FIG. 42A depicts the effecton internalization in BT-474 cells. FIG. 42B depicts the effect oninternalization in JIMT-1 cells. FIG. 42C depicts the effect oninternalization in MCF7 cells.

FIG. 43 depicts the effect of anti-HER2 biparatopic antibody format onthe ability to mediate ADCC in HER2+ cells. FIG. 43A depicts the effectin JIMT-1 cells. FIG. 43B depicts the effect in MCF7 cells. FIG. 43Cdepicts the effect in HER2 0/1+ MDA-MB-231 breast tumor cells.

FIG. 44 depicts the effect of anti-HER2 biparatopic antibody format onthe ability of the antibodies to inhibit HER2+ tumor cell growth inBT-474 cells in the presence or absence of growth-stimulatory ligands.

FIG. 45 depicts the effect of anti-HER2 biparatopic antibody format onthe ability of the antibodies to inhibit growth of SKBR3 cells.

FIG. 46 depicts the effect of anti-HER2 biparatopic antibody format onthe ability of antibodies to inhibit growth of HER2+ tumor cells. FIG.46A depicts growth inhibition in SKOV3 cells. FIG. 46B depicts growthinhibition in JIMT-1 cells. FIG. 46C depicts growth inhibition in MCF7cells.

FIG. 47 depicts a comparison of binding characteristics of anti-HER2biparatopic antibodies of differing format as measured by SPR. FIG. 47Adepicts the plot and linear regression analysis for the kd (1/s) atdifferent antibody capture levels with v6903 and v7091. FIG. 47B depictsthe plot and linear regression analysis for the KD (M) at differentantibody capture levels with v6903 and v7091.

References found in FIG. 38 are as follows: 1. Labouret et al. 2012,Neoplasia 14:121-130; 2. Ghasemi et al. 2014, Oncogenesisdoi:10.1038/oncsis.2014.31; 3. Gaborit et al. 2011 J Bio Chem,286:1133-11345; 4. Kimura et al. 2006, Clin Cancer Res; 12:4925-4932; 5.Komoto et al. 2009, Canc Sci; 101:468-473; 6. Cretella et al. 2014,Molecular Cancer 13:143-155; 7. Bunn et al. 2001, Clin Cancer Res;7:3239-3250; 8. Lewis Phillips et al. 2013, Clin Cancer Res, 20:456-468;9. McDonagh et al. 2012, 11:582-593; 10. Coldren et al. 2006, Mol CancerRes: 521-528; 11. Cavazzoni et al. 2012 Mol Cancer, 11:91-115; 12. Li etal. 2014, Mol Cancer Res, doi:10.1158/1541-7786.MCR-13-0396; 13.Chmielewski et al. 2004, Immunology, 173:7647-7653; 14. Kuwada et al.2004, Int J Cancer, 109:291-301; 15. Fujimoto-Ouchi et al. 2007, ClinChemother Pharmacol, 59:795-805; 16. Chavez-Blanco et al. 2004, BMCCancer, 4:59; 17. Campiglio et al. 2004, J Cellular Physiology.198:259-268; 18. Lehmann et al. 2011, J Clin Investigation,121:2750-2767; 19. Collins et al. 2011, Annals Oncology, 23:1788-1795;20. Takai et al. 2005, Cancer, 104:2701-2708; 21. Rusnack et al. 2007,Cell Prolif, 40:580-594; 22. Ma et al. 2013, PLOS ONE, 8:e73261-e73261;23. Meira et al. 2009, British J Cancer, 101:782-791; 24. HayashiMP28-14 poster; 25. Wang et al. 2005 J Huazhong Univ Sci Technolog MedSci. 25:326-8; 26. Makhja et al. 2010. J Clinc Oncolo 28:1215-1223.

FIG. 48A-B depicts the effect of a biparatopic anti-HER2 antibody in axenograft model of HER2-low, non-small cell lung cancer. FIG. 48A showsthe effect of the antibody on tumor volume. FIG. 48B shows the effect ofthe antibody on percent survival of the animals.

FIG. 49A-B depicts the effect of a biparatopic anti-HER2 antibody in axenograft model of HER2-low, head and neck squamous cell carcinoma. FIG.49A shows the effect of the antibody on tumor volume. FIG. 49B shows theeffect of the antibody on percent survival of the animals.

FIG. 50A-B depicts the effect of a biparatopic anti-HER2 antibody in axenograft model of HER2-low, ER+ breast cancer. FIG. 50A shows theeffect of the antibody on tumor volume. FIG. 50B shows the effect of theantibody on percent survival of the animals.

FIG. 51A-B shows tumor volume and survival in a xenograft model ofpancreatic cancer.

FIG. 52 shows tumor volume in a xenograft model of gastric cancer.

DETAILED DESCRIPTION

Described herein are methods of using bispecific antigen-bindingconstructs that bind HER2.

Antigen-Binding Constructs

Provided herein are antigen-binding constructs, e.g., antibodies, thatbind HER2. The antigen-binding constructs include at least oneantigen-binding polypeptide construct binding a HER2 ECD2 antigen. Insome embodiments, antigen-binding constructs include a secondantigen-binding polypeptide construct binding a second antigen, e.g., aHER2 ECD4 antigen or the HER2 ECD2 antigen. As described in more detailbelow, the antigen-binding polypeptide constructs can be, but are notlimited to, protein constructs such as Fab (fragment antigen-binding),scFv (single chain Fv) and sdab (single domain antibody). In someembodiments, the antigen-binding construct includes a scaffold, e.g, anFc.

The term “antigen-binding construct” refers to any agent, e.g.,polypeptide or polypeptide complex capable of binding to an antigen. Insome aspects an antigen-binding construct is a polypeptide thatspecifically binds to an antigen of interest. An antigen-bindingconstruct can be a monomer, dimer, multimer, a protein, a peptide, or aprotein or peptide complex; an antibody, an antibody fragment, or anantigen-binding fragment thereof; an scFv and the like. Anantigen-binding construct can be monospecific, bispecific, ormultispecific. In some aspects, an antigen-binding construct caninclude, e.g., one or more antigen-binding polypeptide constructs (e.g.,Fabs or scFvs) linked to one or more Fc. Further examples ofantigen-binding constructs are described below and provided in theExamples.

In some embodiments, the antigen-binding construct is monospecific. Amonospecific antigen-binding construct refers to an antigen-bindingconstruct with one binding specificity. In other words, theantigen-binding polypeptide construct binds to the same epitope on thesame antigen. Examples of monospecific antigen-binding constructsinclude trastuzumab and pertuzumab.

A bispecific antigen binding construct has two antigen bindingpolypeptide constructs, each with a unique binding specificity. Forexample, a first antigen binding polypeptide construct binds to anepitope on a first antigen, and a second antigen binding polypeptideconstruct binds to an epitope on a second antigen. The term“biparatopic” as used herein, refers to a bispecific antibody where thefirst antigen binding moiety and the second antigen binding moiety bindto different epitopes on the same antigen.

An antigen-binding construct can be an antibody or antigen-bindingportion thereof. As used herein, an “antibody” or “immunoglobulin”refers to a polypeptide substantially encoded by an immunoglobulin geneor immunoglobulin genes, or fragments thereof, which specifically bindand recognize an analyte (e.g., antigen). The recognized immunoglobulingenes include the kappa, lambda, alpha, gamma, delta, epsilon and muconstant region genes, as well as the myriad immunoglobulin variableregion genes. Light chains are classified as either kappa or lambda. The“class” of an antibody or immunoglobulin refers to the type of constantdomain or constant region possessed by its heavy chain. There are fivemajor classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several ofthese may be further divided into subclasses (isotypes), e.g., IgG1,IgG₂, IgG₃, IgG₄, IgA1, and IgA₂. The heavy chain constant domains thatcorrespond to the different classes of immunoglobulins are called α, δ,ε, γ, and respectively.

An exemplary immunoglobulin (antibody) structural unit is composed oftwo pairs of polypeptide chains, each pair having one “light” (about 25kD) and one “heavy” chain (about 50-70 kD). The N-terminal domain ofeach chain defines a variable region of about 100 to 110 or more aminoacids primarily responsible for antigen recognition. The terms variablelight chain (VL) and variable heavy chain (VH) refer to these light andheavy chain domains respectively. The IgG1 heavy chain comprises of theVH, CH1, CH2 and CH3 domains respectively from the N to C-terminus. Thelight chain comprises of the VL and CL domains from N to C terminus. TheIgG1 heavy chain comprises a hinge between the CH1 and CH2 domains.

The term “hypervariable region” or “HVR”, as used herein, refers to eachof the regions of an antibody variable domain which are hypervariable insequence and/or form structurally defined loops (“hypervariable loops”).Generally, native four-chain antibodies comprise six HVRs; three in theVH (H1, H2, H3), and three in the VL (L1, L2, L3). HVRs generallycomprise amino acid residues from the hypervariable loops and/or fromthe complementarity determining regions (CDRs), the latter being ofhighest sequence variability and/or involved in antigen recognition.With the exception of CDR1 in VH, CDRs generally comprise the amino acidresidues that form the hypervariable loops. Hypervariable regions (HVRs)are also referred to as “complementarity determining regions” (CDRs),and these terms are used herein interchangeably in reference to portionsof the variable region that form the antigen-binding regions. Thisparticular region has been described by Kabat et al., U.S. Dept. ofHealth and Human Services, Sequences of Proteins of ImmunologicalInterest (1983) and by Chothia et al., J Mol Biol 196:901-917 (1987),where the definitions include overlapping or subsets of amino acidresidues when compared against each other. Nevertheless, application ofeither definition to refer to a CDR of an antibody or variants thereofis intended to be within the scope of the term as defined and usedherein. The exact residue numbers which encompass a particular CDR willvary depending on the sequence and size of the CDR. Those skilled in theart can routinely determine which residues comprise a particular CDRgiven the variable region amino acid sequence of the antibody.

“Humanized” forms of non-human (e.g., rodent) antibodies are chimericantibodies that contain minimal sequence derived from non-humanimmunoglobulin. For the most part, humanized antibodies are humanimmunoglobulins (recipient antibody) in which residues from ahypervariable region of the recipient are replaced by residues from ahypervariable region of a non-human species (donor antibody) such asmouse, rat, rabbit or nonhuman primate having the desired specificity,affinity, and capacity. In some instances, framework region (FR)residues of the human immunoglobulin are replaced by correspondingnon-human residues. Furthermore, humanized antibodies may compriseresidues that are not found in the recipient antibody or in the donorantibody. These modifications are made to further refine antibodyperformance. In general, the humanized antibody will comprisesubstantially all of at least one, and typically two, variable domains,in which all or substantially all of the hypervariable loops correspondto those of a non-human immunoglobulin and all or substantially all ofthe FRs are those of a human immunoglobulin sequence. The humanizedantibody optionally also will comprise at least a portion of animmunoglobulin constant region (Fc), typically that of a humanimmunoglobulin. For further details, see Jones et al., Nature321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); andPresta, Curr. Op. Struct. Biol. 2:593-596 (1992).

Humanized HER2 antibodies include huMAb4D5-1, huMAb4D5-2, huMAb4D5-3,huMAb4D5-4, huMAb4D5-5, huMAb4D5-6, huMAb4D5-7 and huMAb4D5-8 orTrastuzumab (HERCEPTIN®) as described in Table 3 of U.S. Pat. No.5,821,337 expressly incorporated herein by reference; humanized 520C9(WO93/21319) and humanized 2C4 antibodies as described in US PatentPublication No. 2006/0018899.

Antigen-Binding Polypeptide Construct

The antigen-binding constructs described herein comprise at least oneantigen-binding polypeptide construct that each binds to a HER2 ECD2antigen. In some embodiments, the antigen-binding constructs describedherein include a second antigen-binding polypeptide construct that bindsto, e.g., a HER2 ECD2 antigen or a HER2 ECD4 antigen. In someembodiments the antigen-binding polypeptide construct comprises asequence that is disclosed in the examples below, e.g., the VH or VL orCDRs of v5019, v5020, v7091, v10000, or v6717.

The antigen-binding polypeptide construct is typically monovalent, i.e.can bind only one epitope. In some embodiments, however, theantigen-binding polypeptide construct can be bivalent (binding to twoepitopes) or multivalent.

Either antigen-binding polypeptide construct can be, e.g., a Fab, or anscFv, depending on the application. In some embodiments, the antigenbinding construct includes two antigen-binding polypeptide constructs.The format of the antigen-binding construct may be Fab-Fab, scFv-scFv,or Fab-scFv or scFv-Fab (first antigen-binding polypeptideconstruct-second antigen-binding polypeptide respectively).

A Fab (also referred to as fragment antigen-binding) contains theconstant domain (CL) of the light chain and the first constant domain(CH1) of the heavy chain along with the variable domains VL and VH onthe light and heavy chains respectively. The variable domains comprisethe complementarity determining loops (CDR, also referred to ashypervariable region) that are involved in antigen-binding. Fab′fragments differ from Fab fragments by the addition of a few residues atthe carboxy terminus of the heavy chain CH1 domain including one or morecysteines from the antibody hinge region.

A “single-chain Fv” or “scFv” includes the VH and VL domains of anantibody, wherein these domains are present in a single polypeptidechain. In one embodiment, the Fv polypeptide further comprises apolypeptide linker between the VH and VL domains which enables the scFvto form the desired structure for antigen-binding. For a review of scFvsee Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113,Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).HER2 antibody scFv fragments are described in WO93/16185; U.S. Pat. No.5,571,894; and U.S. Pat. No. 5,587,458.

A “single domain antibody” or “sdAb” format is an individualimmunoglobulin domain. SdAbs are fairly stable and easy to express asfusion partner with the Fc chain of an antibody (Harmsen MM, De Haard HJ(2007). “Properties, production, and applications of camelidsingle-domain antibody fragments”. Appl. Microbiol Biotechnol. 77(1):13-22).

In some embodiments the antigen binding polypeptide construct is derivedfrom an antibody, a fibronectin, an affibody, anticalin, cysteine knotprotein, DARPin, avimer, Kunitz domain or variant or derivative thereof.

The antigen binding polypeptide constructs described herein can beconverted to different formats. For example, a Fab can be converted toan scFv or an scFv can be converted to a Fab. Methods of convertingbetween types of antigen-binding domains are known in the art (see forexample methods for converting an scFv to a Fab format described at,e.g., Zhou et al (2012) Mol Cancer Ther 11:1167-1476. The methodsdescribed therein are incorporated by reference.).

The antigen binding constructs described herein specifically bind HER2.“Specifically binds”, “specific binding” or “selective binding” meansthat the binding is selective for the antigen and can be discriminatedfrom unwanted or non-specific interactions. The ability of anantigen-binding construct to bind to a specific antigenic determinantcan be measured either through an enzyme-linked immunosorbent assay(ELISA) or other techniques familiar to one of skill in the art, e.g.surface plasmon resonance (SPR) technique (analyzed on a BIAcoreinstrument) (Liljeblad et al, Glyco J 17, 323-329 (2000)), andtraditional binding assays (Heeley, Endocr Res 28, 217-229 (2002)).

In one embodiment, the extent of binding of an antigen-binding moiety toan unrelated protein is less than about 10% of the binding of theantigen-binding construct to the antigen as measured, e.g., by SPR.

HER2

The antigen-binding constructs described herein include anantigen-binding polypeptide construct that binds to the ECD2 of HER2.

The expressions “ErbB2” and “HER2” are used interchangeably herein andrefer to human HER2 protein described, for example, in Semba et al.,PNAS (USA) 82:6497-6501 (1985) and Yamamoto et al. Nature 319:230-234(1986) (Genebank accession number X03363). The term “erbB2” and “neu”refers to the gene encoding human ErbB2 protein. p185 or p185neu refersto the protein product of the neu gene.

HER2 is a HER receptor. A “HER receptor” is a receptor protein tyrosinekinase which belongs to the human epidermal growth factor receptor (HER)family and includes EGFR, HER2, HER3 and HER4 receptors. A HER receptorwill generally comprise an extracellular domain, which may bind an HERligand; a lipophilic transmembrane domain; a conserved intracellulartyrosine kinase domain; and a carboxyl-terminal signaling domainharboring several tyrosine residues which can be phosphorylated. By “HERligand” is meant a polypeptide which binds to and/or activates an HERreceptor.

The extracellular (ecto) domain of HER2 comprises four domains, Domain I(ECD1, amino acid residues from about 1-195), Domain II (ECD2, aminoacid residues from about 196-319), Domain III (ECD3, amino acid residuesfrom about 320-488), and Domain IV (ECD4, amino acid residues from about489-630) (residue numbering without signal peptide). See Garrett et al.Mol. Cell. 11: 495-505 (2003), Cho et al. Nature 421: 756-760 (2003),Franklin et al. Cancer Cell 5:317-328 (2004), Tse et al. Cancer TreatRev. 2012 April; 38(2):133-42 (2012), or Plowman et al. Proc. Natl.Acad. Sci. 90:1746-1750 (1993).

The sequence of HER2 is as follows; ECD boundaries are Domain I: 1-165;Domain II: 166-322; Domain III: 323-488; Domain IV: 489-607.

(SEQ ID NO: 349)   1tqvctgtdmk lrlpaspeth ldmlrhlyqg cqvvqgnlel tylptnasls flgdigevqg  61yvliahnqvr qvplqrlriv rgtqlfedny alavldngdp lnnttpvtga spgglrelql 121rslteilkgg vliqrnpq1c yqdtilwkdi fhknnqlalt lidtnrsrac hpcspmckgs 181rcwgessedc qsltrtvcag gcarckgplp tdccheqcaa gctgpkhsdc laclhfnhsg 241icelhcpalv tyntdtfesm pnpegrytfg ascvtacpyn ylstdvgsct lvcplhnqev 301taedgtqrce kcskpcarvc yglgmehlre vravtsaniq efagckkifg slaflpesfd 361gdpasntapl gpeqlqvfet leeitgylyi sawpdslpdl svfqnlqvir grilhngays 421ltlqglgisw lglrslrelg sglalihhnt hlcfvhtvpw dqlfrnphqa llhtanrped 481ecvgeglach qlcarghcwg pgptqcvncs qflrggecve ecrvlqglpr eyvnarhclp 541chpecqpqng svtcfgpead qcvacahykd ppfcvarcps gvkpdlsymp iwkfpdeega 601cqpcpin

The “epitope 2C4” is the region in the extracellular domain of HER2 towhich the antibody 2C4 binds. Epitope 2C4 comprises residues from domainII in the extracellular domain of HER2. 2C4 and Pertuzumab bind to theextracellular domain of HER2 at the junction of domains I, II and III.Franklin et al. Cancer Cell 5:317-328 (2004). In order to screen forantibodies which bind to the 2C4 epitope, a routine cross-blocking assaysuch as that described in Antibodies, A Laboratory Manual, Cold SpringHarbor Laboratory, Ed Harlow and David Lane (1988), can be performed.Alternatively, epitope mapping can be performed to assess whether theantibody binds to the 2C4 epitope of HER2 using methods known in the artand/or one can study the antibody-HER2 structure (Franklin et al. CancerCell 5:317-328 (2004)) to see what domain(s) of HER2 is/are bound by theantibody.

The “epitope 4D5” is the region in the extracellular domain of HER2 towhich the antibody 4D5 (ATCC CRL 10463) and Trastuzumab bind. Thisepitope is close to the transmembrane domain of HER2, and within DomainIV of HER2. To screen for antibodies which bind to the 4D5 epitope, aroutine cross-blocking assay such as that described in Antibodies, ALaboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and DavidLane (1988), can be performed. Alternatively, epitope mapping can beperformed to assess whether the antibody binds to the 4D5 epitope ofHER2 (e.g. any one or more residues in the region from about residue 529to about residue 625, inclusive, see FIG. 1 of US Patent Publication No.2006/0018899).

Exemplary Anti-HER2 Antigen Binding Constructs

Exemplary anti-HER2 antibodies (or antigen-binding constructs) andcontrols are provided herein. Representations of exemplary biparatopicformats are shown in FIG. 1. In all of the formats shown in FIG. 1, theheterodimeric Fc is depicted with one chain (Chain A) shown in black andthe other (Chain B) shown in grey, while one antigen-binding domain (1)is shown in hatched fill and the other antigen-binding domain (2) isshown in white.

FIG. 1A depicts the structure of a biparatopic antibody in a Fab-Fabformat. FIGS. 1B to 1E depict the structure of possible versions of abiparatopic antibody in an scFv-Fab format. In FIG. 1B, antigen-bindingdomain 1 is an scFv, fused to Chain A, while antigen-binding domain 2 isa Fab, fused to Chain B. In FIG. 1C, antigen-binding domain 1 is a Fab,fused to Chain A, while antigen-binding domain 2 is an scFv, fused toChain B. In FIG. 1D, antigen-binding domain 2 is a Fab, fused to ChainA, while antigen-binding domain 1 is an scFv, fused to Chain B. In FIG.1E, antigen-binding domain 2 is an scFv, fused to Chain A, whileantigen-binding domain 1 is a Fab, fused to Chain B. In FIG. 1F, bothantigen-binding domains are scFvs.

The sequences of the following variants are provided in the SequenceTable found after the Examples. CDR regions were identified using acombination of the Kabat and Chothia methods. Regions may vary slightlybased on method used for identification.

Exemplary Anti-HER2 Biparatopic Antibodies

Exemplary anti-HER2 biparatopic antibodies are shown in Table 1.

TABLE 1 Exemplary anti-HER2 biparatbopic antibodies Variant Chain AChain B 5019 domain ECD2 ECD4 containing the epitope Format Fab scFvAntibody Pertuzumab Trastuzumab name CH3 T350V_L351Y_F405A_Y407VT366I_N390R_K392M_T394W sequence substitutions 5020 domain ECD4 ECD2containing the epitope format scFv Fab Antibody Trastuzumab Pertuzumabname CH3 L351Y_S400E_F405A_Y407V T350V_T366L_K392L_T394W sequencesubstitutions 7091 domain ECD2 ECD4 containing the epitope format FabscFv Antibody Pertuzumab Trastuzumab name CH3 T350V_L351Y_F405A_Y407VT350V_T366L_K392L_T394W sequence substitutions 10000 domain ECD2 ECD4containing the epitope format Fab scFv Antibody Pertuzumab - with Y96Ain VL Trastuzumab name region and T30A/A49G/L69F in VH region CH3T350V_L351Y_F405A_Y407V T350V_T366L_K392L_T394W sequence substitutions6902 domain ECD2 ECD4 containing the epitope format Fab Fab AntibodyTrastuzumab Pertuzumab name Fab HC: L143E_K145T HC: D146G_Q179Ksubstitutions LC: Q124R LC: Q124E_Q160E_T180E CH3T350V_L351Y_F405A_Y407V T350V_T366L_K392L_T394W sequence substitutions6903 domain ECD2 ECD4 containing the epitope format Fab Fab Fab HC:L143E_K145T HC: D146G_Q179K substitutions LC: Q124R_Q1160K_T178R LC:Q124E_Q160E_T180E Antibody Trastuzumab Pertuzumab name CH3T350V_L351Y_F405A_Y407V T350V_T366L_K392L_T394W sequence substitutions6717 domain ECD4 ECD2 containing the epitope format scFv scFv AntibodyPertuzumab Trastuzumab name CH3 T350V_L351Y_F405A_Y407VT366I_N390R_K392M_T394W sequence substitutions Notes: CH3 numberingaccording to EU index as in Kabat referring to the numbering of the EUantibody (Edelman et al., 1969, Proc Natl Acad Sci USA 63: 78-85); Fabor variable domain numbering according to Kabat (Kabat and Wu, 1991;Kabat et al, Sequences of proteins of immunological interest. 5thEdition - US Department of Health and Human Services, NIH publicationn^(o) 91-3242, p 647 (1991)) “domain containing the epitope” = domain ofHER2 to which antigen-binding moiety binds; “Antibody name” = antibodyfrom which antigen-binding moiety is derived, includes substitutionscompared to wild-type when present; “Fab substitutions” = substitutionsin Fab that promote correct light chain pairing; “CH3 sequencesubstitutions” = substitutions in CH3 domain that promote formation ofheterodimeric Fc

Exemplary Anti-HER2 Monovalent Control Antibodies

v1040: a monovalent anti-HER2 antibody, where the HER2 binding domain isa Fab derived from trastuzumab on chain A, and the Fc region is aheterodimer having the mutations T350V_L351Y_F405A_Y407V in Chain A,T350V_T366L_K392L_T394W in Chain B, and the hinge region of Chain Bhaving the mutation C226S; the antigen-binding domain binds to domain 4of HER2.

v630—a monovalent anti-HER2 antibody, where the HER2 binding domain isan scFv derived from trastuzumab on Chain A, and the Fc region is aheterodimer having the mutations L351Y_S400E_F405A_Y407V in Chain A,T366I_N390R_K392M_T394W in Chain B; and the hinge region having themutation C226S (EU numbering) in both chains; the antigen-binding domainbinds to domain 4 of HER2.

v4182: a monovalent anti-HER2 antibody, where the HER2 binding domain isa Fab derived from pertuzumab on chain A, and the Fc region is aheterodimer having the mutations T350V_L351Y_F405A_Y407V in Chain A,T350V_T366L_K392L_T394W in Chain B, and the hinge region of Chain Bhaving the mutation C226S; the antigen-binding domain binds to domain 2of HER2.

Exemplary Anti-HER2 Monospecific Bivalent Antibody Controls (Full-SizedAntibodies, FSAs)

v506 is a wild-type anti HER2 produced in-house in Chinese Hamster Ovary(CHO) cells, as a control. Both HER2 binding domains are derived fromtrastuzumab in the Fab format and the Fc is a wild type homodimer; theantigen-binding domain binds to domain 4 of HER2. This antibody is alsoreferred to as a trastuzumab analog.

v792, is wild-type trastuzumab with a IgG1 hinge, where both HER2binding domains are derived from trastuzumab in the Fab format, and theand the Fc region is a heterodimer having the mutationsT350V_L351Y_F405A_Y407V in Chain A, and T350V_T366L_K392L_T394W Chain B;the antigen-binding domain binds to domain 4 of HER2. This antibody isalso referred to as a trastuzumab analog.

v4184, a bivalent anti-HER2 antibody, where both HER2 binding domainsare derived from pertuzumab in the Fab format, and the Fc region is aheterodimer having the mutations T350V_L351Y_F405A_Y407V in Chain A, andT350V_T366L_K392L_T394W Chain B. The antigen-binding domain binds todomain 2 of HER2. This antibody is also referred to as a pertuzumabanalog.

Exemplary Anti-HER2 Biparatopic Antibody Drug Conjugates (ADCs)

The following are exemplary anti-HER2 biparatopic antibody drugconjugates (anti-HER2 biparatopic-ADCs). ADCs of variants 5019, 7091,10000 and 506 are identified as follows:

-   -   v6363 (v5019 conjugated to DM1)    -   v7148 (v7091 conjugated to DM1)    -   v10553 (v10000 conjugated to DM1)    -   v6246 (v506 conjugated to DM1, analogous to T-DM1,        trastuzumab-emtansine)    -   v6249 (human IgG conjugated to DM1)

Fc of Antigen-Binding Constructs.

In some embodiments, the antigen-binding constructs described hereincomprise an Fc, e.g., a dimeric Fc. A dimeric Fc can be homodimeric orheterodimeric

The term “Fc domain” or “Fc region” herein is used to define aC-terminal region of an immunoglobulin heavy chain that contains atleast a portion of the constant region. The term includes nativesequence Fc regions and variant Fc regions. Unless otherwise specifiedherein, numbering of amino acid residues in the Fc region or constantregion is according to the EU numbering system, also called the EUindex, as described in Kabat et al, Sequences of Proteins ofImmunological Interest, 5th Ed. Public Health Service, NationalInstitutes of Health, Bethesda, Md., 1991. An “Fc polypeptide” of adimeric Fc as used herein refers to one of the two polypeptides formingthe dimeric Fc domain, i.e. a polypeptide comprising C-terminal constantregions of an immunoglobulin heavy chain, capable of stableself-association. For example, an Fc polypeptide of a dimeric IgG Fccomprises an IgG CH2 and an IgG CH3 constant domain sequence.

An Fc domain comprises either a CH3 domain or a CH3 and a CH2 domain.The CH3 domain comprises two CH3 sequences, one from each of the two Fcpolypeptides of the dimeric Fc. The CH2 domain comprises two CH2sequences, one from each of the two Fc polypeptides of the dimeric Fc.

In some aspects, the Fc comprises at least one or two CH3 sequences. Insome aspects, the Fc is coupled, with or without one or more linkers, toa first antigen-binding construct and/or a second antigen-bindingconstruct. In some aspects, the Fc is a human Fc. In some aspects, theFc is a human IgG or IgG1 Fc. In some aspects, the Fc is a heterodimericFc. In some aspects, the Fc comprises at least one or two CH2 sequences.

In some aspects, the Fc comprises one or more modifications in at leastone of the CH3 sequences. In some aspects, the Fc comprises one or moremodifications in at least one of the CH2 sequences. In some aspects, anFc is a single polypeptide. In some aspects, an Fc is multiple peptides,e.g., two polypeptides.

In some aspects, an Fc is an Fc described in patent applicationsPCT/CA2011/001238, filed Nov. 4, 2011 or PCT/CA2012/050780, filed Nov.2, 2012, the entire disclosure of each of which is hereby incorporatedby reference in its entirety for all purposes.

Modified CH3 Domains

In some aspects, the antigen-binding construct described hereincomprises a heterodimeric Fc comprising a modified CH3 domain that hasbeen asymmetrically modified. The heterodimeric Fc can comprise twoheavy chain constant domain polypeptides: a first Fc polypeptide and asecond Fc polypeptide, which can be used interchangeably provided thatFc comprises one first Fc polypeptide and one second Fc polypeptide.Generally, the first Fc polypeptide comprises a first CH3 sequence andthe second Fc polypeptide comprises a second CH3 sequence.

Two CH3 sequences that comprise one or more amino acid modificationsintroduced in an asymmetric fashion generally results in a heterodimericFc, rather than a homodimer, when the two CH3 sequences dimerize. Asused herein, “asymmetric amino acid modifications” refers to anymodification where an amino acid at a specific position on a first CH3sequence is different from the amino acid on a second CH3 sequence atthe same position, and the first and second CH3 sequence preferentiallypair to form a heterodimer, rather than a homodimer. Thisheterodimerization can be a result of modification of only one of thetwo amino acids at the same respective amino acid position on eachsequence; or modification of both amino acids on each sequence at thesame respective position on each of the first and second CH3 sequences.The first and second CH3 sequence of a heterodimeric Fc can comprise oneor more than one asymmetric amino acid modification.

Table A provides the amino acid sequence of the human IgG1 Fc sequence,corresponding to amino acids 231 to 447 of the full-length human IgG1heavy chain. The CH3 sequence comprises amino acid 341-447 of thefull-length human IgG1 heavy chain.

Typically an Fc can include two contiguous heavy chain sequences (A andB) that are capable of dimerizing. In some aspects, one or bothsequences of an Fc include one or more mutations or modifications at thefollowing locations: L351, F405, Y407, T366, K392, T394, T350, S400,and/or N390, using EU numbering. In some aspects, an Fc includes amutant sequence shown in Table X. In some aspects, an Fc includes themutations of Variant 1 A-B. In some aspects, an Fc includes themutations of Variant 2 A-B. In some aspects, an Fc includes themutations of Variant 3 A-B. In some aspects, an Fc includes themutations of Variant 4 A-B. In some aspects, an Fc includes themutations of Variant 5 A-B.

TABLE A IgG1 Fc sequences Human IgG1 Fc APELLGGPSVFLFPPKPKDTLMISRTPsequence 231-447 EVTCVVVDVSHEDPEVKFNWYVDGVEV (EU-numbering)HNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 350) Variant IgG1 Fc sequence (231-447) Chain Mutations 1A L351Y_F405A_Y407V 1 B T366L_K392M_T394W 2 A L351Y_F405A_Y407V 2 BT366L_K392L_T394W 3 A T350V_L351Y_F405A_Y407V 3 BT350V_T366L_K392L_T394W 4 A T350V_L351Y_F405A_Y407V 4 BT350V_T366L_K392M_T394W 5 A T350V_L351Y_S400E_F405A_ Y407V 5 BT350V_T366L_N390R_K392M_ T394W

The first and second CH3 sequences can comprise amino acid mutations asdescribed herein, with reference to amino acids 231 to 447 of thefull-length human IgG1 heavy chain. In one embodiment, the heterodimericFc comprises a modified CH3 domain with a first CH3 sequence havingamino acid modifications at positions F405 and Y407, and a second CH3sequence having amino acid modifications at position T394. In oneembodiment, the heterodimeric Fc comprises a modified CH3 domain with afirst CH3 sequence having one or more amino acid modifications selectedfrom L351Y, F405A, and Y407V, and the second CH3 sequence having one ormore amino acid modifications selected from T366L, T366I, K392L, K392M,and T394W.

In one embodiment, a heterodimeric Fc comprises a modified CH3 domainwith a first CH3 sequence having amino acid modifications at positionsL351, F405 and Y407, and a second CH3 sequence having amino acidmodifications at positions T366, K392, and T394, and one of the first orsecond CH3 sequences further comprising amino acid modifications atposition Q347, and the other CH3 sequence further comprising amino acidmodification at position K360. In another embodiment, a heterodimeric Fccomprises a modified CH3 domain with a first CH3 sequence having aminoacid modifications at positions L351, F405 and Y407, and a second CH3sequence having amino acid modifications at position T366, K392, andT394, one of the first or second CH3 sequences further comprising aminoacid modifications at position Q347, and the other CH3 sequence furthercomprising amino acid modification at position K360, and one or both ofsaid CH3 sequences further comprise the amino acid modification T350V.

In one embodiment, a heterodimeric Fc comprises a modified CH3 domainwith a first CH3 sequence having amino acid modifications at positionsL351, F405 and Y407, and a second CH3 sequence having amino acidmodifications at positions T366, K392, and T394 and one of said firstand second CH3 sequences further comprising amino acid modification ofD399R or D399K and the other CH3 sequence comprising one or more ofT411E, T411D, K409E, K409D, K392E and K392D. In another embodiment, aheterodimeric Fc comprises a modified CH3 domain with a first CH3sequence having amino acid modifications at positions L351, F405 andY407, and a second CH3 sequence having amino acid modifications atpositions T366, K392, and T394, one of said first and second CH3sequences further comprises amino acid modification of D399R or D399Kand the other CH3 sequence comprising one or more of T411E, T411D,K409E, K409D, K392E and K392D, and one or both of said CH3 sequencesfurther comprise the amino acid modification T350V.

In one embodiment, a heterodimeric Fc comprises a modified CH3 domainwith a first CH3 sequence having amino acid modifications at positionsL351, F405 and Y407, and a second CH3 sequence having amino acidmodifications at positions T366, K392, and T394, wherein one or both ofsaid CH3 sequences further comprise the amino acid modification ofT350V.

In one embodiment, a heterodimeric Fc comprises a modified CH3 domaincomprising the following amino acid modifications, where “A” representsthe amino acid modifications to the first CH3 sequence, and “B”represents the amino acid modifications to the second CH3 sequence:A:L351Y_F405A_Y407V, B:T366L_K392M_T394W, A:L351Y_F405A_Y407V,B:T366L_K392L_T394W, A:T350V_L351Y_F405A_Y407V,B:T350V_T366L_K392L_T394W, A:T350V_L351Y_F405A_Y407V,B:T350V_T366L_K392M_T394W, A:T350V_L351Y_S400E_F405A_Y407V, and/orB:T350V_T366L_N390R_K392M_T394W.

The one or more asymmetric amino acid modifications can promote theformation of a heterodimeric Fc in which the heterodimeric CH3 domainhas a stability that is comparable to a wild-type homodimeric CH3domain. In an embodiment, the one or more asymmetric amino acidmodifications promote the formation of a heterodimeric Fc domain inwhich the heterodimeric Fc domain has a stability that is comparable toa wild-type homodimeric Fc domain. In an embodiment, the one or moreasymmetric amino acid modifications promote the formation of aheterodimeric Fc domain in which the heterodimeric Fc domain has astability observed via the melting temperature (Tm) in a differentialscanning calorimetry study, and where the melting temperature is within4° C. of that observed for the corresponding symmetric wild-typehomodimeric Fc domain. In some aspects, the Fc comprises one or moremodifications in at least one of the C_(H3) sequences that promote theformation of a heterodimeric Fc with stability comparable to a wild-typehomodimeric Fc.

In one embodiment, the stability of the CH3 domain can be assessed bymeasuring the melting temperature of the CH3 domain, for example bydifferential scanning calorimetry (DSC). Thus, in a further embodiment,the CH3 domain has a melting temperature of about 68° C. or higher. Inanother embodiment, the CH3 domain has a melting temperature of about70° C. or higher. In another embodiment, the CH3 domain has a meltingtemperature of about 72° C. or higher. In another embodiment, the CH3domain has a melting temperature of about 73° C. or higher. In anotherembodiment, the CH3 domain has a melting temperature of about 75° C. orhigher. In another embodiment, the CH3 domain has a melting temperatureof about 78° C. or higher. In some aspects, the dimerized CH3 sequenceshave a melting temperature (Tm) of about 68, 69, 70, 71, 72, 73, 74, 75,76, 77, 77.5, 78, 79, 80, 81, 82, 83, 84, or 85° C. or higher.

In some embodiments, a heterodimeric Fc comprising modified CH3sequences can be formed with a purity of at least about 75% as comparedto homodimeric Fc in the expressed product. In another embodiment, theheterodimeric Fc is formed with a purity greater than about 80%. Inanother embodiment, the heterodimeric Fc is formed with a purity greaterthan about 85%. In another embodiment, the heterodimeric Fc is formedwith a purity greater than about 90%. In another embodiment, theheterodimeric Fc is formed with a purity greater than about 95%. Inanother embodiment, the heterodimeric Fc is formed with a purity greaterthan about 97%. In some aspects, the Fc is a heterodimer formed with apurity greater than about 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85,86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% whenexpressed. In some aspects, the Fc is a heterodimer formed with a puritygreater than about 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% when expressed via asingle cell.

Additional methods for modifying monomeric Fc polypeptides to promoteheterodimeric Fc formation are described in International PatentPublication No. WO 96/027011 (knobs into holes), in Gunasekaran et al.(Gunasekaran K. et al. (2010) J Biol Chem. 285, 19637-46, electrostaticdesign to achieve selective heterodimerization), in Davis et al. (Davis,J H. et al. (2010) Prot Eng Des Sel; 23(4): 195-202, strand exchangeengineered domain (SEED) technology), and in Labrijn et al [Efficientgeneration of stable bispecific IgG1 by controlled Fab-arm exchange.Labrijn A F, Meesters J I, de Goeij B E, van den Bremer E T, Neijssen J,van Kampen M D, Strumane K, Verploegen S, Kundu A, Gramer M J, vanBerkel P H, van de Winkel J G, Schuurman J, Parren P W. Proc Natl AcadSci USA. 2013 Mar. 26; 110(13):5145-50.

CH2 Domains

In some embodiments, the Fc of the antigen-binding construct comprises aCH2 domain. One example of an CH2 domain of an Fc is amino acid 231-340of the sequence shown in Table A. Several effector functions aremediated by Fc receptors (FcRs), which bind to the Fc of an antibody.

The terms “Fc receptor” and “FcR” are used to describe a receptor thatbinds to the Fc region of an antibody. For example, an FcR can be anative sequence human FcR. Generally, an FcR is one which binds an IgGantibody (a gamma receptor) and includes receptors of the FcγRI, FcγRII,and FcγRIII subclasses, including allelic variants and alternativelyspliced forms of these receptors. FcγRII receptors include FcγRIIA (an“activating receptor”) and FcγRIIB (an “inhibiting receptor”), whichhave similar amino acid sequences that differ primarily in thecytoplasmic domains thereof. Immunoglobulins of other isotypes can alsobe bound by certain FcRs (see, e.g., Janeway et al., Immuno Biology: theimmune system in health and disease, (Elsevier Science Ltd., NY) (4thed., 1999)). Activating receptor FcγRIIA contains an immunoreceptortyrosine-based activation motif (ITAM) in its cytoplasmic domain.Inhibiting receptor FcγRIIB contains an immunoreceptor tyrosine-basedinhibition motif (ITIM) in its cytoplasmic domain (reviewed in Daeron,Annu. Rev. Immunol. 15:203-234 (1997)). FcRs are reviewed in Ravetch andKinet, Annu. Rev. Immunol 9:457-92 (1991); Capel et al., Immunomethods4:25-34 (1994); and de Haas et al., J. Lab. Clin. Med. 126:330-41(1995). Other FcRs, including those to be identified in the future, areencompassed by the term “FcR” herein. The term also includes theneonatal receptor, FcRn, which is responsible for the transfer ofmaternal IgGs to the fetus (Guyer et al., J. Immunol. 117:587 (1976);and Kim et al., J. Immunol. 24:249 (1994)).

Modifications in the CH2 domain can affect the binding of FcRs to theFc. A number of amino acid modifications in the Fc region are known inthe art for selectively altering the affinity of the Fc for differentFcgamma receptors. In some aspects, the Fc comprises one or moremodifications to promote selective binding of Fc-gamma receptors.

Exemplary mutations that alter the binding of FcRs to the Fc are listedbelow:

S298A/E333A/K334A, S298A/E333A/K334A/K326A (Lu Y, Vernes J M, Chiang N,et al. J Immunol Methods. 2011 Feb. 28; 365(1-2):132-41);

F243L/R292P/Y300L/V305I/P396L, F243L/R292P/Y300L/L235V/P396L(Stavenhagen J B, Gorlatov S, Tuaillon N, et al. Cancer Res. 2007 Sep.15; 67(18):8882-90; Nordstrom J L, Gorlatov S, Zhang W, et al. BreastCancer Res. 2011 Nov. 30; 13(6):R123);

F243L (Stewart R, Thom G, Levens M, et al. Protein Eng Des Sel. 2011September; 24(9):671-8.), S298A/E333A/K334A (Shields R L, Namenuk A K,Hong K, et al. J Biol Chem. 2001 Mar. 2; 276(9):6591-604);

S239D/I332E/A330L, S239D/I332E (Lazar G A, Dang W, Karki S, et al. ProcNatl Acad Sci USA. 2006 Mar. 14; 103(11):4005-10);

S239D/S267E, S267E/L328F (Chu S Y, Vostiar I, Karki S, et al. MolImmunol. 2008 September; 45(15):3926-33);

S239D/D265S/S298A/I332E, S239E/S298A/K326A/A327H, G237F/S298A/A330L/I332E, S239D/I332E/S298A, S239D/K326E/A330L/I332E/S298A,G236A/S239D/D270L/I3 32E, S239E/S267E/H268D, L234F/S267E/N325L,G237F/V266L/S267D and other mutations listed in WO2011/120134 andWO2011/120135, herein incorporated by reference. Therapeutic AntibodyEngineering (by William R. Strohl and Lila M. Strohl, WoodheadPublishing series in Biomedicine No 11, ISBN 1 907568 37 9, October2012) lists mutations on page 283.

In some embodiments an antigen-binding construct described hereincomprises an antigen-binding polypeptide construct which binds anantigen; and a dimeric Fc that has superior biophysical properties likestability and ease of manufacture relative to an antigen-bindingconstruct which does not include the same dimeric Fc. In someembodiments a CH2 domain comprises one or more asymmetric amino acidmodifications. Exemplary asymmetric mutations are described inInternational Patent Application No. PCT/CA2014/050507.

Additional Modifications to Improve Effector Function.

In some embodiments an antigen-binding construct described hereinincludes modifications to improve its ability to mediate effectorfunction. Such modifications are known in the art and includeafucosylation, or engineering of the affinity of the Fc towards anactivating receptor, mainly FCGR3a for ADCC, and towards C1q for CDC.The following Table B summarizes various designs reported in theliterature for effector function engineering.

Methods of producing antigen-binding constructs with little or no fucoseon the Fc glycosylation site (Asn 297 EU numbering) without altering theamino acid sequence are well known in the art. The GlymaX® technology(ProBioGen AG) is based on the introduction of a gene for an enzymewhich deflects the cellular pathway of fucose biosynthesis into cellsused for antigen-binding construct production. This prevents theaddition of the sugar “fucose” to the N-linked antibody carbohydratepart by antigen-binding construct-producing cells. (von Horsten et al.(2010) Glycobiology. 2010 December; 20 (12):1607-18. Another approach toobtaining antigen-binding constructs with lowered levels of fucosylationcan be found in U.S. Pat. No. 8,409,572, which teaches selecting celllines for antigen-binding construct production for their ability toyield lower levels of fucosylation on antigen-binding constructsAntigen-binding constructs can be fully afucosylated (meaning theycontain no detectable fucose) or they can be partially afucosylated,meaning that the isolated antibody contains less than 95%, less than85%, less than 75%, less than 65%, less than 55%, less than 45%, lessthan 35%, less than 25%, less than 15% or less than 5% of the amount offucose normally detected for a similar antibody produced by a mammalianexpression system.

Thus, in one embodiment, an antigen-binding construct described hereincan include a dimeric Fc that comprises one or more amino acidmodifications as noted in Table B that confer improved effectorfunction. In another embodiment, the antigen-binding construct can beafucosylated to improve effector function.

TABLE B CH2 domains and effector function engineering. ReferenceMutations Effect Lu, 2011, Afucosylated Increased ADCC Ferrara 2011,Mizushima 2011 Lu, 2011 S298A/E333A/K334A Increased ADCC Lu, 2011S298A/E333A/K334A/K326A Increased ADCC Stavenhagen,F243L/R292P/Y300L/V305I/ Increased ADCC 2007 P396L Nordstrom, 2011F243L/R292P/Y300L/L235V/ Increased ADCC P396L Stewart, 2011 F243LIncreased ADCC Shields, 2001 S298A/E333A/K334A Increased ADCC Lazar,2006 S239D/I332E/A330L Increased ADCC Lazar, 2006 S239D/I332E IncreasedADCC Bowles, 2006 AME-D, not specified mutations Increased ADCC Heider,2011 37.1, mutations not disclosed Increased ADCC Moore, 2010S267E/H268F/S324T Increased CDC

Fc modifications reducing FcγR and/or complement binding and/or effectorfunction are known in the art. Recent publications describe strategiesthat have been used to engineer antibodies with reduced or silencedeffector activity (see Strohl, W R (2009), Curr Opin Biotech 20:685-691,and Strohl, W R and Strohl L M, “Antibody Fc engineering for optimalantibody performance” In Therapeutic Antibody Engineering, Cambridge:Woodhead Publishing (2012), pp 225-249). These strategies includereduction of effector function through modification of glycosylation,use of IgG2/IgG4 scaffolds, or the introduction of mutations in thehinge or CH2 regions of the Fc. For example, US Patent Publication No.2011/0212087 (Strohl), International Patent Publication No. WO2006/105338 (Xencor), US Patent Publication No. 2012/0225058 (Xencor),US Patent Publication No. 2012/0251531 (Genentech), and Strop et al((2012) J. Mol. Biol. 420: 204-219) describe specific modifications toreduce FcγR or complement binding to the Fc.

Specific, non-limiting examples of known amino acid modifications toreduce FcγR or complement binding to the Fc include those identified inthe following table:

TABLE C modifications to reduce FcγR or complement binding to the FcCompany Mutations GSK N297A Ortho Biotech L234A/L235A Protein Designlabs IGG2 V234A/G237A Wellcome Labs IGG4 L235A/G237A/E318A GSK IGG4S228P/L236E Alexion IGG2/IGG4combo Merck IGG2 H268Q/V309L/A330S/A331SBristol-Myers C220S/C226S/C229S/P238S Seattle GeneticsC226S/C229S/E3233P/L235V/L235A Amgen E. coli production, non glycoMedimune L234F/L235E/P331S Trubion Hinge mutant, possibly C226S/P230S

In one embodiment, the Fc comprises at least one amino acid modificationidentified in the above table. In another embodiment the Fc comprisesamino acid modification of at least one of L234, L235, or D265. Inanother embodiment, the Fc comprises amino acid modification at L234,L235 and D265. In another embodiment, the Fc comprises the amino acidmodification L234A, L235A and D265S.

Linkers and Linker Polypeptides

In some embodiments, the antigen-binding constructs described hereininclude two antigen-binding polypeptide constructs. In theseembodiments, the antigen-binding polypeptide constructs are eachoperatively linked to a linker polypeptide wherein the linkerpolypeptides are capable of forming a complex or interface with eachother. In some embodiments, the linker polypeptides are capable offorming a covalent linkage with each other. The spatial conformation ofthe antigen-binding construct comprising a first and secondantigen-binding polypeptide constructs with the linker polypeptides issimilar to the relative spatial conformation of the paratopes of aF(ab′)2 fragment generated by papain digestion, albeit in the context ofan antigen-binding construct with 2 antigen-binding polypeptideconstructs.

In some embodiments, the linker polypeptides are selected such that theymaintain the relative spatial conformation of the paratopes of a F(ab′)fragment, and are capable of forming a covalent bond equivalent to thedisulphide bond in the core hinge of IgG. Suitable linker polypeptidesinclude IgG hinge regions such as, for example those from IgG1, IgG2, orIgG4. Modified versions of these exemplary linkers can also be used. Forexample, modifications to improve the stability of the IgG4 hinge areknown in the art (see for example, Labrijn et al. (2009) NatureBiotechnology 27, 767-771).

In one embodiment, the linker polypeptides are operatively linked to ascaffold as described here, for example an Fc. In some aspects, an Fc iscoupled to the one or more antigen-binding polypeptide constructs withone or more linkers. In some aspects, Fc is coupled to the heavy chainof each antigen-binding polypeptide by a linker.

In other embodiments, the linker polypeptides are operatively linked toscaffolds other than an Fc. A number of alternate protein or moleculardomains are know in the art and can be used to form selective pairs oftwo different antigen-binding polypeptides. An example is the leucinezipper domains such as Fos and Jun that selectively pair together [S AKostelny, M S Cole, and J Y Tso. Formation of a bispecific antibody bythe use of leucine zippers. J Immunol 1992 148:1547-53; Bernd J. Wranik,Erin L. Christensen, Gabriele Schaefer, Janet K. Jackman, Andrew C.Vendel, and Dan Eaton. LUZ-Y, a Novel Platform for the Mammalian CellProduction of Full-length IgG-bispecific AntibodiesJ. Biol. Chem. 2012287: 43331-43339]. Alternately, other selectively pairing molecularpairs such as the barnase barstar pair [Deyev, S. M., Waibel, R.,Lebedenko, E. N., Schubiger, A. P., and Plückthun, A. (2003). Design ofmultivalent complexes using the barnase*barstar module. Nat Biotechnol21, 1486-1492], DNA strand pairs [Zahida N. Chaudri, MichaelBartlet-Jones, George Panayotou, Thomas Klonisch, Ivan M. Roitt, TorbenLund, Peter J. Delves, Dual specificity antibodies using adouble-stranded oligonucleotide bridge, FEBS Letters, Volume 450, Issues1-2, 30 Apr. 1999, Pages 23-26], split fluorescent protein pairs [UlrichBrinkmann, Alexander Haas. Fluorescent antibody fusion protein, itsproduction and use, WO 2011135040 A1] can also be employed.

Affinity

In some embodiments, affinity is determined by SPR (surface plasmonresonance) and/or FACS (fluorescence activated cell sorting). In someembodiments, affinity is determined by SPR and/or FACS as describedbelow.

Dissociation Constant (K) and Maximal Binding (Bmax)

In some embodiments, an antigen-binding construct is described byfunctional characteristics including but not limited to a dissociationconstant and a maximal binding.

The term “dissociation constant (K_(D))” as used herein, is intended torefer to the equilibrium dissociation constant of a particularligand-protein interaction. As used herein, ligand-protein interactionsrefer to, but are not limited to protein-protein interactions orantibody-antigen interactions. The K_(D) measures the propensity of twoproteins (e.g. AB) to dissociate reversibly into smaller components(A+B), and is define as the ratio of the rate of dissociation, alsocalled the “off-rate (k_(off))”, to the association rate, or “on-rate(k_(on))”. Thus, K_(D) equals k_(off)/k_(on) and is expressed as a molarconcentration (M). It follows that the smaller the K_(D), the strongerthe affinity of binding. Therefore, a K_(D) of 1 mM indicates weakbinding affinity compared to a K_(D) of 1 nM. K_(D) values forantigen-binding constructs can be determined using methods wellestablished in the art. One method for determining the K_(D) of anantigen-binding construct is by using surface plasmon resonance (SPR),typically using a biosensor system such as a Biacore® system. Isothermaltitration calorimetry (ITC) is another method that can be used todetermine.

The binding characteristics of an antigen-binding construct can bedetermined by various techniques. One of which is the measurement ofbinding to target cells expressing the antigen by flow cytometry (FACS,Fluorescence-activated cell sorting). Typically, in such an experiment,the target cells expressing the antigen of interest are incubated withantigen-binding constructs at different concentrations, washed,incubated with a secondary agent for detecting the antigen-bindingconstruct, washed, and analyzed in the flow cytometer to measure themedian fluorescent intensity (MFI) representing the strength ofdetection signal on the cells, which in turn is related to the number ofantigen-binding constructs bound to the cells. The antigen-bindingconstruct concentration vs. MFI data is then fitted into a saturationbinding equation to yield two key binding parameters, Bmax and apparentK_(D).

Apparent K_(D), or apparent equilibrium dissociation constant,represents the antigen-binding construct concentration at which halfmaximal cell binding is observed. Evidently, the smaller the K_(D)value, the smaller antigen-binding construct concentration is requiredto reach maximum cell binding and thus the higher is the affinity of theantigen-binding construct. The apparent K_(D) is dependent on theconditions of the cell binding experiment, such as different receptorlevels expressed on the cells and incubation conditions, and thus theapparent K_(D) is generally different from the K_(D) values determinedfrom cell-free molecular experiments such as SPR and ITC. However, thereis generally good agreement between the different methods.

The term “Bmax”, or maximal binding, refers to the maximumantigen-binding construct binding level on the cells at saturatingconcentrations of antigen-binding construct. This parameter can bereported in the arbitrary unit MFI for relative comparison, or convertedinto an absolute value corresponding to the number of antigen-bindingconstructs bound to the cell with the use of a standard curve.

Testing of Antigen-Binding Constructs: HER2 Binding

The antigen-binding constructs or pharmaceutical compositions describedherein are tested in vitro, and then in vivo for the desired therapeuticor prophylactic activity, prior to use in humans. For example, in vitroassays to demonstrate the therapeutic or prophylactic utility of acompound or pharmaceutical composition include, the effect of a compoundon a cell line or a patient tissue sample. The effect of the compound orcomposition on the cell line and/or tissue sample can be determinedutilizing techniques known to those of skill in the art including, butnot limited to, rosette formation assays and cell lysis assays. Inaccordance with the invention, in vitro assays which can be used todetermine whether administration of a specific antigen-binding constructis indicated, include in vitro cell culture assays, or in vitro assaysin which a patient tissue sample is grown in culture, and exposed to orotherwise administered antigen-binding construct, and the effect of suchantigen-binding construct upon the tissue sample is observed.

Candidate antigen-binding constructs can be assayed using cells, e.g.,breast cancer cell lines, expressing HER2. The following Table Ddescribes the expression level of HER2 in several representative cancercell lines.

TABLE D Relative expression levels of HER2 in cell lines of interest.IHC HER2 Cell Line Description scoring receptors/cell NCI-N87 Humangastric carcinoma 3+ Not assessed A549 Human lung alveolar 0/1+ Notassessed carcinoma (non-small cell lung cancer) BxPC-3 Human pancreatic1+ Not assessed adenocarcinoma MIA Human pancreatic ductal 2+ Notassessed PaCa-2 adenocarcinoma FaDu Human pharyngeal 2+ Not assessedsquamous cell carcinoma HCT-116 Human colorectal 1+ Not assessedepithelial carcinoma WI-38 Normal fetal lung 0  1.0 × 10E4  MDA- Humantriple negative 0/1+ 1.7 × 10E4-2.3 × 10E4 MB-231 breast epithelialadenocarcinoma MCF-7 Human estrogen receptor 1+ 4 × 10E4-7 × 10E4positive breast epithelial adenocarcinoma JIMT-1 Trastuzumab resistant2+ 2 × 10E5-8 × 10E5 breast epithelial carcinoma, amplified HER2oncogene, insensitive to HER2-inhibiting drugs (i.e. Herceptin ™)ZR-75-1 Estrogen receptor 2+  3 × 10E5 positive breast ductal carcinomaSKOV-3 Human ovarian epithelial 2/3+ 5 × 10E5-1 × 10E6 adenocarcinoma,HER2 gene amplified SK-BR-3 Human breast epithelial 3+ >1 × 10E6adenocarcinoma BT-474 Human breast epithelial 3+ >1 × 10E6 ductalcarcinoma,

McDonagh et al Mol Cancer Ther. 2012 March; 11(3):582-93; Subik et al.(2010) Breast Cancer: Basic Clinical Research: 4; 35-41; Carter et al.PNAS, 1994:89; 4285-4289; Yarden 2000, HER2: Basic Research, Prognosisand Therapy; Hendricks et al Mol Cancer Ther 2013; 12:1816-28.

As is known in the art, a number of assays may be employed in order toidentify antigen-binding constructs suitable for use in the methodsdescribed herein. These assays can be carried out in cancer cellsexpressing HER2. Examples of suitable cancer cells are identified inTable A5. Examples of assays that may be carried out are described asfollows.

For example, to identify growth inhibitory candidate antigen-bindingconstructs that bind HER2, one may screen for antibodies which inhibitthe growth of cancer cells which express HER2. In one embodiment, thecandidate antigen-binding construct of choice is able to inhibit growthof cancer cells in cell culture by about 20-100% and preferably by about50-100% at compared to a control antigen-binding construct.

To select for candidate antigen-binding constructs which induce celldeath, loss of membrane integrity as indicated by, e.g., PI(phosphatidylinositol), trypan blue or 7AAD uptake may be assessedrelative to control.

In order to select for candidate antigen-binding constructs which induceapoptosis, an annexin binding assay may be employed. In addition to theannexin binding assay, a DNA staining assay may also be used.

In one embodiment, the candidate antigen-binding construct of interestmay block heregulin dependent association of ErbB2 with ErbB3 in bothMCF7 and SK-BR-3 cells as determined in a co-immunoprecipitationexperiment substantially more effectively than monoclonal antibody 4D5,and preferably substantially more effectively than monoclonal antibody7F3.

To screen for antigen-binding constructs which bind to an epitope onErbB2 bound by an antibody of interest, a routine cross-blocking assaysuch as that described in Antibodies, A Laboratory Manual, Cold SpringHarbor Laboratory, Ed Harlow and David Lane (1988), can be performed.Alternatively, or additionally, epitope mapping can be performed bymethods known in the art.

Competition between antigen-binding constructs can be determined by anassay in which an antigen-binding construct under test inhibits orblocks specific binding of a reference antigen-binding construct to acommon antigen (see, e.g., Junghans et al., Cancer Res. 50:1495, 1990;Fendly et al. Cancer Research 50: 1550-1558; U.S. Pat. No. 6,949,245). Atest antigen-binding construct competes with a reference antigen-bindingconstruct if an excess of a test antigen-binding construct (e.g., atleast 2×, 5×, 10×, 20×, or 100×) inhibits or blocks binding of thereference antigen-binding construct by, e.g., at least 50%, 60%, 70%,75%, 80%, 85%, 90%, 95%, or 99% as measured in a competitive bindingassay. Antigen-binding constructs identified by competition assay(competing antigen-binding construct) include antigen-binding constructsbinding to the same epitope as the reference antigen-binding constructand antigen-binding constructs binding to an adjacent epitopesufficiently proximal to the epitope bound by the referenceantigen-binding construct for steric hindrance to occur. For example, asecond, competing antigen-binding construct can be identified thatcompetes for binding to HER2 with a first antigen-binding constructdescribed herein. In certain instances, the second construct can blockor inhibit binding of the first construct by, e.g., at least 50%, 60%,70%, 75%, 80%, 85%, 90%, 95%, or 99% as measured in a competitivebinding assay. In certain instances, the second construct can displacethe first construct by greater than 50%, 60%, 70%, 75%, 80%, 85%, 90%,95%, or 99%.

In some embodiments, antigen-binding constructs described herein areassayed for function in vivo, e.g., in animal models. In someembodiments, the animal models are those described in Table E. In someembodiments, the animal models are those described in the Examples. Insome embodiments, the antigen-binding constructs display an increase inefficacy of treatment in an animal model compared to a referenceantigen-binding construct.

TABLE E Animal models for testing HER2 binding antigen-bindingconstructs Xenograft Model Description Reference SKOV3 human HER2+/3+,gene amplified, Rhodes et al. 2002. American Journal of ovarian cancermoderately sensitive to trastuzumab Pathology 118: 408-417; Sims et al.2012. British Journal of Cancer 106: 1779-1789 HBCx-13b human HER2 3+,estrogen receptor negative, Marangoni et al. 2007. Clinical Cancermetastatic progesterone receptor negative; Research 13: 3989-3998; Reyalet al. 2012. breast cancer Invasive ductal breast carcinoma; BreastCancer Research 14: R11 Chemotherapy resistant, Trastuzumab resistantT226 human HER2 3+, estrogen receptor negative, breast cancerprogesterone receptor negative; Inflammatory breast cancer; Trastuzumabresistant, Docetaxel and capecitabine moderately sensitive,Adriamycin/cyclophosphamide sensitive HBCx-5 human HER2 3+, estrogenreceptor negative, Marangoni et al. 2007. Clinical Cancer breast cancerprogesterone receptor negative; Research 13: 3989-3998; Reyal et al.2012. Invasive ductal carcinoma, luminal B; Breast Cancer Research 14:R11 Trastuzumab resistant, Docetaxel moderately sensitive, Capecitabine,Adriamycin/Cyclophosphamide sensitive JIMT-1 human HER2 2+, HER2 geneamplified, Tanner et al. 2004. Molecular Cancer breast cancerTrastuzumab and pertuzumab Therapeutics 3: 1585-1592 resistant

Reference Antigen-Binding Construct

In some embodiments, the functional characteristics of theantigen-binding constructs described herein are compared to those of areference antigen-binding construct. The identity of the referenceantigen-binding construct depends on the functional characteristic beingmeasured or the distinction being made. For example, when comparing thefunctional characteristics of antigen-binding constructs describedherein, the reference antigen-binding construct may be a trastuzumab(for example v6336), or analog thereof, or may be a control IgG, forexample a non-specific polyclonal human antibody.

Antigen-Binding Constructs and Antibody Drug Conjugates (ADC)

In certain embodiments an antigen-binding construct is conjugated to adrug, e.g., a toxin, a chemotherapeutic agent, an immune modulator, or aradioisotope. Several methods of preparing ADCs (antibody drugconjugates or antigen-binding construct drug conjugates) are known inthe art and are described below.

In some embodiments, the drug is selected from a maytansine, auristatin,calicheamicin, or derivative thereof. In other embodiments, the drug isa maytansine selected from DM1 and DM4. Further examples are describedbelow.

In some embodiments the drug is conjugated to the isolatedantigen-binding construct with an SMCC linker (DM1), or an SPDB linker(DM4). Additional examples are described below. Thedrug-to-antigen-binding protein ratio (DAR) can be, e.g., 1.0 to 6.0 or3.0 to 5.0 or 3.5-4.2.

In some embodiments the antigen-binding construct is conjugated to acytotoxic agent. The term “cytotoxic agent” as used herein refers to asubstance that inhibits or prevents the function of cells and/or causesdestruction of cells. The term is intended to include radioactiveisotopes (e.g. At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32,and Lu177), chemotherapeutic agents, and toxins such as small moleculetoxins or enzymatically active toxins of bacterial, fungal, plant oranimal origin, including fragments and/or variants thereof. Furtherexamples are described below.

Drugs

Non-limiting examples of drugs or payloads used in various embodimentsof ADCs include DM1 (maytansine,N2′-deacetyl-N2′-(3-mercapto-1-oxopropyl)- orN2′-deacetyl-N2′-(3-mercapto-1-oxopropyl)-maytansine), mc-MMAD(6-maleimidocaproyl-monomethylauristatin-D orN-methyl-L-valyl-N-[(1S,2R)-2-methoxy-4-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(2-thiazolyl)ethyl]amino]propyl]-1-pyrrolidinyl]-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-(9Cl)-L-valinamide),mc-MMAF (maleimidocaproyl-monomethylauristatin F orN-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-N-methyl-L-valyl-L-valyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(αR,βR,2S)-β-methoxy-α-methyl-2-pyrrolidinepropanoyl-L-phenylalanine) andmc-Val-Cit-PABA-MMAE(6-maleimidocaproyl-ValcCit-(p-aminobenzyloxycarbonyl)-monomethylauristatinE orN-[[[4-[[N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide).DM1 is a derivative of the tubulin inhibitor maytansine while MMAD,MMAE, and MMAF are auristatin derivatives.

Maytansinoid Drug Moieties

As indicated above, in some embodiments the drug is a maytansinoid.Exemplary maytansinoids include DM1, DM3(N²′-deacetyl-N²′-(4-mercapto-1-oxopentyl) maytansine), and DM4(N²′-deacetyl-N²′-(4-methyl-4-mercapto-1-oxopentyl)methylmaytansine)(see US20090202536).

Many positions on maytansine compounds are known to be useful as thelinkage position, depending upon the type of link. For example, forforming an ester linkage, the C-3 position having a hydroxyl group, theC-14 position modified with hydroxymethyl, the C-15 position modifiedwith a hydroxyl group and the C-20 position having a hydroxyl group areall suitable.

All stereoisomers of the maytansinoid drug moiety are contemplated forthe ADCs described herein, i.e. any combination of R and Sconfigurations at the chiral carbons of D.

Auristatins

In some embodiments, the drug is an auristatin, such as auristatin E(also known in the art as a derivative of dolastatin-10) or a derivativethereof. The auristatin can be, for example, an ester formed betweenauristatin E and a keto acid. For example, auristatin E can be reactedwith paraacetyl benzoic acid or benzoylvaleric acid to produce AEB andAEVB, respectively. Other typical auristatins include AFP, MMAF, andMMAE. The synthesis and structure of exemplary auristatins are describedin U.S. Pat. Nos. 6,884,869, 7,098,308, 7,256,257, 7,423,116, 7,498,298and 7,745,394, each of which is incorporated by reference herein in itsentirety and for all purposes.

Chemotherapeutic Agents

In some embodiments the antigen-binding construct is conjugated to achemotherapeutic agent. Examples include but are not limited toCisplantin and Lapatinib. A “chemotherapeutic agent” is a chemicalcompound useful in the treatment of cancer.

Examples of chemotherapeutic agents include alkylating agents such asthiotepa and cyclosphosphamide (CYTOXAN™); alkyl sulfonates such asbusulfan, improsulfan and piposulfan; aziridines such as benzodopa,carboquone, meturedopa, and uredopa; ethylenimines and methylamelaminesincluding altretamine, triethylenemelamine, trietylenephosphoramide,triethylenethiophosphaoramide and trimethylolomelamine; nitrogenmustards such as chlorambucil, chlomaphazine, cholophosphamide,estramustine, ifosfamide, mechlorethamine, mechlorethamine oxidehydrochloride, melphalan, novembichin, phenesterine, prednimustine,trofosfamide, uracil mustard; nitrosureas such as carmustine,chlorozotocin, fotemustine, lomustine, nimustine, ranimustine;antibiotics such as aclacinomysins, actinomycin, authramycin, azaserine,bleomycins, cactinomycin, calicheamicin, carabicin, carminomycin,carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin,6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin,idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin,olivomycins, peplomycin, potfiromycin, puromycin, quelamycin,rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex,zinostatin, zorubicin; anti-metabolites such as methotrexate and5-fluorouracil (5-FU); folic acid analogues such as denopterin,methotrexate, pteropterin, trimetrexate; purine analogs such asfludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidineanalogs such as ancitabine, azacitidine, 6-azauridine, carmofur,cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine,5-FU; androgens such as calusterone, dromostanolone propionate,epitiostanol, mepitiostane, testolactone; anti-adrenals such asaminoglutethimide, mitotane, trilostane; folic acid replenisher such asfrolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinicacid; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine;demecolcine; diaziquone; elfornithine; elliptinium acetate; etoglucid;gallium nitrate; hydroxyurea; lentinan; lonidamine; mitoguazone;mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin;podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK7; razoxane;sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2′,2′=-trichlorotriethylamine; urethan; vindesine; dacarbazine;mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine;arabinoside (“Ara-C”); cyclophosphamide; thiotepa; taxanes, e.g.paclitaxel (TAXOL®, Bristol-Myers Squibb Oncology, Princeton, N.J.) anddoxetaxel (TAXOTERE®, Rhone-Poulenc Rorer, Antony, France);chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate;platinum analogs such as cisplatin and carboplatin; vinblastine;platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone;vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin;aminopterin; xeloda; ibandronate; CPT-11; topoisomerase inhibitor RFS2000; difluoromethylornithine (DMFO); retinoic acid; esperamicins;capecitabine; and pharmaceutically acceptable salts, acids orderivatives of any of the above. Also included in this definition areanti-hormonal agents that act to regulate or inhibit hormone action ontumors such as anti-estrogens including for example tamoxifen,raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen,trioxifene, keoxifene, LY117018, onapristone, and toremifene (Fareston);and anti-androgens such as flutamide, nilutamide, bicalutamide,leuprolide, and goserelin; and pharmaceutically acceptable salts, acidsor derivatives of any of the above.

Conjugate Linkers

In some embodiments, the drug is linked to the antigen-bindingconstruct, e.g., antibody, by a linker. Attachment of a linker to anantibody can be accomplished in a variety of ways, such as throughsurface lysines, reductive-coupling to oxidized carbohydrates, andthrough cysteine residues liberated by reducing interchain disulfidelinkages. A variety of ADC linkage systems are known in the art,including hydrazone-, disulfide- and peptide-based linkages.

Suitable linkers include, for example, cleavable and non-cleavablelinkers. A cleavable linker is typically susceptible to cleavage underintracellular conditions. Suitable cleavable linkers include, forexample, a peptide linker cleavable by an intracellular protease, suchas lysosomal protease or an endosomal protease. In exemplaryembodiments, the linker can be a dipeptide linker, such as avaline-citrulline (val-cit), a phenylalanine-lysine (phe-lys) linker, ormaleimidocapronic-valine-citruline-p-aminobenzyloxycarbonyl(mc-Val-Cit-PABA) linker. Another linker isSulfosuccinimidyl-4-[N-maleimidomethyl]cyclohexane-1-carboxylate (SMCC).Sulfo-smcc conjugation occurs via a maleimide group which reacts withsulfhydryls (thiols, —SH), while its Sulfo-NHS ester is reactive towardprimary amines (as found in Lysine and the protein or peptideN-terminus). Yet another linker is maleimidocaproyl (MC). Other suitablelinkers include linkers hydrolyzable at a specific pH or a pH range,such as a hydrazone linker. Additional suitable cleavable linkersinclude disulfide linkers. The linker may be covalently bound to theantibody to such an extent that the antibody must be degradedintracellularly in order for the drug to be released e.g. the MC linkerand the like.

Preparation of ADCs

The ADC may be prepared by several routes, employing organic chemistryreactions, conditions, and reagents known to those skilled in the art,including: (1) reaction of a nucleophilic group or an electrophilicgroup of an antibody with a bivalent linker reagent, to formantibody-linker intermediate Ab-L, via a covalent bond, followed byreaction with an activated drug moiety D; and (2) reaction of anucleophilic group or an electrophilic group of a drug moiety with alinker reagent, to form drug-linker intermediate D-L, via a covalentbond, followed by reaction with the nucleophilic group or anelectrophilic group of an antibody. Conjugation methods (1) and (2) maybe employed with a variety of antibodies, drug moieties, and linkers toprepare the antibody-drug conjugates described here.

Several specific examples of methods of preparing ADCs are known in theart and are described in U.S. Pat. No. 8,624,003 (pot method), U.S. Pat.No. 8,163,888 (one-step), and U.S. Pat. No. 5,208,020 (two-step method).

Methods of Preparation of Antigen-Binding Constructs

Antigen-binding constructs described herein may be produced usingrecombinant methods and compositions, e.g., as described in U.S. Pat.No. 4,816,567.

In one embodiment, isolated nucleic acid encoding an antigen-bindingconstruct described herein is provided. Such nucleic acid may encode anamino acid sequence comprising the VL and/or an amino acid sequencecomprising the VH of the antigen-binding construct (e.g., the lightand/or heavy chains of the antigen-binding construct). In a furtherembodiment, one or more vectors (e.g., expression vectors) comprisingsuch nucleic acid are provided. In one embodiment, the nucleic acid isprovided in a multicistronic vector. In a further embodiment, a hostcell comprising such nucleic acid is provided. In one such embodiment, ahost cell comprises (e.g., has been transformed with): (1) a vectorcomprising a nucleic acid that encodes an amino acid sequence comprisingthe VL of the antigen-binding construct and an amino acid sequencecomprising the VH of the antigen-binding polypeptide construct, or (2) afirst vector comprising a nucleic acid that encodes an amino acidsequence comprising the VL of the antigen-binding polypeptide constructand a second vector comprising a nucleic acid that encodes an amino acidsequence comprising the VH of the antigen-binding polypeptide construct.In one embodiment, the host cell is eukaryotic, e.g. a Chinese HamsterOvary (CHO) cell, or human embryonic kidney (HEK) cell, or lymphoid cell(e.g., Y0, NS0, Sp20 cell). In one embodiment, a method of making anantigen-binding construct is provided, wherein the method comprisesculturing a host cell comprising nucleic acid encoding theantigen-binding construct, as provided above, under conditions suitablefor expression of the antigen-binding construct, and optionallyrecovering the antigen-binding construct from the host cell (or hostcell culture medium).

For recombinant production of the antigen-binding construct, nucleicacid encoding an antigen-binding construct, e.g., as described above, isisolated and inserted into one or more vectors for further cloningand/or expression in a host cell. Such nucleic acid may be readilyisolated and sequenced using conventional procedures (e.g., by usingoligonucleotide probes that are capable of binding specifically to genesencoding the heavy and light chains of the antigen-binding construct).

The term “substantially purified” refers to a construct describedherein, or variant thereof that may be substantially or essentially freeof components that normally accompany or interact with the protein asfound in its naturally occurring environment, i.e. a native cell, orhost cell in the case of recombinantly produced heteromultimer that incertain embodiments, is substantially free of cellular material includespreparations of protein having less than about 30%, less than about 25%,less than about 20%, less than about 15%, less than about 10%, less thanabout 5%, less than about 4%, less than about 3%, less than about 2%, orless than about 1% (by dry weight) of contaminating protein. When theheteromultimer or variant thereof is recombinantly produced by the hostcells, the protein in certain embodiments is present at about 30%, about25%, about 20%, about 15%, about 10%, about 5%, about 4%, about 3%,about 2%, or about 1% or less of the dry weight of the cells. When theheteromultimer or variant thereof is recombinantly produced by the hostcells, the protein, in certain embodiments, is present in the culturemedium at about 5 g/L, about 4 g/L, about 3 g/L, about 2 g/L, about 1g/L, about 750 mg/L, about 500 mg/L, about 250 mg/L, about 100 mg/L,about 50 mg/L, about 10 mg/L, or about 1 mg/L or less of the dry weightof the cells. In certain embodiments, “substantially purified”heteromultimer produced by the methods described herein, has a puritylevel of at least about 30%, at least about 35%, at least about 40%, atleast about 45%, at least about 50%, at least about 55%, at least about60%, at least about 65%, at least about 70%, specifically, a puritylevel of at least about 75%, 80%, 85%, and more specifically, a puritylevel of at least about 90%, a purity level of at least about 95%, apurity level of at least about 99% or greater as determined byappropriate methods such as SDS/PAGE analysis, RP-HPLC, SEC, andcapillary electrophoresis.

Suitable host cells for cloning or expression of antigen-bindingconstruct-encoding vectors include prokaryotic or eukaryotic cellsdescribed herein.

A “recombinant host cell” or “host cell” refers to a cell that includesan exogenous polynucleotide, regardless of the method used forinsertion, for example, direct uptake, transduction, f-mating, or othermethods known in the art to create recombinant host cells. The exogenouspolynucleotide may be maintained as a nonintegrated vector, for example,a plasmid, or alternatively, may be integrated into the host genome.

As used herein, the term “eukaryote” refers to organisms belonging tothe phylogenetic domain Eucarya such as animals (including but notlimited to, mammals, insects, reptiles, birds, etc.), ciliates, plants(including but not limited to, monocots, dicots, algae, etc.), fungi,yeasts, flagellates, microsporidia, protists, etc.

As used herein, the term “prokaryote” refers to prokaryotic organisms.For example, a non-eukaryotic organism can belong to the Eubacteria(including but not limited to, Escherichia coli, Thermus thermophilus,Bacillus stearothermophilus, Pseudomonas fluorescens, Pseudomonasaeruginosa, Pseudomonas putida, etc.) phylogenetic domain, or theArchaea (including but not limited to, Methanococcus jannaschii,Methanobacterium thermoautotrophicum, Halobacterium such as Haloferaxvolcanii and Halobacterium species NRC-1, Archaeoglobus fulgidus,Pyrococcus furiosus, Pyrococcus horikoshii, Aeuropyrum pemix, etc.)phylogenetic domain.

For example, antigen-binding construct may be produced in bacteria, inparticular when glycosylation and Fc effector function are not needed.For expression of antigen-binding construct fragments and polypeptidesin bacteria, see, e.g., U.S. Pat. Nos. 5,648,237, 5,789,199, and5,840,523. (See also Charlton, Methods in Molecular Biology, Vol. 248(B.K.C. Lo, ed., Humana Press, Totowa, N.J., 2003), pp. 245-254,describing expression of antibody fragments in E. coli.) Afterexpression, the antigen-binding construct may be isolated from thebacterial cell paste in a soluble fraction and can be further purified.

In addition to prokaryotes, eukaryotic microbes such as filamentousfungi or yeast are suitable cloning or expression hosts forantigen-binding construct-encoding vectors, including fungi and yeaststrains whose glycosylation pathways have been “humanized,” resulting inthe production of an antigen-binding construct with a partially or fullyhuman glycosylation pattern. See Gerngross, Nat. Biotech. 22:1409-1414(2004), and Li et al., Nat. Biotech. 24:210-215 (2006).

Suitable host cells for the expression of glycosylated antigen-bindingconstructs are also derived from multicellular organisms (invertebratesand vertebrates). Examples of invertebrate cells include plant andinsect cells. Numerous baculoviral strains have been identified whichmay be used in conjunction with insect cells, particularly fortransfection of Spodoptera frugiperda cells.

Plant cell cultures can also be utilized as hosts. See, e.g., U.S. Pat.Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429(describing PLANTIBODIES™ technology for producing antigen-bindingconstructs in transgenic plants).

Vertebrate cells may also be used as hosts. For example, mammalian celllines that are adapted to grow in suspension may be useful. Otherexamples of useful mammalian host cell lines are monkey kidney CV1 linetransformed by SV40 (COS-7); human embryonic kidney line (293 or 293cells as described, e.g., in Graham et al., J Gen Virol. 36:59 (1977));baby hamster kidney cells (BHK); mouse sertoli cells (TM4 cells asdescribed, e.g., in Mather, Biol. Reprod. 23:243-251 (1980)); monkeykidney cells (CV1); African green monkey kidney cells (VERO-76); humancervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo ratliver cells (BRL 3A); human lung cells (W138); human liver cells (HepG2); mouse mammary tumor (MMT 060562); TRI cells, as described, e.g., inMather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982); MRC 5 cells; andFS4 cells. Other useful mammalian host cell lines include Chinesehamster ovary (CHO) cells, including DHFR CHO cells (Urlaub et al.,Proc. Natl. Acad. Sci. USA 77:4216 (1980)); and myeloma cell lines suchas Y0, NS0 and Sp2/0. For a review of certain mammalian host cell linessuitable for antigen-binding construct production, see, e.g., Yazaki andWu, Methods in Molecular Biology, Vol. 248 (B.K.C. Lo, ed., HumanaPress, Totowa, N.J.), pp. 255-268 (2003).

In one embodiment, the antigen-binding constructs described herein areproduced in stable mammalian cells, by a method comprising: transfectingat least one stable mammalian cell with: nucleic acid encoding theantigen-binding construct, in a predetermined ratio; and expressing thenucleic acid in the at least one mammalian cell. In some embodiments,the predetermined ratio of nucleic acid is determined in transienttransfection experiments to determine the relative ratio of inputnucleic acids that results in the highest percentage of theantigen-binding construct in the expressed product.

In some embodiments is the method of producing a antigen-bindingconstruct in stable mammalian cells as described herein wherein theexpression product of the at least one stable mammalian cell comprises alarger percentage of the desired glycosylated antigen-binding constructas compared to the monomeric heavy or light chain polypeptides, or otherantibodies.

In some embodiments is the method of producing a glycosylatedantigen-binding construct in stable mammalian cells described herein,said method comprising identifying and purifying the desiredglycosylated antigen-binding construct. In some embodiments, the saididentification is by one or both of liquid chromatography and massspectrometry.

If required, the antigen-binding constructs can be purified or isolatedafter expression. Proteins may be isolated or purified in a variety ofways known to those skilled in the art. Standard purification methodsinclude chromatographic techniques, including ion exchange, hydrophobicinteraction, affinity, sizing or gel filtration, and reversed-phase,carried out at atmospheric pressure or at high pressure using systemssuch as FPLC and HPLC. Purification methods also includeelectrophoretic, immunological, precipitation, dialysis, andchromatofocusing techniques. Ultrafiltration and diafiltrationtechniques, in conjunction with protein concentration, are also useful.As is well known in the art, a variety of natural proteins bind Fc andantibodies, and these proteins can find use in the present invention forpurification of antigen-binding constructs. For example, the bacterialproteins A and G bind to the Fc region. Likewise, the bacterial proteinL binds to the Fab region of some antibodies. Purification can often beenabled by a particular fusion partner. For example, antibodies may bepurified using glutathione resin if a GST fusion is employed, Ni⁺²affinity chromatography if a His-tag is employed, or immobilizedanti-flag antibody if a flag-tag is used. For general guidance insuitable purification techniques, see, e.g. incorporated entirely byreference Protein Purification: Principles and Practice, 3^(rd) Ed.,Scopes, Springer-Verlag, N.Y., 1994, incorporated entirely by reference.The degree of purification necessary will vary depending on the use ofthe antigen-binding constructs. In some instances no purification isnecessary.

In certain embodiments the antigen-binding constructs are purified usingAnion Exchange Chromatography including, but not limited to,chromatography on Q-sepharose, DEAE sepharose, poros HQ, poros DEAF,Toyopearl Q, Toyopearl QAE, Toyopearl DEAE, Resource/Source Q and DEAE,Fractogel Q and DEAE columns.

In specific embodiments the proteins described herein are purified usingCation Exchange Chromatography including, but not limited to,SP-sepharose, CM sepharose, poros HS, poros CM, Toyopearl SP, ToyopearlCM, Resource/Source S and CM, Fractogel S and CM columns and theirequivalents and comparables.

In addition, antigen-binding constructs described herein can bechemically synthesized using techniques known in the art (e.g., seeCreighton, 1983, Proteins: Structures and Molecular Principles, W. H.Freeman & Co., N.Y and Hunkapiller et al., Nature, 310:105-111 (1984)).For example, a polypeptide corresponding to a fragment of a polypeptidecan be synthesized by use of a peptide synthesizer. Furthermore, ifdesired, nonclassical amino acids or chemical amino acid analogs can beintroduced as a substitution or addition into the polypeptide sequence.Non-classical amino acids include, but are not limited to, to theD-isomers of the common amino acids, 2,4diaminobutyric acid, alpha-aminoisobutyric acid, 4aminobutyric acid, Abu, 2-amino butyric acid, g-Abu,e-Ahx, 6amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-aminopropionic acid, ornithine, norleucine, norvaline, hydroxyproline,sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine,t-butylalanine, phenylglycine, cyclohexylalanine, □-alanine,fluoro-amino acids, designer amino acids such as □-methyl amino acids,C□-methyl amino acids, N□-methyl amino acids, and amino acid analogs ingeneral. Furthermore, the amino acid can be D (dextrorotary) or L(levorotary).

Post-Translational Modifications:

In certain embodiments antigen-binding constructs described herein aredifferentially modified during or after translation.

The term “modified,” as used herein refers to any changes made to agiven polypeptide, such as changes to the length of the polypeptide, theamino acid sequence, chemical structure, co-translational modification,or post-translational modification of a polypeptide. The form“(modified)” term means that the polypeptides being discussed areoptionally modified, that is, the polypeptides under discussion can bemodified or unmodified.

The term “post-translationally modified” refers to any modification of anatural or non-natural amino acid that occurs to such an amino acidafter it has been incorporated into a polypeptide chain. The termencompasses, by way of example only, co-translational in vivomodifications, co-translational in vitro modifications (such as in acell-free translation system), post-translational in vivo modifications,and post-translational in vitro modifications.

In some embodiments, the modification is at least one of: glycosylation,acetylation, phosphorylation, amidation, derivatization by knownprotecting/blocking groups, proteolytic cleavage and linkage to anantibody molecule or antigen-binding construct or other cellular ligand.In some embodiments, the antigen-binding construct is chemicallymodified by known techniques, including but not limited, to specificchemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8protease, NaBH₄; acetylation, formylation, oxidation, reduction; andmetabolic synthesis in the presence of tunicamycin.

Additional post-translational modifications of antigen-bindingconstructs described herein include, for example, N-linked or O-linkedcarbohydrate chains, processing of N-terminal or C-terminal ends),attachment of chemical moieties to the amino acid backbone, chemicalmodifications of N-linked or O-linked carbohydrate chains, and additionor deletion of an N-terminal methionine residue as a result ofprocaryotic host cell expression. The antigen-binding constructsdescribed herein are modified with a detectable label, such as anenzymatic, fluorescent, isotopic or affinity label to allow fordetection and isolation of the protein. In certain embodiments, examplesof suitable enzyme labels include horseradish peroxidase, alkalinephosphatase, beta-galactosidase, or acetylcholinesterase; examples ofsuitable prosthetic group complexes include streptavidin biotin andavidin/biotin; examples of suitable fluorescent materials includeumbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine,dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; anexample of a luminescent material includes luminol; examples ofbioluminescent materials include luciferase, luciferin, and aequorin;and examples of suitable radioactive material include iodine, carbon,sulfur, tritium, indium, technetium, thallium, gallium, palladium,molybdenum, xenon, fluorine.

In specific embodiments, antigen-binding constructs described herein areattached to macrocyclic chelators that associate with radiometal ions.

In some embodiments, the antigen-binding constructs described herein aremodified by either natural processes, such as post-translationalprocessing, or by chemical modification techniques which are well knownin the art. In certain embodiments, the same type of modification may bepresent in the same or varying degrees at several sites in a givenpolypeptide. In certain embodiments, polypeptides from antigen-bindingconstructs described herein are branched, for example, as a result ofubiquitination, and in some embodiments are cyclic, with or withoutbranching. Cyclic, branched, and branched cyclic polypeptides are aresult from posttranslation natural processes or made by syntheticmethods. Modifications include acetylation, acylation, ADP-ribosylation,amidation, covalent attachment of flavin, covalent attachment of a hememoiety, covalent attachment of a nucleotide or nucleotide derivative,covalent attachment of a lipid or lipid derivative, covalent attachmentof phosphotidylinositol, cross-linking, cyclization, disulfide bondformation, demethylation, formation of covalent cross-links, formationof cysteine, formation of pyroglutamate, formylation,gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation,iodination, methylation, myristylation, oxidation, pegylation,proteolytic processing, phosphorylation, prenylation, racemization,selenoylation, sulfation, transfer-RNA mediated addition of amino acidsto proteins such as arginylation, and ubiquitination. (See, forinstance, PROTEINS—STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E.Creighton, W. H. Freeman and Company, New York (1993);POST-TRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson,Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth.Enzymol. 182:626-646 (1990); Rattan et al., Ann. N.Y. Acad. Sci.663:48-62 (1992)).

In certain embodiments, antigen-binding constructs described herein areattached to solid supports, which are particularly useful forimmunoassays or purification of polypeptides that are bound by, thatbind to, or associate with proteins described herein. Such solidsupports include, but are not limited to, glass, cellulose,polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

Pharmaceutical Compositions

Also provided herein are pharmaceutical compositions comprising anantigen-binding construct described herein. Pharmaceutical compositionscomprise the construct and a pharmaceutically acceptable carrier.

The term “pharmaceutically acceptable” means approved by a regulatoryagency of the Federal or a state government or listed in the U.S.Pharmacopeia or other generally recognized pharmacopeia for use inanimals, and more particularly in humans. The term “carrier” refers to adiluent, adjuvant, excipient, or vehicle with which the therapeutic isadministered. Such pharmaceutical carriers can be sterile liquids, suchas water and oils, including those of petroleum, animal, vegetable orsynthetic origin, such as peanut oil, soybean oil, mineral oil, sesameoil and the like. In some aspects, the carrier is a man-made carrier notfound in nature. Water can be used as a carrier when the pharmaceuticalcomposition is administered intravenously. Saline solutions and aqueousdextrose and glycerol solutions can also be employed as liquid carriers,particularly for injectable solutions. Suitable pharmaceuticalexcipients include starch, glucose, lactose, sucrose, gelatin, malt,rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate,talc, sodium chloride, dried skim milk, glycerol, propylene, glycol,water, ethanol and the like. The composition, if desired, can alsocontain minor amounts of wetting or emulsifying agents, or pH bufferingagents. These compositions can take the form of solutions, suspensions,emulsion, tablets, pills, capsules, powders, sustained-releaseformulations and the like. The composition can be formulated as asuppository, with traditional binders and carriers such astriglycerides. Oral formulation can include standard carriers such aspharmaceutical grades of mannitol, lactose, starch, magnesium stearate,sodium saccharine, cellulose, magnesium carbonate, etc. Examples ofsuitable pharmaceutical carriers are described in “Remington'sPharmaceutical Sciences” by E. W. Martin. Such compositions will containa therapeutically effective amount of the compound, preferably inpurified form, together with a suitable amount of carrier so as toprovide the form for proper administration to the patient. Theformulation should suit the mode of administration.

In certain embodiments, the composition comprising the construct isformulated in accordance with routine procedures as a pharmaceuticalcomposition adapted for intravenous administration to human beings.Typically, compositions for intravenous administration are solutions insterile isotonic aqueous buffer. Where necessary, the composition mayalso include a solubilizing agent and a local anesthetic such aslignocaine to ease pain at the site of the injection. Generally, theingredients are supplied either separately or mixed together in unitdosage form, for example, as a dry lyophilized powder or water freeconcentrate in a hermetically sealed container such as an ampoule orsachette indicating the quantity of active agent. Where the compositionis to be administered by infusion, it can be dispensed with an infusionbottle containing sterile pharmaceutical grade water or saline. Wherethe composition is administered by injection, an ampoule of sterilewater for injection or saline can be provided so that the ingredientsmay be mixed prior to administration.

In certain embodiments, the compositions described herein are formulatedas neutral or salt forms. Pharmaceutically acceptable salts includethose formed with anions such as those derived from hydrochloric,phosphoric, acetic, oxalic, tartaric acids, etc., and those formed withcations such as those derived from sodium, potassium, ammonium, calcium,ferric hydroxide isopropylamine, triethylamine, 2-ethylamino ethanol,histidine, procaine, etc.

Methods of Treatment

In certain embodiments, provided is a method of treating a disease ordisorder comprising administering to a subject in which such treatment,prevention or amelioration is desired, an antigen-binding constructdescribed herein, in an amount effective to treat, prevent or amelioratethe disease or disorder.

“Disorder” refers to any condition that would benefit from treatmentwith an antigen-binding construct or method described herein. Thisincludes chronic and acute disorders or diseases including thosepathological conditions which predispose the mammal to the disorder inquestion. In some embodiments, the disorder is cancer, as described inmore detail below.

The term “subject” refers to an animal, in some embodiments a mammal,which is the object of treatment, observation or experiment. An animalmay be a human, a non-human primate, a companion animal (e.g., dogs,cats, and the like), farm animal (e.g., cows, sheep, pigs, horses, andthe like) or a laboratory animal (e.g., rats, mice, guinea pigs, and thelike).

The term “mammal” as used herein includes but is not limited to humans,non-human primates, canines, felines, murines, bovines, equines, andporcines.

“Treatment” refers to clinical intervention in an attempt to alter thenatural course of the individual or cell being treated, and can beperformed either for prophylaxis or during the course of clinicalpathology. Desirable effects of treatment include preventing occurrenceor recurrence of disease, alleviation of symptoms, diminishing of anydirect or indirect pathological consequences of the disease, preventingmetastasis, decreasing the rate of disease progression, amelioration orpalliation of the disease state, and remission or improved prognosis. Insome embodiments, antigen-binding constructs described herein are usedto delay development of a disease or disorder. In one embodiment,antigen-binding constructs and methods described herein effect tumorregression. In one embodiment, antigen-binding constructs and methodsdescribed herein effect inhibition of tumor/cancer growth.

Desirable effects of treatment include, but are not limited to,preventing occurrence or recurrence of disease, alleviation of symptoms,diminishment of any direct or indirect pathological consequences of thedisease, preventing metastasis, decreasing the rate of diseaseprogression, amelioration or palliation of the disease state, improvedsurvival, and remission or improved prognosis. In some embodiments,antigen-binding constructs described herein are used to delaydevelopment of a disease or to slow the progression of a disease.

The term “effective amount” as used herein refers to that amount ofconstruct being administered, which will accomplish the goal of therecited method, e.g., relieve to some extent one or more of the symptomsof the disease, condition or disorder being treated. The amount of thecomposition described herein which will be effective in the treatment,inhibition and prevention of a disease or disorder associated withaberrant expression and/or activity of a therapeutic protein can bedetermined by standard clinical techniques. In addition, in vitro assaysmay optionally be employed to help identify optimal dosage ranges. Theprecise dose to be employed in the formulation will also depend on theroute of administration, and the seriousness of the disease or disorder,and should be decided according to the judgment of the practitioner andeach patient's circumstances. Effective doses are extrapolated fromdose-response curves derived from in vitro or animal model test systems.

The antigen-binding construct is administered to the subject. Variousdelivery systems are known and can be used to administer anantigen-binding construct formulation described herein, e.g.,encapsulation in liposomes, microparticles, microcapsules, recombinantcells capable of expressing the compound, receptor-mediated endocytosis(see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)),construction of a nucleic acid as part of a retroviral or other vector,etc. Methods of introduction include but are not limited to intradermal,intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal,epidural, and oral routes. The compounds or compositions may beadministered by any convenient route, for example by infusion or bolusinjection, by absorption through epithelial or mucocutaneous linings(e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may beadministered together with other biologically active agents.Administration can be systemic or local. In addition, in certainembodiments, it is desirable to introduce the antigen-binding constructcompositions described herein into the central nervous system by anysuitable route, including intraventricular and intrathecal injection;intraventricular injection may be facilitated by an intraventricularcatheter, for example, attached to a reservoir, such as an Ommayareservoir. Pulmonary administration can also be employed, e.g., by useof an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it is desirable to administer theantigen-binding constructs, or compositions described herein locally tothe area in need of treatment; this may be achieved by, for example, andnot by way of limitation, local infusion during surgery, topicalapplication, e.g., in conjunction with a wound dressing after surgery,by injection, by means of a catheter, by means of a suppository, or bymeans of an implant, said implant being of a porous, non-porous, orgelatinous material, including membranes, such as sialastic membranes,or fibers. Preferably, when administering a protein, including anantigen-binding construct, described herein, care must be taken to usematerials to which the protein does not absorb.

In another embodiment, the antigen-binding constructs or composition canbe delivered in a vesicle, in particular a liposome (see Langer, Science249:1527-1533 (1990); Treat et al., in Liposomes in the Therapy ofInfectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss,New York, pp. 353-365 (1989); Lopez-Berestein, ibid., pp. 317-327; seegenerally ibid.)

In yet another embodiment, the antigen-binding constructs or compositioncan be delivered in a controlled release system. In one embodiment, apump may be used (see Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng.14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N.Engl. J. Med. 321:574 (1989)). In another embodiment, polymericmaterials can be used (see Medical Applications of Controlled Release,Langer and Wise (eds.), CRC Pres., Boca Raton, Fla. (1974); ControlledDrug Bioavailability, Drug Product Design and Performance, Smolen andBall (eds.), Wiley, New York (1984); Ranger and Peppas, J., Macromol.Sci. Rev. Macromol. Chem. 23:61 (1983); see also Levy et al., Science228:190 (1985); During et al., Ann. Neurol. 25:351 (1989); Howard etal., J. Neurosurg. 71:105 (1989)). In yet another embodiment, acontrolled release system can be placed in proximity of the therapeutictarget, e.g., the brain, thus requiring only a fraction of the systemicdose (see, e.g., Goodson, in Medical Applications of Controlled Release,vol. 2, pp. 115-138 (1984)).

In a specific embodiment comprising a nucleic acid encodingantigen-binding constructs decribed herein, the nucleic acid can beadministered in vivo to promote expression of its encoded protein, byconstructing it as part of an appropriate nucleic acid expression vectorand administering it so that it becomes intracellular, e.g., by use of aretroviral vector (see U.S. Pat. No. 4,980,286), or by direct injection,or by use of microparticle bombardment (e.g., a gene gun; Biolistic,Dupont), or coating with lipids or cell-surface receptors ortransfecting agents, or by administering it in linkage to ahomeobox-like peptide which is known to enter the nucleus (see e.g.,Joliot et al., Proc. Natl. Acad. Sci. USA 88:1864-1868 (1991)), etc.Alternatively, a nucleic acid can be introduced intracellularly andincorporated within host cell DNA for expression, by homologousrecombination.

In certain embodiments an antigen-binding construct described herein isadministered as a combination with antigen-binding constructs withnon-overlapping binding target epitopes.

The amount of the antigen-binding construct which will be effective inthe treatment, inhibition and prevention of a disease or disorder can bedetermined by standard clinical techniques. In addition, in vitro assaysmay optionally be employed to help identify optimal dosage ranges. Theprecise dose to be employed in the formulation will also depend on theroute of administration, and the seriousness of the disease or disorder,and should be decided according to the judgment of the practitioner andeach patient's circumstances. Effective doses are extrapolated fromdose-response curves derived from in vitro or animal model test systems.

The antigen-binding constructs described herein may be administeredalone or in combination with other types of treatments (e.g., radiationtherapy, chemotherapy, hormonal therapy, immunotherapy and anti-tumoragents). Generally, administration of products of a species origin orspecies reactivity (in the case of antibodies) that is the same speciesas that of the patient is preferred. Thus, in an embodiment, humanantigen-binding constructs, fragments derivatives, analogs, or nucleicacids, are administered to a human patient for therapy or prophylaxis.

Methods of Treating Cancers

Described herein are methods of treating a HER2+ cancer or a tumor in asubject, and methods of inhibiting the growth of a HER2+ tumor cell orkilling a HER2+ tumor cell using the antigen-binding constructsdescribed herein.

By a HER2+ cancer is meant a cancer that expresses HER2 such that theantigen-binding constructs described herein are able to bind to thecancer. As is known in the art, HER2+ cancers express HER2 at varyinglevels. To determine ErbB, e.g. ErbB2 (HER2) expression in the cancer,various diagnostic/prognostic assays are available. In one embodiment,ErbB2 overexpression may be analyzed by IHC, e.g. using the HERCEPTEST®(Dako). Paraffin embedded tissue sections from a tumor biopsy may besubjected to the IHC assay and accorded a ErbB2 protein stainingintensity criteria as follows:

Score 0 no staining is observed or membrane staining is observed in lessthan 10% of tumor cells.

Score 1+ a faint/barely perceptible membrane staining is detected inmore than 10% of the tumor cells. The cells are only stained in part oftheir membrane.

Score 2+ a weak to moderate complete membrane staining is observed inmore than 10% of the tumor cells.

Score 3+ a moderate to strong complete membrane staining is observed inmore than 10% of the tumor cells.

Those tumors with 0 or 1+ scores for ErbB2 overexpression assessment maybe characterized as not overexpressing ErbB2, whereas those tumors with2+ or 3+ scores may be characterized as overexpressing ErbB2.

Alternatively, or additionally, fluorescence in situ hybridization(FISH) assays such as the INFORM™ (sold by Ventana, Ariz.) orPATHVISION™ (Vysis, Ill.) may be carried out on formalin-fixed,paraffin-embedded tumor tissue to determine the extent (if any) of ErbB2overexpression in the tumor. In comparison with IHC assay, the FISHassay, which measures HER2 gene amplification, seems to correlate betterwith response of patients to treatment with HERCEPTIN®, and is currentlyconsidered to be the preferred assay to identify patients likely tobenefit from HERCEPTIN® treatment.

Table D describes the expression level of HER2 on several representativebreast cancer and other cancer cell lines (Subik et al. (2010) BreastCancer: Basic Clinical Research: 4; 35-41; Prang et a. (2005) BritishJournal of Cancer Research: 92; 342-349). As shown in the table, MCF-7and MDA-MB-231 cells are considered to be low HER2 expressing cells;JIMT-1, and ZR-75-1 cells are considered to be medium HER2 expressingcells, and SKBR3 and BT-474 cells are considered to be high HER2expressing cells. SKOV3 (ovarian cancer) cells are considered to bemedium HER2 expressing cells.

Described herein are methods of treating a subject having a HER2+ canceror a tumor comprising providing to the subject an effective amount of apharmaceutical composition comprising an antigen-binding constructdescribed herein.

Also described herein is the use of an HER2 antigen-binding constructdescribed herein for the manufacture of a medicament for treating acancer or a tumor. Also described herein are HER2 antigen-bindingconstructs for use in the treatment of cancer or a tumor.

In some embodiments, the subject being treated has pancreatic cancer,head and neck cancer, gastric cancer, colorectal cancer, breast cancer,renal cancer, cervical cancer, ovarian cancer, brain cancer, endometrialcancer, bladder cancer, non-small cell lung cancer or anepidermal-derived cancer. In some embodiments, the tumor is metastatic.

In general, the tumor in the subject being treated expresses an averageof 10,000 or more copies of HER2 per tumor cell. In certain embodimentsthe tumor is HER2 0-1+, 1+, HER2 2+ or HER2 3+ as determined by IHC. Insome embodiments the tumor is HER2 2+ or lower, or HER2 1+ or lower. Insome embodiments, the tumor has an amplified HER2 gene. In someembodiments the HER2 gene is non-amplified.

In some embodiments, the tumor of the subject being treated with theantigen-binding constructs is a breast cancer. In some embodiments, thebreast cancer expresses HER2 at a 3+ level. In some embodiments thebreast cancer expresses HER2 at less than a 3+ level. In a specificembodiment, the breast cancer expresses HER2 at a 2+ level or lower. Ina specific embodiment, the breast cancer expresses HER2 at a 1+ level orlower. In some embodiments, the breast cancer expresses estrogenreceptors (ER+) and/or progesterone receptors (PR+). In someembodiments, the breast cancer is ER− and or PR−. In some embodimentsthe breast cancer has an amplified HER2 gene. In some embodiments theHER2 gene is non-amplified. In some embodiments, the breast cancer is aHER2 3+ estrogen receptor negative (ER−), progesterone receptor negative(PR−), trastuzumab resistant, chemotherapy resistant invasive ductalbreast cancer. In another embodiment, the breast cancer is a HER2 3+ER−,PR−, trastuzumab resistant inflammatory breast cancer. In anotherembodiment, the breast cancer is a HER2 3+, ER−, PR−, invasive ductalcarcinoma. In another embodiment, the breast cancer is a HER2 2+ HER2gene amplified trastuzumab and pertuzumab resistant breast cancer. Insome embodiments, the breast cancer is triple negative (ER−, PR− and lowHER2-expressing). In some embodiments the breast cancer is resistant orrefractory to trastuzumab, pertuzumab and/or trastuzumab conjugated toDM1 (ado-trastuzumab emtansine or T-DM1).

In one embodiment, the tumor is an HER2 2/3+ ovarian epithelialadenocarcinoma having an amplified HER2 gene.

Provided herein are methods for treating a subject having a HER2+ tumorthat is resistant or becomes resistant to other standard-of-caretherapies comprising administering to the subject a pharmaceuticalcomposition comprising the antigen-binding constructs described herein.In certain embodiments the antigen-binding constructs described hereinare provided to subjects that are unresponsive to current therapies,optionally in combination with one or more current anti-HER2 therapies.In some embodiments the current anti-HER2 therapies include, but are notlimited to, anti-HER2 or anti-HER3 monospecific bivalent antibodies,trastuzumab, pertuzumab, T-DM1, a bi-specific HER2/HER3 scFv, orcombinations thereof. In some embodiments, the cancer is resistant tovarious chemotherapeutic agents such as taxanes. In some embodiments thecancer is resistant to trastuzumab. In some embodiment the cancer isresistant to pertuzumab. In one embodiment, the cancer is resistant orrefractory to TDM1 (trastuzumab conjugated to DM1). In some embodiments,the subject has previously been treated with an anti-HER2 antibody suchas trastuzumab, pertuzumab or DM1. In some embodiments, the subject hasnot been previously treated with an anti-HER2 antibody. In oneembodiment, the antigen-binding construct is provided to a subject forthe treatment of metastatic cancer when the patient has progressed onprevious anti-HER2 therapy.

Provided herein are methods of treating a subject having a HER2+ tumorcomprising providing an effective amount of a pharmaceutical compositioncomprising an antigen-binding construct described herein in conjunctionwith an additional anti-tumor agent. The additional anti-tumor agent maybe a therapeutic antibody as noted above, or a chemotherapeutic agent.Chemotherapeutic agents useful for use in combination with theantigen-binding constructs of the invention include cisplatin,carboplatin, paclitaxel, albumin-bound paclitaxel, nab-paclitaxel,docetaxel, gemcitabine, vinorelbine, irinotecan, etoposide, vinblastine,pemetrexed, 5-fluorouracil (with or without folinic acid), capecitabine,carboplatin, epirubicin, oxaliplatin, folfirinox, abraxane, navelbineand cyclophosphamide, capecitabine, gemcitabine, navelbine, paclitaxel,nab-paclitaxel.

In some embodiments, the tumor is non-small cell lung cancer, and theadditional agent is one or more of cisplatin, carboplatin, paclitaxel,albumin-bound paclitaxel, nab-paclitaxel, capecitabine, navelbine,docetaxel, gemcitabine, vinorelbine, irinotecan, etoposide, vinblastineor pemetrexed. In embodiments, the tumor is gastric or stomach cancer,and the additional agent is one or more of 5-fluorouracil (with orwithout folinic acid), capecitabine, carboplatin, cisplatin, docetaxel,epirubicin, irinotecan, oxaliplatin, nab-paclitaxel or paclitaxel. Inother embodiments the tumor is pancreatic cancer, and the additionalagent is one or more of nab-paclitaxel, capecitabine, navelbine,gemcitabine, folfirinox, abraxane, or 5-fluorouracil. In otherembodiments the tumor is a estrogen and/or progesterone positive breastcancer, and the additional agent is one or more of paclitaxel,capecitabine, navelbine, gemcitabine, paclitaxel or nab-paclitaxel or acombination of (a) doxorubicin and epirubicin, (b) a combination ofpaclitaxel and docetaxel, or (c) a combination of 5-fluorouracil,cyclophosphamide and carboplatin. In other embodiments, the tumor ishead and neck cancer, and the additional agent is one or more ofpaclitaxel, capecitabine, navelbine, gemcitabine or nab-paclitaxelcarboplatin, doxorubicin or cisplatin. In other embodiments, the tumoris ovarian cancer and the additional agent may be one or more ofcapecitabine, navelbine, gemcitabine, nab-paclitaxel, cisplatin,carboplatin, or a taxane such as paclitaxel or docetaxel.

The additional agents may be administered to the subject being treatedconcurrently with the antigen-binding constructs or sequentially.

The subject being treated with the antigen-binding constructs may be ahuman, a non-human primate or other mammal such as a mouse.

In some embodiments, the result of providing an effective amount of theantigen-binding construct to a subject having a tumor is shrinking thetumor, inhibiting growth of the tumor, increasing time to progression ofthe tumor, prolonging disease-free survival of the subject, decreasingmetastases, increasing the progression-free survival of the subject, orincreasing overall survival of the subject or increasing the overallsurvival of a group of subjects receiving the treatment.

Also described herein are methods of killing or inhibiting the growth ofa HER2-expressing tumor cell comprising contacting the cell with theantigen-binding construct provided herein.

In various embodiments, a tumor cell may be a HER2 1+ or 2+ humanpancreatic carcinoma cell, a HER2 3+ human lung carcinoma cell, a HER22+ human Caucasian bronchioaveolar carcinoma cell, a human pharyngealcarcinoma cell, a HER2 2+ human tongue squamous cell carcinoma cell, aHER2 2+ squamous cell carcinoma cell of the pharynx, a HER2 1+ or 2+human colorectal carcinoma cell, a HER2 3+ human gastric carcinoma cell,a HER2 1+ human breast ductal ER+ (estrogen receptor-positive) carcinomacell, a HER2 2+/3+ human ER+, HER2-amplified breast carcinoma cell, aHER2 0+/1+ human triple negative breast carcinoma cell, a HER2 2+ humanendometrioid carcinoma cell, a HER2 1+ lung-metastatic malignantmelanoma cell, a HER2 1+ human cervix carcinoma cell, Her2 1+ humanrenal cell carcinoma cell, or a HER2 1+ human ovary carcinoma cell.

In embodiments in which the antigen-binding constructs are conjugated toDM1, the tumor cell may be a HER2 1+ or 2+ or 3+ human pancreaticcarcinoma cell, a HER2 2+ metastatic pancreatic carcinoma cell, a HER20+/1+, +3+ human lung carcinoma cell, a HER2 2+ human Caucasianbronchioaveolar carcinoma cell, a HER2 0+ anaplastic lung carcinoma, ahuman non-small cell lung carcinoma cell, a human pharyngeal carcinomacell, a HER2 2+ human tongue squamous cell carcinoma cell, a HER2 2+squamous cell carcinoma cell of the pharynx, a HER2 1+ or 2+ humancolorectal carcinoma cell, a HER2 0+, 1+ or 3+ human gastric carcinomacell, a HER2 1+ human breast ductal ER+ (estrogen receptor-positive)carcinoma cell, a HER2 2+/3+ human ER+, HER2-amplified breast carcinomacell, a HER2 0+/1+ human triple negative breast carcinoma cell, a HER20+ human breast ductal carcinoma (Basal B, Mesenchymal-like triplenegative) cell, a HER2 2+ER+ breast carcinoma, a HER2 0+ humanmetastatic breast carcinoma cell (ER−, HER2-amplified, luminal A, TN), ahuman uterus mesodermal tumor (mixed grade III) cell, a 2+ humanendometrioid carcinoma cell, a HER2 1+ human skin epidermoid carcinomacell, a HER2 1+ lung-metastatic malignant melanoma cell, a HER2 1+malignant melanoma cell, a human cervix epidermoid carcinoma vcell, aHER2 1+ human urinary bladder carcinoma cell, a HER2 1+ human cervixcarcinoma cell, Her2 1+ human renal cell carcinoma cell, or a HER2 1+,2+ or 3+ human ovary carcinoma cell.

In some embodiments the tumor cell may be one or more of the followingcell lines: pancreatic tumor cell lines BxPC3, Capan-1, MiaPaca2; lungtumor cell lines Calu-3, NCI-H322; head and neck tumor cells linesDetroit 562, SCC-25, FaDu; colorectal tumor cell lines HT29, SNU-C2B;gastric tumor cell line NCI-N87; breast tumor cell lines MCF-7,MDA-MB-175, MDA-MB-361, MDA-MB-231, BT-20, JIMT-1, SkBr3, BT-474;uterine tumor cell line TOV-112D; skin tumor cell line Malme-3M;cervical tumor cell lines Caski, MS751; bladder tumor cell line T24,ovarian tumor cell lines CaOV3, and SKOV3.

In some embodiments in which the antigen-binding constructs areconjugated to DM1, the tumor cell may be one or more of the followingcell lines: pancreatic tumor cell lines BxPC3, Capan-1, MiaPaca2, SW1990, Pancl; lung tumor cell lines A549, Calu-3, Calu-6, NCI-H2126,NCI-H322; head and neck tumor cells lines Detroit 562, SCC-15, SCC-25,FaDu; colorectal tumor cell lines Colo201, DLD-1, HCT116, HT29, SNU-C2B;gastric tumor cell lines SNU-1, SNU-16, NCI-N87; breast tumor cell linesSkBr3, MCF-7, MDA-MB-175, MDA-MB-361, MDA-MB-231, ZR-75-1, BT-20, BT549,BT-474, CAMA-1, MDA-MB-453, JIMT-1, T47D; Uterine tumor cell linesSK-UT-1, TOV-112D; skin tumor cell lines A431, Malme-3M, SKEMEL28;cervical tumor cell lines Caski, MS751; bladder tumor cell line T24,renal tumor cell line ACHN; ovarian tumor cell lines CaOV3, Ovar-3, andSKOV3.

Also described herein are methods of treating a subject having a HER2expressing (HER2+) tumor such as a HER2+ lung, head and neck, or breasttumor by administering an antigen binding construct disclosed herein. Insome aspects, the tumor volume in the subject after receiving at leastseven doses of the antigen binding construct is less than the tumorvolume of a control subject receiving an equivalent amount oftrastuzumab. In some aspects, the survival of the subject receiving theantigen binding construct is increased as compared to a control subjectreceiving an equivalent amount of a non-specific control antibody or ascompared to a control subject not receiving treatment.

In some aspects, the tumor is a lung tumor, optionally wherein the tumoris a non-squamous non-small cell lung tumor that is HER2-low, non-HER2gene amplified. In some aspects, the tumor is HER3+. In some aspects,the tumor is EGFR low. In some aspects, the tumor is moderatelysensitive to Cisplatin at the MTD.

In some aspects, the tumor is a head and neck tumor, optionally whereinthe tumor is a squamous cell tumor of the head and neck that is HER2low, non-HER2 gene amplified. In some aspects, the tumor is HER3+ low.In some aspects, the tumor is EGFR+. In some aspects, the tumor ishighly sensitive to Cisplatin at the MTD.

In some aspects, the tumor is a breast tumor, optionally wherein thetumor is a ER+/PR− breast cancer with a luminal B molecularclassification.

In some aspects, the subject is administered at least 2, 3, 4, 5, 6, 7,8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 doses. In someaspects, the amount of at least one of the plurality of doses is atleast 0.3, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,17, 18, 19, or 20 mg/kg. In some aspects, the amount of each of theplurality of doses is at least 0.3, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 mg/kg. In some aspects, eachdose is administered at least daily, weekly, or monthly. In someaspects, each dose is administered at least every 1, 2, 3, 4, 5, 6, 7,8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, or 31 days. In some aspects, treatment continues forat least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31 days; at least 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20weeks; or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,16, 17, 18, 19, or 20 months.

In some aspects, the mean tumor volume in the subject after receiving atleast 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 doses is lessthan the mean tumor volume of a control subject receiving an equivalentamount of trastuzumab.

In some aspects, overall survival of the subject is significantlyincreased as compared to a control subject receiving an equivalentamount of a non-specific control antibody or as compared to a controlsubject not receiving treatment. In some aspects, the significance ismeasured by a log rank test. In some aspects, the p value is less than0.5, 0.01, or 0.001.

In some aspects, overall survival of the subject is more significantlyincreased as compared to a control subject receiving an equivalentamount of trastuzumab. In some aspects, the antigen-binding construct pvalue is less than 0.001 and wherein the trastuzumab p value is greaterthan 0.001.

In some aspects, the p value of the significance of the increaserelative to the control subject receiving an equivalent amount of anon-specific control antibody is less than the p value of an increase insurvival of a second control receiving an equivalent amount oftrastuzumab as compared to the control subject receiving an equivalentamount of a non-specific control antibody. In some aspects, theantigen-binding construct p value is less than 0.001 and wherein thetrastuzumab p value is greater than 0.001.

In some aspects, overall survival of the subject after receiving acombination of the antigen-binding construct and an additional agent issignificantly increased as compared to a control subject receiving anequivalent amount of trastuzumab alone.

In some aspects, overall survival of the subject is significantlyincreased as compared to a control subject receiving a lesser amount oftrastuzumab.

Kits and Articles of Manufacture

Also described herein are kits comprising one or more antigen-bindingconstruct described herein. Individual components of the kit would bepackaged in separate containers and, associated with such containers,can be a notice in the form prescribed by a governmental agencyregulating the manufacture, use or sale of pharmaceuticals or biologicalproducts, which notice reflects approval by the agency of manufacture,use or sale. The kit may optionally contain instructions or directionsoutlining the method of use or administration regimen for theantigen-binding construct.

When one or more components of the kit are provided as solutions, forexample an aqueous solution, or a sterile aqueous solution, thecontainer means may itself be an inhalant, syringe, pipette, eyedropper, or other such like apparatus, from which the solution may beadministered to a subject or applied to and mixed with the othercomponents of the kit.

The components of the kit may also be provided in dried or lyophilizedform and the kit can additionally contain a suitable solvent forreconstitution of the lyophilized components. Irrespective of the numberor type of containers, the kits described herein also may comprise aninstrument for assisting with the administration of the composition to apatient. Such an instrument may be an inhalant, nasal spray device,syringe, pipette, forceps, measured spoon, eye dropper or similarmedically approved delivery vehicle.

In another aspect described herein, an article of manufacture containingmaterials useful for the treatment, prevention and/or diagnosis of thedisorders described above is provided. The article of manufacturecomprises a container and a label or package insert on or associatedwith the container. Suitable containers include, for example, bottles,vials, syringes, IV solution bags, etc. The containers may be formedfrom a variety of materials such as glass or plastic. The containerholds a composition which is by itself or combined with anothercomposition effective for treating, preventing and/or diagnosing thecondition and may have a sterile access port (for example the containermay be an intravenous solution bag or a vial having a stopper pierceableby a hypodermic injection needle). At least one active agent in thecomposition is a T cell activating antigen-binding construct describedherein. The label or package insert indicates that the composition isused for treating the condition of choice. Moreover, the article ofmanufacture may comprise (a) a first container with a compositioncontained therein, wherein the composition comprises an antigen-bindingconstruct described herein; and (b) a second container with acomposition contained therein, wherein the composition comprises afurther cytotoxic or otherwise therapeutic agent. The article ofmanufacture in this embodiment described herein may further comprise apackage insert indicating that the compositions can be used to treat aparticular condition. Alternatively, or additionally, the article ofmanufacture may further comprise a second (or third) containercomprising a pharmaceutically-acceptable buffer, such as bacteriostaticwater for injection (BWFI), phosphate-buffered saline, Ringer's solutionand dextrose solution. It may further include other materials desirablefrom a commercial and user standpoint, including other buffers,diluents, filters, needles, and syringes.

Polypeptides and Polynucleotides

The antigen-binding constructs described herein comprise at least onepolypeptide. Also described are polynucleotides encoding thepolypeptides described herein. The antigen-binding constructs aretypically isolated.

As used herein, “isolated” means an agent (e.g., a polypeptide orpolynucleotide) that has been identified and separated and/or recoveredfrom a component of its natural cell culture environment. Contaminantcomponents of its natural environment are materials that would interferewith diagnostic or therapeutic uses for the antigen-binding construct,and may include enzymes, hormones, and other proteinaceous ornon-proteinaceous solutes. Isolated also refers to an agent that hasbeen synthetically produced, e.g., via human intervention.

The terms “polypeptide,” “peptide” and “protein” are usedinterchangeably herein to refer to a polymer of amino acid residues.That is, a description directed to a polypeptide applies equally to adescription of a peptide and a description of a protein, and vice versa.The terms apply to naturally occurring amino acid polymers as well asamino acid polymers in which one or more amino acid residues is anon-naturally encoded amino acid. As used herein, the terms encompassamino acid chains of any length, including full length proteins, whereinthe amino acid residues are linked by covalent peptide bonds.

The term “amino acid” refers to naturally occurring and non-naturallyoccurring amino acids, as well as amino acid analogs and amino acidmimetics that function in a manner similar to the naturally occurringamino acids. Naturally encoded amino acids are the 20 common amino acids(alanine, arginine, asparagine, aspartic acid, cysteine, glutamine,glutamic acid, glycine, histidine, isoleucine, leucine, lysine,methionine, phenylalanine, praline, serine, threonine, tryptophan,tyrosine, and valine) and pyrrolysine and selenocysteine. Amino acidanalogs refers to compounds that have the same basic chemical structureas a naturally occurring amino acid, i.e., an a carbon that is bound toa hydrogen, a carboxyl group, an amino group, and an R group, such as,homoserine, norleucine, methionine sulfoxide, methionine methylsulfonium. Such analogs have modified R groups (such as, norleucine) ormodified peptide backbones, but retain the same basic chemical structureas a naturally occurring amino acid. Reference to an amino acidincludes, for example, naturally occurring proteogenic L-amino acids;D-amino acids, chemically modified amino acids such as amino acidvariants and derivatives; naturally occurring non-proteogenic aminoacids such as β-alanine, ornithine, etc.; and chemically synthesizedcompounds having properties known in the art to be characteristic ofamino acids. Examples of non-naturally occurring amino acids include,but are not limited to, a-methyl amino acids (e.g. a-methyl alanine),D-amino acids, histidine-like amino acids (e.g., 2-amino-histidine,β-hydroxy-histidine, homohistidine), amino acids having an extramethylene in the side chain (“homo” amino acids), and amino acids inwhich a carboxylic acid functional group in the side chain is replacedwith a sulfonic acid group (e.g., cysteic acid). The incorporation ofnon-natural amino acids, including synthetic non-native amino acids,substituted amino acids, or one or more D-amino acids into the proteinsof the present invention may be advantageous in a number of differentways. D-amino acid-containing peptides, etc., exhibit increasedstability in vitro or in vivo compared to L-amino acid-containingcounterparts. Thus, the construction of peptides, etc., incorporatingD-amino acids can be particularly useful when greater intracellularstability is desired or required. More specifically, D-peptides, etc.,are resistant to endogenous peptidases and proteases, thereby providingimproved bioavailability of the molecule, and prolonged lifetimes invivo when such properties are desirable. Additionally, D-peptides, etc.,cannot be processed efficiently for major histocompatibility complexclass II-restricted presentation to T helper cells, and are therefore,less likely to induce humoral immune responses in the whole organism.

Amino acids may be referred to herein by either their commonly knownthree letter symbols or by the one-letter symbols recommended by theIUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise,may be referred to by their commonly accepted single-letter codes.

Also included in the invention are polynucleotides encoding polypeptidesof the antigen-binding constructs. The term “polynucleotide” or“nucleotide sequence” is intended to indicate a consecutive stretch oftwo or more nucleotide molecules. The nucleotide sequence may be ofgenomic, cDNA, RNA, semisynthetic or synthetic origin, or anycombination thereof.

The term “nucleic acid” refers to deoxyribonucleotides,deoxyribonucleosides, ribonucleosides, or ribonucleotides and polymersthereof in either single- or double-stranded form. Unless specificallylimited, the term encompasses nucleic acids containing known analoguesof natural nucleotides which have similar binding properties as thereference nucleic acid and are metabolized in a manner similar tonaturally occurring nucleotides. Unless specifically limited otherwise,the term also refers to oligonucleotide analogs including PNA(peptidonucleic acid), analogs of DNA used in antisense technology(phosphorothioates, phosphoroamidates, and the like). Unless otherwiseindicated, a particular nucleic acid sequence also implicitlyencompasses conservatively modified variants thereof (including but notlimited to, degenerate codon substitutions) and complementary sequencesas well as the sequence explicitly indicated. Specifically, degeneratecodon substitutions may be achieved by generating sequences in which thethird position of one or more selected (or all) codons is substitutedwith mixed-base and/or deoxyinosine residues (Batzer et al., NucleicAcid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608(1985); Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).

“Conservatively modified variants” applies to both amino acid andnucleic acid sequences. With respect to particular nucleic acidsequences, “conservatively modified variants” refers to those nucleicacids which encode identical or essentially identical amino acidsequences, or where the nucleic acid does not encode an amino acidsequence, to essentially identical sequences. Because of the degeneracyof the genetic code, a large number of functionally identical nucleicacids encode any given protein. For instance, the codons GCA, GCC, GCGand GCU all encode the amino acid alanine. Thus, at every position wherean alanine is specified by a codon, the codon can be altered to any ofthe corresponding codons described without altering the encodedpolypeptide. Such nucleic acid variations are “silent variations,” whichare one species of conservatively modified variations. Every nucleicacid sequence herein which encodes a polypeptide also describes everypossible silent variation of the nucleic acid. One of ordinary skill inthe art will recognize that each codon in a nucleic acid (except AUG,which is ordinarily the only codon for methionine, and TGG, which isordinarily the only codon for tryptophan) can be modified to yield afunctionally identical molecule. Accordingly, each silent variation of anucleic acid which encodes a polypeptide is implicit in each describedsequence.

As to amino acid sequences, one of ordinary skill in the art willrecognize that individual substitutions, deletions or additions to anucleic acid, peptide, polypeptide, or protein sequence which alters,adds or deletes a single amino acid or a small percentage of amino acidsin the encoded sequence is a “conservatively modified variant” where thealteration results in the deletion of an amino acid, addition of anamino acid, or substitution of an amino acid with a chemically similaramino acid. Conservative substitution tables providing functionallysimilar amino acids are known to those of ordinary skill in the art.Such conservatively modified variants are in addition to and do notexclude polymorphic variants, interspecies homologs, and allelesdescribed herein.

Conservative substitution tables providing functionally similar aminoacids are known to those of ordinary skill in the art. The followingeight groups each contain amino acids that are conservativesubstitutions for one another: 1) Alanine (A), Glycine (G); 2) Asparticacid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4)Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine(M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7)Serine (S), Threonine (T); and [0139] 8) Cysteine (C), Methionine (M)(see, e.g., Creighton, Proteins: Structures and Molecular Properties (WH Freeman & Co.; 2nd edition (December 1993)

The terms “identical” or percent “identity,” in the context of two ormore nucleic acids or polypeptide sequences, refer to two or moresequences or subsequences that are the same. Sequences are“substantially identical” if they have a percentage of amino acidresidues or nucleotides that are the same (i.e., about 60% identity,about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, orabout 95% identity over a specified region), when compared and alignedfor maximum correspondence over a comparison window, or designatedregion as measured using one of the following sequence comparisonalgorithms (or other algorithms available to persons of ordinary skillin the art) or by manual alignment and visual inspection. Thisdefinition also refers to the complement of a test sequence. Theidentity can exist over a region that is at least about 50 amino acidsor nucleotides in length, or over a region that is 75-100 amino acids ornucleotides in length, or, where not specified, across the entiresequence of a polynucleotide or polypeptide. A polynucleotide encoding apolypeptide of the present invention, including homologs from speciesother than human, may be obtained by a process comprising the steps ofscreening a library under stringent hybridization conditions with alabeled probe having a polynucleotide sequence described herein or afragment thereof, and isolating full-length cDNA and genomic clonescontaining said polynucleotide sequence. Such hybridization techniquesare well known to the skilled artisan.

For sequence comparison, typically one sequence acts as a referencesequence, to which test sequences are compared. When using a sequencecomparison algorithm, test and reference sequences are entered into acomputer, subsequence coordinates are designated, if necessary, andsequence algorithm program parameters are designated. Default programparameters can be used, or alternative parameters can be designated. Thesequence comparison algorithm then calculates the percent sequenceidentities for the test sequences relative to the reference sequence,based on the program parameters.

A “comparison window”, as used herein, includes reference to a segmentof any one of the number of contiguous positions selected from the groupconsisting of from 20 to 600, usually about 50 to about 200, moreusually about 100 to about 150 in which a sequence may be compared to areference sequence of the same number of contiguous positions after thetwo sequences are optimally aligned. Methods of alignment of sequencesfor comparison are known to those of ordinary skill in the art. Optimalalignment of sequences for comparison can be conducted, including butnot limited to, by the local homology algorithm of Smith and Waterman(1970) Adv. Appl. Math. 2:482c, by the homology alignment algorithm ofNeedleman and Wunsch (1970) J. Mol. Biol. 48:443, by the search forsimilarity method of Pearson and Lipman (1988) Proc. Nat'l. Acad. Sci.USA 85:2444, by computerized implementations of these algorithms (GAP,BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package,Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by manualalignment and visual inspection (see, e.g., Ausubel et al., CurrentProtocols in Molecular Biology (1995 supplement)).

One example of an algorithm that is suitable for determining percentsequence identity and sequence similarity are the BLAST and BLAST 2.0algorithms, which are described in Altschul et al. (1997) Nuc. AcidsRes. 25:3389-3402, and Altschul et al. (1990) J. Mol. Biol. 215:403-410,respectively. Software for performing BLAST analyses is publiclyavailable through the National Center for Biotechnology Informationavailable at the World Wide Web at ncbi.nlm.nih.gov. The BLAST algorithmparameters W, T, and X determine the sensitivity and speed of thealignment. The BLASTN program (for nucleotide sequences) uses asdefaults a wordlength (W) of 11, an expectation (E) or 10, M=5, N=−4 anda comparison of both strands. For amino acid sequences, the BLASTPprogram uses as defaults a wordlength of 3, and expectation (E) of 10,and the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1992) Proc.Natl. Acad. Sci. USA 89:10915) alignments (B) of 50, expectation (E) of10, M=5, N=−4, and a comparison of both strands. The BLAST algorithm istypically performed with the “low complexity” filter turned off

The BLAST algorithm also performs a statistical analysis of thesimilarity between two sequences (see, e.g., Karlin and Altschul (1993)Proc. Natl. Acad. Sci. USA 90:5873-5787). One measure of similarityprovided by the BLAST algorithm is the smallest sum probability (P(N)),which provides an indication of the probability by which a match betweentwo nucleotide or amino acid sequences would occur by chance. Forexample, a nucleic acid is considered similar to a reference sequence ifthe smallest sum probability in a comparison of the test nucleic acid tothe reference nucleic acid is less than about 0.2, or less than about0.01, or less than about 0.001.

The phrase “selectively (or specifically) hybridizes to” refers to thebinding, duplexing, or hybridizing of a molecule only to a particularnucleotide sequence under stringent hybridization conditions when thatsequence is present in a complex mixture (including but not limited to,total cellular or library DNA or RNA).

The phrase “stringent hybridization conditions” refers to hybridizationof sequences of DNA, RNA, or other nucleic acids, or combinationsthereof under conditions of low ionic strength and high temperature asis known in the art. Typically, under stringent conditions a probe willhybridize to its target subsequence in a complex mixture of nucleic acid(including but not limited to, total cellular or library DNA or RNA) butdoes not hybridize to other sequences in the complex mixture. Stringentconditions are sequence-dependent and will be different in differentcircumstances. Longer sequences hybridize specifically at highertemperatures. An extensive guide to the hybridization of nucleic acidsis found in Tijssen, Laboratory Techniques in Biochemistry and MolecularBiology—Hybridization with Nucleic Probes, “Overview of principles ofhybridization and the strategy of nucleic acid assays” (1993).

As used herein, the terms “engineer, engineered, engineering”, areconsidered to include any manipulation of the peptide backbone or thepost-translational modifications of a naturally occurring or recombinantpolypeptide or fragment thereof. Engineering includes modifications ofthe amino acid sequence, of the glycosylation pattern, or of the sidechain group of individual amino acids, as well as combinations of theseapproaches. The engineered proteins are expressed and produced bystandard molecular biology techniques.

By “isolated nucleic acid molecule or polynucleotide” is intended anucleic acid molecule, DNA or RNA, which has been removed from itsnative environment. For example, a recombinant polynucleotide encoding apolypeptide contained in a vector is considered isolated. Furtherexamples of an isolated polynucleotide include recombinantpolynucleotides maintained in heterologous host cells or purified(partially or substantially) polynucleotides in solution. An isolatedpolynucleotide includes a polynucleotide molecule contained in cellsthat ordinarily contain the polynucleotide molecule, but thepolynucleotide molecule is present extrachromosomally or at achromosomal location that is different from its natural chromosomallocation. Isolated RNA molecules include in vivo or in vitro RNAtranscripts, as well as positive and negative strand forms, anddouble-stranded forms. Isolated polynucleotides or nucleic acidsdescribed herein, further include such molecules produced synthetically,e.g., via PCR or chemical synthesis. In addition, a polynucleotide or anucleic acid, in certain embodiments, include a regulatory element suchas a promoter, ribosome binding site, or a transcription terminator.

The term “polymerase chain reaction” or “PCR” generally refers to amethod for amplification of a desired nucleotide sequence in vitro, asdescribed, for example, in U.S. Pat. No. 4,683,195. In general, the PCRmethod involves repeated cycles of primer extension synthesis, usingoligonucleotide primers capable of hybridising preferentially to atemplate nucleic acid.

By a nucleic acid or polynucleotide having a nucleotide sequence atleast, for example, 95% “identical” to a reference nucleotide sequenceof the present invention, it is intended that the nucleotide sequence ofthe polynucleotide is identical to the reference sequence except thatthe polynucleotide sequence may include up to five point mutations pereach 100 nucleotides of the reference nucleotide sequence. In otherwords, to obtain a polynucleotide having a nucleotide sequence at least95% identical to a reference nucleotide sequence, up to 5% of thenucleotides in the reference sequence may be deleted or substituted withanother nucleotide, or a number of nucleotides up to 5% of the totalnucleotides in the reference sequence may be inserted into the referencesequence. These alterations of the reference sequence may occur at the5′ or 3′ terminal positions of the reference nucleotide sequence oranywhere between those terminal positions, interspersed eitherindividually among residues in the reference sequence or in one or morecontiguous groups within the reference sequence. As a practical matter,whether any particular polynucleotide sequence is at least 80%, 85%,90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of thepresent invention can be determined conventionally using known computerprograms, such as the ones discussed above for polypeptides (e.g.ALIGN-2).

A derivative, or a variant of a polypeptide is said to share “homology”or be “homologous” with the peptide if the amino acid sequences of thederivative or variant has at least 50% identity with a 100 amino acidsequence from the original peptide. In certain embodiments, thederivative or variant is at least 75% the same as that of either thepeptide or a fragment of the peptide having the same number of aminoacid residues as the derivative. In certain embodiments, the derivativeor variant is at least 85% the same as that of either the peptide or afragment of the peptide having the same number of amino acid residues asthe derivative. In certain embodiments, the amino acid sequence of thederivative is at least 90% the same as the peptide or a fragment of thepeptide having the same number of amino acid residues as the derivative.In some embodiments, the amino acid sequence of the derivative is atleast 95% the same as the peptide or a fragment of the peptide havingthe same number of amino acid residues as the derivative. In certainembodiments, the derivative or variant is at least 99% the same as thatof either the peptide or a fragment of the peptide having the samenumber of amino acid residues as the derivative.

The term “modified,” as used herein refers to any changes made to agiven polypeptide, such as changes to the length of the polypeptide, theamino acid sequence, chemical structure, co-translational modification,or post-translational modification of a polypeptide. The form“(modified)” term means that the polypeptides being discussed areoptionally modified, that is, the polypeptides under discussion can bemodified or unmodified.

In some aspects, an antigen-binding construct comprises an amino acidsequence that is at least 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98,99, or 100% identical to a relevant amino acid sequence or fragmentthereof set forth in the Table(s) or accession number(s) disclosedherein. In some aspects, an isolated antigen-binding construct comprisesan amino acid sequence encoded by a polynucleotide that is at least 80,85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identical to arelevant nucleotide sequence or fragment thereof set forth in Table(s)or accession number(s) disclosed herein.

It is to be understood that this invention is not limited to theparticular protocols; cell lines, constructs, and reagents describedherein and as such may vary. It is also to be understood that theterminology used herein is for the purpose of describing particularembodiments only, and is not intended to limit the scope of the presentinvention

All publications and patents mentioned herein are incorporated herein byreference for the purpose of describing and disclosing, for example, theconstructs and methodologies that are described in the publications,which might be used in connection with the presently describedinvention. The publications discussed herein are provided solely fortheir disclosure prior to the filing date of the present application.Nothing herein is to be construed as an admission that the inventors arenot entitled to antedate such disclosure by virtue of prior invention orfor any other reason.

EXAMPLES

Below are examples of specific embodiments for carrying out the presentinvention. The examples are offered for illustrative purposes only, andare not intended to limit the scope of the present invention in any way.Efforts have been made to ensure accuracy with respect to numbers used(e.g., amounts, temperatures, etc.), but some experimental error anddeviation should, of course, be allowed for.

The practice of the present invention will employ, unless otherwiseindicated, conventional methods of protein chemistry, biochemistry,recombinant DNA techniques and pharmacology, within the skill of theart. Such techniques are explained fully in the literature. See, e.g.,T. E. Creighton, Proteins: Structures and Molecular Properties (W.H.Freeman and Company, 1993); A. L. Lehninger, Biochemistry (WorthPublishers, Inc., current addition); Sambrook, et al., MolecularCloning: A Laboratory Manual (2nd Edition, 1989); Methods In Enzymology(S. Colowick and N. Kaplan eds., Academic Press, Inc.); Remington'sPharmaceutical Sciences, 18th Edition (Easton, Pa.: Mack PublishingCompany, 1990); Carey and Sundberg Advanced Organic Chemistry 3^(rd) Ed.(Plenum Press) Vols A and B (1992).

Example 1: Preparation of Exemplary Anti-HER2 Bispecific Antibodies andControls

A number of exemplary anti-HER2 biparatopic antibodies (orantigen-binding constructs) and controls were prepared as describedbelow. The antibodies and controls have been prepared in differentformats, and representations of exemplary biparatopic formats are shownin FIG. 1. In all of the formats shown in FIG. 1, the heterodimeric Fcis depicted with one chain (Chain A) shown in black and the other (ChainB) shown in grey, while one antigen-binding domain (1) is shown inhatched fill, while the other antigen-binding domain (2) is shown inwhite.

FIG. 1A depicts the structure of a biparatopic antibody in a Fab-Fabformat. FIGS. 1B to 1E depict the structure of possible versions of abiparatopic antibody in an scFv-Fab format. In FIG. 1B, antigen-bindingdomain 1 is an scFv, fused to Chain A, while antigen-binding domain 2 isa Fab, fused to Chain B. In FIG. 1C, antigen-binding domain 1 is a Fab,fused to Chain A, while antigen-binding domain 2 is an scFv, fused toChain B. In FIG. 1D, antigen-binding domain 2 is a Fab, fused to ChainA, while antigen-binding domain 1 is an scFv, fused to Chain B. In FIG.1E, antigen-binding domain 2 is an scFv, fused to Chain A, whileantigen-binding domain 1 is a Fab, fused to Chain B. In FIG. 1F, bothantigen-binding domains are scFvs.

The sequences of the following variants are provided in the SequenceTable found after the Examples. CDR regions were identified using acombination of the Kabat and Chothia methods. Regions may vary slightlybased on method used for identification.

Exemplary Anti-HER2 Biparatopic Antibodies

Exemplary anti-HER2 biparatopic antibodies were prepared as shown inTable 1.

TABLE 1 Exemplary anti-HER2 biparatbopic antibodies Variant Chain AChain B 5019 domain ECD2 ECD4 containing the epitope Format Fab scFvAntibody Pertuzumab Trastuzumab name CH3 T350V_L351Y_F405A_Y407VT366I_N390R_K392M_T394W sequence substitutions 5020 domain ECD4 ECD2containing the epitope format scFv Fab Antibody Trastuzumab Pertuzumabname CH3 L351Y_S400E_F405A_Y407V T350V_T366L_K392L_T394W sequencesubstitutions 7091 domain ECD2 ECD4 containing the epitope format FabscFv Antibody Pertuzumab Trastuzumab name CH3 T350V_L351Y_F405A_Y407VT350V_T366L_K392L_T394W sequence substitutions 10000 domain ECD2 ECD4containing the epitope format Fab scFv Antibody Pertuzumab - with Y96Ain VL Trastuzumab name region and T30A/A49G/L69F in VH region CH3T350V_L351Y_F405A_Y407V T350V_T366L_K392L_T394W sequence substitutions6902 domain ECD2 ECD4 containing the epitope format Fab Fab AntibodyTrastuzumab Pertuzumab name Fab HC: L143E_K145T HC: D146G_Q179Ksubstitutions LC: Q124R LC: Q124E_Q160E_T180E CH3T350V_L351Y_F405A_Y407V T350V_T366L_K392L_T394W sequence substitutions6903 domain ECD2 ECD4 containing the epitope format Fab Fab Fab HC:L143E_K145T HC: D146G_Q179K substitutions LC: Q124R_Q1160K_T178R LC:Q124E_Q160E_T180E Antibody Trastuzumab Pertuzumab name CH3T350V_L351Y_F405A_Y407V T350V_T366L_K392L_T394W sequence substitutions6717 domain ECD4 ECD2 containing the epitope format scFv scFv AntibodyPertuzumab Trastuzumab name CH3 T350V_L351Y_F405A_Y407VT366I_N390R_K392M_T394W sequence substitutions Notes: CH3 numberingaccording to EU index as in Kabat referring to the numbering of the EUantibody (Edelman et al., 1969, Proc Natl Acad Sci USA 63: 78-85); Fabor variable domain numbering according to Kabat (Kabat and Wu, 1991;Kabat et al, Sequences of proteins of immunological interest. 5thEdition - US Department of Health and Human Services, NIH publication no91-3242, p 647 (1991)) “domain containing the epitope” = domain of HER2to which antigen-binding moiety binds; “Antibody name” = antibody fromwhich antigen-binding moiety is derived, includes substitutions comparedto wild-type when present; “Fab substitutions” = substitutions in Fabthat promote correct light chain pairing; “CH3 sequence substitutions” =substitutions in CH3 domain that promote formation of heterodimeric Fc

Exemplary Anti-HER2 Monovalent Control Antibodies

v1040: a monovalent anti-HER2 antibody, where the HER2 binding domain isa Fab derived from trastuzumab on chain A, and the Fc region is aheterodimer having the mutations T350V_L351Y_F405A_Y407V in Chain A,T350V_T366L_K392L_T394W in Chain B, and the hinge region of Chain Bhaving the mutation C226S; the antigen-binding domain binds to domain 4of HER2.

v630—a monovalent anti-HER2 antibody, where the HER2 binding domain isan scFv derived from trastuzumab on Chain A, and the Fc region is aheterodimer having the mutations L351Y_S400E_F405A_Y407V in Chain A,T366I_N390R_K392M_T394W in Chain B; and the hinge region having themutation C226S (EU numbering) in both chains; the antigen-binding domainbinds to domain 4 of HER2.

v4182: a monovalent anti-HER2 antibody, where the HER2 binding domain isa Fab derived from pertuzumab on chain A, and the Fc region is aheterodimer having the mutations T350V_L351Y_F405A_Y407V in Chain A,T350V_T366L_K392L_T394W in Chain B, and the hinge region of Chain Bhaving the mutation C226S; the antigen-binding domain binds to domain 2of HER2.

Exemplary Anti-HER2 Monospecific Bivalent Antibody Controls (Full-SizedAntibodies, FSAs)

v506 is a wild-type anti HER2 produced in-house in Chinese Hamster Ovary(CHO) cells, as a control. Both HER2 binding domains are derived fromtrastuzumab in the Fab format and the Fc is a wild type homodimer; theantigen-binding domain binds to domain 4 of HER2. This antibody is alsoreferred to as a trastuzumab analog.

v792, is wild-type trastuzumab with a IgG1 hinge, where both HER2binding domains are derived from trastuzumab in the Fab format, and theand the Fc region is a heterodimer having the mutationsT350V_L351Y_F405A_Y407V in Chain A, and T350V_T366L_K392L_T394W Chain B;the antigen-binding domain binds to domain 4 of HER2. This antibody isalso referred to as a trastuzumab analog.

v4184, a bivalent anti-HER2 antibody, where both HER2 binding domainsare derived from pertuzumab in the Fab format, and the Fc region is aheterodimer having the mutations T350V_L351Y_F405A_Y407V in Chain A, andT350V_T366L_K392L_T394W Chain B. The antigen-binding domain binds todomain 2 of HER2. This antibody is also referred to as a pertuzumabanalog.

hIgG, is a commercial non-specific polyclonal antibody control (JacksonImmunoResearch, #009-000-003).

These antibodies and controls (other than human IgG) were cloned andexpressed as follows. The genes encoding the antibody heavy and lightchains were constructed via gene synthesis using codons optimized forhuman/mammalian expression. The Trastuzumab Fab sequence was generatedfrom a known HER2/neu domain 4 binding antibody (Carter P. et al. (1992)Humanization of an anti p185 HER2 antibody for human cancer therapy.Proc Natl Acad Sci 89, 4285.) And the Fc was an IgG1 isotype. The scFvsequence was generated from the VH and VL domains of Trastuzumab using aglycine-serine linker (Carter P. et al. (1992) Humanization of an antip185 her2 antibody for human cancer therapy. Proc Natl Acad Sci 89,4285.). The Pertuzumab Fab sequence was generated from a known HER2/neudomain 2 binding Ab (Adams C W et al. (2006) Humanization of arecombinant monoclonal antibody to produce a therapeutic herdimerization inhibitor, Pertuzumab. Cancer Immunol Immunother. 2006;55(6):717-27).

The final gene products were sub-cloned into the mammalian expressionvector PTT5 (NRC-BRI, Canada) and expressed in CHO cells (Durocher, Y.,Perret, S. & Kamen, A. High-level and high-throughput recombinantprotein production by transient transfection of suspension-growing CHOcells. Nucleic acids research 30, e9 (2002)).

The CHO cells were transfected in exponential growth phase (1.5 to 2million cells/ml) with aqueous 1 mg/ml 25 kDa polyethylenimine (PEI,polysciences) at a PEI:DNA ratio of 2.5:1. (Raymond C. et al. Asimplified polyethylenimine-mediated transfection process forlarge-scale and high-throughput applications. Methods. 55(1):44-51(2011)). To determine the optimal concentration range for formingheterodimers, the DNA was transfected in optimal DNA ratios of the heavychain a (HC-A), light chain (LC), and heavy chain B (HC-B) that allowfor heterodimer formation (e.g. HC-A/HC-B/LC ratios=30:30:40 (v5019).Transfected cells were harvested after 5-6 days with the culture mediumcollected after centrifugation at 4000 rpm and clarified using a 0.45 μmfilter.

The clarified culture medium was loaded onto a MabSelect SuRe (GEHealthcare) protein-A column and washed with 10 column volumes of PBSbuffer at pH 7.2. The antibody was eluted with 10 column volumes ofcitrate buffer at pH 3.6 with the pooled fractions containing theantibody neutralized with TRIS at pH 11.

The protein-A antibody eluate was further purified by gel filtration(SEC). For gel filtration, 3.5 mg of the antibody mixture wasconcentrated to 1.5 mL and loaded onto a Sephadex 200 HiLoad 16/600 200pg column (GE Healthcare) via an AKTA Express FPLC at a flow-rate of 1mL/min. PBS buffer at pH 7.4 was used at a flow-rate of 1 mL/min.Fractions corresponding to the purified antibody were collected,concentrated to ˜1 mg/mL.

Exemplary anti-HER2 ECD2×ECD4 biparatopic antibodies with differentmolecular formats (e.g. v6717, scFv-scFv IgG1; v6903 and v6902 Fab-FabIgG1; v5019, v7091 and v10000 Fab-scFv IgG1) were cloned, expressed andpurified as described above.

To quantify antibody purity and to determine the amount of targetheterodimer protein and possible homodimer and/or half antibody and/ormispaired light chain contaminant, LC-MS intact mass analysis wasperformed. The LC-MS intact mass analysis was performed as described inExample 2, excluding DAR analysis calculations used for ADC molecules.

The data is shown in Table 2. Table 2 shows that expression andpurification of these biparatopic antibodies resulted in 100% of thedesired product for v6717, 91% of the desired heterodimeric product forv6903, and 62% of the desired product for v6902. The numbers in bracketsindicate the quantities of the main peak plus a side peak of +81 Da.This side peak is typically detected with variants that containC-terminal HA tags (such of v6903 and v6902). Adding the main and sidepeaks yields heterodimer purities of approximately 98% and 67% for v6903and v6903. Based on the high heterodimer purity, v6903 was identified asthe representative Fab-Fab anti-HER2 biparatopic variant for directcomparison to the scFv-scFv and Fab-scFv formats. v6903 was included inall format comparison assays.

TABLE 2 Expression and purification of antibodies Variant Desiredheterodimer species (+side peak) 6717 100.0 6903 90.9 (97.7) 6902 62.4(67.4)

Example 2: Preparation of Exemplary Anti-HER2 Biparatopic Antibody DrugConjugates (ADCs)

The following anti-HER2 biparatopic antibody drug conjugates (anti-HER2biparatopic-ADCs) were prepared. ADCs of variants 5019, 7091, 10000 and506 were prepared. These ADCs are identified as follows:

-   -   v6363 (v5019 conjugated to DM1)    -   v7148 (v7091 conjugated to DM1)    -   v10553 (v10000 conjugated to DM1)    -   v6246 (v506 conjugated to DM1, analogous to T-DM1,        trastuzumab-emtansine)    -   v6249 (human IgG conjugated to DM1)

The ADCs were prepared via direct coupling to maytansine. Antibodiespurified by Protein A and SEC, as described in Example 1 (>95% purity),were used in the preparation of the ADC molecules. ADCs were conjugatedfollowing the method described in Kovtun Y V, Audette C A, Ye Y, et al.Antibody-drug conjugates designed to eradicate tumors with homogeneousand heterogeneous expression of the target antigen. Cancer Res 2006;66:3214-21. The ADCs had an average molar ratio of 3.0 maytansinoidmolecules per antibody as determined by LC/MS and described below.

Details of the reagents used in the ADC conjugation reaction are asfollows: Conjugation Buffer 1: 50 mM Potassium Phosphate/50 mM SodiumChloride, pH 6.5, 2 mM EDTA. Conjugation Buffer 2: 50 mM SodiumSuccinate, pH 5.0. ADC formulation buffer: 20 mM Sodium Succinate, 6%(w/v) Trehalose, 0.02% polysorbate 20, pH 5.0. Dimethylacetamide (DMA);10 mM SMCC in DMA (prepared before conjugation), 10 mM DM1-SH in DMA(prepared before conjugation), 1 mM DTNB in PBS, 1 mM Cysteine inbuffer, 20 mM Sodium Succinate, pH 5.0. UV-VIS spectrophotometer (Nanodrop 100 from Fisher Scientific), PD-10 columns (GE Healthcare).

The ADCs were prepared as follows. The starting antibody solution wasloaded onto the PD-10 column, previously equilibrated with 25 mL ofConjugation Buffer 1, followed by 0.5 ml Conjugation Buffer 1. Theantibody eluate was collect and the concentration measured at A₂₈₀ andthe concentration was adjusted to 20 mg/mL. The 10 mM SMCC-DM1 solutionin DMA was prepared. A 7.5 molar equivalent of SMCC-DM1 to antibody wasadded to the antibody solution and DMA was added to a final DMA volumeof 10% v/v. The reaction was briefly mixed and incubated at RT for 2 h.A second PD-10 column was equilibrated with 25 ml of Conjugation Buffer1 and the antibody-MCC-DM1 solution was added to the column follow by0.5 ml of Buffer 1. The antibody-MCC-DM1 eluate was collected and theA₂₅₂ and A₂₈₀ of antibody solution was measured. The Antibody-MCC-DM1concentration was calculated (□=1.45 mg⁻¹cm⁻¹, or 217500 M⁻¹cm⁻¹). TheADCs were analyzed on a SEC-HPLC column for high MW analysis (SEC-HPLCcolumn TOSOH, G3000-SWXL, 7.8 mm×30 cm, Buffer, 100 mM Sodium phosphate,300 mM Sodium Chloride, pH 7.0, flow rate: 1 ml/min).

ADC drug to antibody ratio (DAR) was analysed by HIC-HPLC_using theTosoh TSK gel Butyl-NPR column (4.6 mm×3.5 mm×2.5 mm). Elution wasperformed at 1 ml/min using a gradient of 10-90% buffer B over 25 minfollowed by 100% buffer B for 4 min. Buffer A comprises 20 mM sodiumphosphate, 1.5 M ammonium sulphate, pH 7.0. Buffer B comprises 20 mMsodium phosphate, 25% v/v isopropanol, pH 7.0.

ADC drug to antibody ratio (DAR) was determined by LC-MS by thefollowing method. The antibodies were deglycosylated with PNGase F priorto loading on the LC-MS. Liquid chromatography was carried out on anAgilent 1100 Series HPLC under the following conditions:

Flow rate: 1 mL/min split post column to 100 uL/min to MS. Solvents:A=0.1% formic acid in ddH2O, B=65% acetonitrile, 25% THF, 9.9% ddH2O,0.1% formic acid. Column: 2.1×30 mm PorosR2. Column Temperature: 80° C.;solvent also pre-heated. Gradient: 20% B (0-3 min), 20-90% B (3-6 min),90-20% B (6-7 min), 20% B (7-9 min).

Mass Spectrometry (MS) was subsequently carried out on an LTQ-OrbitrapXL mass spectrometer under the following conditions: Ionization methodusing Ion Max Electrospray. Calibration and Tuning Method: 2 mg/mLsolution of CsI is infused at a flowrate of 104/min. The Orbitrap wastuned on m/z 2211 using the Automatic Tune feature (overall CsI ionrange observed: 1690 to 2800). Cone Voltage: 40V; Tube Lens: 115V; FTResolution: 7,500; Scan range m/z 400-4000; Scan Delay: 1.5 min. Amolecular weight profile of the data was generated using Thermo'sPromass deconvolution software. Average DAR of the sample was determinedas a function of DAR observed at each fractional peak (using thecalculation: (DAR×fractional peak intensity)).

Table 3 summarizes the average DAR for the ADC molecules. The averageDAR for the exemplary anti-HER2 biparatopic antibody and control wasapproximately 3.

TABLE 3 Average DAR for ADCs DAR (LC-MS) DAR (HIC) n v6246 2.9 3.0 5v6363 2.6 3.3 5 v7148 3.4 3.9 1 v10553 4.0 4.0 1

Example 3: Expression and Bench-Scale Purification of Anti-HER2Biparatopic Antibody

The anti-HER2 biparatopic antibodies (v5019, v7091 and v10000) describedin Example 1 were expressed in 10 and/or 25 L volumes and purified byprotein A and size exclusion chromatography (SEC) as follows.

The clarified culture medium was loaded onto a MabSelect SuRe (GEHealthcare) protein-A column and washed with 10 column volumes of PBSbuffer at pH 7.2. The antibody was eluted with 10 column volumes ofcitrate buffer at pH 3.6 with the pooled fractions containing theantibody neutralized with Tris at pH 11.

The protein-A antibody eluate was further purified by gel filtration(SEC). For gel filtration, 3.5 mg of the antibody mixture wasconcentrated to 1.5 mL and loaded onto a Sephadex 200 HiLoad 16/600 200pg column (GE Healthcare) via an AKTA Express FPLC at a flow-rate of 1mL/min. PBS buffer at pH 7.4 was used at a flow-rate of 1 mL/min.Fractions corresponding to the purified antibody were collected,concentrated to ˜1 mg/mL. The purified proteins were analyzed by LC-MSas described in Example 2.

The results of the 10 L expression and bench-scale protein A and SECpurification are shown in FIGS. 2A and 2B. FIG. 2A shows the SECchromatograph of the protein A purified v5019 and FIG. 2B shows thenon-reducing SDS-PAGE gel that compares the relative purity of a proteinA pooled fraction as well as SEC fractions 15 and 19 and pooled SECfractions 16-18. These results show that the anti-HER2 biparatopicantibody was expressed and that purification by protein A and SECyielded a pure protein sample. Further quantification was performed byUPLC-SEC and LC-MS analysis and is described in Example 4.

The results of the 25 L expression and bench-scale protein Apurification is shown in FIG. 2C. FIG. 2C shows SDS-PAGE gel thatcompares the relative purity of a protein A purified v10000. Lane Mcontains: protein marker; lane 1 contains: v10000 under reducingconditions; lane 2 contains v10000 under non-reducing conditions. TheSDS-PAGE gel shows that v10000 is pure and runs at the correct predictedMW of approximately 125 kDa under non-reducing conditions. Underreducing conditions two heavy chains bands are visible corresponding tothe CH-A heavy chain (approximately 49 kDa) and the CH-B heavy chain(approximately 52.5 kDa); the CH-A light chain is visible and runs atthe correct predicted mass of approximately 23.5 kDa. These results showthat the anti-HER2 biparatopic antibody was expressed and that one-steppurification by protein A yielded a pure protein sample. Furtherquantification was performed by UPLC-SEC and LC-MS analysis and isdescribed in Example 4.

Example 4: Analysis of Biparatopic Anti-HER2 Antibody Purity by UPLC-SECand LC-MS

The purity and percent aggregation of exemplary protein A and SECpurified biparatopic anti-HER2 heteromultimers was determined byUPLC-SEC by the method described.

UPLC-SEC analysis was performed using a Waters BEH200 SEC column set to30° C. (2.5 mL, 4.6×150 mm, stainless steel, 1.7 μm particles) at 0.4ml/min. Run times consisted of 7 min and a total volume per injection of2.8 mL with running buffers of 25 mM sodium phosphate, 150 mM sodiumacetate, pH 7.1; and, 150 mM sodium phosphate, pH 6.4-7.1. Detection byabsorbance was facilitated at 190-400 nm and by fluorescence withexcitation at 280 nm and emission collected from 300-360 nm. Peakintegration was analyzed by Empower 3 software.

UPLC-SEC results of the pooled v5019 SEC fractions are shown in FIG. 3A.These results indicate that the exemplary anti-HER2 biparatopic antibodywas purified to >99% purity with less than 1% HMW species by protein Aand SEC chromatography.

UPLC-SEC results of the v10000 pooled Protein A fractions are shown inFIG. 3B. These results indicate that the exemplary anti-HER2 biparatopicantibody was purified to >96% purity with less than 1% HMW species byprotein A chromatography.

The purity of exemplary biparatopic anti-HER2 antibodies was determinedusing LC-MS under standard conditions by the method described in Example2. Results from LC-MS analysis of the pooled SEC fractions of v5019 areshown in FIG. 4A. This data shows that the exemplary biparatopicanti-HER2 heterodimer has a heterodimer purity of 100%. Results fromLC-MS analysis of the pooled protein A fractions of v10000 are shown inFIG. 4B. This data shows that the exemplary biparatopic anti-HER2heterodimer has a heterodimer purity of 98% following a one-step proteinA purification.

Antibodies purified by protein A chromatography and/or protein A and SECwere used for the assays described in the following Examples.

Example 5. Large-Scale Expression and Manufacturability Assessment ofBiparatopic Anti-HER2 Antibody Purified by Protein A and CEXChromatography

The exemplary anti-HER2 biparatopic antibody v5019 described in Example1 was expressed in a 25 L scale and purified as follows.

Antibody was obtained from supernatant followed by a two-steppurification method that consisted of Protein A purification (MabSelect™resin; GE Healthcare) followed by cation exchange chromatography(HiTrap™ SP FF resin; GE Healthcare) by the protocol described.

CHO-3E7 cells were maintained in serum-free Freestyle CHO expressionmedium (Invitrogen, Carlsbad, Calif., USA) in Erlenmeyer Flasks at 37°C. with 5% CO2 (Corning Inc., Acton, Mass.) on an orbital shaker (VWRScientific, Chester, Pa.). Two days before transfection, the cells wereseeded at an appropriate density in a 50 L CellBag with a volume of 25 Lusing the Wave Bioreactor System 20/50 (GE Healthcare Bio-Science Corp).On the day of transfection, DNA and PEI (Polysciences, Eppelheim,Germany) were mixed at an optimal ratio and added to the cells using themethod described in Example 1. Cell supernatants collected on day 6 wasused for further purification.

Cell culture broth was centrifuged and filtered before loading onto 30mL Mabselect™ resin packed in XK26/20 (GE Healthcare, Uppsala, Sweden)at 10.0 mL/min. After washing and elution with appropriate buffer, thefractions were collected and neutralized with 1 M Tris-HCl, pH 9.0. Thetarget protein was further purified via 20 mL SP FF resin packed inXK16/20 (GE Healthcare, Uppsala, Sweden). MabSelect™ purified sample wasdiluted with 20 mM NaAC, pH5.5 to adjust the conductivity to <5 ms/cmand 50 mM citrate acid (pH3.0) was added adjust the sample pH value to5.5. Sample was loaded at a 1 mL/min onto the HiTrap™ SP FF resin (GEHealthcare) and washed with 20 mM NaAC. Protein was eluted using agradient elution 0-100% of 20 mM NaAC, 1 M NaCl, pH5.5, 10 CV at 1mL/min.

The purified protein was analyzed by SDS-PAGE as described in Example 1,and LC-MS for heterodimer purity by the method described in example 4.The results are shown in FIGS. 5A and 5B. FIG. 5A shows the SDS-PAGEresults of v5019 following MabSelect™ and HiTrap™ SP FF purification;lane M contains: protein marker; lane 1: v5019 under reducing conditions(3 μg); Lane 2: v5019 under non-reducing conditions (2.5 μg). TheSDS-PAGE gel shows that v5019 is relatively pure following MabSelect™and HiTrap™ SP FF purification and, under non-reducing conditions, runsat the correct predicted MW of approximately 125 kDa. Under reducingconditions two heavy chains bands are visible corresponding to the CH-Aheavy chain (approximately 49 kDa) and the CH-B heavy chain(approximately 52.5 kDa); the CH-A light chain is visible and runs atthe correct predicted mass of approximately 23.5 kDa.

LC-MS analysis of the MabSelect™ and HiTrap™ SP FF purified v5019 wasperformed to determine heterodimer purity using the method described inExample 4. Results from the LC-MS analysis are shown in FIG. 5B. Theseresults show that v5019 purification using MabSelect™ and HiTrap™ SP FFyields protein with >99% heterodimer purity and with little (<1%) orundetectable homodimer or half antibody contamination.

Example 6: Comparison of Bmax of a Biparatopic Anti-HER2 AntibodyAgainst Bmax of Controls in Cell Lines Expressing Low to High Levels ofHER2

The following experiment was performed to measure the ability of anexemplary biparatopic anti-HER2 antibody to bind to cells expressingvarying levels of HER2 in comparison to controls. The cell lines usedwere SKOV3 (HER2 2+/3+), JIMT-1 (HER2 2+), MDA-MB-231 (HER2 0/1+), andMCF7 (HER2 1+). The biparatopic anti-HER2 antibodies tested includev5019, v7091 and v10000. The ability of the biparatopic anti-HER2antibodies to bind to the HER2 expressing (HER2+) cells was determinedas described below, with specific measurement of B_(max) and apparentK_(D) (equilibrium dissociation constant).

Binding of the test antibodies to the surface of HER2+ cells wasdetermined by flow cytometry. Cells were washed with PBS and resuspendedin DMEM at 1×10⁵ cells/100 μl. 100 μl cell suspension was added intoeach microcentrifuge tube, followed by 10 μl/tube of the antibodyvariants. The tubes were incubated for 2 hr 4° C. on a rotator. Themicrocentrifuge tubes were centrifuged for 2 min 2000 RPM at roomtemperature and the cell pellets washed with 500 μl media. Each cellpellet was resuspended 100 μl of fluorochrome-labelled secondaryantibody diluted in media to 2 μg/sample. The samples were thenincubated for 1 hr at 4° C. on a rotator. After incubation, the cellswere centrifuged for 2 min at 2000 rpm and washed in media. The cellswere resuspended in 500 μl media, filtered in tube containing 5 μlpropidium iodide (PI) and analyzed on a BD LSR II flow cytometeraccording to the manufacturer's instructions. The K_(D) of exemplarybiparatopic anti-HER2 heterodimer antibody and control antibodies wereassessed by FACS with data analysis and curve fitting performed inGraphPad Prism.

The results are shown in FIGS. 6A-6G. These results demonstrate thatexemplary biparatopic anti-HER2 antibodies (v5019, v7091 and v10000) canbind to HER2+ cells with approximately a 1.5-fold higher Bmax comparedto an anti-HER2 FSA (v506). The results in FIG. 6A-6G also show thatbiparatopic anti-HER2 antibodies (v5019, v7091 and v10000) can bind toHER2+ cells with a similar Bmax compared to a combination of twoanti-HER2 FSAs (v506+v4184).

The binding results for HER2+ SKOV3 cells (HER2 2/3+) are shown in FIGS.6A, 6E and Table 4 and Table 5. The results in FIG. 6A and Table 4 showthat exemplary biparatopic anti-HER2 antibody (v5019) displaysapproximately a 1.5-fold higher Bmax in binding to SKOV3 cells comparedto two different anti-HER2 FSAs (v506 or v4184). The results also showthat exemplary biparatopic anti-HER2 antibody (v5019) displaysequivalent Bmax compared to the combination of two anti-HER2 FSAs(v506+v4184). The apparent K_(D) of v5019 for binding to SKOV3 wasapproximately 2 to 4-fold higher compared to either anti-HER2 FSA alone(v506 or v4184), or the combination of two anti-HER2 FSAs (v506+v4184).

TABLE 4 Binding to SKOV3 cells Antibody variant K_(D) (nM) Bmax v5062.713 29190 v4184 4.108 29204 v5019 8.084 47401 v506 + v4184 4.414 49062

The results in FIG. 6E and Table 5 show that exemplary biparatopicanti-HER2 antibodies (v5019, 7091 and v10000) display approximately a1.5 to 1.6-fold higher Bmax in binding to SKOV3 cells compared to twodifferent anti-HER2 FSAs (v506 or v4184). The results also show thatexemplary biparatopic anti-HER2 antibodies (v5019, 7091 and v10000)display equivalent Bmax compared to the combination of two anti-HER2FSAs (v506+v4184). The apparent K_(D) of v5019, v7091, v10000 and thecombination of two anti-HER2 FSAs (v506+v4184) for binding to SKOV3 wasapproximately 2 to 3-fold higher compared to either anti-HER2 FSA alone(v506 or v4184).

TABLE 5 Binding to SKOV3 Antibody Variant K_(D) (nM) Bmax v506 4.8 30007v4184 5.6 27628 v506 + v4184 10.0 49014 v5019 13.6 47693 v7091 14.544737 v10000 10.3 48054

Binding curves in the JIMT-1 cell line (HER2 2+) are shown in FIG. 6Band Table 6. These results show that exemplary biparatopic anti-HER2antibody (v5019) displays approximately a 1.5-fold higher Bmax inbinding to JIMT-1 cells compared to an anti-HER2 FSAs (v506). Theresults also show that exemplary biparatopic anti-HER2 antibody (v5019)displays equivalent Bmax compared to the combination of two anti-HER2FSAs (v506+v4184). The apparent K_(D) of v5019 for binding to JIMT-1 wasapproximately 2-fold higher compared to the anti-HER2 FSA (v506), andwas similar (approximately 1.2 fold greater) compared to the combinationof two anti-HER2 FSAs (v506+v4184).

TABLE 6 Binding to JIMT-1 cells Antibody variant K_(D) (nM) Bmax v5061.875 4905 v5019 4.317 7203 v506 + v4184 5.057 7200

Binding curves in the MCF7 cell line (HER2 1+) are shown in FIG. 6C, 6Fand Tables 7 and 8. These results show that exemplary biparatopicanti-HER2 antibodies (v5019, 7091 and v10000) display approximately a1.5-fold higher Bmax in binding to MCF7 cells compared to an anti-HER2FSAs (v506). The results in FIG. 6C also show that exemplary biparatopicanti-HER2 antibody (v5019) displays equivalent Bmax compared to thecombination of two anti-HER2 FSAs (v506+v4184). The apparent K_(D) ofv5019 for binding to MCF7 was similar to the anti-HER2 FSA (v506) andthe combination of two anti-HER2 FSAs (v506+v4184).

TABLE 7 Binding to MCF7 cells Antibody variant K_(D) (nM) Bmax v5061.301 542 v5019 1.506 872 v506 + v4184 2.095 903The results in FIG. 6F and Table 8 show that exemplary biparatopicanti-HER2 antibodies (v5019, v7091 and v10000) display approximately 1.6to 1.7-fold greater Bmax compared to the FSA monospecific v506. Theapparent K_(D) of v5019, v7091 and v10000 was similar to the anti-HER2FSA (v506).

TABLE 8 Binding to MCF7 cells Antibody Variant K_(D) (nM) Bmax v506 3.5571 v5019 5.6 968 v7091 6.5 918 v10000 3.7 915

Binding curves in the MDA-MB-231 cell line (HER2 0/1+) are shown in FIG.6D and Table 9. These results show that exemplary biparatopic anti-HER2antibody (v5019) displays approximately a 1.5-fold higher Bmax inbinding to MDA-MB-231 cells compared to an anti-HER2 FSA (v506). Theresults also show that exemplary biparatopic anti-HER2 antibody (v5019)displays equivalent Bmax compared to the combination of two anti-HER2FSAs (v506+v4184). The apparent K_(D) of v5019 for binding to MDA-MB-231was approximately 2.4-fold lower compared to the anti-HER2 FSA (v506)and was approximately 1.7-fold higher compared to the combination of twoanti-HER2 FSAs (v506+v4184).

TABLE 9 Binding to MDA-MB-231 cells Antibody variant K_(D) (nM) Bmaxv506 8.364 0.9521 v5019 3.543 1.411 v506 + v4184 2.040 1.542

Binding curves in the WI-38 lung fibroblast cell line are shown in FIG.6G and Table 10. The WI-38 cell line is a normal lung epithelium thatexpresses basal levels (HER2 0+, ˜10,000 receptors/cell) of HER2 (Carteret al. 1992, PNAS, 89:4285-4289; Yarden 2000, HER2: Basic Research,Prognosis and Therapy). These results show that exemplary biparatopicanti-HER2 antibodies (v5019, v7091, v10000) displays equivalent cellsurface decoration (Bmax) in binding to WI-38 cells compared to ananti-HER2 FSAs (v506); however, note that binding for v506 did notappear to reach saturation, and thus KD could not be determined. Theapparent K_(D) among the exemplary biparatopic anti-HER2 antibodies wasequivalent.

TABLE 10 Binding to WI-38 cells Antibody Variant K_(D) (nM) Bmax v506Not determined ~366 v5019 7.0 380 v7091 8.3 371 v10000 8.4 418

These results show that an exemplary biparatopic anti-HER2 antibody canbind to HER2 1+, 2+ and 3+ tumor cells to levels that are approximately1.5 to 1.6-fold greater than an anti-HER2 monospecific FSA, and thatexemplary biparatopic anti-HER2 antibodies can bind to HER2 1+, 2+ and3+ tumor cells to equivalent levels compared to the combination of twounique monospecific anti-HER2 FSAs with different epitope specificities.These results also show that the biparatopic anti-HER2 antibodies do notshow increased binding (i.e. compared to monospecific anti-HER2antibody, v506) to basal HER2 expressing cells that expressapproximately 10,000 HER2 receptors/cell or less, and that a thresholdfor increased cell surface binding to the biparatopic anti-HER2antibodies occurs when the HER2 receptor level is approximately >10,000receptors/cell. Based on this data it would be expected that theexemplary biparatopic anti-HER2 antibodies would have increased cellsurface binding to HER2 3+, 2+ and 1+ tumor cells but would not haveincreased cell surface binding to non-tumor cells that express basallevels of the HER2 receptor at approximately 10,000 receptors or less.

Example 7: Ability of Biparatopic Anti-HER2 Antibody to Inhibit Growthof HER2+ Cells

The ability of an exemplary biparatopic anti-HER2 antibody to inhibitgrowth of cells expressing HER2 at the 3+ and 2+ level was measured. Theexperiment was carried out in the HER2 3+ cell lines BT-474, SKBr3,SKOV3, and HER2 2+ JIMT-1. The biparatopic anti-HER2 antibodies v5019,v7091 and v10000 were tested. The ability of the biparatopic anti-HER2antibodies to inhibit the growth of BT-474 cells (200 nM antibody);SKOV3, SKBr3 and JIMT-1 cells (300 nM antibody) was measured asdescribed below.

Test antibodies were diluted in media and added to the cells at 10μl/well in triplicate. The plates were incubated for 3 days 37° C. Cellviability was measured using either AlamarBlue™ (Biosource # dal1100),or CelltiterGlo® and absorbance read as per the manufacturer'sinstructions. Data was normalized to untreated control and analysis wasperformed in GraphPad prism.

The growth inhibition results are shown in FIG. 7A-E. A summary of theresults is provided in Tables 11A and 11B. The results FIGS. 7A-B andTable 11A indicate that exemplary anti-HER2 biparatopic (v5019) iscapable of growth inhibition of HER2+ SKOV3 and BT-474 cell lines. FIG.10A shows that anti-HER2 biparatopic antibody mediated the greatestgrowth inhibition of SKOV3 when compared to anti-HER2 FSA (v506) andwhen compared to the combination of two anti-HER2 FSA antibodies(v506+v4184).

TABLE 11A Growth Inhibition of HER2 3+ Cancer Cells % Survival TreatmentSKOV3 HER2 2+/3+ BT-474 HER2 3+ v506 88 37 v506 + v4184 96 32 v5019 7743

The results in FIGS. 7C-E and Table 11B indicate that exemplaryanti-HER2 biparatopic antibodies (v5019, v7091 and v10000) can inhibitgrowth of HER2 3+ SKBR3, HER2 2+/3+ SKOV3, and HER2 2+ JIMT-1 tumor celllines. FIG. 7C shows that anti-HER2 biparatopic antibodies v7091 andv10000 mediated the greatest growth inhibition of HER2 3+ SKBr3 breasttumor cells. FIG. 7D shows that anti-HER2 biparatopic antibodies (v7091and v10000) mediated the greatest growth inhibition of HER2 3+ SKOV3ovarian tumor cells. FIG. 7E shows that anti-HER2 biparatopic antibodies(v7091 and v10000) mediated the greatest growth inhibition of HER2 2+Herceptin-resistant JIMT-1 tumor cells. In all cell lines tested,exemplary anti-HER2 biparatopic antibodies (v7091 and v10000) mediatedgreater growth inhibition compared to the anti-HER2 FSA monospecificantibody (v506).

TABLE 11B Growth inhibition of HER2 3+ Cancer Cells % Survival TreatmentSKBr3 HER2 3+ SKOV3 HER2 2+/3+ JIMT-1 HER2 2+ v506 52 107 107 v5019 5983 106 v7091 35 79 85 v10000 34 73 84

These results show that exemplary saturating concentrations ofbiparatopic anti-HER2 antibodies can growth inhibit HER2 3+ and 2+breast and ovarian and HER2 2+ Trastuzumab resistant tumor cellsapproximately 20% greater than a FSA anti-HER2 monospecific antibody.

Example 8: Preferential Binding of Paratopes of Biparatopic Anti-HER2Antibodies to Dimeric HER2 Compared to HER2 ECD

This experiment was performed to determine the ability of the individualparatopes of exemplary biparatopic anti-HER2 antibodies to bind todimeric HER2 and the HER2 ECD as a surrogate for differential bindingbetween membrane bound HER2 (HER2-Fc) and the shed HER2 ECD. Theexperiment was carried out as follows.

Surface plasmon resonance (SPR) analysis: affinity of monovalentanti-HER2 antibodies (v1040 or v4182) for binding to the HER2extracellular domain (sHER-2, Ebioscience BMS362, encoding amino acid23-652 of the full length protein) and HER2-Fc (dimeric HER2-Fc fusionencoding the amino acid 1-652 of the extracellular domain; SinoBiological Inc., 10004-H02H) was measured by SPR using the T200 systemfrom Biacore (GE Healthcare). Binding to the HER2 ECD was determined bythe following method. HER2 ECD in 10 mm Hepes pH 6.8, was immobilized onCMS chip through amine coupling to a level of 44 RU (response units).Monovalent anti-HER2 antibodies were passed over the surface of the HER2immobilized chip at concentrations ranging from 0.76-60 nM. Binding tothe HER2-Fc was determined by the following method. HER2-Fc in 10 mmHepes pH 6.8, was immobilized on CMS chip through amine coupling to alevel of 43 RU. Monovalent anti-HER2 antibodies were passed over thesurface of the HER2 immobilized chip at concentrations ranging from0.76-60 nM. Antibody concentrations were analyzed for binding intriplicate. Equilibrium dissociation binding constants (K_(D)) andkinetics (ka and kd) were determined using the single cycle kineticsmethod. Sensograms were fit globally to a 1:1 Langmuir binding model.All experiments were conducted at room temperature.

Results are shown in FIG. 8A, FIG. 8B, Table 11C and Table 11D. Theresults in FIG. 8A and Table 11C show SPR binding data of the monovalentanti-HER2 antibody (v1040; representing the antigen-binding domain onCH-B of exemplary anti-HER2 biparatopic antibody). FIG. 8A illustratesthe K_(D) values (nM) of v1040 binding to immobilized HER2 ECD orHER2-Fc and shows that monovalent anti-HER2 antibody has a lower K_(D)for binding to the HER2-Fc compared to the HER2 ECD. Table 11C shows theka (1/M s) and kd (1/s) values of the monovalent anti-HER2 antibody (OA)compared to the full-sized anti-HER2 antibody (FSA) in binding to theHER2 ECD and HER2-FC (‘HER2 mem’). This data shows comparable on (ka)and off (kd) rates of the OA and FSA for binding to the HER2 ECD andHER2-Fc.

TABLE 11C ka (1/M s) and kd (1/s) values of the monovalent anti-HER2antibody (OA) compared to the full-sized anti-HER2 antibody (FSA) inbinding to the HER2 ECD and HER2-FC (‘HER2 mem’ ka (1/Ms) kd (1/s) OAvs. HER2 ECD 2.00E+05 6.15E−05 FSA vs. HER2 ECD 4.14E+05 2.01E−05 OA vs.HER2 mem 1.88E+05 4.38E−05 FSA vs. HER2 mem 3.41E+05  4.94E−06*

Results in FIG. 8B and Table 11D show the SPR binding data of themonovalent anti-HER2 antibody (v4182; representing the antigen-bindingdomain on CH-A of exemplary anti-HER2 biparatopic antibody). FIG. 8Billustrates the K_(D) values (nM) of v4182 binding to immobilized HER2ECD or HER2-Fc and shows that monovalent anti-HER2 antibody has a lowerK_(D) for binding to the HER2-Fc compared to the HER2 ECD. Table 11Dshows the ka (1/M s) and kd (1/s) values of the monovalent anti-HER2antibody (OA) compared to the full-sized anti-HER2 antibody (FSA) inbinding to the HER2 ECD and HER2-FC (‘HER2 mem’). This data showscomparable on rates (ka) and off rates (kd) of the OA and FSA forbinding to the HER2 ECD and HER2-Fc.

TABLE 11D ka (1/Ms) kd (1/s) OA vs. HER2 ECD 9.08E+04 6.17E−04 FSA vs.HER2 ECD 9.55E+04 3.93E−04 OA vs. HER2 mem 1.39E+05 2.04E−04 FSA vs.HER2 mem 1.77E+05 6.84E−05

These data show that each of the paratopes of the exemplary anti-HER2biparatopic antibody have lower K_(D) values for binding to the dimericHER2 antigen, a representative of membrane bound HER2, as compared tothe HER2 ECD. Based on this data it would be expected that the exemplaryanti-HER2 antibody would have a higher binding affinity for the membranebound HER2 antigen as compared to the shed HER2 ECD that is present inthe serum of diseased patients and can act as a sink for the therapeuticantibody (Brodowicz T, et al. Soluble HER-2/neu neutralizes biologiceffects of anti-HER-2/neu antibody on breast cancer cells in vitro. IntJ Cancer. 1997; 73:875-879). For example, baseline HER2 ECD levels≦15ng/mL; whereas patients with progressive disease have HER2 ECD≧38 ng/mL.

Example 9: Whole Cell Loading and Internalization of BiparatopicAnti-HER2 Antibody in HER2+ Cells

This experiment was performed to assess the ability of an exemplarybiparatopic anti-HER2 antibody to be internalized in HER2 2+ cells. Thedirect internalization method was followed according to the protocoldetailed in Schmidt, M. et al., Kinetics of anti-carcinoembryonicantigen antibody internalization: effects of affinity, bivalency, andstability. Cancer Immunol Immunother (2008) 57:1879-1890. Specifically,the antibodies were directly labeled using the AlexaFluor® 488 ProteinLabeling Kit (Invitrogen, cat. no. A10235), according to themanufacturer's instructions.

For the internalization assay, 12 well plates were seeded with 1×10⁵cells/well and incubated overnight at 37° C.+5% CO2. The following day,the labeled antibodies were added at 200 nM in DMEM+10% FBS andincubated 24 hours at 37° C.+5% CO2. Under dark conditions, media wasaspirated and wells were washed 2×500 μL PBS. To harvest cells, celldissociation buffer was added (250 μL) at 37° C. Cells were pelleted andresuspended in 100 μL DMEM+10% FBS without or with anti-Alexa Fluor 488,rabbit IgG fraction (Molecular Probes, A11094) at 50 μg/mL, andincubated on ice for 30 min. Prior to analysis 300 μL DMEM+10% FBS thesamples filtered 4 μl propidium iodide was added. Samples were analyzedusing the LSRII flow cytometer.

The ability of exemplary anti-HER2 biparatopic antibody to internalizein HER2+ cells is shown in FIG. 9A and FIG. 9B. FIG. 9A shows theresults of detectable surface and internal antibody in BT-474 cellsfollowing 24 h incubation with the exemplary anti-HER2 biparatopicantibody and anti-HER2 FSA control. These results show that incubationwith exemplary anti-HER2 biparatopic antibody (v5019) results inapproximately 2-fold more internalized antibody in BT-474 cells comparedto the anti-HER2 FSA control. FIG. 9B shows the results of detectablesurface and internal antibody in JIMT-1 cells following 24 h incubationwith the exemplary anti-HER2 biparatopic antibody and anti-HER2 FSAcontrol. These results show that incubation with exemplary anti-HER2biparatopic antibody (v5019) results in approximately 2-fold moreinternalized antibody in JIMT-1 cells compared to the anti-HER2 FSAcontrol. The amount of surface staining post 24 h was comparable amongthe biparatopic anti-HER2 and anti-HER2 FSA in both BT-474 and JIMT-1cells.

The results in FIG. 10A-F show a comparison of detectable antibody boundto the surface of whole cells after 2 h at 4° C., compared to antibodybound to the surface following incubation for 24 h at 37° C.; inaddition to the amount of internalized antibody following 24 h at 37° C.FIG. 10A shows the results in BT-474 cells following incubation with theexemplary anti-HER2 biparatopic antibody and anti-HER2 FSA control.These results show that incubation of exemplary anti-HER2 biparatopicantibody with BT-474 cells for 24 h results in approximately a 15%reduction of antibody detected on the surface of whole cells. FIG. 10Aalso shows that incubation with exemplary anti-HER2 biparatopic antibody(v5019) results in approximately 2-fold more internalized antibody inBT-474 cells compared to the anti-HER2 FSA control.

FIG. 10B shows the results in JIMT-1 cells following incubation with theexemplary anti-HER2 biparatopic antibody and anti-HER2 FSA control. FIG.10B is a repeat of the experiment shown in FIG. 9B with the addition ofsurface staining following 2 h at 4° C. These results show thatincubation of exemplary anti-HER2 biparatopic antibody with JIMT-1 cellsfor 24 h results in approximately a 57% reduction of antibody detectedon the surface of whole cells. FIG. 10B also shows that incubation withexemplary anti-HER2 biparatopic antibody (v5019) results moreinternalized antibody in BT-474 cells following 24 incubation at 37° C.,compared to the anti-HER2 FSA control.

FIG. 10C shows the results in SKOV3 cells following incubation with theexemplary anti-HER2 biparatopic antibody. These results show thatincubation of exemplary anti-HER2 biparatopic antibody with SKOV3 cellsfor 24 h results in approximately a 32% reduction of antibody detectedon the surface of whole cells.

FIG. 10D shows the results in MCF7 cells following incubation with theexemplary anti-HER2 biparatopic antibody. These results show thatincubation of exemplary anti-HER2 biparatopic antibody with MCF7 cellsfor 24 h results in approximately a 45% reduction of antibody detectedon the surface of whole cells.

FIG. 10E shows the results in SKOV3 cells following incubation with theexemplary anti-HER2 biparatopic antibodies, v5019, v7091 and v10000.These results show that incubation of exemplary anti-HER2 biparatopicantibodies results in 1.5 to 1.8-fold more internalized antibody withSKOV3 cells compared to the anti-HER2 FSA control. Incubation with theanti-HER2 FSA control for 24 h resulted in the greatest reduction (˜77%)of antibody detected on the surface of whole cells.

FIG. 10F shows the results in JIMT-1 cells following incubation with theexemplary anti-HER2 biparatopic antibodies, v5019, v7091 and v10000.These results show that incubation of exemplary anti-HER2 biparatopicantibodies results in 1.4 to 1.8-fold more internalized antibody withJIMT-1 cells compared to the anti-HER2 FSA control. Incubation with theanti-HER2 biparatopic antibodies (v5019 and v10000) for 24 h resulted inthe greatest reduction (˜64%) of antibody detected on the surface ofwhole cells.

These results show that exemplary anti-HER2 biparatopic antibodies havesuperior internalization properties in HER2+ cells compared to amonospecific anti-HER2 FSA. The reduction of surface antibody detectedfollowing 24 h incubation at 37° C. shows that an exemplary anti-HER2biparatopic antibody is capable of reducing the amount of cell surfaceHER2 receptor following incubation in HER2+ cells and that surface HER2reduction post incubation is greatest in HER2 2+ tumor cells.

Example 10: Cellular Staining and Location of an Anti-HER2 BiparatopicAntibody Following Incubation with HER2+ Cells at 1, 3 and 16 Hours

This experiment was performed to analyze internalization of theexemplary anti-HER2 biparatopic antibody in HER2+ JIMT-1 cells atdifferent time points and as an orthogonal method to that presented inExample 9 to analyze whole cell loading and internalization.

JIMT-1 cells were incubated with the antibody (v506, v4184, v5019, or acombination of v506 and v4184) at 200 nM in serum-free DMEM, 37° C.+5%CO₂ for 1h, 3h and 16h. Cells were gently washed two times with warmedsterile PBS (500 ml/well). Cells were fixed with 250 ml of 10%formalin/PBS solution for 10 min at RT. The fixed cells were washedthree times with PBS (500 μl/well), permeabilized with 250 μl/well ofPBS containing 0.2% Triton X-100 for 5 min, and washed three times with500 μl/well PBS. Cells were blocked with 500 μl/well of PBS+5% goatserum for 1 h at RT. Blocking buffer was removed, and 300 μl/wellsecondary antibody (Alexa Fluor 488-conjugated AffiniPure Fab FragmentGoat anti-Human IgG (H+L); Jackson ImmunoResearch Laboritories, Inc.;109-547-003) was incubated for 1 h at RT. Cells were washed three timeswith 500 μl/well of PBS and the coverslips containing fixed cells werethen mounted on a slide using Prolong gold anti-fade with DAPI (LifeTechnologies; #P36931). 60× single images were acquired using OlympusFV1000 Confocal microscope.

The results indicated that the exemplary anti-HER2 biparatopic antibody(v5019) was internalized into JIMT-1 cells at 3 h and was primarilylocated close to the nuclei. Comparing images at the 3h incubationshowed a greater amount of internal staining associated with theanti-HER2 biparatopic antibody compared to the combination of twoanti-HER2 FSAs (v506+v4184) and compared to the individual anti-HER2 FSA(v506 or v4184). Differences in the cellular location of antibodystaining were seen when the anti-HER2 biparatopic antibody (v5019)results were compared with the anti-HER2 FSA (v4184); where theanti-HER2 FSA (v4184) showed pronounced plasma membrane staining at the1, 3 and 16 h time points. The amount of detectable antibody was reducedat the 16 h for the anti-HER2 FSA (v506), the combination of twoanti-HER2 FSAs (v506+v4184) and anti-HER2 biparatopic antibodytreatments (data not shown).

These results show that the exemplary anti-HER2 biparatopic antibodyv5019 was internalized in HER2+ cells and the internalized antibody wasdetectable after 3 h incubation. These results are consistent with theresults presented in Example 9 that show exemplary anti-HER2 biparatopicantibody can internalize to greater amounts in HER2+ cells compared toan anti-HER2 FSA.

Example 11: ADCC of HER2+ Cells Mediated by Biparatopic Anti-HER2Antibody Compared to Controls

This experiment was performed in order to measure the ability of anexemplary biparatopic anti-HER2 antibody to mediate ADCC in SKOV3 cells(ovarian cancer, HER2 2+/3+).

Target cells were pre-incubated with test antibodies (10-fold descendingconcentrations from 45 μg/ml) for 30 min followed by adding effectorcells with effector/target cell ratio of 5:1 and the incubationcontinued for 6 hours at 37° C.+5% CO₂. Samples were tested with 8concentrations, 10 fold descending from 45 μg/ml. LDH release wasmeasured using LDH assay kit.

Dose-response studies were performed with various concentrations of thesamples with a effector/target (E/T) ratios of 5:1. 3:1 and 1:1. Halfmaximal effective concentration (EC₅₀) values were analyzed with thesigmoidal dose-response non-linear regression fit using GraphPad prism.

Cells were maintained in McCoy's 5a complete medium at 37° C./5% CO₂ andregularly sub-cultured with suitable medium supplemented with 10% FBSaccording to protocol from ATCC. Cells with passage number fewer thanp10 were used in the assays. The samples were diluted to concentrationsbetween 0.3-300 nM with phenol red free DMEM medium supplemented with 1%FBS and 1% pen/strep prior to use in the assay.

The ADCC results in HER2+ SKOV3 cells at an effector to target cellratio of 5:1 are shown in FIG. 11A and Table 12. These results show thatthe exemplary biparatopic anti-HER2 antibody (v5019) mediated thegreatest percentage of maximum target cell lysis by ADCC when comparedto the anti-HER2 FSA (v792) and combination of two different anti-HER2FSAs (v792+v4184). The difference in maximum cell lysis mediated by theexemplary biparatopic anti-HER2 antibody was approximately 1.6-foldgreater compared to the anti-HER2 FSA, and approximately 1.2-foldgreater compared to a combination of two different anti-HER2 FSAs(v792+v4184).

TABLE 12 Antibody variant EC₅₀ (nM) % Max Cell Lysis v792 ~0.032 17.82v5019 ~0.164 28.57 v792 + v4184 ~0.042 23.85

The ADCC results in HER2+ SKOV3 cells at an effector to target cellratio of 3:1 are shown in FIG. 11B and Table 13. These results show thatthe exemplary biparatopic anti-HER2 antibody (v5019) mediated thegreatest percentage of maximum target cell lysis by ADCC when comparedto the anti-HER2 FSA (v792) and combination of two different anti-HER2FSAs (v792+v4184). The difference in maximum cell lysis mediated by theexemplary biparatopic anti-HER2 antibody was approximately 1.3-foldgreater compared to the anti-HER2 FSA, and approximately 1.8-foldgreater compared to a combination of two different anti-HER2 FSAs(v792+v4184).

TABLE 13 Antibody variant EC₅₀ (nM) % Max Cell Lysis v792 1.064 16.9v5019 ~0.4608 22.3 v792 + v4184 ~1.078 12.3

The ADCC results in HER2+ SKOV3 cells at an effector to target cellratio of 1:1 are shown in FIG. 11C and Table 14. These results show thatthe exemplary biparatopic anti-HER2 antibody (v5019) mediated thegreatest percentage of maximum target cell lysis by ADCC when tocompared to the anti-HER2 FSA (v792) and combination of two differentanti-HER2 FSAs (v792+v4184). The difference in maximum cell lysismediated by the exemplary biparatopic anti-HER2 antibody wasapproximately 1.8-fold greater compared to the anti-HER2 FSA, andapproximately 1.13-fold greater compared to a combination of twodifferent anti-HER2 FSAs (v792+v4184).

TABLE 14 Antibody variant EC₅₀ (nM) % Max Cell Lysis v792 1.429 7.529v5019 ~1.075 13.29 v792 + v4184 ~0.1121 11.73

The results in FIG. 11 and Tables 12-14 show that the exemplarybiparatopic HER2 antibody mediates the greatest ADCC of SKOV3 cells atdifferent E:T ratios when compared to an anti-HER2 FSA and combinationof two anti-HER2 FSAs. The observation of increased ADCC mediated by theanti-HER2 biparatopic antibody would be expected in HER2+ diseasedpatients who express variable and/or reduced circulating effector cellsfollowing chemotherapy (Suzuki E. et al. Clin Cancer Res 2007;13:1875-1882). The observations in FIG. 11 are consistent with the wholecell binding Bmax data presented in Example 6, that shows an approximate1.5-fold increase in cell binding to the exemplary anti-HER2 biparatopicantibody compared to the anti-HER2 FSA.

Example 12: Ability of Exemplary Anti-HER2 Antibody to Bind to HER2 ECD

An SPR assay was used to evaluate the mechanism by which an exemplaryanti-HER2 biparatopic antibody binds to HER2 ECD; specifically, tounderstand whether both paratopes of one biparatopic antibody moleculecan bind to one HER2 ECD (Cis binding; 1:1 antibody to HER2 molecules)or if each paratope of one biparatopic antibody can bind two differentHER2 ECDs (Trans binding; 1:2 antibody to HER2 molecules). Arepresentation of cis vs. trans binding is illustrated in FIG. 14. Thecorrelation between a reduced (slower) off-rate with increasing antibodycapture levels (surface density) is an indication of Trans binding (i.e.one antibody molecule binding to two HER2 molecules.

Affinity and binding kinetics of the exemplary biparatopic anti-HER2antibody (v5019) to recombinant human HER2 were measured and compared tothat of monovalent anti-HER2 antibodies (v630 or v4182; comprising theindividual paratopes of v5019) was measured by SPR using the T200 systemfrom Biacore (GE Healthcare). Between 2000 and 4000 RU of anti-human Fcinjected at concentration between 5 and 10 μg/ml was immobilized on aCMS chip using standard amine coupling. Monovalent anti-HER2 antibody(v630 or v4182) and exemplary biparatopic anti-HER2 antibody (v5019)were captured on the anti-human Fc (injected at concentration ranging0.08 to 8 μg/ml in PBST, 1 min at 10 ul/min) at response levels rangingfrom 350-15 RU. Recombinant human HER2 was diluted in PBST and injectedat starting concentration of either 120 nM, 200 nM or 300 nM with 3-folddilutions and injected at a flow rate of 50 μl/min for 3 minutes,followed by dissociation for another 30 minutes at the end of the lastinjection. HER2 dilutions were analyzed in duplicate. Sensograms werefit globally to a 1:1 Langmuir binding model. All experiments wereconducted at 25° C.

The results are shown in FIG. 12 and FIG. 13.

The results in FIG. 12A show the ka (1/Ms) of monovalent anti-HER2 (v630and v4182) and exemplary biparatopic anti-HER2 antibody (v5019) forbinding to recombinant human HER2 over a range of injected and capturedantibody concentrations on the surface of the chip. These results showthat ka does not change when for v630, v4182 and v5019 at differentantibody capture levels.

The results in FIG. 12B show the kd (1/s) of monovalent anti-HER2 (v630and v4182) and exemplary biparatopic anti-HER2 antibody (v5019) forbinding to recombinant human HER2 over a range of injected and capturedantibody concentrations on the surface of the chip. These results showthat kd decreased only for the exemplary anti-HER2 biparatopic antibody(v5019) at increasing antibody capture levels.

The results in FIG. 12C show the K_(D) (M) of monovalent anti-HER2 (v630and v4182) and exemplary biparatopic anti-HER2 antibody (v5019) forbinding to recombinant human HER2 over a range of injected and capturedantibody concentrations on the surface of the chip. These results showthat K_(D) decreased only for the exemplary anti-HER2 biparatopicantibody (v5019) at increasing antibody capture levels. This resultcorrelated to the decreasing kd values shown in FIG. 15B.

The results in FIG. 13A show the kd (1/s) of exemplary biparatopicanti-HER2 antibody (v5019) for binding to recombinant human HER2 over arange of antibody capture levels. These results show kd values areinversely proportional to higher RUs of antibody captured on the surfaceof the chip (i.e slower off-rates at higher antibody capture levels).The results indicate that exemplary biparatopic anti-HER2 antibody(v5019) is capable of binding HER2 ECD2 and HER2 ECD4 on two separateHER2 molecules (i.e. trans binding) as is evidenced by the reduction inoff-rate at higher antibody capture levels. This data is supported by asimilar experiment presented in FIG. 47 and discussed in Example 43,where bivalent monospecific anti-HER2 FSA (v506) demonstrated Cisbinding (1:1 antibody to HER2) where the kd (1/s) and K_(D) (M) valuesremained constant at increasing antibody capture levels as is expectedfor this molecule.

The results in FIG. 13B show the kd (1/s) of monovalent anti-HER2antibody (v4182) for binding to recombinant human HER2 over a range ofantibody capture levels. These results show no change in kd values overthe range of different antibody RUs captured on the surface of the chip.These results show that monovalent anti-HER2 antibody (v4182) is bindingmonovalently 1:1 (cis binding).

The results in FIG. 13C show the kd (1/s) of monovalent anti-HER2antibody (v630) for binding to recombinant human HER2 over a range ofantibody capture levels. These results show no change in kd values overthe range of different antibody RUs captured on the surface of the chip.These results show that monovalent anti-HER2 antibody (v630) is bindingmonovalently 1:1 (cis binding). This data is supported by the experimentpresented in FIG. 47 and discussed in Example 43X, where the bivalentmonospecific anti-HER2 FSA (v506) showed no change in kd (1/s).

The results in FIG. 12, and FIG. 13 indicate that exemplary biparatopicanti-HER2 antibody (v5019) is capable of simultaneously binding to twoHER2 molecules in trans (antibody to HER2 ratio 1:2). The transmechanism of binding detected by SPR is consistent with the higher cellsurface saturation binding data (Bmax), presented in Example 6, incombination with the internalization data presented in Examples 9 and10.

Example 13: Effect of Exemplary Biparatopic Anti-HER2 AntibodyIncubation on AKT Phosphorylation in BT-474 Cells

The ability of an exemplary anti-HER2 biparatopic antibody to reducepAKT signaling in BT-474 cells was tested using the AKT ColorimetricIn-Cell ELISA Kit (Thermo Scientific; cat no. 62215) according to themanufacturer's instructions with the following modifications. Cells wereseeded at 5×10³/well and incubated 24 h at 37° C.+5% CO₂. Cells wereincubated with 100 nM antibody for with 30 min followed by a 15 minincubation with rhHRG-f31. Cells were washed, fixed, and permeabilizedaccording to the instructions. Secondary antibodies (1:5000; JacksonImmunoReasearch, HRP-donkey anti-mouse IgG, JIR, Cat#715-036-150,HRP-donkey anti-rabbit IgG, JIR, Cat#711-036-452) were added and theassay processed according to the manufacturer's instructions.

The results in FIG. 15 show that incubation with exemplary anti-HER2biparatopic antibody mediated an approximate 1.2-fold reduction in p-Aktlevels in the presence of HRGβ1 relative to the human IgG control (CTL).The combination of two anti-HER2 FSAs (v506+v4184) mediated the greatestreduction in p-Akt levels in the presence HRGβ1 that was approximately1.5-fold less compared to the human IgG control. A modest reduction inp-Akt was detected with the exemplary anti-HER2 biparatopic antibody inthe absence of ligand (HRGβ1) compared to the human IgG controlantibody.

These data show that exemplary anti-HER2 biparatopic antibody can blockligand-activated signaling in HER2+ cells.

Example 14: Effect of Biparatopic Anti-HER2 Antibody on CardiomyocyteViability

The effect of exemplary biparatopic anti-HER2 antibodies and ADCs oncardiomyocyte viability was measured in order to obtain a preliminaryindication of potentially cardiotoxic effects.

iCell cardiomyocytes (Cellular Dynamics International, CMC-100-010),that express basal levels of the HER2 receptor, were grown according themanufacturer's instructions and used as target cells to assesscardiomyocyte health following antibody treatment. The assay wasperformed as follows. Cells were seeded in 96-well plates (15,000cells/well) and maintained for 48 h. The cell medium was replaced withmaintenance media and cells were maintained for 72h. To access theeffects of antibody-induced cardiotoxicity, cells were treated for 72 hwith 10 and 100 nM of, variants alone or in combinations. To access theeffects of anthracycline-induced cardiotoxicity (alone or in combinationwith the exemplary biparatopic anti-HER2 antibodies), cells were treatedwith 3 uM (˜IC₂₀) of doxorubicin for 1 hr followed by 72 h with 10 and100 nM of, antibody variants alone or in combinations. Cell viabilitywas assessed by quantitating cellular ATP levels with the CellTiter-Glo®Luminescent Cell Viability Assay (Promega, G7570) and/or Sulphorhodamine(Sigma 230162-5G) as per the manufacturer's instructions.

The results are shown in FIG. 16A-C. The results in FIG. 16A show thatincubation of the cardiomyocytes with therapeutically relevantconcentrations of exemplary anti-HER2 biparatopic antibody (v5019) andexemplary anti-HER2 biparatopic-ADC (v6363), did not affectcardiomyocyte viability relative to the untreated control (‘mock’).

The results in FIG. 16B show that incubation of the cardiomyocytes withtherapeutically relevant concentrations of exemplary anti-HER2biparatopic antibodies (v5019, v7091 and v10000), and exemplaryanti-HER2 biparatopic-ADCs (v6363, v7148 and v10553), had no effect oncardiomyocyte viability relative to the untreated control (‘mock’).Based on the results in FIGS. 16A and 16B it is expected that exemplaryanti-HER2 biparatopic antibodies and exemplary anti-HER2biparatopic-ADCs should not induce cardiomyopathy, for example throughmitochondrial dysfunction, as is reported with other anti-HER2 targetingantibodies (Grazette L. P. et al. Inhibition of ErbB2 CausesMitochondrial Dysfunction in Cardiomyocytes; Journal of the AmericanCollege of Cardiology: 2004; 44:11).

The results in FIG. 16C show that pretreatment of the cardiomyocyteswith doxorubicin followed by incubation with therapeutically relevantconcentrations of exemplary anti-HER2 biparatopic antibodies (v5019,v7091 and v10000) and exemplary anti-HER2 biparatopic-ADCs (v6363, v7148and v10553), had no effect on cardiomyocyte viability relative to theuntreated control+doxorubicin (‘Mock+Dox’). Based on the results in FIG.16C it is expected that exemplary anti-HER2 biparatopic antibodies andexemplary anti-HER2 biparatopic-ADCs should not result in an increasedrisk of cardiac dysfunction in patients receiving concurrentanthracycline treatment (Seidman A, Hudis C, Pierri M K, et al. Cardiacdysfunction in the trastuzumab clinical trials experience. J Clin Oncol(2002) 20:1215-1221).

FIGS. 16A-C show that incubation of cardiomyocytes with the anti-HER2biparatopic antibodies and ADCs had equivalent effects compared tomonospecific anti-HER2 FSA antibody (v506), anti-HER2 FSA combination(v506+v4184) and ADC (v6246) when treated either alone, or incombination with doxorubicin. Based on these results, it is expectedthat exemplary anti-HER2 biparatopic antibodies and ADCs would not havegreater cardiotoxic effects compared to anti-monospecific anti-HER2 FSA,trastuzumab or ADC, T-DM1.

Example 15: Cytotoxicity of Exemplary Biparatopic Anti-HER2-ADCs inHER2+ Cells

The ability of exemplary biparatopic anti-HER2-ADC antibodies (v6363,v7148 and v10553) to mediate cellular cytotoxicity in HER2+ cells wasmeasured. Human IgG conjugated to DM1 (v6249) was used as a control insome cases. The experiment was carried out in HER2+ breast tumor celllines JIMT-1, MCF7, MDA-MB-231, the HER2+ ovarian tumor cell line SKOV3,and HER2+ gastric cell line NCI-N87. The cytotoxicity of exemplarybiparatopic anti-HER2-ADC antibodies in HER2+ cells was evaluated andcompared to the monospecific anti-HER2 FSA-ADC (v6246) andanti-HER2-FSA-ADC+ anti-HER2-FSA controls (v6246+v4184). The method wasconducted as described in Example 7 with the following modifications.The anti-HER2 ADCs were incubated with the target SKOV3 and JIMT-1(FIGS. 17A and B) cells for 24 h, cells washed, media replaced and cellsurvival was evaluated after 5 day incubation at 37° C. The anti-HER2ADCs were incubated with target MCF7 and MDA-MB-231 target cells for 6 h(FIGS. 17C and D), cells washed media replaced and cell survival wasevaluated at 5 days incubation at 37° C. In FIG. 17E-G, anti-HER2 ADCswere incubated continuously with target SKOV3, JIMT-1, NCI-N87 cells for5 days. Cell viability was measured as described in Example 7 usingeither AlamarBlue™ (FIGS. 17A-D) or Celltiter-Glo® (FIGS. 17E-G).

The results are shown in FIG. 17A-G and the data is summarized in Tables15 and 16.

The results in FIG. 17A and Table 15 and 16 show that exemplaryanti-HER2 biparatopic-ADC (v6363) is more cytotoxic in JIMT-1 comparedto the anti-HER2-FSA-ADC (v6246) and the combination ofanti-HER2-FSA-ADC+ anti-HER2 FSA (v6246+v4184). The exemplary anti-HER2biparatopic-ADC had a superior EC₅₀ that was approximately 13-fold lowercompared to the anti-HER2 FSA-ADC control.

The results in FIG. 17B and Table 15 show that exemplary anti-HER2biparatopic-ADC (v6363) is more cytotoxic in SKOV3 compared to theanti-HER2-FSA-ADC (v6246) and the combination of anti-HER2-FSA-ADC+anti-HER2 FSA (v6246+v4184). The exemplary anti-HER2 biparatopic-ADC hada superior EC₅₀ that was approximately 5-fold lower compared to theanti-HER2 FSA-ADC control.

The results in FIG. 17C and Table 15 show that exemplary anti-HER2biparatopic-ADC (v6363) is more cytotoxic in MCF7 compared to theanti-HER2-FSA-ADC (v6246) and the combination of anti-HER2-FSA-ADC+anti-HER2 FSA (v6246+v4184). The exemplary anti-HER2 biparatopic-ADC hada superior EC₅₀ that was approximately 2-fold lower compared to theanti-HER2 FSA-ADC control.

The results in FIG. 17D and Table 15 show that exemplary anti-HER2biparatopic-ADC (v6363) is more cytotoxic in MDA-MB-231 compared to theanti-HER2-FSA-ADC (v6246) and the combination of anti-HER2-FSA-ADC+anti-HER2 FSA (v6246+v4184). The exemplary anti-HER2 biparatopic-ADC hada superior EC₅₀ that was approximately 2-fold lower compared to theanti-HER2 FSA-ADC control.

TABLE 15

v6246 0.9225 5.942 122.0 ~1075 v6246 + 4184 3.146 12.68 ~24432 136.4v6363 0.1776 0.4443 58.55 141.0

indicates data missing or illegible when filed

The results in FIG. 17E and Table 16 show that exemplary anti-HER2biparatopic-ADCs (v6363, v7148 and v10553) are more cytotoxic in SKOV3ovarian tumor cells compared to the anti-HER2-FSA-ADC (v6246). Theexemplary anti-HER2 biparatopic-ADCs had a superior EC₅₀ values thatwere approximately 2 to 7-fold lower compared to the anti-HER2 FSA-ADCcontrol.

The results in FIG. 17F and Table 16 show that exemplary anti-HER2biparatopic-ADCs (v6363, v7148 and v10553) are more cytotoxic in JIMT-1breast tumor cells compared to the anti-HER2-FSA-ADC (v6246). Theexemplary anti-HER2 biparatopic-ADCs had a superior EC₅₀ values wereapproximately 6 to 9-fold lower compared to the anti-HER2 FSA-ADCcontrol.

The results in FIG. 17G and Table 16 show that exemplary anti-HER2biparatopic-ADCs (v6363, v7148 and v10553) are cytotoxic in NCI-N87gastric tumor cells. The exemplary anti-HER2 biparatopic-ADCs had hasapproximately equivalent EC₅₀ values compared to the anti-HER2 FSA-ADCcontrol.

TABLE 16 Antibody EC₅₀ (nM) variant SKOV3 JIMT-1 NCI-N87 v6246 0.22 3.521.04 v6363 0.03 0.56 1.33 v7148 0.06 0.56 2.74 v10553 0.09 0.39 1.69These results show that exemplary anti-HER2 biparatopic-ADCs (v6363,v7148 and v10553) are more cytotoxic compared to anti-HER-FSA-ADCcontrol in HER2 3+, 2+, and 1+ breast tumor cells. These results alsoshow that exemplary anti-HER2 biparatopic-ADCs (v6363, v7148 and v10553)are cytotoxic in HER2 2/3+ gastric tumor cells. These results areconsistent with the internalization results presented in Example 9.

Example 16: Effect of a Biparatopic Anti-HER2 Antibody in a HumanOvarian Cancer Cell Xenograft Model

The established human ovarian cancer cell derived xenograft model SKOV3was used to assess the anti-tumor efficacy of an exemplary biparatopicanti-HER2 antibody.

Female athymic nude mice were inoculated with the tumor via theinsertion of a 1 mm³ tumor fragment subcutaneously. Tumors weremonitored until they reached an average volume of 220 mm³; animals werethen randomized into 3 treatment groups: IgG control, anti-HER2 FSA(v506), and biparatopic anti-HER2 antibody (v5019).

Fifteen animals were included in each group. Dosing for each group is asfollows:

A) IgG control was dosed intravenously with a loading dose of 30 mg/kgon study day 1 then with maintenance doses of 20 mg/kg twice per week tostudy day 39.

B) Anti-HER2 FSA (v506) was dosed intravenously with a loading dose of15 mg/kg on study day 1 then with maintenance doses of 10 mg/kg twiceper week to study day 18. On days 22 through 39, 5 mg/kg anti-HER2 FSAwas dosed intravenously twice per week. Anti-HER2 FSA (v4184) was dosedsimultaneously at 5 mg/kg intraperitoneally twice per week.

C) Biparatopic anti-HER2 antibody was dosed intravenously with a loadingdose of 15 mg/kg on study day 1 then with maintenance doses of 10 mg/kgtwice per week to study day 39.

Tumor volume was measured twice weekly over the course of the study,number of responders and median survival was assessed at day 22. Theresults are shown in FIG. 18 and Table 17.

The biparatopic anti-HER2 and anti-HER2 FSA demonstrated superior tumorgrowth inhibition compared to IgG control. The biparatopic anti-HER2antibody induced superior tumor growth inhibition compared to anti-HER2FSA combination (FIG. 18A). The biparatopic anti-HER2 antibody wasassociated with an increase in the number of responding tumors comparedto anti-HER2 FSA v506 at day 22 (11 and 5, respectively)(Table 17). Theexemplary biparatopic anti-HER2 antibody and anti-HER2 FSA demonstratedsuperior survival compared to IgG control. The biparatopic anti-HER2antibody had a superior median survival (61 days) compared to anti-HER2FSA (36 days)(FIG. 18B and Table 17). On study day 22 a second anti-HER2FSA (v4184) was added in combination to the anti-HER2 FSA (v506). Thecombination of two anti-HER2 FSAs induced a further tumour growthinhibition compared to anti-HER2 FSA (v506) alone.

TABLE 17 n = 15, Day 22 IgG v506 v5019 Mean TV 1908 (+766%) 1291 (+486%)697 (+217%) (mm3) (% change from Baseline) % TGI  0 32 63 Responders0/15 5/15 11/15 (TV <50% of control) Median Survival (days) 22 36 61

Example 17: Effect of a Biparatopic Anti-HER2 Antibody Drug Conjugate(ADC) in a Human Ovarian Cancer Cell Line Xenograft Model

The established human ovarian cancer cell derived xenograft model SKOV3was used to assess the anti-tumor efficacy of an exemplary biparatopicanti-HER2 antibody conjugated to DM1 (v6363).

Female athymic nude mice were inoculated with the tumor via theinsertion of a 1 mm³ tumor fragment subcutaneously. Tumors weremonitored until they reached an average volume of 220 mm³; animals werethen randomized into 3 treatment groups: IgG control, anti-HER2 FSA-ADC,and a biparatopic anti-HER2-ADC.

Fifteen animals were included in each group. Dosing for each group is asfollows:

A) IgG control was dosed intravenously with a loading dose of 30 mg/kgon study day 1 then with maintenance doses of 20 mg/kg twice per week tostudy day 39.

B) Anti-HER2 FSA-ADC (v6246) was dosed intravenously with a loading doseof 10 mg/kg on study day 1 then with a maintenance dose of 5 mg/kg onday 15 and 29.

C) Biparatopic anti-HER2 antibody-ADC (v6363) was dosed intravenouslywith a loading dose of 10 mg/kg on study day 1 then with a maintenancedose of 5 mg/kg on day 15 and 29.

Tumor volume was measured throughout the study, and the number ofresponders and median survival was assessed at day 22. The results areshown in FIG. 19. A summary of the results is shown in Table 18.

The biparatopic anti-HER2-ADC and anti-HER2 FSA-ADC inhibited tumorgrowth better than IgG control (FIG. 19A and Table 18). The biparatopicanti-HER2-ADC inhibited tumor growth to a greater degree than did theanti-HER2 FSA-ADC. The biparatopic anti-HER2-ADC group was associatedwith an increase in the number of responding tumors compared toanti-HER2 FSA-ADC (11 and 9, respectively). The biparatopicanti-HER2-ADC and anti-HER2 FSA-ADC groups demonstrated superiorsurvival compared to IgG control (FIG. 19B and Table 18). Thebiparatopic anti-HER2 antibody group demonstrated median survival of 61days compared to the anti-HER2 FSA-ADC which had a median survival of 36days (FIG. 19B and Table 18).

TABLE 18 n = 15, Day 22 IgG v6246 v6363 Mean TV 1908 (+766%) 873 (+297%)632 (+187%) (mm3) (% change from Baseline) % TGI  0 54% 67% Responders0/15 9/15 11/15 (TV <50% of control) Median survival (days) 22 36 61

Example 18: Effect of a Biparatopic Anti-HER2 Antibody Drug Conjugate(ADC) in a Human Primary Cell Xenograft Model (HBCx-13b)

The trastuzumab resistant patient derived xenograft model from humanbreast cancer, HBCx-13B, was used to assess the anti-tumor efficacy ofan exemplary biparatopic anti-HER2 antibody conjugated to DM1.

Female athymic nude mice were inoculated with the tumor via theinsertion of a 20 mm³ tumor fragment subcutaneously. Tumors weremonitored until they reached an average volume of 100 mm³; animals werethen randomized into 3 treatment groups: anti-HER2 FSA (v506), anti-HER2FSA-ADC (v6246), and the biparatopic anti-HER2-ADC (v6363). Sevenanimals were included in each group. Dosing for each group was asfollows:

A) Anti-HER2 FSA was dosed intravenously with a loading dose of 15 mg/kgon study day 1 and maintenance doses of 10 mg/kg administered on studydays 4, 8, 11, 15, 18, 22, and 25.

B) Anti-HER2 FSA-ADC was dosed intravenously with a loading dose of 10mg/kg on study day 1 then with a maintenance dose of 5 mg/kg on day 22.

C) Biparatopic anti-HER2 antibody-ADC was dosed intravenously with aloading dose of 10 mg/kg on study day 1 then with a maintenance dose of5 mg/kg on day 22.

Tumor volume was measured throughout the study, and mean tumor volume,complete response, and zero residual disease parameters were assessed atDay 50. The results are shown in FIG. 20. A summary of the results isshown in Table 19.

The biparatopic anti-HER2-ADC and anti-HER2 FSA-ADC demonstrated greatertumor growth inhibition compared to an anti-HER2 FSA (v506). Thebiparatopic anti-HER2-ADC inhibited tumor growth better than theanti-HER2 FSA-ADC. The biparatopic anti-HER2-ADC group as compared tothe anti-HER2 FSA-ADC group was associated with an increase in thenumber of tumors showing complete responses (more than a 10% decreasebelow baseline), 7 and 4 respectively, and showing zero residualdisease, 5 and 2 respectively.

TABLE 19 n = 7, Day 50 v506 v6246 v6363 Mean TV 1149 (+1018%) 262(+153%) 26 (−75%) (mm3) (% change from Baseline) % TGI 0% 77% 98%Complete response 0 4/7 7/7 (>10% baseline regression) Zero residualdisease 0 2/7 5/7 (TV <20 mm3)

Example 19: Effect of a Biparatopic Anti-HER2 Antibody Drug Conjugate(ADC) in a Human Primary Cell Xenograft Model (T226)

The patient derived trastuzumab resistant xenograft model from humanbreast cancer, T226, was used to assess the anti-tumor efficacy of anexemplary biparatopic anti-HER2-ADC.

Female athymic nude mice were inoculated with the tumor via theinsertion of a 20 mm³ tumor fragment subcutaneously. Tumors weremonitored until they reached an average volume of 100 mm³; animals werethen randomized into 4 treatment groups: IgG control (n=15), anti-HER2FSA (v506; n=15), anti-HER2 FSA-ADC (v6246; n=16), and the biparatopicanti-HER2-ADC conjugate (v6363; n=16). Dosing for each group was asfollows:

A) IgG control was dosed intravenously with a loading dose of 15 mg/kgon study day 1 and maintenance doses of 10 mg/kg administered on studydays 4, 8, 11, 15, 18, 22, and 25

B) Anti-HER2 FSA was dosed intravenously with a loading dose of 15 mg/kgon study day 1 and maintenance doses of 10 mg/kg administered on studydays 4, 8, 11, 15, 18, 22, and 25

C) Anti-HER2 FSA-ADC was dosed intravenously with 5 mg/kg on study days1 and 15

D) Biparatopic anti-HER2-ADC conjugate was dosed intravenously with 5mg/kg on study days 1 and 15.

Tumor volume was measured throughout the course of the study, and meantumor volume and complete response parameters were assessed at day 31.The results are shown in FIG. 21. A summary of the results is shown inTable 20.

The biparatopic anti-HER2-ADC and anti-HER2 FSA-ADC demonstrated bettertumor growth inhibition compared to the anti-HER2 FSA (v506) and IgGcontrol. The exemplary biparatopic anti-HER2-ADC induced equivalenttumor growth inhibition and complete baseline regression compared toanti-HER2 FSA-ADC (FIG. 21 and Table 20) in this model.

TABLE 20 v506 v6363 Day 31 IgG (n = 13) (n = 13) v6246 (n = 16) (n = 16)Mean TV 1797 1611 422 572 (mm3) (% change (+1728%) (+1573) (+332%)(+483%) from Baseline) % TGI (vs. hIgG) 0% 11% 77% 68% Complete response0/13 0/14 1/16 1/16 (>10% baseline regression)

Example 20: Effect of a Biparatopic Anti-HER2 Antibody Drug Conjugate(ADC) in a Human Primary Cell Xenograft Model (HBCx-5)

The patient derived trastuzumab resistant xenograft model from humanbreast cancer, HBCx-5 (invasive ductal carcinoma, luminal B), was usedto assess the anti-tumor efficacy of an exemplary biparatopicanti-HER2-ADC.

Female athymic nude mice were inoculated with the tumor via theinsertion of a 20 mm³ tumor fragment subcutaneously. Tumors weremonitored until they reached an average volume of 100 mm³; animals werethen randomized into 4 treatment groups: IgG control (n=15), anti-HER2FSA (v506; n=15), anti-HER2 FSA-ADC (v6246; n=16), and the biparatopicanti-HER2-ADC (v6363; n=16). Dosing for each group was as follows:

A) IgG control was dosed intravenously with a loading dose of 15 mg/kgon study day 1 and maintenance doses of 10 mg/kg administered on studydays 4, 8, 11, 15, 18, 22, and 25

B) Anti-HER2 FSA was dosed intravenously with a loading dose of 15 mg/kgon study day 1 and maintenance doses of 10 mg/kg administered on studydays 4, 8, 11, 15, 18, 22, and 25

C) Anti-HER2 FSA-ADC was dosed intravenously with 10 mg/kg on study days1 and 15, 22, 29, 36

D) Biparatopic anti-HER2-ADC was dosed intravenously with 10 mg/kg onstudy days 1 and 15, 22, 29, 36.

Tumor volume was measured throughout the course of the study, and themean tumor volume, T/C ratio, number of responders, complete response,and zero residual disease parameters were assessed at day 43. Theresults are shown in FIG. 22. A summary of the results is shown in Table21.

The biparatopic anti-HER2-ADC and anti-HER2 FSA-ADC demonstrated bettertumor growth inhibition compared to an anti-HER2 FSA (v506) and IgGcontrol. The exemplary biparatopic anti-HER2-ADC induced equivalenttumor growth inhibition and had an increased number of responderscompared to anti-HER2 FSA-ADC (FIG. 22 and Table 21) in the trastuzumabresistant HBCx-5 human breast cancer xenograft model.

TABLE 21 IgG Herceptin T-DM1 6363 Day 43 (n = 4) (n = 5) (n = 7) (n = 7)Mean TV 922 815 193 241 (mm3) (% change (+693%) (+598%) (+65%) (+106%)from Baseline) T/C (IgG) ratio 1 0.88 0.21 0.26 Responders 0/4 1/5 6/77/7 (TV<50% of control) Complete response 0/4 0/5 1/7 0/7 (>10% baselineregression) Zero residual disease 0/4 0/5 0/7 0/7 (TV <20 mm3)

Example 21: Effect of a Biparatopic Anti-HER2 Antibody Drug Conjugate(ADC) to Anti-HER2 Treatment Resistant Tumors in a Human Cell LineXenograft Model (SKOV3)

The established human ovarian cancer cell derived xenograft model SKOV3,described in Example 17, was used to assess the anti-tumor efficacy ofan exemplary biparatopic anti-HER2-ADC in anti-HER2 treatment resistanttumors.

The methods were followed as described in Example 17 with the followingmodifications. A cohort of animals was dosed with an anti-HER2 antibodyintravenously with 15 mg/kg on study day 1 and with 10 mg/kg on day 4,8, 15; however, this treatment failed to demonstrate an efficaciousresponse by day 15 in this model. This treatment group was thenconverted to treatment with the exemplary biparatopic anti-HER2 antibodydrug conjugate (v6363) and was dosed with 5 mg/kg and on study day 19and 27 and 15 mg/kg on study day 34, 41 and 48.

Tumor volume was measured twice weekly throughout the course of theexperiment.

The results are shown in FIG. 23 and indicate that the group treatedwith exemplary biparatopic anti-HER2-ADC (v6363) showed tumor regressionto a mean tumor volume less than the initial mean starting volume of 220mm³.

Example 22: Effect of a Biparatopic Anti-HER2 Antibody Drug Conjugate(ADC) on Anti-HER2 Treatment Resistant Tumors in Human Primary CellXenograft Model (HBCx-13b)

The trastuzumab resistant patient derived xenograft model from humanbreast cancer, HBCx-13B, was used to assess the anti-tumor efficacy ofan exemplary biparatopic anti-HER2 antibody conjugated to DM1.

The methods were followed as described in Example 18 with the followingmodifications. A cohort of animals was dosed with a bi-specificanti-ErbB family targeting antibody intravenously with 15 mg/kg on studyday 1 and with 10 mg/kg on day 4, 8, 15, 18, 22, and 25; however, thistreatment failed to demonstrate an efficacious response. This treatmentgroup was then converted to treatment with the exemplary biparatopicanti-HER2 antibody drug conjugate (v6363) and was dosed with 10 mg/kg ondays 31, 52 and with 5 mg/kg on day 45. Tumor volume was measuredthroughout the duration of the study.

The results are shown in FIG. 24. These results show that the exemplarybiparatopic anti-HER2-ADC (v6363) prevented tumour progression. From thefirst dose to day 57 the tumour volume of the v6363 treated groupincreased by less than 2% while in the same interval the v506 treatedgroup grew by more than 110%.

Example 23: Analysis of Fucose Content of an Exemplary BiparatopicAnti-HER2 Antibody

Glycopeptide analysis was performed to quantify the fucose content ofthe N-linked glycan of the exemplary biparatopic anti-HER2 antibodies(v5019, v7091 and v10000).

The glycopeptide analysis was performed as follows. Antibody sampleswere reduced with 10 mM DTT at 56° C. 1 h and alkylated with 55 mMiodoacetamide at RT 1 h and digested in-solution with trypsin in 50 mMammonium bicarbonate overnight at 37° C. Tryptic digests were analyzedby nanoLC-MS/MS on a QTof-Ultima. The NCBI database was searched withMascot to identify protein sequences. MaxEnt3 (MassLynx) was used todeconvolute the glycopeptide ions and to quantify the differentglycoforms.

A summary of the glycopeptide analysis results is in Table 22. TheN-linked glycans of exemplary biparatopic anti-HER2 antibodies (v5019,v7091 and v10000) are, approximately 90% fucosylated (10% N-linkedglycans without fucose). The N-linked glycans of monospecific anti-HER2FSA (v506) are, approximately 96% fucosylated (4% N-linked glycanswithout fucose) and Herceptin® is approximately 87% fucosylated (4%N-linked glycans without fucose).

TABLE 22 Fc N-linked Glycopeptide Analysis Average Antibody % ofGlycopeptides Average % of Glycopeptides Variant Observed With FucoseObserved Without Fucose n v506 96.4 3.6 5 Herceptin ® 86.5 13.4 4 v501990.5 9.4 6 v7091 89.9 26.9 3 v10000 89.2 10.7 5

These results show that biparatopic anti-HER2 antibodies (with aheterodimeric Fc), expressed transiently in CHO cells, haveapproximately 3% higher fucose content in the N-glycan compared tocommercial Herceptin®. The homodimeric anti-HER2 FSA (v506), expressedtransiently in CHO cells, has the highest fucose content ofapproximately 96%.

Example 24: Thermal Stability of an Exemplary Biparatopic Anti-HER2Antibody

Thermal stability of exemplary biparatopic anti-HER2 antibodies (v5019,v7091 and v10000) and ADCs (v6363, v7148 and v10533) was measured by DSCas described below.

DSC was performed in the MicroCal™ VP-Capillary DSC (GE Healthcare)using a purified protein sample (anti-HER2 biparatopic antibodies andanti-HER2 biparatopic-ADCs) adjusted to about 0.3 mg/ml in PBS. Thesample was scanned from 20 to 100° C. at a 60° C./hr rate, with lowfeedback, 8 sec filter, 5 min preTstat, and 70 psi nitrogen pressure.The resulting thermogram was analyzed using Origin 7 software.

The thermal stability results of exemplary biparatopic anti-HER2antibodies (v5019, v7091 and v10000) are shown in FIG. 25A-C. FIG. 25Ashows the thermogram for v5019; the Fc and chain A Fab of each have aT_(m) of 75° Celsius and the chain B scFv of 5019 has a T_(m) of 69°Celsius. FIG. 25B shows the thermogram for v10000; the Fc CH3 domain hasa T_(m) 82° Celsius, Fab chain A has T_(m) of 76.5° Celsius and thechain B scFv has a T_(m) of 69.5° Celsius. FIG. 25C shows the thermogramfor v7091; the Fc CH3 domain has a T_(m) 82° Celsius, Fab chain A hasT_(m) of 76.7° Celsius and the chain B scFv has a T_(m) of 69.5°Celsius.

The thermal stability results of exemplary biparatopic anti-HER2 ADCs(v6363, v7148 and v10533) are shown in FIG. 26A-C. FIG. 26A shows thethermogram for v6363; the Fc has a T_(m) of 75° Celsius and the chain AFab and Fc CH3 domain have a T_(m) of 75° Celsius. The chain B scFv of6363 has a T_(m) of 69° Celsius. FIG. 26B shows the thermogram forv10553; the Fc CH3 domain has a T_(m) of 83° Celsius, the chain A Fabhas a T_(m) of 75.7° Celsius and the chain B scFv has a T_(m) of 66.2°Celsius. FIG. 26C shows the thermogram for v7148; the Fc CH3 domain hasa T_(m) of 82.6° Celsius, the chain A Fab has a T_(m) of 74.8° Celsiusand the chain B scFv has a T_(m) of 66.6° Celsius.

The exemplary biparatopic antibodies and ADCs have thermal stabilitycomparable to wildtype IgG.

Example 25: Ability of an Exemplary Biparatopic Anti-HER2 Antibody toElicit ADCC of Breast Tumor Cells Expressing Varying Levels of HER2

The ability of exemplary biparatopic antibody (v5019) to elicitdose-dependent ADCC of HER2 positive 3+, 2+, and 0/1+ HER2 expressing(triple-negative) breast cancer cell lines was examined. The ADCCexperiments were performed as described in Example 11 with the exceptionthat NK effector cell to target cell ratio remained constant at 5:1.

The ADCC results are shown in FIG. 27 and Table 23. The results in FIG.27A-C show that exemplary biparatopic antibody (v5019) elicitsapproximately 1.2 to 1.3-fold greater maximum cell lysis of HER2positive 3+, 2+ and 0/1+ HER2 expressing breast cancer cells compared toHerceptin®. The results also show that v5019 (90% N-glycans with fucose)more effectively mediates ADCC of HER2 positive 3+, 2+ and 0/1+ HER2expressing breast cancer despite having approximately a 4% higher fucosecontent in the N-glycan (resulting in lower binding affinity to CD16 onNK cells) compared to Herceptin® (86% N-glycans with fucose; Example23). The higher target cell killing elicited by v5019 is presumably dueto increased tumor cell decoration as described in Example 6.

TABLE 23 ADCC of HER2 3+, 2+ and 0/1+ HER2 expressing breast cancercells SKBr3 HER2 3+ JIMT-1 HER2 2+ Max % Max % MDA-MB-231 HER2 0/1+Target Cell EC₅₀ Target EC₅₀ Max % Target EC₅₀ Treatment Lysis (nM) CellLysis (nM) Cell Lysis (nM) v5019 30 ~0.9 60 0.001 53 0.9 Herceptin ® 23~0.9 51 0.002 44 0.9

The ADCC results in FIG. 27D show that exemplary biparatopic antibodies(v7091 and v10000) elicit similar maximal cell lysis compared toHerceptin® in the basal HER2 expressing WI-38 cell line. The ADCCresults support the cell binding data (Example 6), showing that athreshold for increased binding and ADCC occurs when the HER2 receptorlevels are greater than 10,000 HER2/cell. Based on this data it would beexpected that the exemplary biparatopic anti-HER2 antibodies would haveincreased cell surface binding and ADCC of HER2 3+, 2+ and 1+ tumorcells but would not have increase cell surface binding and ADCC ofnon-tumor cells that express basal levels of the HER2 receptor atapproximately 10,000 receptors or less.

Example 26: Effect of Antibody Afucosylation on ADCC

The ability of afucosylated exemplary biparatopic antibodies(v5019-afuco, 10000-afuco) to elicit dose-dependent ADCC of HER2positive 2/3+, 2+ and 0/1+ HER2 expressing (triple-negative) breastcancer cell lines, was examined. ADCC experiments were performed asdescribed in Example 11, in SKOV3 cells, MDA-MB-231 cells and ZR75-1cells with the exception that a constant NK effector cell or PBMCeffector to target (E:T) cell ratio of 5:1 was used. Afucosylatedexemplary biparatopic antibodies were produced transiently in CHO cellsas described in Example 1, using the transiently expressed RMD enzyme asdescribed in von Horsten et al. 2010 Glycobiology 20:1607-1618. Thefucose content of v5019-afuco and v10000-afuco were measured asdescribed in Example 23 and determined to be less <2% fucosylated (datanot shown). Data using NK effector cells is shown in FIG. 28A-B, whiledata using PBMCs is shown in FIG. 28C.

FIG. 28A, FIG. 28B and Table 24 show that afucosylated v5019(v5019-afuco) elicits ADCC of HER 2/3+ and 0/1+ HER2 expressing breastcancer cells with approximately 1.5 to 1.7-fold higher maximum celllysis than Herceptin®.

TABLE 24 ADCC of HER2 2/3+ and basal HER2 expressing (triple-negative)breast cancer cells MDA- SKOV3 HER2 2+/3+ MD-231 HER2 0/1+ Max % TargetMax % Target Treatment Cell Lysis  EC₅₀ (nM) Cell Lysis EC₅₀ (nM) v5019-24 ~0.6 58 ~0.6 afucosylated Herceptin ® 14 ~0.6 40 ~0.3

The results in FIG. 28C and Table 25 show that v10000 elicits ADCC ofHER2 2+ ZR-75-1 breast cancer cells with approximately 1.3-fold greatermaximal cell lysis than Herceptin®, and v10000-afuco elicitsapproximately 1.5-fold greater maximal cell lysis than Herceptin®.

TABLE 25 ADCC of HER2 2/3+ breast cancer cells ZR-751 HER2 2+ Max %Target Treatment Cell Lysis EC₅₀ (nM) v10000 28 ~0.06v10000-afucosylated 32 ~0.7 Herceptin ® 21 ~0.5

The ADCC results show that the exemplary afucosylated biparatopicantibodies (v5019-afuco, v10000-afuco) elicit approximately 15-25%greater maximum cell lysis compared to the fucosylated antibodies (v5019Example 25, v10000) when Herceptin® is used as a benchmark. Theseresults show that reducing the fucose content of the Fc N-glycan resultsin increased maximal cell lysis by ADCC.

Example 27: Ability of Exemplary Biparatopic Anti-HER2 Antibody toInhibit Growth of HER2 3+ Breast Cancer Cells in the Presence ofExogenous Growth-Stimulatory Ligands (EGF and HRG)

The ability of 5019 to inhibit growth of HER2 3+ breast cancer cells inthe presence of exogenous growth-stimulatory ligands (EGF and HRG) wasexamined.

Test antibodies and exogenous ligand (10 ng/mL HRG or 50 ng/mL EGF) wereadded to the target BT-474 HER2 3+ cells in triplicate and incubated for5 days at 37° C. Cell viability was measured using AlamarBlue™ (37° C.for 2 hr), absorbance read at 530/580 nm. Data was normalised tountreated control and analysis was performed using GraphPad Prism.

The results are shown in FIG. 29 and Table 26. The results show thatexemplary biparatopic antibody v5019 inhibits the growth of HER2 3+breast cancer cells in the absence of growth stimulatory ligand (70%inhibition), as well as in the presence of EGF (40% inhibition) or HRG(˜10% inhibition). The anti-HER2 monospecific FSA (v506) does not blockEGF or HRG induced tumor cell growth via other erbB receptors EGFR andHER3. v5019 is superior to v506 in inhibiting HER2 and ligand-dependentdimerization and growth via other companion erbB receptors.

TABLE 26 Growth Inhibition of HER2 3+ Cancer Cells % Survival TreatmentAntibody only +EGF +HRG Mock 100 122 110 v506 41 114 129 v5019 31 56 92

These results show that exemplary biparatopic antibody is capable ofreducing ligand-dependent growth of HER2+ cells, presumably due bindingof the anti-ECD2 chain A Fab arm and subsequent blocking of ligandstimulated receptor homo- and heterodimerization, and erbB signaling.

Example 28: Effect of a Biparatopic Anti HER2 Antibody in aTrastuzumab-Resistant and Chemotherapy Resistant HER2 3+ Patient-Derived(PDX) Metastatic Breast Cancer Xenograft Model of Invasive Ductal BreastCarcinoma

The HER2 3+ (ER-PR negative) patient derived xenograft model frominvasive ductal human breast cancer, HBCx-13B, was used to assess theanti-tumor efficacy of an exemplary biparatopic anti-HER2 antibody,v7187. v7187 is an afucosylated version of v5019. The model is resistantto single agent trastuzumab, the combination of trastuzumab andpertuzumab (see example 31), capecitabine, docetaxel, andadriamycin/cyclophosphamide.

Female athymic nude mice were inoculated subcutaneously with a 20 mm³tumor fragment. Tumors were then monitored until reaching an averagevolume of 140 mm3. Animals were then randomized into 2 treatment groups:vehicle control and v7187 with eight animals in each group. IV Dosingwas as follows. Vehicle control was dosed intravenously with 5 ml/kg offormulation buffer twice per week to study day 43. v7187 was dosedintravenously with 10 mg/kg twice per week to study day 43. Tumor volumewas measured throughout the study, and other parameters assessed at day43 as shown in Table 27.

The results are shown in FIG. 30 and Table 27. The results show thattumors treated with vehicle control showed continual progression andexceeded 1600 mm³ by study day 43. Mice treated with v7187 showedsignificantly greater tumor growth inhibition (T/C−0.44) with a meantumor volume of 740 mm³ on day 43. v7187 induced responses in 5/8 tumorswith a single tumor showing complete regression with zero residualdisease on study day 43. Animals treated with v7187 had a superiorresponse rate with 5/8 tumors responding to therapy compared to 0/8 micetreated with vehicle control. In addition, treatment with v7187significantly delayed tumor progression compared to vehicle control withdoubling times of 19 and 11 days respectively.

TABLE 27 Tumour Response Vehicle V7087 Day 43 Mean TV (mm3) 1683 740  (%Change from (+1079%) (+422%) Baseline) T/C ratio   1    0.44 Responders0/8 5/8 (TV < 50% of control) PR (>10% 0/8 1/8 baseline regression) ZRD(TV < 20 mm3) 0/8 1/8 Time to Doubling  11 19 progression time (days)

These data show that the exemplary anti-HER2 biparatopic (v7187) isefficacious in a Trastuzumab+Pertuzumab resistant HER2 3+ metastaticbreast cancer tumor xenograft model. V7187 treatment has a high responserate and can significantly impair tumor progression of standard of caretreatment resistant HER2 3+ breast cancers.

Example 29: Assessment of Biparatopic Anti-HER2 ADC Binding to HER2+Tumor Cell Lines

The ability of exemplary biparatopic anti-HER2 ADCs to bind and saturateHER2 positive 3+, 2+, breast and ovarian tumor cell lines was analyzedby FACS as described in Example 6.

The data is shown in FIG. 31. FIG. 31A shows v6363 binding to SKOV3tumor cell lines with approximately a 2.0-fold greater Bmax (MFI) thanT-DM1 (v6246) at saturating concentrations. FIG. 31B shows v6363 bindsto JIMT-1 tumor cell lines with approximately a 1.6-fold greater Bmax(MFI) than T-DM1 (v6246) at saturating concentrations. These data showthat v6363 (ADC) has similar tumor cell binding properties of increasedcell surface binding compared to the parent unconjugated v5019 antibody(Example 6). Conjugation of v5019 with SMCC-DM1 (v6363) does not alterthe antigen-binding properties of the antibody.

The FACS binding assay was repeated to include direct comparison to theexemplary biparatopic antibodies (v5019, v7091 and v10000) and ADCs(v6363, v7148 and v10553). The data is shown in FIG. 31C and FIG. 31D.The exemplary biparatopic anti-HER2 ADCs (v6363, v7148 and v10553) haveequivalent cell surface saturation (Bmax) compared to the unlabeledbiparatopic antibodies (v5019, v7091 and v10000).

These data show that conjugation of exemplary biparatopic antibodies(v5019, v7091 and v10000) with SMCC-DM1 does not alter the bindingproperties. The exemplary anti-HER2 biparatopic anti-HER2 ADCs (v6363,v7148 and v10553) have approximately 1.5-fold (or greater) increasedcell surface binding compared to a monospecific anti-HER2 ADC (v6246,T-DM1).

Example 30: Dose-Dependent Tumour Growth Inhibition of an ExemplaryAnti-HER2 Biparatopic-ADC in a HER2 3+ (ER-PR Negative) Patient DerivedXenograft Model

The HER2 3+ (ER-PR negative) patient derived xenograft model frominvasive ductal human breast cancer, HBCx-13B, was used to assess theanti-tumor efficacy of an exemplary biparatopic anti-HER2 ADC, v6363.The model is resistant to single agent trastuzumab, the combination oftrastuzumab and pertuzumab (see example 31), capecitabine, docetaxel,and adriamycin/cyclophosphamide.

Female athymic nude mice were inoculated with the tumor via thesubcutaneous insertion of a 20 mm³ tumor fragment. Tumors were monitoreduntil they reached an average volume of 160 mm³; animals were thenrandomized into 5 treatment groups: non-specific human IgG control, and4 escalating doses of v6363. 8-10 animals were included in each group.Dosing for each group was as follows. IgG control was dosedintravenously with 10 mg/kg twice per week to study day 29. v6363 wasdosed intravenously with 0.3, 1, 3, or 10 mg/kg on study days 1, 15, and29. Tumor volume was assessed throughout the study and parametersassessed as indicated in Table 29.

The results are shown in FIG. 32 and Table 28. These results show thatthe exemplary anti-HER2 biparatopic ADC (v6363) mediated dose-dependenttumor growth inhibition in the Trastuzumab-resistant HBCx-13b PDX model(FIG. 32A). In addition, v6363 improved overall survival in adose-dependent manner, with median survival time of more than 63 daysfor 3 mg/kg and 10 mg/kg doses compared to 43 days for IgG control (FIG.32B and Table 28). The 3 mg/kg dose was associated with an increasedresponse rate (5/10) compared to control (0/8). All mice treated withv6363 at 10 mg/kg dose not only responded to therapy (9/9) but alsoshowed prevention of tumor progression. Moreover, the majority of tumorshad objective partial responses (7/9) and, at the end of the study, manyhad zero residual disease (6/9). v6363 was well tolerated at all doses,no adverse events were observed and no body weight loss was observed.

TABLE 28 6363 6363 6363 6363 0.3 1 3 10 Tumour Response IgG mg/kg mg/kgmg/kg mg/kg Day 43 Mean TV 1963 1916 1613 1268 84 (mm3) (% (+1119%)(+1073%) (+895%) (+682%) (−49%) change from Baseline) T/C (IgG) 1 0.970.82 0.64 0.04 ratio Re- 0/8 0/10 2/10 5/10 9/9 sponders (TV < 50% ofcontrol) PR 0/8 0/10 0/10 0/10 7/9 (>10% baseline re- gression) ZRD 0/80/10 0/10 0/10 6/9 (TV < 20 mm3) Time to Tumor 9 9 14 17 52 pro-doubling gression time (days) Survival Median 43 41 50 >63 >63 Re-Survival sponse (Days) Body % Change  +10%  +10%  +9%  +5%  +0% Weightfrom Baseline

These data show that the exemplary anti-HER2 biparatopic ADC (v6363) isefficacious in a Trastuzumab+Pertuzumab resistant HER2 3+ metastaticbreast cancer tumor xenograft model. v6363 treatment is associated witha high response rate, significantly impairs tumor progression, andprolongs survival in a standard of care resistant HER2 3+ breastcancers.

Example 31: Biparatopic Anti-HER2-ADC Compared to Standard of CareCombinations in the Trastuzumab Resistant PDX HBCx-13b

The efficacy of v6363 in a HER2 3+, ER-PR negative Trastuzumab resistantpatient-derived breast cancer xenograft model (HBCx-13b), was evaluatedand compared to to the combination of: Herceptin™+Perjeta™; andHerceptin™+Docetaxel.

Female athymic nude mice were inoculated with the tumor via thesubcutaneous insertion of a 20 mm3 tumor fragment. Tumors were monitoreduntil they reached an average volume of 100 mm3; animals were thenrandomized into 4 treatment groups (8-10 animals/group): non-specifichuman IgG control, Herceptin™+Docetaxel, Herceptin™+Perjeta™, and v6363.Dosing for each group was as follow. IgG control was dosed intravenouslywith 10 mg/kg twice per week to study day 29. Herceptin™+Docetaxelcombination Herceptin™ was dosed intravenously with 10 mg/kg IV twiceweekly to study day 29 and Docetaxel was dosed intraperitoneally with 20mg/kg on study day 1 and 22. Herceptin™+Perjeta™ combination Herceptinwas dosed intravenously with 5 mg/kg twice per week to study day 29 andPerjeta™ was dosed intravenously with 5 mg/kg twice per week to studyday 29. The dosing of Herceptin™ and Perjeta™ was concurrent. v6363 wasdosed intravenously with 10 mg/kg on study day 1, 15, and 29.

The results are shown in FIG. 33 and Table 29. FIG. 33A shows tumorvolume over time, and FIG. 33B shows a survival plot. These results showthat the combination of Herceptin™+Perjeta™ did not produce any tumorgrowth inhibition compared to control IgG and exceeded 1800 mm³ on day39. The combination of Herceptin™+Docetaxel did not significantly reducetumor growth but did prolong median survival to 53 days compared to 43days for IgG control. v6363 produced significant tumor growth inhibition(T/C−0.04), where, all tumors responded to therapy and 7/10 tumorsexperienced complete regressions (zero residual disease). v6363significantly prolonged survival compared to both combination therapies.Body weights across cohorts were not significantly affected bytreatments.

TABLE 29 HerceptinTM + HerceptinTM + v6363 Tumour Response IgG PerjetaTMDocetaxel 10 mg/kg Day 39 Mean TV (mm3) 1809 1975 1328  76 (% changefrom (+1023%) (+1085%) (+714%) (−54%) Baseline) T/C (IgG) ratio    1.01.10 0.73    0.04 Responders 0/8 0/8 1/10 9/9 (TV < 50% of control) PR0/8 0/8 0/10 8/9 (>10% baseline regression) ZRD 0/8 0/8 0/10 6/9 (TV <20 mm3) Survival Median Survival  43 39 53 >63 Response (days) Body %Change from  +10%   +7%  +3%  −2% Weight Baseline

These results show that exemplary anti-HER2 biparatopic ADC (v6363) issuperior to standard of care combinations with respect to all parameterstested in this xenograft model.

Example 32: Efficacy of a Biparatopic Anti-HER2-ADC in HER2+Trastuzumab-Resistant Breast Cancer Cell Derived Tumour Xenograft Model

The efficacy of v6363 in a HER2 3+ Trastuzumab resistant breast cancercell-derived (JIMT-1, HER2 2+) xenograft model was evaluated (Tanner etal. 2004. Molecular Cancer Therapeutics 3: 1585-1592).

Female RAG2 mice were inoculated with the tumor subcutaneously. Tumorswere monitored until they reached an average volume of 115 mm³; animalswere then randomized into 2 treatment groups: Trastuzumab (n=10) andv6363. Dosing for each group was as follows. Trastuzumab was dosedintravenously with 15 mg/kg on study day 1 and 10 mg/kg twice per weekto study day 26. v6363 was dosed intravenously with 5 mg/kg on studydays 1 and 15 and with 10 mg/kg on day 23 and 30 and 9 mg/kg on day 37and 44.

The results are shown in FIG. 34 and Table 30. These results show thatv6363 significantly inhibited tumor growth (T/C−0.74) compared toTrastuzumab on study day 36. v6363 and Trastuzumab treatment did notsignificantly change body weight. v6363 serum exposure was 17.9 μg/ml 7days after the first 10 mg/kg dose.

TABLE 30 Tumour Response Trastuzumab 6363 Day 36 Mean TV (mm3)  718532   (% change from (+541) (+335%) Baseline) T/C (Tras) ratio   1  0.74Responders 1/10 2/13 (TV < 50% of control) PR 0/10 0/13 (>10% baselineregression) ZRD 0/10 0/13 (TV < 20 mm3) Body % Change from +5.8%  +3.1%Weight Baseline Drug Mean Serum   187.2 17.9 Exposure Concentration (day7) (ug/ml)

These results show that exemplary anti-HER2 biparatopic ADC (v6363) isefficacious in a Trastuzumab-resistant breast cancer and has a potentialutility in treating breast cancers that are resistant to currentstandards of care.

Example 33: FcγR Binding to Heterodimeric Fc of Anti-HER2 BiparatopicAntibodies and Anti-HER2 Biparatopic-ADCs

The binding of anti-HER2 biparatopic antibody (v5019, v7019 v10000) andADC (v6363, v7148 and v10553) having a heterodimeric Fc, to human FcγRswas assessed and compared to anti-HER2 FSA (v506) and ADC (v6246) havinga homodimeric Fc.

Affinity of FcγR to antibody Fc region was measured by SPR using aProteOn XPR36 (BIO-RAD). HER2 was immobilized (3000 RU) on CMS chip bystandard amine coupling. Antibodies were antigen captured on the HER2surface. Purified FcγR was injected various concentration (20-30 μl/min)for 2 minutes, followed by 4 minute dissociation. Sensograms were fitglobally to a 1:1 Langmuir binding model. Experiments were conducted at25° C.

The results are shown in Table 31. The exemplary heterodimeric anti-HER2biparatopic antibodies and ADCs bound to CD16aF, CD16aV158, CD32aH,CD32aR131, CD32bY163 and CD64A with comparable affinities. Conjugationof the antibodies with SMCC-DM1 does not negatively affect FcγR binding.The heterodimeric anti-HER2 biparatopic antibodies have approximately1.3 to 2-fold higher affinity to CD16aF, CD32aR131, CD32aH compared tohomodimeric anti-HER2 FSA (v506) and ADC (v6246). These results showthat the heterodimeric anti-HER2 biparatopic antibodies and ADCs binddifferent polymorphic forms of FcγRs on immune effector cells withsimilar or greater affinity than a WT homodimeric IgG1.

TABLE 31 Human Fc7R Binding by SPR 10 uM 10 uM 10 uM 10 uM 10 uM CD16av158 CD16aF CD32aR131 CD32aH CD32b Y163 100 nM CD64A Variant KD Ave SDKD Ave SD KD Ave SD KD Ave SD KD Ave SD KD Ave SD v506 1.5E−07 2E−087.1E−07 1.E−08 7.6E−07 1.E−07 6.3E−07 2E−08 2.4E−06 1.E−07 8.64E−104.33E−10 v6246 1.6E−07 2E−08 7.0E−07 9.E−09 7.4E−07 7.E−08 6.3E−07 2E−082.1E−06 7.E−08 1.08E−09 5.13E−10 v10000 1.2E−07 1E−08 4.8E−07 2.E−085.1E−07 9.E−08 4.6E−07 2E−08 1.5E−06 7.E−08 8.41E−10 4.74E−10 v105531.2E−07 2E−08 4.9E−07 2.E−07 3.5E−07 1.E−07 3.6E−07 4E−09 1.2E−06  7E−084.95E−10 1.41E−10 v7091 1.2E−07 1E−08 5.1E−07 2.E−08 5.6E−07 9.E−085.0E−07 3E−08 1.7E−06  8E−08 9.68E−10 5.05E−10 v7148 1.2E−07 2E−085.4E−07 2.E−07 3.7E−07 1.E−07 4.2E−07 1E−08 1.5E−06 1.E−07 5.77E−102.02E−10 v5019 1.3E−07 1E−08 5.2E−07 1.E−08 5.6E−07 6.E−08 4.7E−07 2E−081.6E−06 2.E−07 8.44E−10 4.88E−10 v6363 1.2E−07 2E−08 4.5E−07 1.E−073.5E−07 1.E−07 3.4E−07 1E−08 1.2E−06 5.E−08 4.58E−10 1.13E−10

Example 34: Efficacy of Exemplary Anti-HER2 Biparatopic Antibodies InVivo in a Trastuzumab Sensitive Ovarian Cancer Cell Derived TumourXenograft Model

The established human ovarian cancer cell derived xenograft model SKOV3,described in Example 17, was used to assess the anti-tumor efficacy ofthe exemplary biparatopic anti-HER2 antibodies, v5019, v7091 and v10000.

Female athymic nude mice were inoculated with a tumor suspension of325,000 cells in HBSS subcutaneously on the left flank. Tumors weremonitored until they reached an average volume of 190 mm³ and enrolledin a randomized and staggered fashion into 4 treatment groups:non-specific human IgG control, v5019, v7091, and v10000. Dosing foreach group was as follows. Non-specific human IgG was dosedintravenously with 10 mg/kg starting on study day 1 twice per week tostudy day 26. V5019, v7091, and v10000 were dosed intravenously with 3mg/kg starting on study day 1 twice per week to study day 26. Tumorvolume was measured throughout the study, and the parameters listed inTable 32 were measured at day 29.

The data are presented in FIG. 35A (tumor growth), FIG. 35B (survivalplot) and Table 32 and show that treatment with v5019, v7091 and v10000resulted in comparable tumor growth inhibition (T/C: 0.53-0.71), numberof responding tumors, time to progression, and survival on study day 29compared to IgG control. The serum exposure of v5019, v7091, and v10000was similar (31-41 microg/ml) on study day 7.

TABLE 32 IgG v5019 V7091 V10000 Tumour Response (n = 8) (n = 11) (n =11) (n = 11) Day 29 Mean TV 1903  1001 1354 1114 (mm3) (% (+899%)(+416%) (+618%) (+503%) change from Baseline) T/C (Tras) ratio  1 0.530.71 0.58 Responders 1/8 5/11 4/11 6/11 (TV < 50% of control) PR 0/81/11 0/11 0/11 (>10% baseline regression) ZRD 0/8 0/11 0/11 0/11 (TV <20 mm3) Time to Tumor doubling 12 15 16 15 progression time (days)Survival Median survival 29 Na 37 41 (days) Drug Mean Serum na 31.2 41.031.2 Exposure Concentration (day 7) (ug/ml)

These results show that the exemplary anti-HER2 biparatopic antibodies,v5019, v7091, and v10000) have potential utility in treating moderatelyTrastuzumab sensitive HER2 overexpressing ovarian cancers.

Example 35: Exemplary Biparatopic Anti-Her2 Antibodies Dose-DependentlyInhibit Tumour Growth in the Trastuzumab-Sensitive Ovarian Cancer CellDerived Tumour Xenograft

The established human ovarian cancer cell derived xenograft model SKOV3,described in Example 17, was used to assess the dose-dependent efficacyof an exemplary biparatopic anti-HER2 antibody, v10000.

Female athymic nude mice were inoculated with a tumor suspension of325,000 cells in HBSS subcutaneously on the left flank. Tumors weremonitored until they reached an average volume of 190 mm³ and enrolledin a randomized and staggered fashion into 6 treatment groups:non-specific human IgG control and 5 escalating doses of v10000. 9-13animals were included in each group. Dosing for each group was asfollows. IgG control was dosed intravenously with 10 mg/kg twice perweek to study day 26. V10000 was dosed intravenously with 0.1, 0.3, 1,3, or 10 mg/kg twice per week.

The data are presented in FIG. 36 and Table 33 and show that treatmentwith v10000 dose dependently induces tumor growth inhibition (T/C:0.28-0.73) compared to control IgG. In addition, v10000 wasdose-dependently associated with responding tumors (7/9 at 10 mg/kg and3/11 at 0.1 mg/kg) increased time to progression (24 days at 10 mg/kgand 12 days at 0.1 mg/kg) on study day 29. The serum exposure of v10000on day 7 was dose dependent and increased from 0.46 microg/ml with a 0.1mg/kg dose to 79.3 microg/ml with a 10 mg/kg dose.

TABLE 33 V10000, V10000, V10000, V10000, V10000, 10 3 mg/kg 1 mg/kg 0.3mg/kg 0.1 mg/kg Tumor Response IgG (n = 8) mg/kg (n = 9) (n = 11) (n =11) (n = 13) (n = 11) Day 29 Mean TV (mm3) 1903 (+899%) 543 1114 15341535 1385 (% change from (+281%) (+503%) (+688%) (+694%) (+643%)Baseline) T/C ratio 1 0.28 0.58 0.81 0.81 0.73 Responders 1/8 7/9 6/112/11 3/13 3/11 (TV < 50% of control) PR 0/8 1/9 0/11 0/11 0/13 0/11(>10% baseline regression) ZRD 0/8 0/9 0/11 0/11 0/13 0/11 (TV < 20 mm3)Time to Tumor doubling 12 24 15 14 12 12 Progression time (days) DrugExposure Mean Serum na 79.3 31.2 4.7 1.5 0.46 (Day 7) Concentration(ug/ml)

These results show that the exemplary anti-HER2 biparatopic antibody,v10000, inhibits tumor progression in a dose-dependent manner.

Example 36: Ability of Anti-HER2 Biparatopic Antibody and Anti-HER2Biparatopic-ADC to Inhibit Growth of Cell Lines Expressing HER2, andEGFR and/or HER3 at the 3+, 2+ or 1+ Levels

The following experiment was performed to measure the ability of anexemplary biparatopic anti-HER2 antibody (v10000) and correspondingbiparatopic anti-HER2 ADC (v10553) to inhibit growth of a selection ofbreast, colorectal, gastric, lung, skin, ovarian, renal, pancreatic,head and neck, uterine and bladder tumor cell lines that express HER2,and EGFR and/or HER3 at the 3+, 2+, 1+ or 0+ level as defined by IHC.

The experiment was conducted as follows. The optimal seeding density foreach cell line was uniquely determined to identify a seeding densitythat yielded approximately 60-90% confluency after the 72 hr duration ofthe assay. Each cell line was seeded at the optimal seeding density, inthe appropriate growth medium per cell line, in a 96-well plate andincubated for 24° C. at 36° C. and 5% CO₂. Antibodies were added atthree concentrations (v10000 at 300, 30 and 0.3 nM; v10553 at 300, 1,0.1 nM), along with the positive and vehicle controls. The positivecontrol chemococktail drug combination of 5-FU (5-fluorouracil),paclitaxel, cisplatin, etoposide (25 microM), the vehicle controlconsisted of PBS. The antibody treatments and controls were incubatedwith the cells for 72 h in a cell culture incubator at 36° C. and 5%CO₂. The plates were centrifuged at 1200 RPM for 10 min and culturemedium completely removed by aspiration. RPMI SFM medium (200 microL)and MTS (20 microL) was added to each well and incubated at 36° C. and5% CO₂ for 3 h. Optical density was read at 490 nM and percent growthinhibition was determined relative to the vehicle control.

The results are shown in FIG. 37 and a summary of all test results areshown in FIG. 38. FIG. 37A shows the growth inhibition results ofv10000. These results show that v10000 can inhibit growth of breast,colorectal, gastric, lung, skin, ovarian, renal, pancreatic, head andneck, uterine, and endometrial tumor cell lines that express HER2 andcoexpress EGFR and/or HER3 at the 3+, 2+, 1+ or 0+ level. The activityof v10000 and v10553 at 300 nM is summarized in FIG. 38, where ‘+’indicates cell lines that showed a reduction in cell viability at 300 nMthat was >5% of the vehicle control, and ‘-’ indicates ≦5% viability ofthe vehicle control.

FIG. 37B shows the growth inhibition results of v10553. These resultsshow that v10553 can inhibit growth of breast, colorectal, gastric,lung, skin, ovarian, renal, pancreatic, head and neck, uterine andbladder tumor cell lines that express HER2 and coexpress EGFR and/orHER3 at the 3+, 2+, 1+ or 0+ level (see also FIG. 38). The resultsplotted in FIG. 37B are defined by cell lines that showed a minimum ofdose-dependent growth inhibition at 300 and 1 nM, and where the growthinhibition at 1 nM is equal or greater than 5% (FIG. 37B).

These results show that exemplary biparatopic antibody v10000 and ADCv10553 can inhibit growth of tumor cells originating from breast,colorectal, gastric, lung, skin, ovarian, renal, pancreatic, head andneck, uterine and bladder histologies that express HER2 at the 3+, 2/3+,2+, 1+ and 0/1+ levels and that coexpress EGFR and/or HER3 at the 2+, 1+levels.

Example 37: Ability of Anti-HER2 Biparatopic Antibodies to Mediate ADCCof HER2 2+, 1+ and 0/1+ Cancer Cells

The following experiment was conducted to determine the ability ofanti-HER2 biparatopic antibodies to mediate ADCC of tumor cells thatexpress HER2 at the 2+, 1+ and/or 0/1+ levels and that coexpress EGFRand/or HER3 at the 2+ or 1+ level. The anti-HER2 biparatopic antibodiestested were 5019, 10000, and 10154 (an afucosylated version of v10000),with Herceptin™ and v506 as controls.

The ADCC experiment was conducted as described in Example 11 and Example25 with E/T: 5:1 with NK-92 effector cells (FIG. 39), and as describedin Example 26 with E/T 30:1 with PBMC effector cells.

The results are shown in FIG. 39 (NK-92 effector cells) and FIG. 40(PBMC effector cells). FIG. 39A shows the ADCC results of the HER2 2+head and neck tumor cell line (hypopharyngeal carcinoma), FaDu, wherethe anti-HER2 biparatopic elicits approximately 15% maximal cell lysis.FIG. 39C shows the ADCC results of the HER2 1+BxPC3 pancreatic tumorcell line, and FIG. 39D the results of the HER2 2+ MiaPaca2 pancreatictumor cell line. FIG. 39B shows the ADCC results of the HER2 0/1+A549NSCLC (non-small cell lung cancer) tumor cell line. In the BxPC3,MiaPaca2 and A549 tumor cell lines, v10000 mediated approximately 5%maximal tumor cell lysis.

FIG. 40 shows the ADCC results in A549, NCI-N87, and HCT-116 cells,where PBMCs were used as the effector cells. FIG. 40A shows the ADCCresults of the HER2 0/1+A549 NSCLC tumor cell line, where v10000elicited ˜28% maximum cell lysis and this was comparable to Herceptin™that has equivalent level of fucose content in the N-linked glycan. Theexemplary 100% afucosylated (0% fucose) biparatopic v10154 shows anincrease in maximal cell lysis (40% maximum cell lysis) and increasedpotency compared to v10000 and Herceptin that have approximately 88%fucose in the N-linked glycan.

FIG. 40B shows the ADCC results of the HER2 3+ gastric tumor cell line,NCI-N87. FIG. 40B shows that exemplary biparatopic v5019 (approximately88% fucosylated) mediates approximately 23% maximal cell lysis and has alower EC50 compared to Trastuzumab v506 (approximately 98% fucosylated).

FIG. 40C shows the ADCC results of the HER2 1+ HCT-116 colorectal tumorcell line. FIG. 40C shows that exemplary biparatopic v5019(approximately 88% fucosylated) mediates approximately 25% maximal celllysis and is more potent compared to Trastuzumab v506 (approximately 98%fucosylated).

These results show that exemplary anti-HER2 biparatopic antibodies canelicit ADCC of HER2 01/+, 2+ and 3+ tumor cells that originate from headand neck, gastric, NSCLC, and pancreatic tumor histologies. ADCC in thepresence of NK-92 cells as the effector cells had an apparent HER2 2+receptor level requirement (i.e. 2+ or greater) to show higher (>5%)percentage of maximum cell lysis. However, when PBMC cells were used aseffector cells higher levels of maximum cell lysis were achieved (>5%and up to 28% or 40%; v10000 and v10154, respectively) and wereindependent of HER2 receptor density as ADCC >5% was seen at the 0/1+,1+ and 3+ HER2 receptor density levels.

Example 38: HER2 Binding Affinity and Kinetics as Measured by SPR

As indicated in Example 1, anti-HER2 biparatopic antibodies havingdifferent antigen-binding moiety formats were constructed, as describedin Table 1. The formats included scFv-scFv format (v6717), Fab-Fabformat (v6902 and v6903), along with Fab-scFv format (v5019, v7091, andv10000). The following experiment was conducted to compare HER2 bindingaffinity and kinetics of these exemplary anti-HER2 biparatopic antibodyformats.

Affinity and binding kinetics to murine HER2 ECD (Sino Biological50714-M08H) was measured by single cycle kinetics with the T200 SPRsystem from Biacore (GE Healthcare). Between 2000-4000 RU of anti-humanFc was immobilized on a CMS chip using standard amine coupling. 5019 wascaptured on the anti-human Fc surface at 50 RU. Recombinant HER2 ECD(1.8-120 nM) was injected at 50 μ1/min for 3 minutes, followed by a 30minute dissociation after the last injection. HER2 dilutions wereanalyzed in duplicate. Sensorgrams were fit globally to a 1:1 Langmuirbinding model. All experiments were conducted at room temperature, 25°C.

The results in Table 34 show that Fab-scFv biparatopic antibodies (v5019and v7091), Fab-Fab variants (v6902 and v6903) and the scFv-scFv variant(v6717) have comparable binding affinity (1-4 nM). The Fab-scFv variantv10000 had higher binding affinity (lower KD) of approximately 0.6 nM.The monspecific anti-HER2 ECD4 antibody (v506) and anti-HER2 ECD2antibody (v4184) were included in the assay as controls. These resultsindicate that the molecular formats including v6717, v6902, v6903, v5019and/or v7091 have equivalent binding affinities, and thus differences infunction between these antibodies may be considered to result fromdifferences in format.

TABLE 34 Anti- STD DEV body AVERAGE Ka Variant Ka (1/Ms) Kd (1/s) KD (M)(1/Ms) Kd (1/s) KD (M) v506 7.34E+04 4.08E−05 5.56E−10 1.13.E+  3.04E− 3.28E− 03 06 11 v4184 3.61E+04 5.46E−04 1.56E−08 7.78.E +  2.80E− 4.12E− 03 05 09 v5019 6.01E+04 7.77E−05 1.29E−09 1.30.E+  8.56E− 4.24E− 03 07 11 v7091 5.17E+04 1.19E−04 2.31E−09 2.70.E +  1.49E− 4.09E− 03 05 10 v10000 6.44E+04 3.69E−05 5.79E−10 6.18.E+ 6.72.E−1.42.E− 03 06 10 v6902 6.83E+04 1.72E−04 2.72E−09  1.93E+  4.49E− 1.43E− 04 05 09 v6903 7.10E+04 1.71E−04 2.75E−09  3.60E+  3.96E− 1.34E− 04 06 09 v6717 1.50E4-05 5.33E−04 4.45E−09  1.28E+  2.54E− 2.11E− 05 04 09

Example 39: Effect of Anti-HER2 Biparatopic Antibody Format on Bindingto HER2+ Tumor Cells

The following experiment was conducted to compare the whole cell bindingproperties (Bmax and apparent K_(D)) of exemplary anti-HER2 ECD2×ECD4biparatopic antibodies that have different molecular formats (e.g.v6717, scFv-scFv IgG1; v6903 and v6902 Fab-Fab IgG1; v5019, v7091 andv10000 Fab-scFv IgG1).

The experiment was conducted as described in Example 6. The results areshown in FIG. 41 and Tables 35-38. FIG. 41A and Table 35 shows the FACSbinding results of the exemplary biparatopic antibodies to the BT474HER2 3+ breast tumor cell line. The results show that all anti-HER2antibodies have a higher Bmax (1.5 to 1.7-fold greater) when compared tothe monospecific bivalent anti-HER2 antibody v506. The Fab-scFv (v5019,v7091 and v10000) and the Fab-Fab (v6903) formats had approximately a1.7-fold increased Bmax and the scFv-scFv format (v6717) had a 1.5-foldincreased Bmax compared to v506. An equimolar combination of FSAs v506and v4184 resulted in a 1.7-fold increase in Bmax. The apparent K_(D) ofthe exemplary anti-HER2 biparatopic antibodies was approximately 2 to3-fold higher compared to the monospecific v506.

TABLE 35 FACS binding BT-474 Antibody Variant K_(D) (nM) Bmax v506 9.023536 v10000 16 39665 v506 + v4184 16 40320 v5019 21 39727 v7091 2236718 v6717 30 36392 v6903 31 40321

FIG. 41B and Table 36 shows the FACS binding results to the JIMT-1 HER22+ breast tumor cell line. The results show that all anti-HER2antibodies have a higher Bmax (1.5 to 1.8-fold greater) when compared tothe monospecific bivalent anti-HER2 antibody v506. The Fab-scFv (v7091and v10000) and the Fab-Fab (v6903) formats had approximately a 1.7-foldincreased Bmax, the scFv-scFv format (v6717) had a 1.5-fold increasedBmax and the Fab-scFv (v5019) and FSA combination (v506+v4184) had a1.8-fold increased Bmax compared to v506. The apparent K_(D) of theexemplary anti-HER2 biparatopic Fab-scFv antibodies was approximately 2to 4-fold higher compared to the monospecific v506; whereas the K_(D) ofthe Fab-Fab (v6903) and scFv-scFv (v6717) were approximately 8-foldhigher compared to v506.

TABLE 36 FACS Binding JIMT-1 Antibody Variant K_(D) (nM) Bmax v506 3.52574 v10000 7.6 4435 v506 + v4184 8.0 4617 v5019 12 4690 v7091 14 4456v6717 26 3769 v6903 28 4452

FIG. 41C and Table 37 shows the FACS binding results of the exemplarybiparatopic antibodies to the HER2 1+ MCF7 breast tumor cell line. Theresults show that anti-HER2 antibody v10000 and FSA combination(v506+v4184) have a 1.6-fold higher Bmax compared to the monospecificbivalent anti-HER2 antibody v506. The Fab-scFv (v5019, v7091) hadapproximately a 1.4-fold; the scFv-scFv format (v6717) a 1.3-fold, andthe Fab-Fab format (v6903) had a 1.2-fold increased Bmax compared tov506. The apparent K_(D) of the exemplary anti-HER2 biparatopicFab-scFv, Fab-Fab (v6903) and FSA combination (v506+v4184) wasapproximately 2 to 3-fold lower compared to v506; whereas the K_(D) ofthe scFv-scFv (v6717) was approximately 3-fold higher compared to v506.

TABLE 37 FACS Binding MCF7 Antibody Variant K_(D) (nM) Bmax v506 + v41844.5 1410 v7091 6.1 1216 v5019 6.3 1201 v10000 6.8 1381 v6903 7.1 1105v506 12 889 v6717 32 1167

FIG. 41D and Table 38 shows the FACS binding results of the exemplarybiparatopic antibodies to the HER2 0/1+ MDA-MD-231 breast tumor cellline. The results show that exemplary biparatopic anti-HER2 antibodieshad approximately 1.3 to 1.4-fold increased Bmax compared to themonospecific bivalent anti-HER2 antibody v506. The FSA combination(v506+v4184) had a 1.7-fold increased Bmax The apparent K_(D) of theexemplary anti-HER2 biparatopic Fab-scFv antibodies (v5019, v7091,v10000) and FSA combination (v506+v4184) had an approximate equivalentKD compared to v506; whereas Fab-Fab (v6903) and scFv-scFv (v6717) wasapproximately 4 and 16-fold higher K_(D) respectively, compared to v506.

TABLE 38 FACS Binding MDA-MB-231 Antibody Variant K_(D) (nM) Bmax v5064.8 395 v10000 5.6 558 v506 + v4184 7.3 662 v7091 7.9 525 v5019 8.7 548v6903 17 534 v6717 77 524

The tumor cell binding results show that anti-HER2 biparatopicantibodies with different molecular formats have an increased Bmax onHER2 3+, 2+, 1+ and 0/1+ tumor cells compared to a bivalent monospecificanti-HER2 antibody. Of the different anti-HER2 biparatopic antibodies,the scFv-scFv format had the lowest Bmax gain relative to v506 on HER23+, 2+, 1+ and 0/1+ tumor cells These results also show that scFv-scFvand Fab-Fab formats have the greatest increase in K_(D) on HER2 3+, 2+,1+ and 0/1+ tumor cells compared monospecific v506 (3 to 16-foldincrease) and the biparatopic Fab-scFv formats (approximately 2-fold orgreater). The increase in K_(D) is an indication of a reduction in avidbinding and suggests that different biparatopic formats have uniquemechanisms of binding to HER2 on the cell surface.

Example 40: Effect of Anti-HER2 Biparatopic Antibody Format onInternalization in HER2+ Cells

The following experiment was conducted to compare the ability ofexemplary anti-HER2 ECD2×ECD4 biparatopic antibodies that have differentmolecular formats (e.g. v6717, scFv-scFv IgG1; v6903 and v6902 Fab-FabIgG1; v5019, v7091 and v10000 Fab-scFv IgG1) to internalize in HER2+cells expressing HER2 at varying levels.

The experiment was conducted as detailed in Example 9. The results areshown in FIG. 42 and Tables 39-41. FIG. 42A and Table 39 show theinternalization results in HER2 3+BT-474. These results show that theFab-scFv format (v10000) and the FSA combination (v506+v4184) have2.2-fold greater quantities of intracellular antibody, compared to themonospecific anti-HER2 v506. The scFv-scFv format (v6717) had 1.9-foldgreater; the Fab-scFv formats (v5019 and v7091) had 1.5 to 1.7-foldgreater; and the Fab-Fab formats (v6902 and v6903) had 1.2 to 1.3-foldgreater quantities of intracellular antibody accumulation compared tov506.

TABLE 39 Internalization BT-474 Antibody Variant Surface 4° C.Surface37° C. Internal 37° C. v506 2156 1590 3453 v6902 2407 2077 4035v6903 2717 986 4573 v7091 2759 2227 5111 v5019 2867 2675 5710 v6717 20061212 6498 v10000 3355 2851 7528 v506 + v4184 3998 2326 7569

FIG. 42B and Table 40 show the internalization results in HER2 2+JIMT-1. These results show that the Fab-scFv format (v10000) and the FSAcombination (v506+v4184) have respectively 1.8 and 1.9-fold greaterquantities of intracellular antibody, compared to the monospecificanti-HER2 v506. The scFv-scFv (v6717) and the Fab-scFv formats (v5019)have 1.4-fold greater; and the Fab-scFv (v7091) and Fab-Fab formats(v6902 and v6903) had 1.2-fold greater quantities of intracellularantibody accumulation compared to v506.

TABLE 40 Internalization JIMT-1 Antibody Variant Surface 4° C. Surface37° C. Internal 37° C. v506 337 −7.1 759 v6902 389 152 926 v7091 426 102935 v6903 392 130 945 v5019 437 5.2 1035 v6717 247 31 1082 v10000 474103 1375 v506 + v4184 583 89 1449

FIG. 42C and Table 41 show the internalization results in HER2 1+ MCF7.These results show that the scFv-scFv format and Fab-scFv formats have3.0 and 2.8-fold greater quantities of intracellular antibody, comparedto the monospecific anti-HER2 v506. The Fab-scFv format (v10000) and theFSA combination (v506+v4184) have approximately 2.0-fold; the Fab-scFv(v7091) and Fab-Fab (v6903) formats have 1.8-fold greater quantities ofintracellular antibody accumulation compared to v506.

TABLE 41 Internalization MCF7 Antibody Variant Surface 4° C. Surface 37°C. Internal 37° C. v506 48 10 48 v7091 77 27 87 v6903 81 35 89 v10000 7820 96 v506 + v4184 87 19 103 v5019 81 17 134 v6717 48 31 145

These results show that anti-HER2 biparatopic antibodies with differentmolecular formats have unique degrees of internalization in HER2 3+, 2+and 1+ tumor cells that varies with respect to the structure and formatof the antigen-binding domains. In general, the monospecific FSAcombination of v506 and v4184, the Fab-scFv (v10000, v7091 and v5019)and the scFv-scFv (v6717) biparatopic formats had the higherinternalization values in the HER2 3+, 2+ and 1+ tumor cells. Whereas,the Fab-Fab biparatopic formats (v6902 and v6903) had the lowestinternalization values in the HER2 3+, 2+ and 1+ tumor cells. These datasuggest that the molecular format and geometric spacing of theantigen-binding domains has an influence on the ability of thebiparatopic antibodies to cross-link HER2 receptors, and subsequently tointernalize in HER2+ tumor cells. The Fab-Fab biparatopic format, havingthe greatest distance between the two antigen-binding domains, resultedin the lowest degree of internalization, whereas the Fab-scFv andscFv-scFv formats, having shorter distances between the antigen-bindingdomains, had greater internalization in HER2+ cells. This is consistentwith the correlation of potency and shorter linker length as describedin Jost et al 2013, Structure 21, 1979-1991).

Example 41: Effect of Anti-HER2 Biparatopic Antibody Format on ADCC inHER2+ Cells

The following experiment was conducted to compare the ability ofexemplary anti-HER2 ECD2×ECD4 biparatopic antibodies that have differentmolecular formats (e.g. v6717, scFv-scFv IgG1; v6903 and v6902 Fab-FabIgG1; v5019, v7091 and v10000 Fab-scFv IgG1) to mediate ADCC in HER2+cells expressing HER2 at varying levels.

Prior to performing the ADCC assay, glycopeptide analysis was performedon the antibody samples to quantify the fucose content in the N-linkedglycopeptide. The method was followed as described in Example 23. Theresults are shown in Table 42; the data shows that exemplary biparatopicvariants v5019, v6717, v6903 have equivalent fucose content in theN-linked glycan (91-93%). Antibody samples with equivalent levels offucose in the N-glycan were selected for the ADCC assay to normalize forfucose content in the interpretation of the ADCC assay results.

TABLE 42 LC-MS Tryptic peptide analysis Percentage of Percentage ofGlycopeptides Observed Glycopeptides Observed Variant WITH FucoseWITHOUT Fucose v6903 90.7 9.3 v6717 92.8 7.2 v5019 91.3 8.7

The ADCC experiment was conducted as described in Example 11 with E/T:5:1 with NK-92 effector cells. The ADCC results are shown in FIG. 43 andTables 43-45. FIG. 43A and Table 43 show the ADCC results in HER2 2+JIMT-1 breast tumor cells. These data show that v5019, v6717 and v6903elicit similar levels of maximum cell lysis and that the scFv-scFvformat (v6717) is less potent compared to v5019 and v6903 when HER2 2+tumor cells are targets.

TABLE 43 JIMT-1 ADCC Antibody variant EC50 (nM) % Max Cell Lysis v6903~0.03 48 v5019 ~0.16 47 v6717 ~0.72 51

FIG. 43B and Table 44 show the ADCC results in HER2 1+ MCF7 breast tumorcells. These data show that v5019 and v6717 have slightly higher maximumcell lysis (27-30%) compared to v6903 (24%). These data also show thatv6717 is the least potent, followed by v6903 and v5019, which have lowerEC50 values.

TABLE 44 MCF7 ADCC Antibody variant EC₅₀ (nM) % Max Cell Lysis v5019~0.69 27 v6717 109 30 v6903 0.94 24

FIG. 43C and Table 45 show the ADCC results in HER2 0/1+ MDA-MB-231breast tumor cells. These data show that v5019 shows slightly highermaximum cell lysis (77%) compared to v6903 (62%) and v6717 (63%). Thesedata also show that v6717 is the least potent, followed by v6903 andv5019, which have lower EC₅₀ values.

TABLE 45 MDA-MB-231 ADCC % Max Cell Lysis Antibody variant EC₅₀ (nM)(top only) v5019 0.20 71 v6717 10 63 v6903 0.79 62

These data show that exemplary anti-HER2 ECD2×ECD4 biparatopicantibodies elicit similar levels of maximum cell lysis by ADCC in HER22+ and 1+ tumor cells. Despite similarities in maximal cell lysis, thesedata also show that the different molecular formats have unique ADCCpotencies. The scFv-scFv was the least potent (greatest EC₅₀ values) inthe HER2 2+ and HER2 1+. Differential potencies among the three formatswas seen in the ADCC data targeting HER2 1+ cells, where the EC50 valuesfor v6717>v6903>v5019. These data are consistent with the observationspresented in Example 40 (FACS binding), where an increase in K_(D)(reduced affinity) was seen with the Fab-Fab and scFv-scFv formats.

Example 42: Effect of Anti-HER2 Biparatopic Antibody Format on Growth ofHER2+ Tumor Cells

The following experiment was conducted to compare the effect ofanti-HER2 biparatopic antibody format on growth of HER2 3+, 2+ and 1+tumor cells, either basal growth or ligand-stimulated. Basal growth wasmeasured as described in Example 15, while ligand-stimulated growth wasmeasured as described in Example 27. In both types of experiments,growth was measured as % survival with respect to control treatment.

FIG. 44 and Table 46 show the effect of exemplary anti-HER2 ECD2×ECD4biparatopic antibodies on growth of HER2 3+ breast cancer cells (BT-474)in the presence of exogenous growth-stimulatory ligands (EGF and HRG).In the absence of EGF or HRG, the anti-HER2 biparatopic antibodies wereable to inhibit growth of BT-474 cells, where % survival of eachtreatment group ranked as follows:v6903<v506+v4184<506<v7091<v5019<v10000<v6717. In the presence of HRG,growth inhibition relative to the mock control was achieved only withthe FSA combination of v506+v4184. In the presence of EGF, growthinhibition relative to the mock control was achieved, where % survivalof each treatment group ranked as follows:v6903<v506+v4184<7091<v10000<5019.

TABLE 46 % Survival Antibody Treatment only +HRG +EGF Mock 100 143 131v6717 113 126 129 v10000 70 118 78 v5019 67 133 81 v7091 61 119 61 v50653 141 118 v506 + v4184 43 89 45 v6903 32 120 39

FIG. 45 shows the dose-dependent effect of the anti-HER2 biparatopicantibody formats on growth inhibition of the SKBr3 HER2 3+ cell line.The data is consistent with the results presented in FIG. 44, where therank order potency/efficacy of the biparatopic formats is as followsFab-Fab>Fab-scFv>scFv-scFv in HER2 3+ tumor cells.

The effect of anti-HER2 biparatopic antibody formats on survival ofHER2+ cells is shown in FIG. 46, where FIG. 46A shows the result in theTrastuzumab sensitive SKOV3 HER2 2+/3+ cell line at 300 nM; FIG. 46Bshows the result in JIMT-1 HER2 2+(Trastuzumab resistant) cells at 300nM, and FIG. 46C shows the result in MCF7 HER2 1+ cell line at 300 nM.In the SKOV3 cell line, little difference was observed among thebiparatopic formats in the extent of growth inhibition, and no growthinhibition was observed by any of the test antibodies in JIMT-1 and MCF7cells.

The data in FIG. 44 and FIG. 45 show that anti-HER2 ECD2×ECD4biparatopic antibodies with the Fab-scFv and Fab-Fab formats (v5019,v7091, v10000, v6903) are capable of growth inhibition HER2 3+ tumorcells in the absence, and presence of EGF or HRG. In the HER2 3+ celllines BT-474 and SKBR3, growth inhibition relative to the mock controlrank ordered as follows, wherev506+v4184>v6903>v7091>v10000>v5019>v506>v6717. The distance betweenantigen-binding domains (Fab-Fab>Fab-scFv>scFv-scFv) correlates with therank order of growth inhibition in the HER2 3+ tumor cells. Based on thedata in trastuzumab-sensitive tumor cells, BT-474, and SKBr3, it may beexpected that the growth inhibition difference among formats issignificant at the HER2 3+ level but less so at the HER2 2+ or HER2 1+levels.

Example 43: Evaluation of HER2 Binding Affinity and Kinetic at VaryingAntibody Capture Levels

The following experiment was conducted to compare HER2 binding kinetics(kd, off-rate) of exemplary anti-HER2 ECD2×ECD4 biparatopic antibodieswhen captured at varying surface densities by SPR. The correlationbetween a reduced (slower) off-rate with increasing antibody capturelevels (surface density) is an indication of Trans binding (i.e. oneantibody molecule binding to two HER2 molecules, described in Example12). In this experiment the Fab-Fab format (v6903) was compared to theFab-scFv format (v7091) to determine potential difference in Transbinding among the variants. Due to the larger spatial distance betweenantigen-binding domains, it is hypothesized that the Fab-Fab format maybe capable of Cis binding (engaging ECD 2 and 4 on one HER2 molecule);whereas, the Fab-scFv would not capable of Cis binding due to theshorter distance between the it's antigen-binding domains. The anti-HER2monospecific v506 was included as a control.

The experiment was conducted by SPR as described in Example 12. The dataare shown in FIG. 47. FIG. 47A shows the plot and linear regressionanalysis for the kd (1/s) at different antibody capture levels withv6903 and v7091. Both v7091 and v6093 show a trend for decreasingoff-rate with increasing surface capture levels; however, thecorrelation is significant with the Fab-scFv variant (v7091; Pvalue=0.023) but not the Fab-Fab format (v6093; P value=0.053). Theoff-rate remained unchanged with varying antibody capture levels for theanti-HER2 monospecific control, v506.

FIG. 47B shows the plot and linear regression analysis for the K_(D) (M)at different antibody capture levels with v6903 and v7091. Similar tothe off-rate comparison, both v7091 and v6093 show a trend forincreasing affinity (lower K_(D) value) with increasing surface capturelevels. However, the correlation is significant with the Fab-scFvvariant (v7091; P value=0.04) but not the Fab-Fab format (v6093; Pvalue=0.51). The K_(D) remained unchanged with varying antibody capturelevels for the anti-HER2 monospecific control, v506. The data in FIG. 47shows that the Fab-Fab and Fab-scFv anti-HER2 biparatopic antibodyformats show trends of decreasing off-rates with increasing antibodysurface capture levels; these trends are unique compared to amonospecific anti-Her2 antibody.

Example 44: Affinity and Stability Engineering of the Pertuzumab Fab

As indicated in Table 1, one variant (v10000) contains mutations in thePertuzumab Fab. This Fab was derived from affinity and stabilityengineering in silico efforts, which were measured experimentally asmonovalent or One-Armed Antibodies (OAAs).

Variant 9996: a monovalent anti-HER2 antibody, where the HER2 bindingdomain is a Fab derived from pertuzumab on chain A, with Y96A in VLregion and T30A/A49G/L69F in VH region (Kabat numbering) and the Fcregion is a heterodimer having the mutations T350V_L351Y_F405A_Y407V (EUnumbering) in Chain A, T350V_T366L_K392L_T394W (EU numbering) in ChainB, and the hinge region of Chain B having the mutation C226S; theantigen-binding domain binds to domain 4 of HER2.

Variant 10014: a monovalent anti-HER2 antibody, where the HER2 bindingdomain is a Fab derived from pertuzumab on chain A, with Y96A in VLregion and T30A in VH region (Kabat numbering) and the Fc region is aheterodimer having the mutations T350V_L351Y_F405A_Y407V (EU numbering)in Chain A, T350V_T366L_K392L_T394W (EU numbering) in Chain B, and thehinge region of Chain B having the mutation C226S; the antigen-bindingdomain binds to domain 4 of HER2.

Variant 10013: a monovalent anti-HER2 antibody, where the HER2 bindingdomain is a Fab derived from wild type pertuzumab on chain A, and the Fcregion is a heterodimer having the mutations T350V_L35 1Y_F405A_Y407V(EU numbering) in Chain A, T350V_T366L_K392L_T394W (EU numbering) inChain B, and the hinge region of Chain B having the mutation C226S; theantigen-binding domain binds to domain 4 of HER2.

The following experiments were conducted to compare HER2 bindingaffinity and stability of the engineered Pertuzumab variants.

OAA variants were cloned and expressed as described in Example 1.

OAA were purified by protein A chromatography and Size ExclusionChromatography, as described in Example 1.

Heterodimer purity (i.e. amount of OAA with a heterodimeric Fc) wasassessed by non-reducing High Throughput Protein Express assay usingCaliper LabChip GXII (Perkin Elmer #760499). Procedures were carried outaccording to HT Protein Express LabChip User Guide version2 LabChip GXIIUser Manual, with the following modifications. Heterodimer samples, ateither 2 μl or 5 μl (concentration range 5-2000 ng/μ1), were added toseparate wells in 96 well plates (BioRad # HSP9601) along with 7 μl ofHT Protein Express Sample Buffer (Perkin Elmer #760328). The heterodimersamples were then denatured at 70° C. for 15 mins. The LabChipinstrument is operated using the HT Protein Express Chip (Perkin Elmer#760499) and the Ab-200 assay setting. After use, the chip was cleanedwith MilliQ water and stored at 4° C.

The stability of the samples was assessed by measuring meltingtemperature or Tm, as determined by DSC with the protocol shown inexample 24. The DSC was measured before and after SEC purification.

The affinity towards HER2 ECD of the samples was measured by SPRfollowing the protocol from example 12. The SPR was measured before andafter SEC purification. As summarized in Table 47A and 47B, themutations in the variable domain have increased the HER2 affinity of theFab compared to wild type pertuzumab, while maintaining WT stability. (¹Purity determined by Caliper LabChip; ² KD(WT)/KD(mut)

TABLE 47A SPR pre-SEC Het SPR post-SEC Pr-A KD Fold purity KD Fold OAAFab HC Yield KD AVE STDEV wrt post- KD AVE STDEV wrt variant mutationsLC mut (mg/L) (nM) (nM) n WT² SEC¹ (nM) (nM) n WT v9996 T30A/A49G/ Y96A22 1.7E−09 1.7E−10 5 9.6 93% 1.8E−09 1.6E−11 2 8.4 L69F v10014 T30A Y96A20 2.0E−09 3.1E−10 4 8.1 81% 2.1E−09 5.2E−10 3 7.0 v10013 WT WT 181.6E−08 5.1E−09 16 1.0 91% 1.5E−08 3.5E−09 4 1.0

TABLE 47B DSC DSC pre-SEC post-SEC ΔTm ΔTm wrt wrt OAA Tm WT Tm WTvariant (C.) (C.) (C.) (C.) v9996 77.2 −0.2 77.2 −0.7 v10014 75.5 −1.975.5 −2.4 v10013 77.4 0.0 77.9 0.0

Example 45: Effect of v10000 on Survival and Tumor Growth in a XenograftModel of HER2-Low, Non-Small Cell Lung Cancer (NSCLC)

This experiment was performed to assess efficacy of v10000 compared tocontrol IgG (v6908) in an A549 xenograft model of lung cancer. A549cells are derived from non-squamous non-small cell lung cancer that isHER2-low, non-HER2 gene amplified, HER3+, EGFR-low and moderatelysensitive to Cisplatin at the MTD (maximum tolerated dose). The studywas carried out as described below.

Tumor cell suspensions were implanted subcutaneously into athymic nudemice. When tumors reached 158 mm³ the animals were randomly assigned togroups as shown in Table A1, and treatment began in a blinded andcontrolled study. Animals were treated according to Regimen 1 on Day 1,followed by treatment according to Regimen 2 on subsequent days asindicated in Table A1.

TABLE A1 Study Design Regimen 1 Regimen 2 Group Dosage Dosage (n) Agent(mg/kg) Route Schedule Agent (mg/kg) Route Schedule 1 (20) v6908  15 ivDay 1 v6908  10 iv Days 4, 8, 11, 15, 18, 22 and 25 2 (20) v10000 15 ivDay 1 v10000 10 iv Days 4, 8, 11, 15, 18, 22 and 25

Tumor volume was measured by calipers twice weekly. The study durationwas 66 days with survival as the primary endpoint. Additional tumorresponse criteria were measured and are shown in Table A2. Mice wereeuthanized when tumor volume exceeded 800 mm³, the surviving percentageversus study day was plotted on a Kaplan-Meier and was statisticallyassessed using a log-rank test. Serum concentration of v10000 wasdetermined by HER2 ELISA on study day 7.

The results are shown in FIG. 48A (tumor volume) and FIG. 48B(Kaplan-Meier survival). Variant 10000 reduced tumor growth compared tov6908 treated controls and significantly prolonged survival by log-ranktest (FIG. 48B and Table A3). Animals treated with v10000 had a mediansurvival of greater than 66 days while those treated with v6908 had amedian survival of 25.78 days (FIG. 48B and Table A2). Tumor volume onstudy day 30 was 461 mm3 and 810 mm3 for v10000 and v6908 treated groupsrespectively (FIG. 48A and Table A2). Serum exposure was 140.9 microg/mLon study day 7, indicating that the anticipated serum concentration wasachieved.

These results show that treatment with v10000 was able to reduce tumorgrowth and prolong survival compared to treatment with a control hIgG inthis HER2-low non-gene amplified NSCLC model.

TABLE A2 A549 Tumor Response Profile 6908 10000 Tumor Response on Day 30Mean TV (mm³) (% Δ from base line) 810 (413%) 461 (191%)Treatment/Control Ratio 1.00 0.57 RECIST Scores CR (TV <20 mm³) 0/200/20 PR (>30% baseline regression) 0/20 1/20 PD (>20% baseline growth)20/20  19/20  SD (neither PD or PR) 0/20 0/20 Median Time to Progression(days) 3.30 2.31 Survival Response Median Survival (days) 25.78 >66CR—Complete Response PR—Partial Response PD—Progressive DiseaseSD—Stable Disease

TABLE A3 Log Rank Summary Group 6908 6908 — 10000 ★★★ Legend: ns = notsignificant, ★ = P < 0.05. ★★ = P < 0.01, ★★★ = P < 0.001

Example 46: Effect of v10000 on Survival and Tumor Growth in a XenograftModel of HER2-Low, Head and Neck Squamous Cell Carcinoma

This experiment was performed to assess efficacy of v10000 compared toHerceptin™ (v6336) and control human IgG (v6908) in the FaDu xenograftmodel of head and neck cancer. FaDu cells are derived from squamous cellcancer of the head and neck that is HER2 low, non-HER2 gene amplified,HER3+, EGFR+ and highly sensitive to Cisplatin at the MTD. The study wascarried out as described below.

Tumor cell suspensions were implanted subcutaneously into athymic nudemice. When tumors reached 121 mm³ the animals were randomly assigned togroups as shown in Table A4, and treatment began in a blinded andcontrolled study. Cisplatin was purchased and provided for the study byCharles River Laboratories (Morrisville, N.C.). Animals were treatedaccording to Regimen 1 at Day 1, followed by Regimen 2 on subsequentdays as noted in Table A4.

TABLE A4 Study Design Regimen 1 Regimen 2 Group Dosage Dosage (n) Agent(mg/kg) Route Schedule Agent (mg/kg) Route Schedule 1 (15) v6908  15 ivDay 1 v6908  10 iv Days 4, 8, 11, 15, 18, 22 and 25 2 (15) v6336  15 ivDay 1 v6336  10 iv Days 4, 8, 11, 15, 18, 22 and 25 3 (15) v10000 15 ivDay 1 v10000 10 iv Days 4, 8, 11, 15, 18, 22 and 25 4 (15) Cisplatin 2ip Day 1, 3, 5, 7, 9, 11 5 (15) v10000 15 iv Day 1 v10000 10 iv Days 4,8, 11, 15, 18, 22 and 25 Cisplatin 2 ip Day 1, 3, 5, 7, 9, 11

Tumor volume was measured by calipers twice weekly. The study durationwas 59 days with survival as the primary endpoint. Additional tumorresponse criteria were measured and are shown in Table A5. Mice wereeuthanized when tumor volume exceeded 2000 mm³, the surviving percentageversus study day was plotted on a Kaplan-Meier and was statisticallyassessed using a log-rank test. Serum concentration of v10000 and v6336was determined by HER2 ELISA on study day 7.

The results are shown in FIG. 49A (tumor volume) and FIG. 49B(Kaplan-Meier survival). Variant 10000 reduced tumor growth compared tov6908 treated controls and v6336, as well as significantly prolongedsurvival by log-rank test compared to v6908 (FIG. 48B and Table A3).Animals treated with v10000 had a median survival of greater than 46days while those treated with v6908 and v6336 had median survivals of 25and 40 days, respectively (FIG. 49B and Table A5). Tumor volume on studyday 25 was 1025, 1979, 1257 mm³ for v10000, v6908 and v6336 treatedgroups respectively (FIG. 49A and Table A5). Serum exposure was 116.6microg/mL for v10000, 119.9 microg/mL for v6336, and 107.2 microg/mL forv10000+Cisplatin on study day 7, indicating that the anticipated serumconcentration was achieved for each test article.

These results show that treatment with v10000 as a monotherapy was ableto decrease tumor volume and prolong survival, compared to treatmentwith control IgG in this model of HER2-low non-gene amplified head andneck cancer. Overall, v10000 showed a trend towards decreasing tumorvolume compared to v6336 (Herceptin™).

Variant 10000 was also tested in combination with cisplatin. Thecombination of v10000 and cisplatin significantly prolonged survivalcompared to v6908, v6336, and single agent cisplatin (Table A5). Themedian survival of the v10000 and cisplatin combination was 53 dayswhile the median survival of v6908, v6336, and single agent cisplatinwas 25, 40, and 40 days, respectively.

These results demonstrate that treatment with v10000 in combination withcisplatin was able to decrease tumor growth and prolong survivalcompared to v6908 and v6336, in this model of head and neck cancer.

TABLE A5 FaDu Tumor Response Profile 6908 6336 10000 cisplatin 10000 +cisplatin Tumor Response on Day 25 Mean TV (mm³) (% Δ from base 19791257 1025 1070 816 line) (1532%) (929%) (782%) (782%) (573%)Treatment/Control Ratio 1.00 0.63 0.52 0.54 0.41 RECIST Scores CR (TV<20 mm³) 0/15 0/14 0/15 0/15 0/15 PR (>30% baseline regression) 0/150/14 0/15 0/15 0/15 PD (>20% baseline growth) 15/15  14/14  15/15 15/15  15/15  SD (neither PD or PR) 0/15 0/15 0/15 0/15 0/15 Median Timeto Progression 5.9 7.6 7.8 8.4 10.8 (days) Survival Response MedianSurvival (days) 25 40 46 40 53 CR—Complete Response PR—Partial ResponsePD—Progressive Disease SD—Stable Disease

TABLE A6 Log Rank Summary Group 6908 6336 10000 Cisplatin 6908 — — — —6336 ★★ — — — 10000 ★★★ n/s — — Cisplatin ★★★ n/s ★ — 10000 + Cisplatin★★★ ★ n/s ★★★ Legend: ns = not significant, ★ = P < 0.05. ★★ = P < 0.01,★★★ = P < 0.001

Example 47: Effect of v10000 on Survival and Tumor Growth Inhibition ina Xenograft Model of HER2 1+, ER+ Breast Cancer

This experiment was performed to assess efficacy of v10000 compared to acontrol IgG (v6908) or Herceptin™ (v6336) in the ST1337B xenograft modelof breast cancer. ST1337B is a patient derived xenograft (PDX)established in nude mice from an ER+/PR− breast cancer with a luminal Bmolecular classification. ST1337 is HER2 1+ as measured by IHC. Thestudy was carried out as described below.

Tumor fragments were implanted subcutaneously into athymic nude mice.When tumors reached 180 mm³ the animals were randomly assigned to groupsas shown in Table A7 and treatment began in a blinded and controlledstudy. Animals were treated according to Regimen 1 as shown in Table A7

TABLE A7 Study Design Regimen 1 Group Dosage (n) Agent (mg/kg) RouteSchedule 1 (15) v6908 30 iv Days 1,4, 8, 11, 15, 18, 22, 25, 28, and 322 (15) V6336 10 iv Days 1, 4, 8, 11, 15, 18, 22, 25, 28, and 32 3 (15)v10000 3 iv Days 1, 4, 8, 11, 15, 18, 22, 25, 28, and 32 4 (15) v1000010 iv Days 1, 4, 8, 11, 15, 18, 22, 25, 28, and 32 5 (15) v10000 30 ivDays 1, 4, 8, 11, 15, 18, 22, 25, 28, and 32

Tumor volume was measured by calipers twice weekly. The study durationwas 63 days with survival as the primary endpoint. Additional tumorresponse criteria were measured and are shown in Table A8. Mice wereeuthanized when tumor volume exceeded 2000 mm³, the surviving percentageversus study day was plotted on a Kaplan-Meier and was statisticallyassessed using a log-rank test. Serum concentration of v10000 and v6336was determined by HER2 ELISA on study day 7 and on day 36, 4 daysfollowing the last dose on day 32.

The results are shown in FIG. 50A (tumor volume) and FIG. 50B(Kaplan-Meier survival). Treatment with variant 10000 at all dosestested reduced tumor growth compared to treatment with v6908 andsignificantly prolonged survival by log-rank test compared to v6908(FIG. 50B and Table A9). In addition, treatment with v10000 at 30 mg/kgsignificantly prolonged survival compared to treatment with v6336 at 10mg/kg (FIG. 50B and Table A8). Animals treated with v10000 had mediansurvivals of 49, 59, and 59 days for the 3, 10 and 30 mg/kg dosesrespectively (FIG. 50B and Table A8). Tumor volume on study day 29 fortreatment with v10000 at 3, 10 and 30 mg/kg was 1010, 1016, and 931 mm3,respectively. Tumor volumes for v6908 and v6336 on study day 29 was 1898and 1264 mm3 respectively (FIG. 50A and Table A8). The serum exposure ofv6336 and v10000 is shown in Table A10. These results confirm thatincreasing the dosage of v10000 results in an increase in serumconcentration of v10000, and that similar doses of v10000 and v6336result in similar serum concentrations of antibody.

These results indicate that treatment with v10000 is able to decreasetumor volume and prolong survival in this model of HER2-low ER+ breastcancer, when compared to the IgG control and to Herceptin™.

TABLE A8 ST1337b Tumor Response Profile 6908, 6336, 10000, 10000, 30mg/kg 10 mg/kg 3 mg/kg 10 mg/kg 10000, 30 mg/kg Tumor Response on Day 29Mean TV (mm³) (% Δ from base 1898 1264 1010 1016 931 line) (953%) (601%)(460%) (457%) (411%) Treatment/Control Ratio 1.00 0.66 0.53 0.53 0.49RECIST Scores CR (TV <20 mm³) 0/15 0/15 0/15 0/15 0/15 PR (>30% baselineregression) 0/15 0/15 0/15 0/15 0/15 PD (>20% baseline growth) 15/15 15/15  15/15  15/15  15/15  SD (neither PD or PR) 0/15 0/15 0/15 0/150/15 Median Time to Progression 11 10 14 26 13 (days) Survival ResponseMedian Survival (days) 29 43 49 59 59 CR—Complete Response PR—PartialResponse PD—Progressive Disease SD—Stable Disease

TABLE A9 Log Rank Summary 6908, 6336, 10000, 10000, 10000, Group 30mg/kg 10 mg/kg 3 mg/kg 10 mg/kg 30 mg/kg 6908, — — — — 30 mg/kg 6336, ★★— — — — 10 mg/kg 10000, ★★ n/s — — — 3 mg/kg 10000, ★★★ n/s n/s — — 10mg/kg 10000, ★★★ ★ n/s n/s — 30 mg/kg Legend: ns = not significant, ★ =P < 0.05. ★★ = P < 0.01, ★★★ = P < 0.001

TABLE A10 Serum Exposure Summary 10000, 10000, Sample Day 6336, 10 mg/kg10000, 3 mg/kg 10 mg/kg 30 mg/kg 7 133.0 30.7 101.7 286.6 36 135.2 46.0186.3 279.7

Example 48: Effect of v10000 on Survival and Tumor Growth Inhibition ina Xenograft Model of HER2 Negative Pancreatic Cancer

This experiment was performed to assess efficacy of v10000 compared to acontrol IgG (v12470), Herceptin™ (v6336), and nab-paclitaxel as singleagents and v10000 in combination with nab-paclitaxel (Abraxane™ Celgene)in the ST803 xenograft model of pancreatic cancer. ST803 is apatient-derived xenograft (PDX) of pancreatic cancer (South TexasAccelerated Research Therapeutics, San Antonio, Tex. 78229) that is HER2negative as measured by IHC. The study was carried out as describedbelow.

Tumor fragments were implanted subcutaneously into athymic nude mice.When tumors reached 170 mm³ the animals were randomly assigned to groupsas shown in Table All and treatment began in a blinded and controlledstudy. Animals were treated according to Regimen 1 and 2 as shown inTable A11. All treatments were administered intravenously.

TABLE A11 Study Design Regimen 1 Regimen 2 Group Dosage Dosage Sched-(n) Agent (mg/kg) Schedule Agent (mg/kg) ule 1 (20) v12470 30 Twiceweekly for four weeks 2 (20) V6336 30 Twice weekly for four weeks 3 (20)v10000 30 Twice weekly for four weeks 4 (20) v12470 30 Twice weekly nab-30 Days 2, for four weeks paclitaxel 9, 16 5 (20) v10000 30 Twice weeklynab- 30 Days 2, for four weeks paclitaxel 9, 16

Tumor volume was measured by calipers twice weekly. The study durationwas 71 days with survival as the primary endpoint. Additional tumorresponse criteria were measured and are shown in Table A12. Mice wereeuthanized when tumor volume exceeded 2000 mm³; the surviving percentageversus study day was plotted on a Kaplan-Meier and was statisticallyassessed using a log-rank test. Serum concentration in groups dosed withv10000 and v6336 was determined by HER2 ELISA on study day 7.

The results are shown in FIG. 51A (tumor volume) and FIG. 51B(Kaplan-Meier survival). Only treatment with variant 10000 incombination with nab-paclitaxel reduced tumor growth and significantlyprolonged survival by log-rank test compared to treatment with controlIgG (v12470) (FIG. 51B and Table A13). In addition, treatment withv10000 in combination with nab-paclitaxel significantly prolongedsurvival compared to treatment with nab-paclitaxel plus control IgG(FIG. 51B and Table A13). The median survival of v10000 in combinationwith nab-paclitaxel was greater than 71 days while the median survivalof v12470, v6336, v10000, and nab-paclitaxel as single agents was 58.8,65.9, 69.3, and 60.6 days respectively. Mean tumor volume on study day54 for treatment with v10000 in combination with nab-paclitaxel was 1073mm3. Tumor volumes for v12470, v6336, v10000, and nab-paclitaxel assingle agents on study day 54 was 1663, 1494, 1305, and 1365 mm3respectively (FIG. 51A and Table A12). The serum exposure of v6336 andv10000 from day 14 serum samples is shown in Table A14.

These results indicate that treatment with v10000 in combination withnab-paclitaxel is able to decrease tumor volume and prolong survival inthis model of HER2 negative pancreatic cancer, when compared to the IgGcontrol, Herceptin™, and single agent v10000.

TABLE A12 ST803 Tumor Response Profile 12470 + nab- 12470 + nab- 124706336 10000 pac* pac* Tumor Response on Day 54 Mean TV (mm³) (% Δ frombase 1663 1494 1305 1365 1073 line) (+888%) (+806%) (+659%) (+693%)(+522%) Treatment/Control Ratio 1.00 0.90 0.78 0.82 0.64 RECIST ScoresCR (TV <20 mm³) 0/18 0/17 0/20 0/16 0/19 PR (>30% baseline regression)0/18 0/17 0/20 0/16 0/19 PD (>20% baseline growth) 18/18  17/17  20/20 16/16  19/19  SD (neither PD or PR) 0/18 0/17 0/20 0/16 0/19 Median Timeto Progression 4.4 3.6 3.6 4.4 5.6 (days) Survival Response MedianSurvival (days) 58.8 65.9 69.3 60.6 >71 CR—Complete Response PR—PartialResponse PD—Progressive Disease SD—Stable Disease *nab-paclitaxel

TABLE A13 Log Rank Summary 12470 + nab- 10000 + nab- Group 12470 633610000 pac* pac* 12470 — — — — 6336 ns — — — — 10000 ns ns — — — 12470 +nab- ns — Ns — — pac 10000, + nab- ★★ — Ns ★★ — pac Legend: ns = notsignificant, ★ = P < 0.05. ★★ = P < 0.01, ★★★ = P < 0.001*nab-paclitaxel

TABLE A14 Serum Exposure Summary 10000 (microg/mL) + 6336 10000 nab-Sample Day (microg/mL) (microg/mL) paclitaxel 14 426.7 279 391

Example 49: Effect of v10000 on Tumor Growth Inhibition in a XenograftModel of HER2 3+ Gastric Cancer

This experiment was performed to assess efficacy of v10000 compared to acontrol IgG (v12470) and Herceptin™ (v6336) as single agents in theGXA3054 xenograft model of gastric cancer. GXA3054 is a patient derivedxenograft (PDX) of gastric cancer that is HER2 3+ (Oncotest GmbH, AmFlughafen 12-14, 79108 Freiburg, Germany). The study was carried out asdescribed below.

Tumor fragments were implanted subcutaneously into athymic nude mice.When tumors reached 144 mm³ the animals were randomly assigned to groupsas shown in Table A15 and treatment began in a blinded and controlledstudy. Animals were treated according to Regimen 1 as shown in TableA15.

TABLE A15 Study Design Regimen 1 Dosage Group (n) Agent (mg/kg) RouteSchedule 1 (10) v12470 30 IV Twice weekly for five weeks 2 (10) V6336 30IV Twice weekly for five weeks 3 (10) v10000 30 IV Twice weekly for fiveweeks

Tumor volume was measured by calipers twice weekly. The study durationwas 59 days with tumor growth inhibition as the primary endpoint.Additional tumor response criteria were measured and are shown in TableA16. Mice were euthanized when tumor volume exceeded 2000 mm³.

The results are shown in FIG. 52 (tumor volume). Treatment with variant10000 and v6336 reduced tumor growth compared to treatment with controlIgG (v12470) (FIG. 52 and Table A16). In addition, treatment with v10000reduced tumor growth compared to treatment with v6336 (FIG. 52 and TableA16). Mean tumor volume on study day 35 for treatment with control IgG,v10000 and v6336 was 1340, 236, and 7.8 mm3, respectively. Tumor growthinhibition on day 35 for v10000 and v6336 was 111 and 92%, respectively(Table A16). On day 35 tumors treated with v10000 showed greaterresponses (7/10 complete and 3/10 partial responses) compared to tumorstreated with v6336 (0/10 complete and 1/10 partial response) (TableA16). At the completion of the study, on day 59, 9/10 tumors treatedwith v10000 had complete responses with no evidence of recurrent tumor,while for v6336 treated tumors only 1/10 tumors had a complete response.

These results indicate that treatment with v10000 can regress tumors inthis model of HER2 3+ gastric cancer. The tumor growth inhibition ofv10000 was superior to IgG control and Herceptin™.

TABLE A16 GXA3054 Tumor Response Profile 12470 6336 10000 Tumor Responseon Day 35 Na 92 111 Tumor Growth Inhibition (%) RECIST Scores CR (≦−95%)0/10 0/10 7/10 PR (>−95% and <−66%) 0/10 1/10 3/10 SD (≧−66% and ≦+73%)0/10 5/10 0/10 PD (>+73%) 10/10  4/10 0/10 CR—Complete ResponsePR—Partial Response PD—Progressive Disease SD—Stable Disease

The reagents employed in the examples are generally commerciallyavailable or can be prepared using commercially availableinstrumentation, methods, or reagents known in the art. The foregoingexamples illustrate various aspects described herein and practice of themethods described herein. The examples are not intended to provide anexhaustive description of the many different embodiments of theinvention. Thus, although the forgoing invention has been described insome detail by way of illustration and example for purposes of clarityof understanding, those of ordinary skill in the art will realizereadily that many changes and modifications can be made thereto withoutdeparting from the spirit or scope of the appended claims.

All publications, patents and patent applications mentioned in thisspecification are herein incorporated by reference into thespecification to the same extent as if each individual publication,patent or patent application was specifically and individually indicatedto be incorporated herein by reference.

SEQUENCE TABLE Variant Ht clone name H2 clone name L1 clone nameL2 clone name   792 1011 1015   -2   -2  5019 3057  720 1811 NA  5020 719 3041 NA 1811  7091 3057 5244 1811 NA 10000 6586 5244 3382 NA  69035065 3468 5037 3904  6902 5065 3468 5034 3904  6717 3317  720 NA NA 1040 4560 4553 NA 4561   630  719  716 NA NA  4182 4560 3057 NA 1811  506  642  642   -2   -2  4184 3057 3041 1811 1811  9996 4372 6586 NA3382 SEQ ID NO. Clone Desc. Sequence (amino acid or 1 642 FullEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 2 642 FullGAGGTGCAGCTGGTGGAAAGCGGAGGAGGACTGGTGCAGCCAGGAGGATCTCTGCGACTGAGTTGCGCCGCTTCAGGATTCAACATCAAGGACACCTACATTCACTGGGTGCGACAGGCTCCAGGAAAAGGACTGGAGTGGGTGGCTCGAATCTATCCCACTAATGGATACACCCGGTATGCCGACTCCGTGAAGGGGAGGTTTACTATTAGCGCCGATACATCCAAAAACACTGCTTACCTGCAGATGAACAGCCTGCGAGCCGAAGATACCGCTGTGTACTATTGCAGTCGATGGGGAGGAGACGGATTCTACGCTATGGATTATTGGGGACAGGGGACCCTGGTGACAGTGAGCTCCGCCTCTACCAAGGGCCCCAGTGTGTTTCCCCTGGCTCCTTCTAGTAAATCCACCTCTGGAGGGACAGCCGCTCTGGGATGTCTGGTGAAGGACTATTTCCCCGAGCCTGTGACCGTGAGTTGGAACTCAGGCGCCCTGACAAGCGGAGTGCACACTTTTCCTGCTGTGCTGCAGTCAAGCGGGCTGTACTCCCTGTCCTCTGTGGTGACAGTGCCAAGTTCAAGCCTGGGCACACAGACTTATATCTGCAACGTGAATCATAAGCCCTCAAATACAAAAGTGGACAAGAAAGTGGAGCCCAAGAGCTGTGATAAGACCCACACCTGCCCTCCCTGTCCAGCTCCAGAACTGCTGGGAGGACCTAGCGTGTTCCTGTTTCCCCCTAAGCCAAAAGACACTCTGATGATTTCCAGGACTCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCTCACGAGGACCCCGAAGTGAAGTTCAACTGGTACGTGGATGGCGTGGAAGTGCATAATGCTAAGACAAAACCAAGAGAGGAACAGTACAACTCCACTTATCGCGTCGTGAGCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGGAAGGAGTATAAGTGCAAAGTCAGTAATAAGGCCCTGCCTGCTCCAATCGAAAAAACCATCTCTAAGGCCAAAGGCCAGCCAAGGGAGCCCCAGGTGTACACACTGCCACCCAGCAGAGACGAACTGACCAAGAACCAGGTGTCCCTGACATGTCTGGTGAAAGGCTTCTATCCTAGTGATATTGCTGTGGAGTGGGAATCAAATGGACAGCCAGAGAACAATTACAAGACCACACCTCCAGTGCTGGACAGCGATGGCAGCTTCTTCCTGTATTCCAAGCTGACAGTGGATAAATCTCGATGGCAGCAGGGGAACGTGTTTAGTTGTTCAGTGATGCATGAAGCCCTGCACAATCATTACACTCAGAAGAGCCTGTCCCTGTCTCCCGGCAAA 3 642 VHEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS 4 642 VHGAGGTGCAGCTGGTGGAAAGCGGAGGAGGACTGGTGCAGCCAGGAGGATCTCTGCGACTGAGTTGCGCCGCTTCAGGATTCAACATCAAGGACACCTACATTCACTGGGTGCGACAGGCTCCAGGAAAAGGACTGGAGTGGGTGGCTCGAATCTATCCCACTAATGGATACACCCGGTATGCCGACTCCGTGAAGGGGAGGTTTACTATTAGCGCCGATACATCCAAAAACACTGCTTACCTGCAGATGAACAGCCTGCGAGCCGAAGATACCGCTGTGTACTATTGCAGTCGATGGGGAGGAGACGGATTCTACGCTATGGATTATTGGGGACAGGGGACCCTGGTGACAGTGAGCTCC 5 642H1 GFNIKDTY 6 642 H1 GGATTCAACATCAAGGACACCTAC 7 642 H3 SRWGGDGFYAMDY 8642 H3 AGTCGATGGGGAGGAGACGGATTCTACGCTATGGATTAT 9 642 H2 IYPTNGYT 10 642H2 ATCTATCCCACTAATGGATACACC 11 642 CH1ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV 12 642 CH1GCCTCTACCAAGGGCCCCAGTGTGTTTCCCCTGGCTCCTTCTAGTAAATCCACCTCTGGAGGGACAGCCGCTCTGGGATGTCTGGTGAAGGACTATTTCCCCGAGCCTGTGACCGTGAGTTGGAACTCAGGCGCCCTGACAAGCGGAGTGCACACTTTTCCTGCTGTGCTGCAGTCAAGCGGGCTGTACTCCCTGTCCTCTGTGGTGACAGTGCCAAGTTCAAGCCTGGGCACACAGACTTATATCTGCAACGTGAATCATAAGCCCTCAAATACAAAAGTGGACAAGAAAGTG13 642 CH2APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 14 642 CH2GCTCCAGAACTGCTGGGAGGACCTAGCGTGTTCCTGTTTCCCCCTAAGCCAAAAGACACTCTGATGATTTCCAGGACTCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCTCACGAGGACCCCGAAGTGAAGTTCAACTGGTACGTGGATGGCGTGGAAGTGCATAATGCTAAGACAAAACCAAGAGAGGAACAGTACAACTCCACTTATCGCGTCGTGAGCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGGAAGGAGTATAAGTGCAAAGTCAGTAATAAGGCCCTGCCTGCTCCAATCGAAAAAACCATCTCTAAGGCCAAA 15 642 CH3GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 16 642 CH3GGCCAGCCAAGGGAGCCCCAGGTGTACACACTGCCACCCAGCAGAGACGAACTGACCAAGAACCAGGTGTCCCTGACATGTCTGGTGAAAGGCTTCTATCCTAGTGATATTGCTGTGGAGTGGGAATCAAATGGACAGCCAGAGAACAATTACAAGACCACACCTCCAGTGCTGGACAGCGATGGCAGCTTCTTCCTGTATTCCAAGCTGACAGTGGATAAATCTCGATGGCAGCAGGGGAACGTGTTTAGTTGTTCAGTGATGCATGAAGCCCTGCACAATCATTACACTCAGAAGAGCCTGTCCCTGTCTCCCGGC 17 3468 FullEVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGCSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKGYFPEPVTVSWNSGALTSGVHTFPAVLKSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVLPPSRDELTKNQVSLLCLVKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 18 3468 FullGAAGTGCAGCTGGTCGAATCTGGAGGAGGACTGGTGCAGCCAGGAGGGTCCCTGCGCCTGTCTTGCGCCGCTAGTGGCTTCACTTTTACCGACTACACCATGGATTGGGTGCGACAGGCACCTGGAAAGGGCCTGGAGTGGGTCGCCGATGTGAACCCAAATAGCGGAGGCTCCATCTACAACCAGCGGTTCAAGGGCCGGTTCACCCTGTCAGTGGACCGGAGCAAAAACACCCTGTATCTGCAGATGAATAGCCTGCGAGCCGAAGATACTGCTGTGTACTATTGCGCCCGGAATCTGGGGCCCTCCTTCTACTTTGACTATTGGGGGCAGGGAACTCTGGTCACCGTGAGCTCCGCCTCCACCAAGGGACCTTCTGTGTTCCCACTGGCTCCCTCTAGTAAATCCACATCTGGGGGAACTGCAGCCCTGGGCTGTCTGGTGAAGGGCTACTTCCCAGAGCCCGTCACAGTGTCTTGGAACAGTGGCGCTCTGACTTCTGGGGTCCACACCTTTCCTGCAGTGCTGAAGTCAAGCGGGCTGTACAGCCTGTCCTCTGTGGTCACCGTGCCAAGTTCAAGCCTGGGAACACAGACTTATATCTGCAACGTGAATCACAAGCCATCCAATACAAAAGTCGACAAGAAAGTGGAACCCAAGTCTTGTGATAAAACCCATACATGCCCCCCTTGTCCTGCACCAGAGCTGCTGGGAGGACCAAGCGTGTTCCTGTTTCCACCCAAGCCTAAAGATACACTGATGATTAGTAGGACCCCAGAAGTCACATGCGTGGTCGTGGACGTGAGCCACGAGGACCCCGAAGTCAAGTTTAACTGGTACGTGGACGGCGTCGAGGTGCATAATGCCAAGACTAAACCCAGGGAGGAACAGTACAACAGTACCTATCGCGTCGTGTCAGTCCTGACAGTGCTGCATCAGGATTGGCTGAACGGGAAAGAGTATAAGTGCAAAGTGAGCAATAAGGCTCTGCCCGCACCTATCGAGAAAACAATTTCCAAGGCAAAAGGACAGCCTAGAGAACCACAGGTGTACGTGCTGCCTCCATCAAGGGATGAGCTGACAAAGAACCAGGTCAGCCTGCTGTGTCTGGTGAAAGGATTCTATCCCTCTGACATTGCTGTGGAGTGGGAAAGTAATGGCCAGCCTGAGAACAATTACCTGACCTGGCCCCCTGTGCTGGACTCAGATGGCAGCTTCTTTCTGTATAGCAAGCTGACCGTCGACAAATCCCGGTGGCAGCAGGGGAATGTGTTTAGTTGTTCAGTCATGCACGAGGCACTGCACAACCATTACACCCAGAAGTCACTGTCACTGTCACCAGGG 19 3468 VHEVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGCSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS 20 3468 VHGAAGTGCAGCTGGTCGAATCTGGAGGAGGACTGGTGCAGCCAGGAGGGTCCCTGCGCCTGTCTTGCGCCGCTAGTGGCTTCACTTTTACCGACTACACCATGGATTGGGTGCGACAGGCACCTGGAAAGGGCCTGGAGTGGGTCGCCGATGTGAACCCAAATAGCGGAGGCTCCATCTACAACCAGCGGTTCAAGGGCCGGTTCACCCTGTCAGTGGACCGGAGCAAAAACACCCTGTATCTGCAGATGAATAGCCTGCGAGCCGAAGATACTGCTGTGTACTATTGCGCCCGGAATCTGGGGCCCTCCTTCTACTTTGACTATTGGGGGCAGGGAACTCTGGTCACCGTGAGCTCC 21 3468 H1GFTFTDYT 22 3468 H1 GGCTTCACTTTTACCGACTACACC 23 3468 H3 ARNLGPSFYFDY 243468 H3 GCCCGGAATCTGGGGCCCTCCTTCTACTTTGACTAT 25 3468 H2 VNPNSGGS 26 3468H2 GTGAACCCAAATAGCGGAGGCTCC 27 3468 CH1ASTKGPSVFPLAPSSKSTSGGTAALGCLVKGYFPEPVTVSWNSGALTSGVHTFPAVLKSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV 28 3468 CH1GCCTCCACCAAGGGACCTTCTGTGTTCCCACTGGCTCCCTCTAGTAAATCCACATCTGGGGGAACTGCAGCCCTGGGCTGTCTGGTGAAGGGCTACTTCCCAGAGCCCGTCACAGTGTCTTGGAACAGTGGCGCTCTGACTTCTGGGGTCCACACCTTTCCTGCAGTGCTGAAGTCAAGCGGGCTGTACAGCCTGTCCTCTGTGGTCACCGTGCCAAGTTCAAGCCTGGGAACACAGACTTATATCTGCAACGTGAATCACAAGCCATCCAATACAAAAGTCGACAAGAAAGTG29 3468 CH2APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 30 3468 CH2GCACCAGAGCTGCTGGGAGGACCAAGCGTGTTCCTGTTTCCACCCAAGCCTAAAGATACACTGATGATTAGTAGGACCCCAGAAGTCACATGCGTGGTCGTGGACGTGAGCCACGAGGACCCCGAAGTCAAGTTTAACTGGTACGTGGACGGCGTCGAGGTGCATAATGCCAAGACTAAACCCAGGGAGGAACAGTACAACAGTACCTATCGCGTCGTGTCAGTCCTGACAGTGCTGCATCAGGATTGGCTGAACGGGAAAGAGTATAAGTGCAAAGTGAGCAATAAGGCTCTGCCCGCACCTATCGAGAAAACAATTTCCAAGGCAAAA 31 3468 CH3GQPREPQVYVLPPSRDELTKNQVSLLCLVKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 32 3468 CH3GGACAGCCTAGAGAACCACAGGTGTACGTGCTGCCTCCATCAAGGGATGAGCTGACAAAGAACCAGGTCAGCCTGCTGTGTCTGGTGAAAGGATTCTATCCCTCTGACATTGCTGTGGAGTGGGAAAGTAATGGCCAGCCTGAGAACAATTACCTGACCTGGCCCCCTGTGCTGGACTCAGATGGCAGCTTCTTTCTGTATAGCAAGCTGACCGTCGACAAATCCCGGTGGCAGCAGGGGAATGTGTTTAGTTGTTCAGTCATGCACGAGGCACTGCACAACCATTACACCCAGAAGTCACTGTCACTGTCACCAGGG 33 1811 FullDIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 341811 FullGATATTCAGATGACCCAGTCCCCAAGCTCCCTGAGTGCCTCAGTGGGCGACCGAGTCACCATCACATGCAAGGCTTCCCAGGATGTGTCTATTGGAGTCGCATGGTACCAGCAGAAGCCAGGCAAAGCACCCAAGCTGCTGATCTATAGCGCCTCCTACCGGTATACCGGCGTGCCCTCTAGATTCTCTGGCAGTGGGTCAGGAACAGACTTTACTCTGACCATCTCTAGTCTGCAGCCTGAGGATTTCGCTACCTACTATTGCCAGCAGTACTATATCTACCCATATACCTTTGGCCAGGGGACAAAAGTGGAGATCAAGAGGACTGTGGCCGCTCCCTCCGTCTTCATTTTTCCCCCTTCTGACGAACAGCTGAAAAGTGGCACAGCCAGCGTGGTCTGTCTGCTGAACAATTTCTACCCTCGCGAAGCCAAAGTGCAGTGGAAGGTCGATAACGCTCTGCAGAGCGGCAACAGCCAGGAGTCTGTGACTGAACAGGACAGTAAAGATTCAACCTATAGCCTGTCAAGCACACTGACTCTGAGCAAGGCAGACTACGAGAAGCACAAAGTGTATGCCTGCGAAGTCACACATCAGGGGCTGTCCTCTCCTGTGACTAAGAGCTTTAACAGAGGAGAGTGT 35 1811 VLDIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIK 36 1811 VLGATATTCAGATGACCCAGTCCCCAAGCTCCCTGAGTGCCTCAGTGGGCGACCGAGTCACCATCACATGCAAGGCTTCCCAGGATGTGTCTATTGGAGTCGCATGGTACCAGCAGAAGCCAGGCAAAGCACCCAAGCTGCTGATCTATAGCGCCTCCTACCGGTATACCGGCGTGCCCTCTAGATTCTCTGGCAGTGGGTCAGGAACAGACTTTACTCTGACCATCTCTAGTCTGCAGCCTGAGGATTTCGCTACCTACTATTGCCAGCAGTACTATATCTACCCATATACCTTTGGCCAGGGGACAAAAGTGGAGATCAAG 37 1811 L1 QDVSIG 38 1811 L1CAGGATGTGTCTATTGGA 39 1811 L3 QQYYIYPYT 40 1811 L3CAGCAGTACTATATCTACCCATATACC 41 1811 L2 SAS 42 1811 L2 AGCGCCTCC 43 1811CLRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 44 1811 CLAGGACTGTGGCCGCTCCCTCCGTCTTCATTTTTCCCCCTTCTGACGAACAGCTGAAAAGTGGCACAGCCAGCGTGGTCTGTCTGCTGAACAATTTCTACCCTCGCGAAGCCAAAGTGCAGTGGAAGGTCGATAACGCTCTGCAGAGCGGCAACAGCCAGGAGTCTGTGACTGAACAGGACAGTAAAGATTCAACCTATAGCCTGTCAAGCACACTGACTCTGAGCAAGGCAGACTACGAGAAGCACAAAGTGTATGCCTGCGAAGTCACACATCAGGGGCTGTCCTCTCCTGTGACTAAGAGCTTTAACAGAGGAGAGTGT 45 5034 FullDYKDDDDKDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDERLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC46 5034 FullGACTACAAAGACGACGATGACAAAGATATCCAGATGACCCAGTCCCCTAGCTCCCTGTCCGCTTCTGTGGGCGATAGGGTCACTATTACCTGCCGCGCATCTCAGGACGTGAACACCGCAGTCGCCTGGTACCAGCAGAAGCCTGGGAAAGCTCCAAAGCTGCTGATCTACAGTGCATCATTCCTGTATTCAGGAGTGCCCAGCCGGTTTAGCGGCAGCAGATCTGGCACCGATTTCACACTGACTATTTCTAGTCTGCAGCCTGAGGACTTTGCCACATACTATTGCCAGCAGCACTATACCACACCCCCTACTTTCGGCCAGGGGACCAAAGTGGAGATCAAGCGAACTGTGGCCGCTCCAAGTGTCTTCATTTTTCCACCCAGCGATGAAAGACTGAAGTCCGGCACAGCTTCTGTGGTCTGTCTGCTGAACAATTTTTACCCCAGAGAGGCCAAAGTGCAGTGGAAGGTCGACAACGCTCTGCAGAGTGGCAACAGCCAGGAGAGCGTGACAGAACAGGATTCCAAAGACTCTACTTATAGTCTGTCAAGCACCCTGACACTGAGCAAGGCAGACTACGAAAAGCATAAAGTGTATGCCTGTGAGGTCACACATCAGGGGCTGTCATCACCAGTCACCAAATCATTCAATCGGGGGGAGTGC47 5034 VLDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK 48 5034 VLGATATCCAGATGACCCAGTCCCCTAGCTCCCTGTCCGCTTCTGTGGGCGATAGGGTCACTATTACCTGCCGCGCATCTCAGGACGTGAACACCGCAGTCGCCTGGTACCAGCAGAAGCCTGGGAAAGCTCCAAAGCTGCTGATCTACAGTGCATCATTCCTGTATTCAGGAGTGCCCAGCCGGTTTAGCGGCAGCAGATCTGGCACCGATTTCACACTGACTATTTCTAGTCTGCAGCCTGAGGACTTTGCCACATACTATTGCCAGCAGCACTATACCACACCCCCTACTTTCGGCCAGGGGACCAAAGTGGAGATCAAG 49 5034 L1 QDVNTA 50 5034 L1CAGGACGTGAACACCGCA 51 5034 L3 QQHYTTPPT 52 5034 L3CAGCAGCACTATACCACACCCCCTACT 53 5034 L2 SAS 54 5034 L2 AGTGCATCA 55 5034CLRTVAAPSVFIFPPSDERLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 56 5034 CLCGAACTGTGGCCGCTCCAAGTGTCTTCATTTTTCCACCCAGCGATGAAAGACTGAAGTCCGGCACAGCTTCTGTGGTCTGTCTGCTGAACAATTTTTACCCCAGAGAGGCCAAAGTGCAGTGGAAGGTCGACAACGCTCTGCAGAGTGGCAACAGCCAGGAGAGCGTGACAGAACAGGATTCCAAAGACTCTACTTATAGTCTGTCAAGCACCCTGACACTGAGCAAGGCAGACTACGAAAAGCATAAAGTGTATGCCTGTGAGGTCACACATCAGGGGCTGTCATCACCAGTCACCAAATCATTCAATCGGGGGGAGTGC 57 5037 FullDYKDDDDKDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDERLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSKESVTEQDSKDSTYSLSSRLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC58 5037 FullGACTACAAAGACGACGATGACAAAGATATCCAGATGACCCAGTCCCCTAGCTCCCTGTCCGCTTCTGTGGGCGATAGGGTCACTATTACCTGCCGCGCATCTCAGGACGTGAACACCGCAGTCGCCTGGTACCAGCAGAAGCCTGGGAAAGCTCCAAAGCTGCTGATCTACAGTGCATCATTCCTGTATTCAGGAGTGCCCAGCCGGTTTAGCGGCAGCAGATCTGGCACCGATTTCACACTGACTATTTCTAGTCTGCAGCCTGAGGACTTTGCCACATACTATTGCCAGCAGCACTATACCACACCCCCTACTTTCGGCCAGGGGACCAAAGTGGAGATCAAGCGAACTGTGGCCGCTCCAAGTGTCTTCATTTTTCCACCCAGCGATGAAAGACTGAAGTCCGGCACAGCTTCTGTGGTCTGTCTGCTGAACAATTTTTACCCCAGAGAGGCCAAAGTGCAGTGGAAGGTCGACAACGCTCTGCAGAGTGGCAACAGCAAGGAGAGCGTGACAGAACAGGATTCCAAAGACTCTACTTATAGTCTGTCAAGCAGACTGACACTGAGCAAGGCAGACTACGAAAAGCATAAAGTGTATGCCTGTGAGGTCACACATCAGGGGCTGTCATCACCAGTCACCAAATCATTCAATCGGGGGGAGTGC59 5037 VLDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK 60 5037 VLGATATCCAGATGACCCAGTCCCCTAGCTCCCTGTCCGCTTCTGTGGGCGATAGGGTCACTATTACCTGCCGCGCATCTCAGGACGTGAACACCGCAGTCGCCTGGTACCAGCAGAAGCCTGGGAAAGCTCCAAAGCTGCTGATCTACAGTGCATCATTCCTGTATTCAGGAGTGCCCAGCCGGTTTAGCGGCAGCAGATCTGGCACCGATTTCACACTGACTATTTCTAGTCTGCAGCCTGAGGACTTTGCCACATACTATTGCCAGCAGCACTATACCACACCCCCTACTTTCGGCCAGGGGACCAAAGTGGAGATCAAG 61 5037 L1 QDVNTA 62 5037 L1CAGGACGTGAACACCGCA 63 5037 L3 QQHYTTPPT 64 5037 L3CAGCAGCACTATACCACACCCCCTACT 65 5037 L2 SAS 66 5037 L2 AGTGCATCA 67 5037CLRTVAAPSVFIFPPSDERLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSKESVTEQDSKDSTYSLSSRLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 68 5037 CLCGAACTGTGGCCGCTCCAAGTGTCTTCATTTTTCCACCCAGCGATGAAAGACTGAAGTCCGGCACAGCTTCTGTGGTCTGTCTGCTGAACAATTTTTACCCCAGAGAGGCCAAAGTGCAGTGGAAGGTCGACAACGCTCTGCAGAGTGGCAACAGCAAGGAGAGCGTGACAGAACAGGATTCCAAAGACTCTACTTATAGTCTGTCAAGCAGACTGACACTGAGCAAGGCAGACTACGAAAAGCATAAAGTGTATGCCTGTGAGGTCACACATCAGGGGCTGTCATCACCAGTCACCAAATCATTCAATCGGGGGGAGTGC 69 3382 FullDIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPATFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 703382 FullGATATTCAGATGACCCAGTCCCCAAGCTCCCTGAGTGCCTCAGTGGGCGACCGAGTCACCATCACATGCAAGGCTTCCCAGGATGTGTCTATTGGAGTCGCATGGTACCAGCAGAAGCCAGGCAAAGCACCCAAGCTGCTGATCTATAGCGCCTCCTACCGGTATACCGGCGTGCCCTCTAGATTCTCTGGCAGTGGGTCAGGAACAGACTTTACTCTGACCATCTCTAGTCTGCAGCCTGAGGATTTCGCTACCTACTATTGCCAGCAGTACTATATCTACCCAGCCACCTTTGGCCAGGGGACAAAAGTGGAGATCAAGAGGACTGTGGCCGCTCCCTCCGTCTTCATTTTTCCCCCTTCTGACGAACAGCTGAAAAGTGGCACAGCCAGCGTGGTCTGTCTGCTGAACAATTTCTACCCTCGCGAAGCCAAAGTGCAGTGGAAGGTCGATAACGCTCTGCAGAGCGGCAACAGCCAGGAGTCTGTGACTGAACAGGACAGTAAAGATTCAACCTATAGCCTGTCAAGCACACTGACTCTGAGCAAGGCAGACTACGAGAAGCACAAAGTGTATGCCTGCGAAGTCACACATCAGGGGCTGTCCTCTCCTGTGACTAAGAGCTTTAACAGAGGAGAGTGT 71 3382 VLDIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPATFGQGTKVEIK 72 3382 VLGATATTCAGATGACCCAGTCCCCAAGCTCCCTGAGTGCCTCAGTGGGCGACCGAGTCACCATCACATGCAAGGCTTCCCAGGATGTGTCTATTGGAGTCGCATGGTACCAGCAGAAGCCAGGCAAAGCACCCAAGCTGCTGATCTATAGCGCCTCCTACCGGTATACCGGCGTGCCCTCTAGATTCTCTGGCAGTGGGTCAGGAACAGACTTTACTCTGACCATCTCTAGTCTGCAGCCTGAGGATTTCGCTACCTACTATTGCCAGCAGTACTATATCTACCCAGCCACCTTTGGCCAGGGGACAAAAGTGGAGATCAAG 73 3382 L1 QDVSIG 74 3382 L1CAGGATGTGTCTATTGGA 75 3382 L3 QQYYIYPAT 76 3382 L3CAGCAGTACTATATCTACCCAGCCACC 77 3382 L2 SAS 78 3382 L2 AGCGCCTCC 79 3382CLRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 80 3382 CLAGGACTGTGGCCGCTCCCTCCGTCTTCATTTTTCCCCCTTCTGACGAACAGCTGAAAAGTGGCACAGCCAGCGTGGTCTGTCTGCTGAACAATTTCTACCCTCGCGAAGCCAAAGTGCAGTGGAAGGTCGATAACGCTCTGCAGAGCGGCAACAGCCAGGAGTCTGTGACTGAACAGGACAGTAAAGATTCAACCTATAGCCTGTCAAGCACACTGACTCTGAGCAAGGCAGACTACGAGAAGCACAAAGTGTATGCCTGCGAAGTCACACATCAGGGGCTGTCCTCTCCTGTGACTAAGAGCTTTAACAGAGGAGAGTGT 81 5065 FullEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCEVTDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVYPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 82 5065 FullGAGGTGCAGCTGGTCGAAAGCGGAGGAGGACTGGTGCAGCCAGGAGGGTCACTGCGACTGAGCTGCGCAGCTTCCGGCTTCAACATCAAGGACACCTACATTCACTGGGTCCGCCAGGCTCCTGGAAAAGGCCTGGAGTGGGTGGCACGAATCTATCCAACTAATGGATACACCCGGTATGCCGACTCCGTGAAGGGCCGGTTCACCATTTCTGCAGATACAAGTAAAAACACTGCCTACCTGCAGATGAACAGCCTGCGAGCCGAAGATACAGCCGTGTACTATTGCAGCCGATGGGGAGGCGACGGCTTCTACGCTATGGATTATTGGGGGCAGGGAACCCTGGTCACAGTGAGCTCCGCATCAACAAAGGGGCCTAGCGTGTTTCCACTGGCCCCCTCTAGTAAATCCACCTCTGGGGGAACAGCAGCCCTGGGATGTGAGGTGACCGACTACTTCCCAGAGCCCGTCACTGTGAGCTGGAACTCCGGCGCCCTGACATCTGGGGTCCATACTTTTCCTGCTGTGCTGCAGTCAAGCGGCCTGTACAGCCTGTCCTCTGTGGTCACTGTGCCAAGTTCAAGCCTGGGGACTCAGACCTATATCTGCAACGTGAATCACAAGCCATCCAATACCAAAGTCGACAAGAAAGTGGAACCCAAGTCTTGTGATAAAACACATACTTGCCCCCCTTGTCCTGCACCAGAGCTGCTGGGAGGACCAAGCGTGTTCCTGTTTCCACCCAAGCCTAAAGACACCCTGATGATTAGTAGGACTCCAGAAGTCACCTGCGTGGTCGTGGACGTGAGCCACGAGGACCCCGAAGTCAAGTTCAACTGGTACGTGGATGGCGTCGAGGTGCATAATGCCAAGACAAAACCCAGGGAGGAACAGTACAACTCCACTTATCGCGTCGTGTCTGTCCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAGGAGTATAAGTGCAAAGTGAGCAATAAGGCTCTGCCCGCACCTATCGAGAAAACAATTTCCAAGGCTAAAGGGCAGCCTAGAGAACCACAGGTGTACGTGTACCCTCCATCTAGGGACGAGCTGACCAAGAACCAGGTCAGTCTGACATGTCTGGTGAAAGGGTTCTATCCCAGCGATATCGCAGTGGAGTGGGAATCCAATGGACAGCCTGAGAACAATTACAAGACCACACCCCCTGTGCTGGACTCTGATGGAAGTTTCGCCCTGGTGAGTAAGCTGACCGTCGATAAATCACGGTGGCAGCAGGGCAACGTGTTCAGCTGTTCAGTGATGCACGAAGCACTGCACAACCACTACACCCAGAAAAGCCTGTCCCTGTCCCCCGGC 83 5065 VHEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS 84 5065 VHGAGGTGCAGCTGGTCGAAAGCGGAGGAGGACTGGTGCAGCCAGGAGGGTCACTGCGACTGAGCTGCGCAGCTTCCGGCTTCAACATCAAGGACACCTACATTCACTGGGTCCGCCAGGCTCCTGGAAAAGGCCTGGAGTGGGTGGCACGAATCTATCCAACTAATGGATACACCCGGTATGCCGACTCCGTGAAGGGCCGGTTCACCATTTCTGCAGATACAAGTAAAAACACTGCCTACCTGCAGATGAACAGCCTGCGAGCCGAAGATACAGCCGTGTACTATTGCAGCCGATGGGGAGGCGACGGCTTCTACGCTATGGATTATTGGGGGCAGGGAACCCTGGTCACAGTGAGCTCC 85 5065H1 GFNIKDTY 86 5065 H1 GGCTTCAACATCAAGGACACCTAC 87 5065 H3 SRWGGDGFYAMDY88 5065 H3 AGCCGATGGGGAGGCGACGGCTTCTACGCTATGGATTAT 89 5065 H2 IYPTNGYT90 5065 H2 ATCTATCCAACTAATGGATACACC 91 5065 CH1ASTKGPSVFPLAPSSKSTSGGTAALGCEVTDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV 92 5065 CH1GCATCAACAAAGGGGCCTAGCGTGTTTCCACTGGCCCCCTCTAGTAAATCCACCTCTGGGGGAACAGCAGCCCTGGGATGTGAGGTGACCGACTACTTCCCAGAGCCCGTCACTGTGAGCTGGAACTCCGGCGCCCTGACATCTGGGGTCCATACTTTTCCTGCTGTGCTGCAGTCAAGCGGCCTGTACAGCCTGTCCTCTGTGGTCACTGTGCCAAGTTCAAGCCTGGGGACTCAGACCTATATCTGCAACGTGAATCACAAGCCATCCAATACCAAAGTCGACAAGAAAGTG93 5065 CH2APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 94 5065 CH2GCACCAGAGCTGCTGGGAGGACCAAGCGTGTTCCTGTTTCCACCCAAGCCTAAAGACACCCTGATGATTAGTAGGACTCCAGAAGTCACCTGCGTGGTCGTGGACGTGAGCCACGAGGACCCCGAAGTCAAGTTCAACTGGTACGTGGATGGCGTCGAGGTGCATAATGCCAAGACAAAACCCAGGGAGGAACAGTACAACTCCACTTATCGCGTCGTGTCTGTCCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAGGAGTATAAGTGCAAAGTGAGCAATAAGGCTCTGCCCGCACCTATCGAGAAAACAATTTCCAAGGCTAAA 95 5065 CH3GQPREPQVYVYPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 96 5065 CH3GGGCAGCCTAGAGAACCACAGGTGTACGTGTACCCTCCATCTAGGGACGAGCTGACCAAGAACCAGGTCAGTCTGACATGTCTGGTGAAAGGGTTCTATCCCAGCGATATCGCAGTGGAGTGGGAATCCAATGGACAGCCTGAGAACAATTACAAGACCACACCCCCTGTGCTGGACTCTGATGGAAGTTTCGCCCTGGTGAGTAAGCTGACCGTCGATAAATCACGGTGGCAGCAGGGCAACGTGTTCAGCTGTTCAGTGATGCACGAAGCACTGCACAACCACTACACCCAGAAAAGCCTGTCCCTGTCCCCCGGC 97 6586 FullEVQLVESGGGLVQPGGSLRLSCAASGFTFADYTMDWVRQAPGKGLEWVGDVNPNSGCSIYNQRFKGRFTFSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVYPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 98 6586 FullGAGGTGCAGCTGGTGGAATCAGGAGGGGGCCTGGTGCAGCCCGGAGGGTCTCTGCGACTGTCATGTGCCGCTTCTGGGTTCACTTTCGCAGACTACACAATGGATTGGGTGCGACAGGCCCCCGGAAAGGGACTGGAGTGGGTGGGCGATGTCAACCCTAATTCTGGCGGGAGTATCTACAACCAGCGGTTCAAGGGGAGATTCACTTTTTCAGTGGACAGAAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGAGGGCCGAAGATACCGCTGTCTACTATTGCGCTCGCAATCTGGGCCCCAGTTTCTACTTTGACTATTGGGGGCAGGGAACCCTGGTGACAGTCAGCTCCGCTAGCACTAAGGGGCCTTCCGTGTTTCCACTGGCTCCCTCTAGTAAATCCACCTCTGGAGGCACAGCTGCACTGGGATGTCTGGTGAAGGATTACTTCCCTGAACCAGTCACAGTGAGTTGGAACTCAGGGGCTCTGACAAGTGGAGTCCATACTTTTCCCGCAGTGCTGCAGTCAAGCGGACTGTACTCCCTGTCCTCTGTGGTCACCGTGCCTAGTTCAAGCCTGGGCACCCAGACATATATCTGCAACGTGAATCACAAGCCATCAAATACAAAAGTCGACAAGAAAGTGGAGCCCAAGAGCTGTGATAAAACTCATACCTGCCCACCTTGTCCGGCGCCAGAACTGCTGGGAGGACCAAGCGTGTTCCTGTTTCCACCCAAGCCTAAAGACACCCTGATGATTTCCCGGACTCCTGAGGTCACCTGCGTGGTCGTGGACGTGTCTCACGAGGACCCCGAAGTCAAGTTCAACTGGTACGTGGATGGCGTCGAAGTGCATAATGCCAAGACCAAACCCCGGGAGGAACAGTACAACTCTACCTATAGAGTCGTGAGTGTCCTGACAGTGCTGCACCAGGACTGGCTGAATGGGAAGGAGTATAAGTGTAAAGTGAGCAACAAAGCCCTGCCCGCCCCAATCGAAAAAACAATCTCTAAAGCAAAAGGACAGCCTCGCGAACCACAGGTCTACGTCTACCCCCCATCAAGAGATGAACTGACAAAAAATCAGGTCTCTCTGACATGCCTGGTCAAAGGATTCTACCCTTCCGACATCGCCGTGGAGTGGGAAAGTAACGGCCAGCCCGAGAACAATTACAAGACCACACCCCCTGTCCTGGACTCTGATGGGAGTTTCGCTCTGGTGTCAAAGCTGACCGTCGATAAAAGCCGGTGGCAGCAGGGCAATGTGTTTAGCTGCTCCGTCATGCACGAAGCCCTGCACAATCACTACACACAGAAGTCCCTGAGCCTGAGCCCTGGC 99 6586 VHEVQLVESGGGLVQPGGSLRLSCAASGFTFADYTMDWVRQAPGKGLEWVGDVNPNSGCSIYNQRFKGRFTFSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS 100 6586 VHGAGGTGCAGCTGGTGGAATCAGGAGGGGGCCTGGTGCAGCCCGGAGGGTCTCTGCGACTGTCATGTGCCGCTTCTGGGTTCACTTTCGCAGACTACACAATGGATTGGGTGCGACAGGCCCCCGGAAAGGGACTGGAGTGGGTGGGCGATGTCAACCCTAATTCTGGCGGGAGTATCTACAACCAGCGGTTCAAGGGGAGATTCACTTTTTCAGTGGACAGAAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGAGGGCCGAAGATACCGCTGTCTACTATTGCGCTCGCAATCTGGGCCCCAGTTTCTACTTTGACTATTGGGGGCAGGGAACCCTGGTGACAGTCAGCTCC 101 6586H1 GFTFADYT 102 6586 H1 GGGTTCACTTTCGCAGACTACACA 103 6586 H3ARNLGPSFYFDY 104 6586 H3 GCTCGCAATCTGGGCCCCAGTTTCTACTTTGACTAT 105 6586H2 VNPNSGGS 106 6586 H2 GTCAACCCTAATTCTGGCGGGAGT 107 6586 CH1ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV 108 6586 CH1GCTAGCACTAAGGGGCCTTCCGTGTTTCCACTGGCTCCCTCTAGTAAATCCACCTCTGGAGGCACAGCTGCACTGGGATGTCTGGTGAAGGATTACTTCCCTGAACCAGTCACAGTGAGTTGGAACTCAGGGGCTCTGACAAGTGGAGTCCATACTTTTCCCGCAGTGCTGCAGTCAAGCGGACTGTACTCCCTGTCCTCTGTGGTCACCGTGCCTAGTTCAAGCCTGGGCACCCAGACATATATCTGCAACGTGAATCACAAGCCATCAAATACAAAAGTCGACAAGAAAGTG109 6586 CH2APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 110 6586 CH2GCGCCAGAACTGCTGGGAGGACCAAGCGTGTTCCTGTTTCCACCCAAGCCTAAAGACACCCTGATGATTTCCCGGACTCCTGAGGTCACCTGCGTGGTCGTGGACGTGTCTCACGAGGACCCCGAAGTCAAGTTCAACTGGTACGTGGATGGCGTCGAAGTGCATAATGCCAAGACCAAACCCCGGGAGGAACAGTACAACTCTACCTATAGAGTCGTGAGTGTCCTGACAGTGCTGCACCAGGACTGGCTGAATGGGAAGGAGTATAAGTGTAAAGTGAGCAACAAAGCCCTGCCCGCCCCAATCGAAAAAACAATCTCTAAAGCAAAA 111 6586 CH3GQPREPQVYVYPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 112 6586 CH3GGACAGCCTCGCGAACCACAGGTCTACGTCTACCCCCCATCAAGAGATGAACTGACAAAAAATCAGGTCTCTCTGACATGCCTGGTCAAAGGATTCTACCCTTCCGACATCGCCGTGGAGTGGGAAAGTAACGGCCAGCCCGAGAACAATTACAAGACCACACCCCCTGTCCTGGACTCTGATGGGAGTTTCGCTCTGGTGTCAAAGCTGACCGTCGATAAAAGCCGGTGGCAGCAGGGCAATGTGTTTAGCTGCTCCGTCATGCACGAAGCCCTGCACAATCACTACACACAGAAGTCCCTGAGCCTGAGCCCTGGC 113 3904 FullYPYDVPDYATGSDIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIKRTVAAPSVFIFPPSDEELKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSEESVTEQDSKDSTYSLSSTLELSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 114 3904 FullTATCCCTACGATGTGCCTGACTACGCTACTGGCTCCGATATCCAGATGACCCAGTCTCCAAGCTCCCTGAGTGCATCAGTGGGGGACCGAGTCACCATCACATGCAAGGCTTCCCAGGATGTGTCTATTGGAGTCGCATGGTACCAGCAGAAGCCAGGCAAAGCACCCAAGCTGCTGATCTACAGCGCCTCCTACCGGTATACTGGGGTGCCTTCCAGATTCTCTGGCAGTGGGTCAGGAACCGACTTTACTCTGACCATCTCTAGTCTGCAGCCCGAGGATTTCGCCACCTACTATTGCCAGCAGTACTATATCTACCCTTATACCTTTGGCCAGGGGACAAAAGTGGAGATCAAGAGGACAGTGGCCGCTCCAAGTGTCTTCATTTTTCCCCCTTCCGACGAAGAGCTGAAAAGTGGAACTGCTTCAGTGGTCTGTCTGCTGAACAATTTCTACCCCCGCGAAGCCAAAGTGCAGTGGAAGGTCGATAACGCTCTGCAGAGCGGCAATTCCGAGGAGTCTGTGACAGAACAGGACAGTAAAGATTCAACTTATAGCCTGTCAAGCACACTGGAGCTGTCTAAGGCAGACTACGAGAAGCACAAAGTGTATGCCTGCGAAGTCACCCATCAGGGGCTGTCCTCTCCCGTGACAAAGAGCTTTAACAGAGGAGAGTGT 115 3904 VLDIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIK 116 3904 VLGATATCCAGATGACCCAGTCTCCAAGCTCCCTGAGTGCATCAGTGGGGGACCGAGTCACCATCACATGCAAGGCTTCCCAGGATGTGTCTATTGGAGTCGCATGGTACCAGCAGAAGCCAGGCAAAGCACCCAAGCTGCTGATCTACAGCGCCTCCTACCGGTATACTGGGGTGCCTTCCAGATTCTCTGGCAGTGGGTCAGGAACCGACTTTACTCTGACCATCTCTAGTCTGCAGCCCGAGGATTTCGCCACCTACTATTGCCAGCAGTACTATATCTACCCTTATACCTTTGGCCAGGGGACAAAAGTGGAGATCAAG 117 3904 L1 QDVSIG 118 3904 L1CAGGATGTGTCTATTGGA 119 3904 L3 QQYYIYPYT 120 3904 L3CAGCAGTACTATATCTACCCTTATACC 121 3904 L2 SAS 122 3904 L2 AGCGCCTCC 1233904 CLRTVAAPSVFIFPPSDEELKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSEESVTEQDSKDSTYSLSSTLELSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 124 3904 CLAGGACAGTGGCCGCTCCAAGTGTCTTCATTTTTCCCCCTTCCGACGAAGAGCTGAAAAGTGGAACTGCTTCAGTGGTCTGTCTGCTGAACAATTTCTACCCCCGCGAAGCCAAAGTGCAGTGGAAGGTCGATAACGCTCTGCAGAGCGGCAATTCCGAGGAGTCTGTGACAGAACAGGACAGTAAAGATTCAACTTATAGCCTGTCAAGCACACTGGAGCTGTCTAAGGCAGACTACGAGAAGCACAAAGTGTATGCCTGCGAAGTCACCCATCAGGGGCTGTCCTCTCCCGTGACAAAGAGCTTTAACAGAGGAGAGTGT 125 4553 FullEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVYPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 126 4553 FullGAAGTCCAGCTGGTCGAAAGCGGAGGAGGACTGGTGCAGCCAGGAGGGTCTCTGCGACTGAGTTGCGCCGCTTCAGGCTTCAACATCAAGGACACCTACATTCACTGGGTGCGCCAGGCTCCTGGAAAAGGCCTGGAGTGGGTGGCACGAATCTATCCAACTAATGGATACACCCGGTATGCAGACAGCGTGAAGGGCCGGTTCACCATTAGCGCAGATACATCCAAAAACACTGCCTACCTGCAGATGAACAGCCTGCGAGCCGAAGATACTGCTGTGTACTATTGCAGTCGGTGGGGAGGCGACGGCTTCTACGCTATGGATTATTGGGGGCAGGGAACCCTGGTCACAGTGAGCTCCGCATCTACAAAGGGGCCTAGTGTGTTTCCACTGGCCCCCTCTAGTAAATCCACCTCTGGGGGAACAGCAGCCCTGGGATGTCTGGTGAAGGACTATTTCCCAGAGCCCGTCACTGTGAGTTGGAACTCAGGCGCCCTGACATCCGGGGTCCATACTTTTCCTGCTGTGCTGCAGTCAAGCGGCCTGTACTCTCTGTCCTCTGTGGTCACCGTGCCAAGTTCAAGCCTGGGGACTCAGACCTATATCTGCAACGTGAATCACAAGCCAAGCAATACAAAAGTCGACAAGAAAGTGGAACCCAAGAGCTGTGATAAAACACATACTTGCCCCCCTTGTCCTGCACCAGAGCTGCTGGGAGGACCATCCGTGTTCCTGTTTCCACCCAAGCCTAAAGACACCCTGATGATTTCCAGGACTCCAGAAGTCACCTGCGTGGTCGTGGACGTGTCTCACGAGGACCCCGAAGTCAAGTTCAACTGGTACGTGGATGGCGTCGAGGTGCATAATGCCAAGACAAAACCCAGGGAGGAACAGTACAACTCAACTTATCGCGTCGTGAGCGTCCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAGGAGTATAAGTGCAAAGTGAGCAATAAGGCTCTGCCCGCACCTATCGAGAAAACCATTAGCAAGGCCAAAGGGCAGCCTAGAGAACCACAGGTCTACGTGTATCCTCCAAGCAGGGACGAGCTGACCAAGAACCAGGTCTCCCTGACATGTCTGGTGAAAGGGTTTTACCCCAGTGATATCGCTGTGGAGTGGGAATCAAATGGACAGCCTGAAAACAATTATAAGACCACACCCCCTGTGCTGGACAGCGATGGCAGCTTCGCTCTGGTCTCCAAGCTGACTGTGGATAAATCTCGGTGGCAGCAGGGCAACGTCTTTAGTTGTTCAGTGATGCATGAGGCACTGCACAATCATTACACCCAGAAGAGCCTGTCCCTGTCTCCCGGCAAA 127 4553 VHEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS 128 4553 VHGAAGTCCAGCTGGTCGAAAGCGGAGGAGGACTGGTGCAGCCAGGAGGGTCTCTGCGACTGAGTTGCGCCGCTTCAGGCTTCAACATCAAGGACACCTACATTCACTGGGTGCGCCAGGCTCCTGGAAAAGGCCTGGAGTGGGTGGCACGAATCTATCCAACTAATGGATACACCCGGTATGCAGACAGCGTGAAGGGCCGGTTCACCATTAGCGCAGATACATCCAAAAACACTGCCTACCTGCAGATGAACAGCCTGCGAGCCGAAGATACTGCTGTGTACTATTGCAGTCGGTGGGGAGGCGACGGCTTCTACGCTATGGATTATTGGGGGCAGGGAACCCTGGTCACAGTGAGCTCC 1294553 H1 GFNIKDTY 130 4553 H1 GGCTTCAACATCAAGGACACCTAC 131 4553 H3SRWGGDGFYAMDY 132 4553 H3 AGTCGGTGGGGAGGCGACGGCTTCTACGCTATGGATTAT 1334553 H2 IYPTNGYT 134 4553 H2 ATCTATCCAACTAATGGATACACC 135 4553 CH1ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV 136 4553 CH1GCATCTACAAAGGGGCCTAGTGTGTTTCCACTGGCCCCCTCTAGTAAATCCACCTCTGGGGGAACAGCAGCCCTGGGATGTCTGGTGAAGGACTATTTCCCAGAGCCCGTCACTGTGAGTTGGAACTCAGGCGCCCTGACATCCGGGGTCCATACTTTTCCTGCTGTGCTGCAGTCAAGCGGCCTGTACTCTCTGTCCTCTGTGGTCACCGTGCCAAGTTCAAGCCTGGGGACTCAGACCTATATCTGCAACGTGAATCACAAGCCAAGCAATACAAAAGTCGACAAGAAAGTG137 4553 CH2APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 138 4553 CH2GCACCAGAGCTGCTGGGAGGACCATCCGTGTTCCTGTTTCCACCCAAGCCTAAAGACACCCTGATGATTTCCAGGACTCCAGAAGTCACCTGCGTGGTCGTGGACGTGTCTCACGAGGACCCCGAAGTCAAGTTCAACTGGTACGTGGATGGCGTCGAGGTGCATAATGCCAAGACAAAACCCAGGGAGGAACAGTACAACTCAACTTATCGCGTCGTGAGCGTCCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAGGAGTATAAGTGCAAAGTGAGCAATAAGGCTCTGCCCGCACCTATCGAGAAAACCATTAGCAAGGCCAAA 139 4553 CH3GQPREPQVYVYPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 140 4553 CH3GGGCAGCCTAGAGAACCACAGGTCTACGTGTATCCTCCAAGCAGGGACGAGCTGACCAAGAACCAGGTCTCCCTGACATGTCTGGTGAAAGGGTTTTACCCCAGTGATATCGCTGTGGAGTGGGAATCAAATGGACAGCCTGAAAACAATTATAAGACCACACCCCCTGTGCTGGACAGCGATGGCAGCTTCGCTCTGGTCTCCAAGCTGACTGTGGATAAATCTCGGTGGCAGCAGGGCAACGTCTTTAGTTGTTCAGTGATGCATGAGGCACTGCACAATCATTACACCCAGAAGAGCCTGTCCCTGTCTCCCGGC 141 716 FullEPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLICLVKGFYPSDIAVEWESNGQPENRYMTWPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 142 716 FullGAGCCCAAGAGCAGCGATAAGACCCACACCTGCCCTCCCTGTCCAGCTCCAGAACTGCTGGGAGGACCTAGCGTGTTCCTGTTTCCCCCTAAGCCAAAAGACACTCTGATGATTTCCAGGACTCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCTCACGAGGACCCCGAAGTGAAGTTCAACTGGTACGTGGATGGCGTGGAAGTGCATAATGCTAAGACAAAACCAAGAGAGGAACAGTACAACTCCACTTATCGCGTCGTGAGCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGGAAGGAGTATAAGTGCAAAGTCAGTAATAAGGCCCTGCCTGCTCCAATCGAAAAAACCATCTCTAAGGCCAAAGGCCAGCCAAGGGAGCCCCAGGTGTACACACTGCCACCCAGCAGAGACGAACTGACCAAGAACCAGGTGTCCCTGATCTGTCTGGTGAAAGGCTTCTATCCTAGTGATATTGCTGTGGAGTGGGAATCAAATGGACAGCCAGAGAACAGATACATGACCTGGCCTCCAGTGCTGGACAGCGATGGCAGCTTCTTCCTGTATTCCAAGCTGACAGTGGATAAATCTCGATGGCAGCAGGGGAACGTGTTTAGTTGTTCAGTGATGCATGAAGCCCTGCACAATCATTACACTCAGAAGAGCCTGTCCCTGTCTCCCGGCAAA 143 716 CH2APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 144 716 CH2GCTCCAGAACTGCTGGGAGGACCTAGCGTGTTCCTGTTTCCCCCTAAGCCAAAAGACACTCTGATGATTTCCAGGACTCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCTCACGAGGACCCCGAAGTGAAGTTCAACTGGTACGTGGATGGCGTGGAAGTGCATAATGCTAAGACAAAACCAAGAGAGGAACAGTACAACTCCACTTATCGCGTCGTGAGCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGGAAGGAGTATAAGTGCAAAGTCAGTAATAAGGCCCTGCCTGCTCCAATCGAAAAAACCATCTCTAAGGCCAAA 145 716 CH3GQPREPQVYTLPPSRDELTKNQVSLICLVKGFYPSDIAVEWESNGQPENRYMTWPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 146 716 CH3GGCCAGCCAAGGGAGCCCCAGGTGTACACACTGCCACCCAGCAGAGACGAACTGACCAAGAACCAGGTGTCCCTGATCTGTCTGGTGAAAGGCTTCTATCCTAGTGATATTGCTGTGGAGTGGGAATCAAATGGACAGCCAGAGAACAGATACATGACCTGGCCTCCAGTGCTGGACAGCGATGGCAGCTTCTTCCTGTATTCCAAGCTGACAGTGGATAAATCTCGATGGCAGCAGGGGAACGTGTTTAGTTGTTCAGTGATGCATGAAGCCCTGCACAATCATTACACTCAGAAGAGCCTGTCCCTGTCTCCCGGC 147 719 FullDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKGGSGGGSGGGSGGGSGGGSGEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSAAEPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTYPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDEDGSFALVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPCK 148 719 FullGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACGTTAACACCGCTGTAGCTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTCTGCATCCTTTTTGTACAGTGGGGTCCCATCAAGGTTCAGTGGCAGTCGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGCATTACACTACCCCACCCACTTTCGGCCAAGGGACCAAAGTGGAGATCAAAGGTGGTTCTGGTGGTGGTTCTGGTGGTGGTTCTGGTGGTGGTTCTGGTGGTGGTTCTGGTGAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGCGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCAACATTAAAGATACTTATATCCACTGGGTCCGGCAAGCTCCAGGGAAGGGCCTGGAGTGGGTCGCACGTATTTATCCCACAAATGGTTACACACGGTATGCGGACTCTGTGAAGGGCCGATTCACCATCTCCGCAGACACTTCCAAGAACACCGCGTATCTGCAAATGAACAGTCTGAGAGCTGAGGACACGGCCGTTTATTACTGTTCAAGATGGGGCGGAGACGGTTTCTACGCTATGGACTACTGGGGCCAAGGGACCCTGGTCACCGTCTCCTCAGCCGCCGAGCCCAAGAGCAGCGATAAGACCCACACCTGCCCTCCCTGTCCAGCTCCAGAACTGCTGGGAGGACCTAGCGTGTTCCTGTTTCCCCCTAAGCCAAAAGACACTCTGATGATTTCCAGGACTCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCTCACGAGGACCCCGAAGTGAAGTTCAACTGGTACGTGGATGGCGTGGAAGTGCATAATGCTAAGACAAAACCAAGAGAGGAACAGTACAACTCCACTTATCGCGTCGTGAGCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGGAAGGAGTATAAGTGCAAAGTCAGTAATAAGGCCCTGCCTGCTCCAATCGAAAAAACCATCTCTAAGGCCAAAGGCCAGCCAAGGGAGCCCCAGGTGTACACATACCCACCCAGCAGAGACGAACTGACCAAGAACCAGGTGTCCCTGACATGTCTGGTGAAAGGCTTCTATCCTAGTGATATTGCTGTGGAGTGGGAATCAAATGGACAGCCAGAGAACAATTACAAGACCACACCTCCAGTGCTGGACGAGGATGGCAGCTTCGCCCTGGTGTCCAAGCTGACAGTGGATAAATCTCGATGGCAGCAGGGGAACGTGTTTAGTTGTTCAGTGATGCATGAAGCCCTGCACAATCATTACACTCAGAAGAGCCTGTCCCTGTCTCCCGGCAAA 149 719 VLDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK 150 719 VLGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACGTTAACACCGCTGTAGCTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTCTGCATCCTTTTTGTACAGTGGGGTCCCATCAAGGTTCAGTGGCAGTCGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGCATTACACTACCCCACCCACTTTCGGCCAAGGGACCAAAGTGGAGATCAAA 151 719 L1 QDVNTA 152 719 L1CAGGACGTTAACACCGCT 153 719 L3 QQHYTTPPT 154 719 L3CAACAGCATTACACTACCCCACCCACT 155 719 L2 SAS 156 719 L2 TCTGCATCC 157 719VHEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS 158 719 VHGAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGCGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCAACATTAAAGATACTTATATCCACTGGGTCCGGCAAGCTCCAGGGAAGGGCCTGGAGTGGGTCGCACGTATTTATCCCACAAATGGTTACACACGGTATGCGGACTCTGTGAAGGGCCGATTCACCATCTCCGCAGACACTTCCAAGAACACCGCGTATCTGCAAATGAACAGTCTGAGAGCTGAGGACACGGCCGTTTATTACTGTTCAAGATGGGGCGGAGACGGTTTCTACGCTATGGACTACTGGGGCCAAGGGACCCTGGTCACCGTCTCCTCA 159 719H1 GFNIKDTY 160 719 H1 GGATTCAACATTAAAGATACTTAT 161 719 H3 SRWGGDGFYAMDY162 719 H3 TCAAGATGGGGCGGAGACGGTTTCTACGCTATGGACTAC 163 719 H2 IYPTNGYT164 719 H2 ATTTATCCCACAAATGGTTACACA 165 719 CH2APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 166 719 CH2GCTCCAGAACTGCTGGGAGGACCTAGCGTGTTCCTGTTTCCCCCTAAGCCAAAAGACACTCTGATGATTTCCAGGACTCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCTCACGAGGACCCCGAAGTGAAGTTCAACTGGTACGTGGATGGCGTGGAAGTGCATAATGCTAAGACAAAACCAAGAGAGGAACAGTACAACTCCACTTATCGCGTCGTGAGCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGGAAGGAGTATAAGTGCAAAGTCAGTAATAAGGCCCTGCCTGCTCCAATCGAAAAAACCATCTCTAAGGCCAAA 167 719 CH3GQPREPQVYTYPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDEDGSFALVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 168 719 CH3GGCCAGCCAAGGGAGCCCCAGGTGTACACATACCCACCCAGCAGAGACGAACTGACCAAGAACCAGGTGTCCCTGACATGTCTGGTGAAAGGCTTCTATCCTAGTGATATTGCTGTGGAGTGGGAATCAAATGGACAGCCAGAGAACAATTACAAGACCACACCTCCAGTGCTGGACGAGGATGGCAGCTTCGCCCTGGTGTCCAAGCTGACAGTGGATAAATCTCGATGGCAGCAGGGGAACGTGTTTAGTTGTTCAGTGATGCATGAAGCCCTGCACAATCATTACACTCAGAAGAGCCTGTCCCTGTCTCCCGGC 169 720 FullDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKGGSGGGSGGGSGGGSGGGSGEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSAAEPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLICLVKGFYPSDIAVEWESNGQPENRYMTWPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPCK 170 720 FullGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACGTTAACACCGCTGTAGCTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTCTGCATCCTTTTTGTACAGTGGGGTCCCATCAAGGTTCAGTGGCAGTCGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGCATTACACTACCCCACCCACTTTCGGCCAAGGGACCAAAGTGGAGATCAAAGGTGGTTCTGGTGGTGGTTCTGGTGGTGGTTCTGGTGGTGGTTCTGGTGGTGGTTCTGGTGAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGCGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCAACATTAAAGATACTTATATCCACTGGGTCCGGCAAGCTCCAGGGAAGGGCCTGGAGTGGGTCGCACGTATTTATCCCACAAATGGTTACACACGGTATGCGGACTCTGTGAAGGGCCGATTCACCATCTCCGCAGACACTTCCAAGAACACCGCGTATCTGCAAATGAACAGTCTGAGAGCTGAGGACACGGCCGTTTATTACTGTTCAAGATGGGGCGGAGACGGTTTCTACGCTATGGACTACTGGGGCCAAGGGACCCTGGTCACCGTCTCCTCAGCCGCCGAGCCCAAGAGCAGCGATAAGACCCACACCTGCCCTCCCTGTCCAGCTCCAGAACTGCTGGGAGGACCTAGCGTGTTCCTGTTTCCCCCTAAGCCAAAAGACACTCTGATGATTTCCAGGACTCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCTCACGAGGACCCCGAAGTGAAGTTCAACTGGTACGTGGATGGCGTGGAAGTGCATAATGCTAAGACAAAACCAAGAGAGGAACAGTACAACTCCACTTATCGCGTCGTGAGCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGGAAGGAGTATAAGTGCAAAGTCAGTAATAAGGCCCTGCCTGCTCCAATCGAAAAAACCATCTCTAAGGCCAAAGGCCAGCCAAGGGAGCCCCAGGTGTACACACTGCCACCCAGCAGAGACGAACTGACCAAGAACCAGGTGTCCCTGATCTGTCTGGTGAAAGGCTTCTATCCTAGTGATATTGCTGTGGAGTGGGAATCAAATGGACAGCCAGAGAACAGATACATGACCTGGCCTCCAGTGCTGGACAGCGATGGCAGCTTCTTCCTGTATTCCAAGCTGACAGTGGATAAATCTCGATGGCAGCAGGGGAACGTGTTTAGTTGTTCAGTGATGCATGAAGCCCTGCACAATCATTACACTCAGAAGAGCCTGTCCCTGTCTCCCGGCAAA 171 720 VLDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK 172 720 VLGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACGTTAACACCGCTGTAGCTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTCTGCATCCTTTTTGTACAGTGGGGTCCCATCAAGGTTCAGTGGCAGTCGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGCATTACACTACCCCACCCACTTTCGGCCAAGGGACCAAAGTGGAGATCAAA 173 720 L1 QDVNTA 174 720 L1CAGGACGTTAACACCGCT 175 720 L3 QQHYTTPPT 176 720 L3CAACAGCATTACACTACCCCACCCACT 177 720 L2 SAS 178 720 L2 TCTGCATCC 179 720VHEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTS SKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVS 180 720 VHGAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGCGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCAACATTAAAGATACTTATATCCACTGGGTCCGGCAAGCTCCAGGGAAGGGCCTGGAGTGGGTCGCACGTATTTATCCCACAAATGGTTACACACGGTATGCGGACTCTGTGAAGGGCCGATTCACCATCTCCGCAGACACTTCCAAGAACACCGCGTATCTGCAAATGAACAGTCTGAGAGCTGAGGACACGGCCGTTTATTACTGTTCAAGATGGGGCGGAGACGGTTTCTACGCTATGGACTACTGGGGCCAAGGGACCCTGGTCACCGTCTCCTCA 181 720H1 GFNIKDTY 182 720 H1 GGATTCAACATTAAAGATACTTAT 183 720 H3 SRWGGDGFYAMDY184 720 H3 TCAAGATGGGGCGGAGACGGTTTCTACGCTATGGACTAC 185 720 H2 IYPTNGYT186 720 H2 ATTTATCCCACAAATGGTTACACA 187 720 CH2APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 188 720 CH2GCTCCAGAACTGCTGGGAGGACCTAGCGTGTTCCTGTTTCCCCCTAAGCCAAAAGACACTCTGATGATTTCCAGGACTCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCTCACGAGGACCCCGAAGTGAAGTTCAACTGGTACGTGGATGGCGTGGAAGTGCATAATGCTAAGACAAAACCAAGAGAGGAACAGTACAACTCCACTTATCGCGTCGTGAGCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGGAAGGAGTATAAGTGCAAAGTCAGTAATAAGGCCCTGCCTGCTCCAATCGAAAAAACCATCTCTAAGGCCAAA 189 720 CH3GQPREPQVYTLPPSRDELTKNQVSLICLVKGFYPSDIAVEWESNGQPENRYMTWPPVLDSDGSFFLYSKLTVDKPG SRWQQGNVFSCSVMHEALHNHYTQKSLSLS 190 720 CH3GGCCAGCCAAGGGAGCCCCAGGTGTACACACTGCCACCCAGCAGAGACGAACTGACCAAGAACCAGGTGTCCCTGATCTGTCTGGTGAAAGGCTTCTATCCTAGTGATATTGCTGTGGAGTGGGAATCAAATGGACAGCCAGAGAACAGATACATGACCTGGCCTCCAGTGCTGGACAGCGATGGCAGCTTCTTCCTGTATTCCAAGCTGACAGTGGATAAATCTCGATGGCAGCAGGGGAACGTGTTTAGTTGTTCAGTGATGCATGAAGCCCTGCACAATCATTACACTCAGAAGAGCCTGTCCCTGTCTCCCGGC 191 4561 FullDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 1924561 FullGATATTCAGATGACCCAGTCCCCTAGCTCCCTGTCCGCTTCTGTGGGCGACAGGGTCACTATCACCTGCCGCGCATCTCAGGATGTGAACACCGCAGTCGCCTGGTACCAGCAGAAGCCTGGGAAAGCTCCAAAGCTGCTGATCTACAGTGCATCATTCCTGTATTCAGGAGTGCCCAGCCGGTTTAGCGGCAGCAGATCTGGCACCGACTTCACACTGACTATCTCTAGTCTGCAGCCTGAGGATTTTGCCACATACTATTGCCAGCAGCACTATACCACACCCCCTACTTTCGGCCAGGGGACCAAAGTGGAGATCAAGCGAACTGTGGCCGCTCCAAGTGTCTTCATTTTTCCACCCAGCGACGAACAGCTGAAATCCGGCACAGCTTCTGTGGTCTGTCTGCTGAACAACTTCTACCCCAGAGAGGCCAAAGTGCAGTGGAAGGTCGATAACGCTCTGCAGAGTGGCAACAGCCAGGAGAGCGTGACAGAACAGGACTCCAAAGATTCTACTTATAGTCTGTCAAGCACCCTGACACTGAGCAAGGCAGACTACGAAAAGCATAAAGTGTATGCCTGTGAGGTGACCCATCAGGGGCTGTCTTCTCCCGTGACCAAGTCTTTCAACCGAGGCGAATGT 193 4561 VLDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK 194 4561 VLGATATTCAGATGACCCAGTCCCCTAGCTCCCTGTCCGCTTCTGTGGGCGACAGGGTCACTATCACCTGCCGCGCATCTCAGGATGTGAACACCGCAGTCGCCTGGTACCAGCAGAAGCCTGGGAAAGCTCCAAAGCTGCTGATCTACAGTGCATCATTCCTGTATTCAGGAGTGCCCAGCCGGTTTAGCGGCAGCAGATCTGGCACCGACTTCACACTGACTATCTCTAGTCTGCAGCCTGAGGATTTTGCCACATACTATTGCCAGCAGCACTATACCACACCCCCTACTTTCGGCCAGGGGACCAAAGTGGAGATCAAG 195 4561 L1 QDVNTA 196 4561 L1CAGGATGTGAACACCGCA 197 4561 L3 QQHYTTPPT 198 4561 L3CAGCAGCACTATACCACACCCCCTACT 199 4561 L2 SAS 200 4561 L2 AGTGCATCA 2014561 CLRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 202 4561 CLCGAACTGTGGCCGCTCCAAGTGTCTTCATTTTTCCACCCAGCGACGAACAGCTGAAATCCGGCACAGCTTCTGTGGTCTGTCTGCTGAACAACTTCTACCCCAGAGAGGCCAAAGTGCAGTGGAAGGTCGATAACGCTCTGCAGAGTGGCAACAGCCAGGAGAGCGTGACAGAACAGGACTCCAAAGATTCTACTTATAGTCTGTCAAGCACCCTGACACTGAGCAAGGCAGACTACGAAAAGCATAAAGTGTATGCCTGTGAGGTGACCCATCAGGGGCTGTCTTCTCCCGTGACCAAGTCTTTCAACCGAGGCGAATGT 203 3041 FullEVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGCSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVLPPSRDELTKNQVSLLCLVKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 204 3041 FullGAAGTGCAGCTGGTCGAATCTGGAGGAGGACTGGTGCAGCCAGGAGGGTCCCTGCGCCTGTCTTGCGCCGCTAGTGGCTTCACTTTTACCGACTACACCATGGATTGGGTGCGACAGGCACCTGGAAAGGGCCTGGAGTGGGTCGCCGATGTGAACCCAAATAGCGGAGGCTCCATCTACAACCAGCGGTTCAAGGGCCGGTTCACCCTGTCAGTGGACCGGAGCAAAAACACCCTGTATCTGCAGATGAATAGCCTGCGAGCCGAAGATACTGCTGTGTACTATTGCGCCCGGAATCTGGGGCCCTCCTTCTACTTTGACTATTGGGGGCAGGGAACTCTGGTCACCGTGAGCTCCGCCTCCACCAAGGGACCTTCTGTGTTCCCACTGGCTCCCTCTAGTAAATCCACATCTGGGGGAACTGCAGCCCTGGGCTGTCTGGTGAAGGACTACTTCCCAGAGCCCGTCACAGTGTCTTGGAACAGTGGCGCTCTGACTTCTGGGGTCCACACCTTTCCTGCAGTGCTGCAGTCAAGCGGGCTGTACAGCCTGTCCTCTGTGGTCACCGTGCCAAGTTCAAGCCTGGGAACACAGACTTATATCTGCAACGTGAATCACAAGCCATCCAATACAAAAGTCGACAAGAAAGTGGAACCCAAGTCTTGTGATAAAACCCATACATGCCCCCCTTGTCCTGCACCAGAGCTGCTGGGAGGACCAAGCGTGTTCCTGTTTCCACCCAAGCCTAAAGATACACTGATGATTAGTAGGACCCCAGAAGTCACATGCGTGGTCGTGGACGTGAGCCACGAGGACCCCGAAGTCAAGTTTAACTGGTACGTGGACGGCGTCGAGGTGCATAATGCCAAGACTAAACCCAGGGAGGAACAGTACAACAGTACCTATCGCGTCGTGTCAGTCCTGACAGTGCTGCATCAGGATTGGCTGAACGGGAAAGAGTATAAGTGCAAAGTGAGCAATAAGGCTCTGCCCGCACCTATCGAGAAAACAATTTCCAAGGCAAAAGGACAGCCTAGAGAACCACAGGTGTACGTGCTGCCTCCATCAAGGGATGAGCTGACAAAGAACCAGGTCAGCCTGCTGTGTCTGGTGAAAGGATTCTATCCCTCTGACATTGCTGTGGAGTGGGAAAGTAATGGCCAGCCTGAGAACAATTACCTGACCTGGCCCCCTGTGCTGGACTCAGATGGCAGCTTCTTTCTGTATAGCAAGCTGACCGTCGACAAATCCCGGTGGCAGCAGGGGAATGTGTTTAGTTGTTCAGTCATGCACGAGGCACTGCACAACCATTACACCCAGAAGTCACTGTCACTGTCACCAGGG 205 3041 VHEVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGCSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS 206 3041 VHGAAGTGCAGCTGGTCGAATCTGGAGGAGGACTGGTGCAGCCAGGAGGGTCCCTGCGCCTGTCTTGCGCCGCTAGTGGCTTCACTTTTACCGACTACACCATGGATTGGGTGCGACAGGCACCTGGAAAGGGCCTGGAGTGGGTCGCCGATGTGAACCCAAATAGCGGAGGCTCCATCTACAACCAGCGGTTCAAGGGCCGGTTCACCCTGTCAGTGGACCGGAGCAAAAACACCCTGTATCTGCAGATGAATAGCCTGCGAGCCGAAGATACTGCTGTGTACTATTGCGCCCGGAATCTGGGGCCCTCCTTCTACTTTGACTATTGGGGGCAGGGAACTCTGGTCACCGTGAGCTCC 207 3041H1 GFTFTDYT 208 3041 H1 GGCTTCACTTTTACCGACTACACC 209 3041 H3ARNLGPSFYFDY 210 3041 H3 GCCCGGAATCTGGGGCCCTCCTTCTACTTTGACTAT 211 3041H2 VNPNSGGS 212 3041 H2 GTGAACCCAAATAGCGGAGGCTCC 213 3041 CH1ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV 214 3041 CH1GCCTCCACCAAGGGACCTTCTGTGTTCCCACTGGCTCCCTCTAGTAAATCCACATCTGGGGGAACTGCAGCCCTGGGCTGTCTGGTGAAGGACTACTTCCCAGAGCCCGTCACAGTGTCTTGGAACAGTGGCGCTCTGACTTCTGGGGTCCACACCTTTCCTGCAGTGCTGCAGTCAAGCGGGCTGTACAGCCTGTCCTCTGTGGTCACCGTGCCAAGTTCAAGCCTGGGAACACAGACTTATATCTGCAACGTGAATCACAAGCCATCCAATACAAAAGTCGACAAGAAAGTG215 3041 CH2APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 216 3041 CH2GCACCAGAGCTGCTGGGAGGACCAAGCGTGTTCCTGTTTCCACCCAAGCCTAAAGATACACTGATGATTAGTAGGACCCCAGAAGTCACATGCGTGGTCGTGGACGTGAGCCACGAGGACCCCGAAGTCAAGTTTAACTGGTACGTGGACGGCGTCGAGGTGCATAATGCCAAGACTAAACCCAGGGAGGAACAGTACAACAGTACCTATCGCGTCGTGTCAGTCCTGACAGTGCTGCATCAGGATTGGCTGAACGGGAAAGAGTATAAGTGCAAAGTGAGCAATAAGGCTCTGCCCGCACCTATCGAGAAAACAATTTCCAAGGCAAAA 217 3041 CH3GQPREPQVYVLPPSRDELTKNQVSLLCLVKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 218 3041 CH3GGACAGCCTAGAGAACCACAGGTGTACGTGCTGCCTCCATCAAGGGATGAGCTGACAAAGAACCAGGTCAGCCTGCTGTGTCTGGTGAAAGGATTCTATCCCTCTGACATTGCTGTGGAGTGGGAAAGTAATGGCCAGCCTGAGAACAATTACCTGACCTGGCCCCCTGTGCTGGACTCAGATGGCAGCTTCTTTCTGTATAGCAAGCTGACCGTCGACAAATCCCGGTGGCAGCAGGGGAATGTGTTTAGTTGTTCAGTCATGCACGAGGCACTGCACAACCATTACACCCAGAAGTCACTGTCACTGTCACCAGGG 219 3057 FullEVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGCSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVYPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 220 3057 FullGAAGTGCAGCTGGTCGAATCTGGAGGAGGACTGGTGCAGCCAGGAGGGTCCCTGCGCCTGTCTTGCGCCGCTAGTGGCTTCACTTTTACCGACTACACCATGGATTGGGTGCGACAGGCACCTGGAAAGGGCCTGGAGTGGGTCGCCGATGTGAACCCAAATAGCGGAGGCTCCATCTACAACCAGCGGTTCAAGGGCCGGTTCACCCTGTCAGTGGACCGGAGCAAAAACACCCTGTATCTGCAGATGAATAGCCTGCGAGCCGAAGATACTGCTGTGTACTATTGCGCCCGGAATCTGGGGCCCTCCTTCTACTTTGACTATTGGGGGCAGGGAACTCTGGTCACCGTGAGCTCCGCCTCCACCAAGGGACCTTCTGTGTTCCCACTGGCTCCCTCTAGTAAATCCACATCTGGGGGAACTGCAGCCCTGGGCTGTCTGGTGAAGGACTACTTCCCAGAGCCCGTCACAGTGTCTTGGAACAGTGGCGCTCTGACTTCTGGGGTCCACACCTTTCCTGCAGTGCTGCAGTCAAGCGGGCTGTACAGCCTGTCCTCTGTGGTCACCGTGCCAAGTTCAAGCCTGGGAACACAGACTTATATCTGCAACGTGAATCACAAGCCATCCAATACAAAAGTCGACAAGAAAGTGGAACCCAAGTCTTGTGATAAAACCCATACATGCCCCCCTTGTCCTGCACCAGAGCTGCTGGGAGGACCAAGCGTGTTCCTGTTTCCACCCAAGCCTAAAGATACACTGATGATTAGTAGGACCCCAGAAGTCACATGCGTGGTCGTGGACGTGAGCCACGAGGACCCCGAAGTCAAGTTTAACTGGTACGTGGACGGCGTCGAGGTGCATAATGCCAAGACTAAACCCAGGGAGGAACAGTACAACAGTACCTATCGCGTCGTGTCAGTCCTGACAGTGCTGCATCAGGATTGGCTGAACGGGAAAGAGTATAAGTGCAAAGTGAGCAATAAGGCTCTGCCCGCACCTATCGAGAAAACAATTTCCAAGGCAAAAGGACAGCCTAGAGAACCACAGGTGTACGTGTATCCTCCATCAAGGGATGAGCTGACAAAGAACCAGGTCAGCCTGACTTGTCTGGTGAAAGGATTCTATCCCTCTGACATTGCTGTGGAGTGGGAAAGTAATGGCCAGCCTGAGAACAATTACAAGACCACACCCCCTGTGCTGGACTCAGATGGCAGCTTCGCGCTGGTGAGCAAGCTGACCGTCGACAAATCCCGGTGGCAGCAGGGGAATGTGTTTAGTTGTTCAGTCATGCACGAGGCACTGCACAACCATTACACCCAGAAGTCACTGTCACTGTCACCAGGG 221 3057 VHEVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGCSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS 222 3057 VHGAAGTGCAGCTGGTCGAATCTGGAGGAGGACTGGTGCAGCCAGGAGGGTCCCTGCGCCTGTCTTGCGCCGCTAGTGGCTTCACTTTTACCGACTACACCATGGATTGGGTGCGACAGGCACCTGGAAAGGGCCTGGAGTGGGTCGCCGATGTGAACCCAAATAGCGGAGGCTCCATCTACAACCAGCGGTTCAAGGGCCGGTTCACCCTGTCAGTGGACCGGAGCAAAAACACCCTGTATCTGCAGATGAATAGCCTGCGAGCCGAAGATACTGCTGTGTACTATTGCGCCCGGAATCTGGGGCCCTCCTTCTACTTTGACTATTGGGGGCAGGGAACTCTGGTCACCGTGAGCTCC 223 3057H1 GFTFTDYT 224 3057 H1 GGCTTCACTTTTACCGACTACACC 225 3057 H3ARNLGPSFYFDY 226 3057 H3 GCCCGGAATCTGGGGCCCTCCTTCTACTTTGACTAT 227 3057H2 VNPNSGGS 228 3057 H2 GTGAACCCAAATAGCGGAGGCTCC 229 3057 CH1ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV 230 3057 CH1GCCTCCACCAAGGGACCTTCTGTGTTCCCACTGGCTCCCTCTAGTAAATCCACATCTGGGGGAACTGCAGCCCTGGGCTGTCTGGTGAAGGACTACTTCCCAGAGCCCGTCACAGTGTCTTGGAACAGTGGCGCTCTGACTTCTGGGGTCCACACCTTTCCTGCAGTGCTGCAGTCAAGCGGGCTGTACAGCCTGTCCTCTGTGGTCACCGTGCCAAGTTCAAGCCTGGGAACACAGACTTATATCTGCAACGTGAATCACAAGCCATCCAATACAAAAGTCGACAAGAAAGTG231 3057 CH2APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 232 3057 CH2GCACCAGAGCTGCTGGGAGGACCAAGCGTGTTCCTGTTTCCACCCAAGCCTAAAGATACACTGATGATTAGTAGGACCCCAGAAGTCACATGCGTGGTCGTGGACGTGAGCCACGAGGACCCCGAAGTCAAGTTTAACTGGTACGTGGACGGCGTCGAGGTGCATAATGCCAAGACTAAACCCAGGGAGGAACAGTACAACAGTACCTATCGCGTCGTGTCAGTCCTGACAGTGCTGCATCAGGATTGGCTGAACGGGAAAGAGTATAAGTGCAAAGTGAGCAATAAGGCTCTGCCCGCACCTATCGAGAAAACAATTTCCAAGGCAAAA 233 3057 CH3GQPREPQVYVYPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 234 3057 CH3GGACAGCCTAGAGAACCACAGGTGTACGTGTATCCTCCATCAAGGGATGAGCTGACAAAGAACCAGGTCAGCCTGACTTGTCTGGTGAAAGGATTCTATCCCTCTGACATTGCTGTGGAGTGGGAAAGTAATGGCCAGCCTGAGAACAATTACAAGACCACACCCCCTGTGCTGGACTCAGATGGCAGCTTCGCGCTGGTGAGCAAGCTGACCGTCGACAAATCCCGGTGGCAGCAGGGGAATGTGTTTAGTTGTTCAGTCATGCACGAGGCACTGCACAACCATTACACCCAGAAGTCACTGTCACTGTCACCAGGG 235 1011 FullEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVYPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 236 1011 FullGAGGTGCAGCTGGTGGAAAGCGGAGGAGGACTGGTGCAGCCAGGAGGATCTCTGCGACTGAGTTGCGCCGCTTCAGGATTCAACATCAAGGACACCTACATTCACTGGGTGCGACAGGCTCCAGGAAAAGGACTGGAGTGGGTGGCTCGAATCTATCCCACTAATGGATACACCCGGTATGCCGACTCCGTGAAGGGGAGGTTTACTATTAGCGCCGATACATCCAAAAACACTGCTTACCTGCAGATGAACAGCCTGCGAGCCGAAGATACCGCTGTGTACTATTGCAGTCGATGGGGAGGAGACGGATTCTACGCTATGGATTATTGGGGACAGGGGACCCTGGTGACAGTGAGCTCCGCCTCTACCAAGGGCCCCAGTGTGTTTCCCCTGGCTCCTTCTAGTAAATCCACCTCTGGAGGGACAGCCGCTCTGGGATGTCTGGTGAAGGACTATTTCCCCGAGCCTGTGACCGTGAGTTGGAACTCAGGCGCCCTGACAAGCGGAGTGCACACTTTTCCTGCTGTGCTGCAGTCAAGCGGGCTGTACTCCCTGTCCTCTGTGGTGACAGTGCCAAGTTCAAGCCTGGGCACACAGACTTATATCTGCAACGTGAATCATAAGCCCTCAAATACAAAAGTGGACAAGAAAGTGGAGCCCAAGAGCTGTGATAAGACCCACACCTGCCCTCCCTGTCCAGCTCCAGAACTGCTGGGAGGACCTAGCGTGTTCCTGTTTCCCCCTAAGCCAAAAGACACTCTGATGATTTCCAGGACTCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCTCACGAGGACCCCGAAGTGAAGTTCAACTGGTACGTGGATGGCGTGGAAGTGCATAATGCTAAGACAAAACCAAGAGAGGAACAGTACAACTCCACTTATCGCGTCGTGAGCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGGAAGGAGTATAAGTGCAAAGTCAGTAATAAGGCCCTGCCTGCTCCAATCGAAAAAACCATCTCTAAGGCCAAAGGCCAGCCAAGGGAGCCCCAGGTGTACGTGTACCCACCCAGCAGAGACGAACTGACCAAGAACCAGGTGTCCCTGACATGTCTGGTGAAAGGCTTCTATCCTAGTGATATTGCTGTGGAGTGGGAATCAAATGGACAGCCAGAGAACAATTACAAGACCACACCTCCAGTGCTGGACAGCGATGGCAGCTTCGCCCTGGTGTCCAAGCTGACAGTGGATAAATCTCGATGGCAGCAGGGGAACGTGTTTAGTTGTTCAGTGATGCATGAAGCCCTGCACAATCATTACACTCAGAAGAGCCTGTCCCTGTCTCCCGGCAAA 237 1011 VHEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS 238 1011 VHGAGGTGCAGCTGGTGGAAAGCGGAGGAGGACTGGTGCAGCCAGGAGGATCTCTGCGACTGAGTTGCGCCGCTTCAGGATTCAACATCAAGGACACCTACATTCACTGGGTGCGACAGGCTCCAGGAAAAGGACTGGAGTGGGTGGCTCGAATCTATCCCACTAATGGATACACCCGGTATGCCGACTCCGTGAAGGGGAGGTTTACTATTAGCGCCGATACATCCAAAAACACTGCTTACCTGCAGATGAACAGCCTGCGAGCCGAAGATACCGCTGTGTACTATTGCAGTCGATGGGGAGGAGACGGATTCTACGCTATGGATTATTGGGGACAGGGGACCCTGGTGACAGTGAGCTCC 2391011 H1 GFNIKDTY 240 1011 H1 GGATTCAACATCAAGGACACCTAC 241 1011 H3SRWGGDGFYAMDY 242 1011 H3 AGTCGATGGGGAGGAGACGGATTCTACGCTATGGATTAT 2431011 H2 IYPTNGYT 244 1011 H2 ATCTATCCCACTAATGGATACACC 245 1011 CH1ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV 246 1011 CH1GCCTCTACCAAGGGCCCCAGTGTGTTTCCCCTGGCTCCTTCTAGTAAATCCACCTCTGGAGGGACAGCCGCTCTGGGATGTCTGGTGAAGGACTATTTCCCCGAGCCTGTGACCGTGAGTTGGAACTCAGGCGCCCTGACAAGCGGAGTGCACACTTTTCCTGCTGTGCTGCAGTCAAGCGGGCTGTACTCCCTGTCCTCTGTGGTGACAGTGCCAAGTTCAAGCCTGGGCACACAGACTTATATCTGCAACGTGAATCATAAGCCCTCAAATACAAAAGTGGACAAGAAAGTG247 1011 CH2APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 248 1011 CH2GCTCCAGAACTGCTGGGAGGACCTAGCGTGTTCCTGTTTCCCCCTAAGCCAAAAGACACTCTGATGATTTCCAGGACTCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCTCACGAGGACCCCGAAGTGAAGTTCAACTGGTACGTGGATGGCGTGGAAGTGCATAATGCTAAGACAAAACCAAGAGAGGAACAGTACAACTCCACTTATCGCGTCGTGAGCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGGAAGGAGTATAAGTGCAAAGTCAGTAATAAGGCCCTGCCTGCTCCAATCGAAAAAACCATCTCTAAGGCCAAA 249 1011 CH3GQPREPQVYVYPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 250 1011 CH3GGCCAGCCAAGGGAGCCCCAGGTGTACGTGTACCCACCCAGCAGAGACGAACTGACCAAGAACCAGGTGTCCCTGACATGTCTGGTGAAAGGCTTCTATCCTAGTGATATTGCTGTGGAGTGGGAATCAAATGGACAGCCAGAGAACAATTACAAGACCACACCTCCAGTGCTGGACAGCGATGGCAGCTTCGCCCTGGTGTCCAAGCTGACAGTGGATAAATCTCGATGGCAGCAGGGGAACGTGTTTAGTTGTTCAGTGATGCATGAAGCCCTGCACAATCATTACACTCAGAAGAGCCTGTCCCTGTCTCCCGGC 251 4560 FullEPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVLPPSRDELTKNQVSLLCLVKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 252 4560 FullGAACCTAAAAGCAGCGACAAGACCCACACATGCCCCCCTTGTCCAGCTCCAGAACTGCTGGGAGGACCAAGCGTGTTCCTGTTTCCACCCAAGCCCAAAGATACACTGATGATCAGCCGAACTCCCGAGGTCACCTGCGTGGTCGTGGACGTGTCCCACGAGGACCCCGAAGTCAAGTTCAACTGGTACGTGGACGGCGTCGAAGTGCATAATGCAAAGACTAAACCACGGGAGGAACAGTACAACTCTACATATAGAGTCGTGAGTGTCCTGACTGTGCTGCATCAGGATTGGCTGAACGGCAAAGAGTATAAGTGCAAAGTGTCTAATAAGGCCCTGCCTGCTCCAATCGAGAAAACTATTAGTAAGGCAAAAGGGCAGCCCAGGGAACCTCAGGTCTACGTGCTGCCTCCAAGTCGCGACGAGCTGACCAAGAACCAGGTCTCACTGCTGTGTCTGGTGAAAGGATTCTATCCTTCCGATATTGCCGTGGAGTGGGAATCTAATGGCCAGCCAGAGAACAATTACCTGACCTGGCCCCCTGTGCTGGACAGCGATGGGTCCTTCTTTCTGTATTCAAAGCTGACAGTGGACAAAAGCAGATGGCAGCAGGGAAACGTCTTTAGCTGTTCCGTGATGCACGAAGCCCTGCACAATCATTACACCCAGAAGTCTCTGAGTCTGTCACCTGGCAAA 253 4560 CH2APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 254 4560 CH2GCTCCAGAACTGCTGGGAGGACCAAGCGTGTTCCTGTTTCCACCCAAGCCCAAAGATACACTGATGATCAGCCGAACTCCCGAGGTCACCTGCGTGGTCGTGGACGTGTCCCACGAGGACCCCGAAGTCAAGTTCAACTGGTACGTGGACGGCGTCGAAGTGCATAATGCAAAGACTAAACCACGGGAGGAACAGTACAACTCTACATATAGAGTCGTGAGTGTCCTGACTGTGCTGCATCAGGATTGGCTGAACGGCAAAGAGTATAAGTGCAAAGTGTCTAATAAGGCCCTGCCTGCTCCAATCGAGAAAACTATTAGTAAGGCAAAA 255 4560 CH3GQPREPQVYVLPPSRDELTKNQVSLLCLVKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 256 4560 CH3GGGCAGCCCAGGGAACCTCAGGTCTACGTGCTGCCTCCAAGTCGCGACGAGCTGACCAAGAACCAGGTCTCACTGCTGTGTCTGGTGAAAGGATTCTATCCTTCCGATATTGCCGTGGAGTGGGAATCTAATGGCCAGCCAGAGAACAATTACCTGACCTGGCCCCCTGTGCTGGACAGCGATGGGTCCTTCTTTCTGTATTCAAAGCTGACAGTGGACAAAAGCAGATGGCAGCAGGGAAACGTCTTTAGCTGTTCCGTGATGCACGAAGCCCTGCACAATCATTACACCCAGAAGTCTCTGAGTCTGTCACCTGGC 257 3317 FullDIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGCSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSSAAEPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVYPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPCK 258 3317 FullGACATTCAGATGACCCAGAGCCCTAGCTCCCTGAGTGCCTCAGTCGGGGACAGGGTGACTATCACCTGCAAGGCTTCACAGGATGTCAGCATTGGCGTGGCATGGTACCAGCAGAAGCCAGGGAAAGCACCCAAGCTGCTGATCTATAGCGCCTCCTACAGGTATACAGGCGTGCCATCCCGCTTCTCTGGCAGTGGGTCAGGAACTGACTTTACACTGACTATTTCTAGTCTGCAGCCCGAAGATTTCGCCACATACTATTGCCAGCAGTACTATATCTACCCTTATACTTTTGGCCAGGGGACCAAAGTGGAGATTAAGGGCGGAGGAGGCTCCGGAGGAGGAGGGTCTGGAGGAGGAGGAAGTGAGGTCCAGCTGGTGGAATCTGGAGGAGGACTGGTGCAGCCAGGAGGGTCCCTGAGGCTGTCTTGTGCCGCTAGTGGCTTCACCTTTACAGACTACACAATGGATTGGGTGCGCCAGGCACCAGGAAAGGGACTGGAATGGGTCGCTGATGTGAACCCTAATAGCGGAGGCTCCATCTACAACCAGCGGTTCAAAGGACGGTTCACCCTGTCAGTGGACCGGAGCAAGAACACCCTGTATCTGCAGATGAACAGCCTGAGAGCCGAGGATACTGCTGTGTACTATTGCGCCAGGAATCTGGGCCCAAGCTTCTACTTTGACTATTGGGGGCAGGGAACACTGGTCACTGTGTCAAGCGCAGCCGAACCCAAATCCTCTGATAAGACTCACACCTGCCCACCTTGTCCAGCTCCAGAGCTGCTGGGAGGACCTAGCGTGTTCCTGTTTCCACCCAAGCCAAAAGACACTCTGATGATTTCTAGAACCCCTGAAGTGACATGTGTGGTCGTGGACGTCAGTCACGAGGACCCCGAAGTCAAATTCAACTGGTACGTGGATGGCGTCGAGGTGCATAATGCCAAGACCAAACCCCGAGAGGAACAGTACAACTCAACCTATCGGGTCGTGAGCGTCCTGACAGTGCTGCATCAGGACTGGCTGAACGGCAAGGAGTATAAGTGCAAAGTGAGCAACAAGGCTCTGCCTGCACCAATCGAGAAGACCATTTCCAAGGCTAAAGGGCAGCCCCGCGAACCTCAGGTCTACGTGTATCCTCCAAGCCGAGATGAGCTGACAAAAAACCAGGTCTCCCTGACTTGTCTGGTGAAGGGATTTTACCCAAGTGACATCGCAGTGGAGTGGGAATCAAATGGCCAGCCCGAAAACAATTATAAGACCACACCCCCTGTGCTGGACTCTGATGGGAGTTTCGCACTGGTCTCCAAACTGACCGTGGACAAGTCTCGGTGGCAGCAGGGAAACGTCTTTAGCTGTTCCGTGATGCACGAGGCCCTGCACAATCATTACACACAGAAATCTCTGAGTCTGTCACCTGGCAAG 259 3317 VLDIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIK 260 3317 VLGACATTCAGATGACCCAGAGCCCTAGCTCCCTGAGTGCCTCAGTCGGGGACAGGGTGACTATCACCTGCAAGGCTTCACAGGATGTCAGCATTGGCGTGGCATGGTACCAGCAGAAGCCAGGGAAAGCACCCAAGCTGCTGATCTATAGCGCCTCCTACAGGTATACAGGCGTGCCATCCCGCTTCTCTGGCAGTGGGTCAGGAACTGACTTTACACTGACTATTTCTAGTCTGCAGCCCGAAGATTTCGCCACATACTATTGCCAGCAGTACTATATCTACCCTTATACTTTTGGCCAGGGGACCAAAGTGGAGATTAAG 261 3317 L1 QDVSIG 262 3317 L1CAGGATGTCAGCATTGGC 263 3317 L3 QQYYIYPYT 264 3317 L3CAGCAGTACTATATCTACCCTTATACT 265 3317 L2 SAS 266 3317 L2 AGCGCCTCC 2673317 VHEVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGCSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS 268 3317 VHGAGGTCCAGCTGGTGGAATCTGGAGGAGGACTGGTGCAGCCAGGAGGGTCCCTGAGGCTGTCTTGTGCCGCTAGTGGCTTCACCTTTACAGACTACACAATGGATTGGGTGCGCCAGGCACCAGGAAAGGGACTGGAATGGGTCGCTGATGTGAACCCTAATAGCGGAGGCTCCATCTACAACCAGCGGTTCAAAGGACGGTTCACCCTGTCAGTGGACCGGAGCAAGAACACCCTGTATCTGCAGATGAACAGCCTGAGAGCCGAGGATACTGCTGTGTACTATTGCGCCAGGAATCTGGGCCCAAGCTTCTACTTTGACTATTGGGGGCAGGGAACACTGGTCACTGTGTCAAGC 269 3317H1 GFTFTDYT 270 3317 H1 GGCTTCACCTTTACAGACTACACA 271 3317 H3ARNLGPSFYFDY 272 3317 H3 GCCAGGAATCTGGGCCCAAGCTTCTACTTTGACTAT 273 3317H2 VNPNSGGS 274 3317 H2 GTGAACCCTAATAGCGGAGGCTCC 275 3317 CH2APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 276 3317 CH2GCTCCAGAGCTGCTGGGAGGACCTAGCGTGTTCCTGTTTCCACCCAAGCCAAAAGACACTCTGATGATTTCTAGAACCCCTGAAGTGACATGTGTGGTCGTGGACGTCAGTCACGAGGACCCCGAAGTCAAATTCAACTGGTACGTGGATGGCGTCGAGGTGCATAATGCCAAGACCAAACCCCGAGAGGAACAGTACAACTCAACCTATCGGGTCGTGAGCGTCCTGACAGTGCTGCATCAGGACTGGCTGAACGGCAAGGAGTATAAGTGCAAAGTGAGCAACAAGGCTCTGCCTGCACCAATCGAGAAGACCATTTCCAAGGCTAAA 277 3317 CH3GQPREPQVYVYPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 278 3317 CH3GGGCAGCCCCGCGAACCTCAGGTCTACGTGTATCCTCCAAGCCGAGATGAGCTGACAAAAAACCAGGTCTCCCTGACTTGTCTGGTGAAGGGATTTTACCCAAGTGACATCGCAGTGGAGTGGGAATCAAATGGCCAGCCCGAAAACAATTATAAGACCACACCCCCTGTGCTGGACTCTGATGGGAGTTTCGCACTGGTCTCCAAACTGACCGTGGACAAGTCTCGGTGGCAGCAGGGAAACGTCTTTAGCTGTTCCGTGATGCACGAGGCCCTGCACAATCATTACACACAGAAATCTCTGAGTCTGTCACCTGGC 279 1015 FullEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVLPPSRDELTKNQVSLLCLVKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 280 1015 FullGAGGTGCAGCTGGTGGAAAGCGGAGGAGGACTGGTGCAGCCAGGAGGATCTCTGCGACTGAGTTGCGCCGCTTCAGGATTCAACATCAAGGACACCTACATTCACTGGGTGCGACAGGCTCCAGGAAAAGGACTGGAGTGGGTGGCTCGAATCTATCCCACTAATGGATACACCCGGTATGCCGACTCCGTGAAGGGGAGGTTTACTATTAGCGCCGATACATCCAAAAACACTGCTTACCTGCAGATGAACAGCCTGCGAGCCGAAGATACCGCTGTGTACTATTGCAGTCGATGGGGAGGAGACGGATTCTACGCTATGGATTATTGGGGACAGGGGACCCTGGTGACAGTGAGCTCCGCCTCTACCAAGGGCCCCAGTGTGTTTCCCCTGGCTCCTTCTAGTAAATCCACCTCTGGAGGGACAGCCGCTCTGGGATGTCTGGTGAAGGACTATTTCCCCGAGCCTGTGACCGTGAGTTGGAACTCAGGCGCCCTGACAAGCGGAGTGCACACTTTTCCTGCTGTGCTGCAGTCAAGCGGGCTGTACTCCCTGTCCTCTGTGGTGACAGTGCCAAGTTCAAGCCTGGGCACACAGACTTATATCTGCAACGTGAATCATAAGCCCTCAAATACAAAAGTGGACAAGAAAGTGGAGCCCAAGAGCTGTGATAAGACCCACACCTGCCCTCCCTGTCCAGCTCCAGAACTGCTGGGAGGACCTAGCGTGTTCCTGTTTCCCCCTAAGCCAAAAGACACTCTGATGATTTCCAGGACTCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCTCACGAGGACCCCGAAGTGAAGTTCAACTGGTACGTGGATGGCGTGGAAGTGCATAATGCTAAGACAAAACCAAGAGAGGAACAGTACAACTCCACTTATCGCGTCGTGAGCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGGAAGGAGTATAAGTGCAAAGTCAGTAATAAGGCCCTGCCTGCTCCAATCGAAAAAACCATCTCTAAGGCCAAAGGCCAGCCAAGGGAGCCCCAGGTGTACGTGCTGCCACCCAGCAGAGACGAACTGACCAAGAACCAGGTGTCCCTGCTGTGTCTGGTGAAAGGCTTCTATCCTAGTGATATTGCTGTGGAGTGGGAATCAAATGGACAGCCAGAGAACAATTACCTGACCTGGCCTCCAGTGCTGGACAGCGATGGCAGCTTCTTCCTGTATTCCAAGCTGACAGTGGATAAATCTCGATGGCAGCAGGGGAACGTGTTTAGTTGTTCAGTGATGCATGAAGCCCTGCACAATCATTACACTCAGAAGAGCCTGTCCCTGTCTCCCGGCAAA 281 1015 VHEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS 282 1015 VHGAGGTGCAGCTGGTGGAAAGCGGAGGAGGACTGGTGCAGCCAGGAGGATCTCTGCGACTGAGTTGCGCCGCTTCAGGATTCAACATCAAGGACACCTACATTCACTGGGTGCGACAGGCTCCAGGAAAAGGACTGGAGTGGGTGGCTCGAATCTATCCCACTAATGGATACACCCGGTATGCCGACTCCGTGAAGGGGAGGTTTACTATTAGCGCCGATACATCCAAAAACACTGCTTACCTGCAGATGAACAGCCTGCGAGCCGAAGATACCGCTGTGTACTATTGCAGTCGATGGGGAGGAGACGGATTCTACGCTATGGATTATTGGGGACAGGGGACCCTGGTGACAGTGAGCTCC 2831015 H1 GFNIKDTY 284 1015 H1 GGATTCAACATCAAGGACACCTAC 285 1015 H3SRWGGDGFYAMDY 286 1015 H3 AGTCGATGGGGAGGAGACGGATTCTACGCTATGGATTAT 2871015 H2 IYPTNGYT 288 1015 H2 ATCTATCCCACTAATGGATACACC 289 1015 CH1ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV 290 1015 CH1GCCTCTACCAAGGGCCCCAGTGTGTTTCCCCTGGCTCCTTCTAGTAAATCCACCTCTGGAGGGACAGCCGCTCTGGGATGTCTGGTGAAGGACTATTTCCCCGAGCCTGTGACCGTGAGTTGGAACTCAGGCGCCCTGACAAGCGGAGTGCACACTTTTCCTGCTGTGCTGCAGTCAAGCGGGCTGTACTCCCTGTCCTCTGTGGTGACAGTGCCAAGTTCAAGCCTGGGCACACAGACTTATATCTGCAACGTGAATCATAAGCCCTCAAATACAAAAGTGGACAAGAAAGTG291 1015 CH2APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 292 1015 CH2GCTCCAGAACTGCTGGGAGGACCTAGCGTGTTCCTGTTTCCCCCTAAGCCAAAAGACACTCTGATGATTTCCAGGACTCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCTCACGAGGACCCCGAAGTGAAGTTCAACTGGTACGTGGATGGCGTGGAAGTGCATAATGCTAAGACAAAACCAAGAGAGGAACAGTACAACTCCACTTATCGCGTCGTGAGCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGGAAGGAGTATAAGTGCAAAGTCAGTAATAAGGCCCTGCCTGCTCCAATCGAAAAAACCATCTCTAAGGCCAAA 293 1015 CH3GQPREPQVYVLPPSRDELTKNQVSLLCLVKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 294 1015 CH3GGCCAGCCAAGGGAGCCCCAGGTGTACGTGCTGCCACCCAGCAGAGACGAACTGACCAAGAACCAGGTGTCCCTGCTGTGTCTGGTGAAAGGCTTCTATCCTAGTGATATTGCTGTGGAGTGGGAATCAAATGGACAGCCAGAGAACAATTACCTGACCTGGCCTCCAGTGCTGGACAGCGATGGCAGCTTCTTCCTGTATTCCAAGCTGACAGTGGATAAATCTCGATGGCAGCAGGGGAACGTGTTTAGTTGTTCAGTGATGCATGAAGCCCTGCACAATCATTACACTCAGAAGAGCCTGTCCCTGTCTCCCGGC 295 5244 FullDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKGGSGGGSGGGSGGGSGGGSGEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSAAEPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVLPPSRDELTKNQVSLLCLVKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 296 5244 FullGACATTCAGATGACACAGAGCCCCAGCTCCCTGAGTGCTTCAGTCGGCGACAGGGTGACTATCACCTGCCGCGCATCCCAGGATGTCAACACCGCTGTGGCATGGTACCAGCAGAAGCCTGGAAAAGCCCCAAAGCTGCTGATCTACAGCGCTTCCTTCCTGTATTCTGGCGTGCCAAGTCGGTTTTCTGGAAGTAGATCAGGCACTGACTTCACACTGACTATCTCTAGTCTGCAGCCCGAAGATTTTGCCACCTACTATTGCCAGCAGCACTATACCACACCCCCTACATTCGGACAGGGCACTAAAGTGGAGATTAAGGGCGGGTCAGGCGGAGGGAGCGGAGGAGGGTCCGGAGGAGGGTCTGGAGGAGGGAGTGGAGAGGTCCAGCTGGTGGAATCTGGAGGAGGACTGGTGCAGCCTGGAGGCTCACTGCGACTGAGCTGTGCCGCTTCCGGCTTTAACATCAAAGACACATACATTCATTGGGTCAGGCAGGCACCAGGGAAGGGACTGGAATGGGTGGCCCGCATCTATCCCACAAATGGGTACACTCGATATGCCGACAGCGTGAAAGGACGGTTTACCATTTCTGCTGATACCAGTAAGAACACAGCATACCTGCAGATGAACAGCCTGCGCGCAGAGGATACAGCCGTGTACTATTGCAGTCGATGGGGGGGAGACGGCTTCTACGCCATGGATTATTGGGGCCAGGGGACTCTGGTCACCGTGTCAAGCGCAGCCGAACCTAAATCCTCTGACAAGACCCACACATGCCCACCCTGTCCTGCTCCAGAGCTGCTGGGAGGACCATCCGTGTTCCTGTTTCCTCCAAAGCCTAAAGATACACTGATGATTAGCCGCACTCCCGAAGTCACCTGTGTGGTCGTGGACGTGTCCCACGAGGACCCCGAAGTCAAGTTCAACTGGTACGTGGACGGCGTCGAGGTGCATAATGCCAAGACTAAACCAAGAGAGGAACAGTACAATTCAACCTATAGGGTCGTGAGCGTCCTGACAGTGCTGCATCAGGATTGGCTGAACGGCAAGGAGTATAAGTGCAAAGTGTCTAACAAGGCCCTGCCCGCTCCTATCGAGAAGACTATTAGCAAGGCAAAAGGGCAGCCACGGGAACCCCAGGTCTACGTGCTGCCCCCTAGCAGAGACGAGCTGACCAAAAACCAGGTCTCCCTGCTGTGTCTGGTGAAGGGCTTTTATCCTAGTGATATCGCTGTGGAGTGGGAATCAAATGGGCAGCCAGAAAACAATTACCTGACATGGCCACCCGTGCTGGACAGCGATGGGTCCTTCTTTCTGTATTCCAAACTGACTGTGGACAAGTCTAGATGGCAGCAGGGAAACGTCTTCAGCTGTTCCGTGATGCACGAGGCCCTGCACAATCATTACACCCAGAAGTCTCTGAGTCTGTCACCCGGC 297 5244 VLDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK 298 5244 VLGACATTCAGATGACACAGAGCCCCAGCTCCCTGAGTGCTTCAGTCGGCGACAGGGTGACTATCACCTGCCGCGCATCCCAGGATGTCAACACCGCTGTGGCATGGTACCAGCAGAAGCCTGGAAAAGCCCCAAAGCTGCTGATCTACAGCGCTTCCTTCCTGTATTCTGGCGTGCCAAGTCGGTTTTCTGGAAGTAGATCAGGCACTGACTTCACACTGACTATCTCTAGTCTGCAGCCCGAAGATTTTGCCACCTACTATTGCCAGCAGCACTATACCACACCCCCTACATTCGGACAGGGCACTAAAGTGGAGATTAAG 299 5244 L1 QDVNTA 300 5244 L1CAGGATGTCAACACCGCT 301 5244 L3 QQHYTTPPT 302 5244 L3CAGCAGCACTATACCACACCCCCTACA 303 5244 L2 SAS 304 5244 L2 AGCGCTTCC 3055244 VHEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS 306 5244 VHGAGGTCCAGCTGGTGGAATCTGGAGGAGGACTGGTGCAGCCTGGAGGCTCACTGCGACTGAGCTGTGCCGCTTCCGGCTTTAACATCAAAGACACATACATTCATTGGGTCAGGCAGGCACCAGGGAAGGGACTGGAATGGGTGGCCCGCATCTATCCCACAAATGGGTACACTCGATATGCCGACAGCGTGAAAGGACGGTTTACCATTTCTGCTGATACCAGTAAGAACACAGCATACCTGCAGATGAACAGCCTGCGCGCAGAGGATACAGCCGTGTACTATTGCAGTCGATGGGGGGGAGACGGCTTCTACGCCATGGATTATTGGGGCCAGGGGACTCTGGTCACCGTGTCAAGC 3075244 H1 GFNIKDTY 308 5244 H1 GGCTTTAACATCAAAGACACATAC 309 5244 H3SRWGGDGFYAMDY 310 5244 H3 AGTCGATGGGGGGGAGACGGCTTCTACGCCATGGATTAT 3115244 H2 IYPTNGYT 312 5244 H2 ATCTATCCCACAAATGGGTACACT 313 5244 CH2APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 314 5244 CH2GCTCCAGAGCTGCTGGGAGGACCATCCGTGTTCCTGTTTCCTCCAAAGCCTAAAGATACACTGATGATTAGCCGCACTCCCGAAGTCACCTGTGTGGTCGTGGACGTGTCCCACGAGGACCCCGAAGTCAAGTTCAACTGGTACGTGGACGGCGTCGAGGTGCATAATGCCAAGACTAAACCAAGAGAGGAACAGTACAATTCAACCTATAGGGTCGTGAGCGTCCTGACAGTGCTGCATCAGGATTGGCTGAACGGCAAGGAGTATAAGTGCAAAGTGTCTAACAAGGCCCTGCCCGCTCCTATCGAGAAGACTATTAGCAAGGCAAAA 315 5244 CH3GQPREPQVYVLPPSRDELTKNQVSLLCLVKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 316 5244 CH3GGGCAGCCACGGGAACCCCAGGTCTACGTGCTGCCCCCTAGCAGAGACGAGCTGACCAAAAACCAGGTCTCCCTGCTGTGTCTGGTGAAGGGCTTTTATCCTAGTGATATCGCTGTGGAGTGGGAATCAAATGGGCAGCCAGAAAACAATTACCTGACATGGCCACCCGTGCTGGACAGCGATGGGTCCTTCTTTCTGTATTCCAAACTGACTGTGGACAAGTCTAGATGGCAGCAGGGAAACGTCTTCAGCTGTTCCGTGATGCACGAGGCCCTGCACAATCATTACACCCAGAAGTCTCTGAGTCTGTCACCCGGC 317 -2 FullDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 318-2 FullGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACGTTAACACCGCTGTAGCTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTCTGCATCCTTTTTGTACAGTGGGGTCCCATCAAGGTTCAGTGGCAGTCGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGCATTACACTACCCCACCCACTTTCGGCCAAGGGACCAAAGTGGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAAGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT 319 -2 VLDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK 320 -2 VLGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACGTTAACACCGCTGTAGCTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTCTGCATCCTTTTTGTACAGTGGGGTCCCATCAAGGTTCAGTGGCAGTCGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGCATTACACTACCCCACCCACTTTCGGCCAAGGGACCAAAGTGGAGATCAAA 321 -2 L1 QDVNTA 322 -2 L1 CAGGACGTTAACACCGCT323 -2 L3 QQHYTTPPT 324 -2 L3 CAACAGCATTACACTACCCCACCCACT 325 -2 L2 SAS326 -2 L2 TCTGCATCC 327 -2 CLRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 328 -2 CLCGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAAGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT 329 4372 FullEPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVLPPSRDELTKNQVSLLCLVKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 330 4372 FullGAACCTAAATCCAGCGACAAGACCCACACATGCCCCCCTTGTCCAGCTCCAGAACTGCTGGGAGGACCAAGCGTGTTCCTGTTTCCACCCAAGCCCAAAGATACACTGATGATCAGCCGAACTCCCGAGGTCACCTGCGTGGTCGTGGACGTGTCCCACGAGGACCCCGAAGTCAAGTTCAACTGGTACGTGGACGGCGTCGAAGTGCATAATGCAAAGACTAAACCACGGGAGGAACAGTACAACTCTACATATAGAGTCGTGAGTGTCCTGACTGTGCTGCATCAGGATTGGCTGAACGGCAAAGAGTATAAGTGCAAAGTGTCTAATAAGGCCCTGCCTGCTCCAATCGAGAAAACTATTAGTAAGGCAAAAGGGCAGCCCAGGGAACCTCAGGTCTACGTGCTGCCTCCAAGTCGCGACGAGCTGACCAAGAACCAGGTCTCACTGCTGTGTCTGGTGAAAGGATTCTATCCTTCCGATATTGCCGTGGAGTGGGAATCTAATGGCCAGCCAGAGAACAATTACCTGACCTGGCCCCCTGTGCTGGACAGCGATGGGTCCTTCTTTCTGTATTCAAAGCTGACAGTGGACAAAAGCAGATGGCAGCAGGGAAACGTCTTTAGCTGTTCCGTGATGCACGAAGCCCTGCACAATCATTACACCCAGAAGTCTCTGAGTCTGTCACCTGGC 331 4372 CH2APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 332 4372 CH2GCTCCAGAACTGCTGGGAGGACCAAGCGTGTTCCTGTTTCCACCCAAGCCCAAAGATACACTGATGATCAGCCGAACTCCCGAGGTCACCTGCGTGGTCGTGGACGTGTCCCACGAGGACCCCGAAGTCAAGTTCAACTGGTACGTGGACGGCGTCGAAGTGCATAATGCAAAGACTAAACCACGGGAGGAACAGTACAACTCTACATATAGAGTCGTGAGTGTCCTGACTGTGCTGCATCAGGATTGGCTGAACGGCAAAGAGTATAAGTGCAAAGTGTCTAATAAGGCCCTGCCTGCTCCAATCGAGAAAACTATTAGTAAGGCAAAA 333 4372 CH3GQPREPQVYVLPPSRDELTKNQVSLLCLVKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 334 4372 CH3GGGCAGCCCAGGGAACCTCAGGTCTACGTGCTGCCTCCAAGTCGCGACGAGCTGACCAAGAACCAGGTCTCACTGCTGTGTCTGGTGAAAGGATTCTATCCTTCCGATATTGCCGTGGAGTGGGAATCTAATGGCCAGCCAGAGAACAATTACCTGACCTGGCCCCCTGTGCTGGACAGCGATGGGTCCTTCTTTCTGTATTCAAAGCTGACAGTGGACAAAAGCAGATGGCAGCAGGGAAACGTCTTTAGCTGTTCCGTGATGCACGAAGCCCTGCACAATCATTACACCCAGAAGTCTCTGAGTCTGTCACCTGGC SEQ ID NO: Pertuzumab WT CDR sequences 335 CDR-H2VNPNSGGS 336 CDR-H3 ARNLGPSFYFDY 337 CDR-H1 GFTFTDYT 338 CDR-L2 SAS 339CDR-L3 QQYYIYPYT 340 CDR-L1 QDVSIG SEQ ID NO: Trastuzumab WT CDRsequences 341 CDR-H2 IYPTNGYT 342 CDR-H3 SRWGGDGFYAMDY 343 CDR-H1GFNIKDTY 344 CDR-L2 SAS 345 CDR-L3 QQHYTTPPT 346 CDR-L1 QDVNTAPertuzumab variant CDR-L3: QQYYIYPATClone 3382, variant 10000 (SEQ ID NO: 347)Pertuzumab variant CDR-H1: GFTFADYTClone 6586, variant 10000 (SEQ ID NO: 348)

We claim:
 1. A method of treating a subject having a tumor; inhibiting,reducing or blocking HER2 signaling; or killing or inhibiting the growthof a HER2-expressing tumor cell, the method comprising administering aneffective amount of an antigen binding construct comprising: a firstantigen-binding polypeptide construct which monovalently andspecifically binds a HER2 (human epidermal growth factor receptor 2)ECD2 (extracellular domain 2) antigen on a HER2-expressing cell; asecond antigen-binding polypeptide construct which monovalently andspecifically binds a HER2 ECD4 (extracellular domain 4) antigen on aHER2-expressing cell; first and second linker polypeptides, wherein thefirst linker polypeptide is operably linked to the first antigen-bindingpolypeptide construct, and the second linker polypeptide is operablylinked to the second antigen-binding polypeptide construct; wherein thelinker polypeptides are capable of forming a covalent linkage with eachother, wherein one or both of the first or the second antigen bindingpolypeptide construct is an scFv, wherein the dissociation constant(K_(D)) of the antigen binding construct to murine HER2 extracellulardomain as measured by surface plasmon resonance (SPR) is equal to orless than the dissociation constant of a monospecific anti-HER2 ECD4antibody (v506; SEQ ID NO:1 and SEQ ID NO:317) to murine HER2extracellular domain as measured by surface plasmon resonance (SPR), andwherein tumor growth is decreased as compared to a control receiving anequivalent amount of a non-specific control antibody, as compared to acontrol receiving an equivalent amount of Herceptin/trastuzumab, or ascompared to a control not receiving treatment.
 2. The method of claim 1wherein the antigen binding construct comprises the full lengthsequences set forth in SEQ ID NOs 97, 295, and 69 (v10000), andoptionally wherein the dissociation constant (K_(D)) of the construct tomurine HER2 extracellular domain as measured by surface plasmonresonance (SPR) is approximately 0.6 nM.
 3. A method of treating asubject having a tumor; inhibiting, reducing or blocking HER2 signaling;or killing or inhibiting the growth of a HER2-expressing tumor cell, themethod comprising administering an effective amount of an antigenbinding construct comprising: a first antigen-binding polypeptideconstruct which monovalently and specifically binds a HER2 (humanepidermal growth factor receptor 2) ECD2 (extracellular domain 2)antigen on a HER2-expressing cell, wherein the first antigen-bindingpolypeptide construct comprises a first variable light-chain (VL1)domain and a first variable heavy-chain (VH1) domain, wherein the firstantigen-binding polypeptide construct comprises VH1 and VL1 CDRsequences that are at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%identical to the VH1 and VL1 CDR sequences of v7091 (SEQ ID NOs 223,225, 227, 37, 39, and 41), and wherein the VL1 domain comprises 1, 2, 3,4, or 5 amino acid substitutions and/or the VH1 domain comprises 1, 2,3, 4, or 5 amino acid substitutions; a second antigen-bindingpolypeptide construct which monovalently and specifically binds a HER2ECD4 (extracellular domain 4) antigen on a HER2-expressing cell; firstand second linker polypeptides, wherein the first linker polypeptide isoperably linked to the first antigen-binding polypeptide construct, andthe second linker polypeptide is operably linked to the secondantigen-binding polypeptide construct; wherein one or both of the firstor the second antigen binding polypeptide construct is an scFv, whereinthe linker polypeptides are capable of forming a covalent linkage witheach other, and wherein tumor growth is decreased as compared to acontrol receiving an equivalent amount of a non-specific controlantibody, as compared to a control receiving an equivalent amount ofHerceptin/trastuzumab, or as compared to a control not receivingtreatment.
 4. The method of any of the above claims, wherein the bindingaffinity of the antigen binding construct to murine HER2 extracellulardomain as measured by surface plasmon resonance (SPR) is greater thanthe binding affinity of v7091 (SEQ ID NOs 33, 219, and 295) to murineHER2 extracellular domain as measured by surface plasmon resonance(SPR), optionally wherein the antigen binding construct and v7091 bindthe same epitope, optionally wherein the antigen binding construct bindsthe same epitope as pertuzamab, optionally wherein the antigen bindingconstruct has a greater Bmax than v7091, and optionally wherein theantigen binding construct is internalized to a greater extent upon cellsurface binding relative to v7091.
 5. The method of any of the aboveclaims, wherein the binding affinity of the antigen binding construct tomurine HER2 extracellular domain as measured by surface plasmonresonance (SPR) is equal to or greater than the binding affinity of amonospecific anti-HER2 ECD4 antibody (v506; SEQ ID NO:1 and SEQ IDNO:317) to murine HER2 extracellular domain as measured by surfaceplasmon resonance (SPR).
 6. The method of any of the above claims,wherein the first antigen-binding polypeptide construct comprises theVH1 and VL1 CDR sequences of v7091 (SEQ ID NOs 223, 225, 227, 37, 39,and 41), wherein the VL1 domain comprises 1, 2, 3, 4, or 5 amino acidsubstitutions and/or the VH1 domain comprises 1, 2, 3, 4, or 5 aminoacid substitutions, optionally wherein the first antigen-bindingpolypeptide construct comprises a substitution at Y96 in the VL1 domain(SEQ ID NO:35), optionally wherein the first antigen-binding polypeptideconstruct comprises a Y96A substitution in the VL1 domain (SEQ IDNO:35), optionally wherein the first antigen-binding polypeptideconstruct comprises substitutions at T30, A49, and/or L69 in the VH1domain (SEQ ID NO:221), optionally wherein the first antigen-bindingpolypeptide construct comprises T30A, A49G, and/or L69F substitution(s)in the VH1 domain (SEQ ID NO:221), and optionally wherein the firstantigen-binding polypeptide construct comprises T30A, A49G, and L69Fsubstitution(s) in the VH1 domain (SEQ ID NO:221).
 7. The method of anyof the above claims, wherein the second antigen-binding polypeptideconstruct comprises VH2 and VL2 CDR sequences that are at least 90, 91,92, 93, 94, 95, 96, 97, 98, or 99% identical to the VH2 and VL2 CDRsequences of v10000 (SEQ ID NOs 299, 301, 303, 307, 309, and 311),optionally wherein the second antigen-binding polypeptide constructcomprises the VH2 and VL2 CDR sequences of v10000 (SEQ ID NOs 299, 301,303, 307, 309, and 311).
 8. The method of any of the above claims,wherein the antigen binding construct comprises the variable domainsequences set forth in SEQ ID NOs 71 and/or 99, the variable domainsequences set forth in SEQ ID NOs 297 and/or 305, or the variable domainsequences set forth in SEQ ID NOs 71, 99, 297, and
 305. 9. The method ofany of the above claims, wherein the antigen binding construct comprisesthe full length sequence set forth in SEQ ID NO 97, the full lengthsequence set forth in SEQ ID NO 295, the full length sequence set forthin SEQ ID NO 69, or the full length sequences set forth in SEQ ID NOs97, 295, and 69 (v10000).
 10. The method of any of the above claims,wherein the first and second linker polypeptide each comprise animmunoglobulin hinge region polypeptide selected from an IgG1, IgG2 orIgG4 hinge region.
 11. The method of any of the above claims, whereinthe first and second linker polypeptides are operably linked to ascaffold, optionally an Fc.
 12. The method of any of the above claims,wherein the first and second linker polypeptides are operably linked toa dimeric Fc comprising first and second Fc polypeptides each comprisinga CH3 sequence, wherein the first Fc polypeptide is operably linked tothe first linker polypeptide and the second Fc polypeptide is operablylinked to the second linker polypeptide.
 13. The method of any of theabove claims, wherein (i) the first antigen binding polypeptideconstruct is an scFv and the second antigen binding polypeptideconstruct is a Fab; or (ii) the first antigen binding polypeptideconstruct is a Fab and the second antigen binding polypeptide constructis an scFv; or (iii) both the first antigen binding polypeptideconstruct and the second antigen binding polypeptide construct arescFvs.
 14. The method of any of the above claims, wherein i. the firstantigen-binding polypeptide construct is a Fab and comprises a. a firstheavy chain variable polypeptide VH1 comprising the VH of the pertuzumabarm of v5019, v 5020 v7091, v6717 or v10000 (SEQ ID NOs 221, 149, 221,259, and 99, respectively), and b. a first variable light chainpolypeptide VL1 comprising the VL of the pertuzumab arm of v5019, v 5020v7091, v6717 or v10000 (SEQ ID NOs 35, 35, and 71 for v5019, v7091, andv10000, respectively); and the second antigen-binding polypeptideconstruct is an scFv and comprises (a) a second variable heavy chainpolypeptide VH2 comprising the VH of the trastuzumab arm of v5019, v5020 v7091, v6717 or v10000 (SEQ ID NOs 171, 205, 297, 171, and 297,respectively), and (b) a second variable light chain polypeptide VL2comprising the VL of the trastzumab arm of v5019, v 5020 v7091, v6717 orv10000 (SEQ ID NO:35 for v5020); or ii. the first antigen-bindingpolypeptide construct is an scFv and comprises (a) a first variableheavy chain polypeptide VH1 comprising the VH of the pertuzumab arm ofv5019, v 5020 v7091, v6717 or v10000 (SEQ ID NOs 221, 149, 221, 259, and99, respectively), and (b) a first variable light chain polypeptide VL1comprising the VL of the pertuzumab arm of v5019, v 5020 v7091, v6717 orv10000 (SEQ ID NOs 35, 35, and 71 for v5019, v7091, and v10000,respectively), and the second antigen-binding polypeptide construct isan Fab and comprises (a) a second heavy chain variable polypeptide VH2comprising the VH of the trastuzumab arm of v5019, v 5020 v7091, v6717or v10000 (SEQ ID NOs 171, 205, 297, 171, and 297, respectively), and(b) a second variable light chain polypeptide VL2 comprising the VL ofthe trastuzumab arm of v5019, v 5020 v7091, v6717 or v10000 (SEQ IDNO:35 for v5020); or iii. the first antigen-binding polypeptideconstruct is an scFv and comprises (a) a first heavy chain variablepolypeptide VH1 comprising the VH of the pertuzumab arm of v5019, v 5020v7091, v6717 or v10000 (SEQ ID NOs 221, 149, 221, 259, and 99,respectively), and (b) a first variable light chain polypeptide VL1comprising the VL of the pertuzumab arm of v5019, v 5020 v7091, v6717 orv10000 (SEQ ID NOs 35, 35, and 71 for v5019, v7091, and v10000,respectively), and the second antigen-binding polypeptide construct isan scFv and comprises (a) a second heavy chain variable polypeptide VH2comprising the VH of the trastuzumab arm of v5019, v 5020 v7091, v6717or v10000 (SEQ ID NOs 171, 205, 297, 171, and 297, respectively), and(b) a second variable light chain polypeptide VL2 comprising the VL ofthe trastuzumab arm of v5019, v 5020 v7091, v6717 or v10000 (SEQ IDNO:35 for v5020).
 15. The method of any of the above claims, wherein thefirst antigen-binding polypeptide construct is selected from: i. apolypeptide construct comprising three VH CDR sequences comprising theamino acid sequences SEQ ID NO: 335, SEQ ID NO:336 and SEQ ID NO:337, orSEQ ID NO:335, SEQ ID NO:336, and SEQ ID NO:348; ii. a polypeptideconstruct comprising three VH CDR sequences comprising amino acidsequences that are at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%identical to the three VH CDR sequences of SEQ ID NO: 335, SEQ ID NO:336and SEQ ID NO:337, or SEQ ID NO:335, SEQ ID NO:336, and SEQ ID NO:348;iii. a polypeptide construct comprising three VL CDR sequencescomprising the amino acid sequences of the three VL CDR sequences of SEQID NO: 338, SEQ ID NO:339 and SEQ ID NO:340, or SEQ ID NO:338, SEQ IDNO:347, and SEQ ID NO:340; iv. a polypeptide construct comprising threeVL CDR sequences that are at least 90, 91, 92, 93, 94, 95, 96, 97, 98,or 99% identical to the amino acid sequences of the three VL CDRsequences are at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%identical to SEQ ID NO: 338, SEQ ID NO:339 and SEQ ID NO:340, or SEQ IDNO:338, SEQ ID NO:347, and SEQ ID NO:340; v. a polypeptide constructcomprising six CDR sequences comprising the amino acid sequences of thesix CDR sequences of SEQ ID NO: 335, SEQ ID NO:336, SEQ ID NO:337, SEQID NO: 338, SEQ ID NO:339 and SEQ ID NO:340; or SEQ ID NO:335, SEQ IDNO:336, SEQ ID NO:348, SEQ ID NO:338, SEQ ID NO:347, and SEQ ID NO:340;or vi. a polypeptide construct comprising six CDR sequences comprisingthe amino acid sequences that are at least 90, 91, 92, 93, 94, 95, 96,97, 98, or 99% identical to the six CDR sequences of SEQ ID NO: 335, SEQID NO:336, SEQ ID NO:337, SEQ ID NO: 338, SEQ ID NO:339 and SEQ IDNO:340; or SEQ ID NO:335, SEQ ID NO:336, SEQ ID NO:348, SEQ ID NO:338,SEQ ID NO:347, and SEQ ID NO:340; and the second antigen-bindingpolypeptide is selected from vii. a polypeptide construct comprisingthree VH CDR sequences comprising the amino acid sequences of the threeVH CDR sequences of SEQ ID NO: 341, SEQ ID NO:342 and SEQ ID NO:343;viii. a polypeptide construct comprising three VH CDR sequencescomprising amino acids sequences that are at least 90, 91, 92, 93, 94,95, 96, 97, 98, or 99% identical to the three VH CDR sequences of SEQ IDNO: 341, SEQ ID NO:342 and SEQ ID NO:343; ix. a polypeptide constructcomprising three VL CDR sequences comprising the amino acid sequences ofthe three VL CDR sequences of SEQ ID NO: 344, SEQ ID NO:345 and SEQ IDNO:346; x. a polypeptide construct comprising three VL CDR sequencesthat are at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identicalto the amino acid sequences of the three VL CDR sequences of SEQ ID NO:344, SEQ ID NO:345 and SEQ ID NO:346; xi. a polypeptide constructcomprising six CDR sequences comprising the amino acid sequences of thesix CDR sequences of SEQ ID NO: 341, SEQ ID NO:342, SEQ ID NO:343, SEQID NO: 344, SEQ ID NO:345 and SEQ ID NO:346; or xii. a polypeptideconstruct comprising six CDR sequences comprising the amino acidsequences that are at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%identical to the six CDR sequences of SEQ ID NO: 341, SEQ ID NO:342, SEQID NO:343, SEQ ID NO: 344, SEQ ID NO:345 and SEQ ID NO:346.
 16. Themethod of any of the above claims wherein the first antigen bindingpolypeptide construct: (i) blocks by 50% or greater the binding ofpertuzumab to ECD2, and/or (ii) the second antigen binding polypeptideblocks by 50% or greater the binding of trastuzumab to ECD4.
 17. Themethod according to any preceding claim wherein the first antigenbinding polypeptide construct comprises one of the v5019, v10000, v7091,v5020 or v6717 antigen binding polypeptide constructs specific for HER2ECD2, and the second antigen binding polypeptide construct comprises oneof the v5019, v10000, v7091, v5020 or v6717 antigen-binding polypeptideconstructs specific for HER2 ECD4.
 18. The method according to anypreceding claim, wherein the first antigen-binding polypeptide constructcomprises an amino acid sequence at least 80%, 90%, 95%, 96%, 97%, 98%,or 99% identical to the v5019, v10000, v7091, v5020 or v6717antigen-binding polypeptide construct specific for HER2 ECD2 and thesecond antigen-binding polypeptide construct comprises an amino acidsequence at least 80%, 90%, 95%, 96%, 97%, 98%, or 99% identical to thev5019, v10000, v7091, v5020 or v6717 antigen-binding polypeptideconstruct specific for HER2 ECD4.
 19. The method according to anypreceding claim, selected from v5019, v10000, v7091, v5020 and v6717.20. The method according to any preceding claim, wherein the firstantigen binding polypeptide construct is an Fab and the second antigenbinding polypeptide construct is an scFv, and wherein the antigenbinding construct (i) induces increased receptor internalization in HER23+ cells and/or (ii) displays higher potency in an ADCC (antibodydirected cellular cytotoxicity) assay against HER2 1+ cells, and/or(iii) comprises one or more of the characteristics described in one ormore of the Examples, Tables, and Figures, as compared to a referencebiparatopic antigen binding construct having two Fabs.
 21. The methodaccording to according to any preceding claim, wherein the first andsecond antigen binding polypeptide constructs are scFvs, and wherein theantigen binding construct induces increased receptor internalization inHER2 1+, 2+ and 3+ cells as compared to a reference antigen bindingconstruct having two Fabs.
 22. The method according to any precedingclaim, wherein the antigen-binding construct comprises an Fc, optionallywherein the Fc is a heterodimeric Fc.
 23. The method according to anypreceding claim, wherein the antigen-binding construct comprises aheterodimeric Fc, wherein the dimerized CH3 sequences have a meltingtemperature (Tm) of about 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 77.5,78, 79, 80, 81, 82, 83, 84, or 85° C. or higher.
 24. The methodaccording to any preceding claim, wherein the antigen-binding constructcomprises a heterodimeric Fc formed with a purity greater than about 75,76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93,94, 95, 96, 97, 98, or 99% when expressed.
 25. The method according toany preceding claim, wherein the antigen-binding construct comprises aheterodimeric Fc formed with a purity greater than about 75, 76, 77, 78,79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96,97, 98, or 99% when expressed via a single cell.
 26. The methodaccording to any preceding claim, wherein the antigen-binding constructcomprises a heterodimeric Fc comprising one or more modifications in atleast one of the CH3 sequences.
 27. The method according to anypreceding claim, wherein the antigen-binding construct comprises aheterodimeric Fc comprising one or more modifications in at least one ofthe CH3 sequences that promote the formation of a heterodimer withstability comparable to a wild-type homodimeric Fc.
 28. The methodaccording to any preceding claim, wherein the antigen-binding constructcomprises: i. a heterodimeric IgG1 Fc having the modificationsL351Y_F405A_Y407V in the first Fc polypeptide, and the modificationsT366L_K392M_T394W in the second polypeptide; ii. a heterodimeric IgG1 Fchaving the modifications L351Y_F405A_Y407V in the first Fc polypeptide,and the modifications T366L_K392L_T394W in the second Fc polypeptide;iii. a heterodimeric IgG1 Fc having the modificationsT350V_L351Y_F405A_Y407V in the first Fc polypeptide, and themodifications T350V_T366L_K392L_T394W in the second Fc polypeptide; iv.a heterodimeric IgG1 Fc having the modifications T350V_L351Y_F405A_Y407Vin the first Fc polypeptide, and the modificationsT350V_T366L_K392M_T394W in the second Fc polypeptide; v. a heterodimericIgG1 Fc having the modifications T350V_L351Y_S400E_F405A_Y407V in thefirst Fc polypeptide, and the modificationsT350V_T366L_N390R_K392M_T394W in the second Fc polypeptide, vi. aheterodimeric IgG1 Fc having the modifications T350V_L351Y_F405A_Y407Vin the first Fc polypeptide, and the modificationsT366I_N390R_K392M_T394W in the second Fc polypeptide; or vii. aheterodimeric IgG1 Fc having the modifications L351Y_S400E_F405A_Y405Vin the first Fc polypeptide, and the modificationsT350V_T366L_K392L_T394W in the second Fc polypeptide; according to EUnumbering compared to a wild-type homodimeric Fc.
 29. The methodaccording to any preceding claim, wherein the antigen-binding constructcomprises a heterodimeric Fc comprising at least one CH2 domain.
 30. Themethod according to claim 29, wherein the CH2 domain(s) of theheterodimeric Fc comprises one or more modifications.
 31. The methodaccording to any preceding claim, wherein the antigen-binding constructcomprises a heterodimeric Fc comprising one or more modifications topromote selective binding of Fc-gamma receptors.
 32. The methodaccording to any preceding claim, wherein the antigen-binding constructcomprises at least one modification, and wherein the modification isafucosylation.
 33. The method according to any preceding claim, whereinthe antigen-binding construct is conjugated to a drug.
 34. The methodconstruct according to claim 33, wherein the drug is maytansine (DM1).35. The method according to claim 34, wherein the construct isconjugated to DM1 through an SMCC linker.
 36. The method according toany preceding claim, wherein the antigen-binding construct is formulatedin a pharmaceutical composition with a pharmaceutical carrier.
 37. Themethod claim 36, wherein the pharmaceutical carrier comprises a buffer,an antioxidant, a low molecular weight molecule, a drug, a protein, anamino acid, a carbohydrate, a lipid, a chelating agent, a stabilizer, oran excipient.
 38. The method according to any preceding claim, whereinthe result of the treatment is shrinking the tumor, inhibiting growth ofthe tumor, increasing time to progression of the tumor, prolongingdisease-free survival of the subject, decreasing metastases, increasingthe progression-free survival of the subject, or increasing overallsurvival of the subject.
 39. The method according to any precedingclaim, wherein the tumor comprises cells that express an average of10,000 or more copies of HER2 per tumor cell, optionally wherein thetumor is HER2 gene-amplified.
 40. The method according to any precedingclaim, wherein the tumor is HER2 1+, HER2 2+ or HER2 3+ as determined byimmunohistochemistry (IHC).
 41. The method according to any precedingclaim, wherein the tumor expresses HER2 at a level of 2+ or lower asdetermined by IHC.
 42. The method according to any preceding claim,wherein the HER2+ tumor is a breast cancer that expresses HER2 at a 2+level or lower, as determined by immunohistochemistry (IHC).
 43. Themethod according to any preceding claim, wherein the tumor is a lungtumor, optionally wherein the tumor is a non-squamous non-small celllung tumor that is HER2-low, non-HER2 gene amplified.
 44. The method ofclaim 43, wherein the tumor is HER3+.
 45. The method of claim 43 or 44,wherein the tumor is EGFR low.
 46. The method of claim 43, 44, or 45,wherein the tumor is moderately sensitive to Cisplatin at the MTD. 47.The method according to any preceding claim, wherein the tumor is a headand neck tumor, optionally wherein the tumor is a squamous cell tumor ofthe head and neck that is HER2 low, non-HER2 gene amplified.
 48. Themethod of claim 47, wherein the tumor is HER3+ low.
 49. The method ofclaim 47 or 48, wherein the tumor is EGFR+.
 50. The method of claim 47,48, or 49, wherein the tumor is highly sensitive to Cisplatin at theMTD.
 51. The method according to any preceding claim, wherein the tumoris a breast tumor, optionally wherein the tumor is a ER+/PR− breastcancer with a luminal B molecular classification.
 52. The methodaccording to any preceding claim, wherein the tumor is a pancreatictumor, optionally wherein the pancreatic tumor is HER2 negative asdetermined by IHC.
 53. The method according to any preceding claim,wherein the tumor is a gastric tumor, optionally wherein the gastrictumor is HER2 3+.
 54. The method according to any preceding claim,wherein the subject has not previously been treated with an anti-HER2antibody.
 55. The method according to any preceding claim, wherein thetumor is resistant or refractory to pertuzumab, trastuzumab and/or TDM1.56. The method according to any preceding claim, wherein the subject haspreviously been treated with pertuzumab, trastuzumab and/or TDM1. 57.The method of any one of claims 1-41, wherein the tumor is (i) a HER2 3+estrogen receptor negative (ER−), progesterone receptor negative (PR−),trastuzumab resistant, chemotherapy resistant invasive ductal breastcancer, (ii) a HER2 3+ ER−, PR−, trastuzumab resistant inflammatorybreast cancer, (iii) a HER2 3+, ER−, PR−, invasive ductal carcinoma or(iv) a HER2 2+ HER2 gene amplified trastuzumab and pertuzumab resistantbreast cancer.
 58. The method any one of claims 1-41 wherein the tumorcell is a HER2 1+ or 2+ human pancreatic carcinoma cell, a HER2 3+ humanlung carcinoma cell, a HER2 2+ human Caucasian bronchioaveolar carcinomacell, a human pharyngeal carcinoma cell, a HER2 2+ human tongue squamouscell carcinoma cell, a HER2 2+ squamous cell carcinoma cell of thepharynx, a HER2 1+ or 2+ human colorectal carcinoma cell, a HER2 3+human gastric carcinoma cell, a HER2 1+ human breast ductal ER+(estrogen receptor-positive) carcinoma cell, a HER2 2+/3+ human ER+,HER2-amplified breast carcinoma cell, a HER2 0+/1+ human triple negativebreast carcinoma cell, a HER2 2+ human endometrioid carcinoma cell, aHER2 1+ lung-metastatic malignant melanoma cell, a HER2 1+ human cervixcarcinoma cell, Her2 1+ human renal cell carcinoma cell, or a HER2 1+human ovary carcinoma cell.
 59. The method of any one of claims 1-41wherein the tumor cell is a HER2 1+ or 2+ or 3+ human pancreaticcarcinoma cell, a HER2 2+ metastatic pancreatic carcinoma cell, a HER20+/1+, +3+ human lung carcinoma cell, a HER2 2+ human Caucasianbronchioaveolar carcinoma cell, a HER2 0+ anaplastic lung carcinoma, ahuman non-small cell lung carcinoma cell, a human pharyngeal carcinomacell, a HER2 2+ human tongue squamous cell carcinoma cell, a HER2 2+squamous cell carcinoma cell of the pharynx, a HER2 1+ or 2+ humancolorectal carcinoma cell, a HER2 0+, 1+ or 3+ human gastric carcinomacell, a HER2 1+ human breast ductal ER+ (estrogen receptor-positive)carcinoma cell, a HER2 2+/3+ human ER+, HER2-amplified breast carcinomacell, a HER2 0+/1+ human triple negative breast carcinoma cell, a HER20+ human breast ductal carcinoma (Basal B, Mesenchymal-like triplenegative) cell, a HER2 2+ER+ breast carcinoma, a HER2 0+ humanmetastatic breast carcinoma cell (ER−, HER2− amplified, luminal A, TN),a human uterus mesodermal tumor (mixed grade III) cell, a 2+ humanendometrioid carcinoma cell, a HER2 1+ human skin epidermoid carcinomacell, a HER2 1+ lung-metastatic malignant melanoma cell, a HER2 1+malignant melanoma cell, a human cervix epidermoid carcinoma vcell, aHER2 1+ human urinary bladder carcinoma cell, a HER2 1+ human cervixcarcinoma cell, Her2 1+ human renal cell carcinoma cell, or a HER2 1+,2+ or 3+ human ovary carcinoma cell, and wherein the antigen-bindingconstruct is conjugated to maytansine (DM1).
 60. The method of any oneof claims 1-41 wherein the tumor cell is selected from a HER2 2/3+, geneamplified ovarian cancer cell, a HER2 0+/1+ triple negative breastcancer cell; an ER+, HER2 1+ breast cancer cell; a trastuzumab resistantHER2 2+ breast cancer cell; an ER+, HER2+ breast cancer cell; or a HER23+ breast cancer cell.
 61. The method according to any preceding claim,wherein the construct is selected from v5019, v10000, v7091, v5020 orv6717.
 62. The method according to any preceding claim, whereinadministering is done by injection or infusion, optionally wherein theadministering is intravenous.
 63. The method according to any precedingclaim, further comprising administering to the subject an additionalagent, optionally a chemotherapeutic agent.
 64. The method of claim 63,wherein the additional agent is one or more of bleomycin, carboplatin,cisplatin, nab-paclitaxel, docetaxel, doxorubicin, erlotinib,fluorouracil, gemcitabine, methotrexate, pemetrexed, topotecan,vinorelbine, capecitabine, navelbine, or paclitaxel.
 65. The method ofclaim 63, wherein i. the tumor is non-small cell lung cancer, and theadditional agent is one or more of cisplatin, carboplatin, paclitaxel,albumin-bound paclitaxel, nab-paclitaxel, docetaxel, gemcitabine,vinorelbine, irinotecan, etoposide, vinblastine, capecitabine, navelbineor pemetrexed; or ii. the tumor is head and neck cancer, and theadditional agent is one or more of paclitaxel, carboplatin, doxorubicinor cisplatin; or iii. the tumor is a estrogen and/or progesteronepositive breast cancer, and the additional agent is one or more ofdoxorubicin, epirubicin, paclitaxel, nab-paclitaxel, docetaxel,fluorouracil, cyclophosphamide, carboplatin, letrozole, mifepristone,capecitabine, gemcitabine, vinorelbine or tamoxifen; or iv. the tumor isa pancreatic tumor and the additional agent is nab-paclitaxel,capecitabine, gemcitabine, navelbine or paclitaxel.
 66. The methodaccording to any preceding claim, wherein the subject is a human. 67.The method according to any preceding claim, wherein the methodcomprises inhibiting, reducing or blocking HER2 signaling.
 68. Themethod according to any preceding claim, wherein the method compriseskilling or inhibiting the growth of a HER2-expressing tumor cell. 69.The method according to any preceding claim, wherein the subject isadministered at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,16, 17, 18, 19, or 20 doses.
 70. The method according to any precedingclaim, wherein the amount of at least one of the plurality of doses isat least 0.3, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,16, 17, 18, 19, or 20 mg/kg.
 71. The method according to any precedingclaim, wherein the amount of each of the plurality of doses is at least0.3, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,19, or 20 mg/kg.
 72. The method according to any preceding claim,wherein each dose is administered at least daily, weekly, or monthly.73. The method according to any preceding claim, wherein each dose isadministered at least every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, or 20 days.
 74. The method according to anypreceding claim, wherein treatment continues for at least 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, or 31 days; at least 1, 2, 3, 4, 5, 6, 7, 8, 9,10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 weeks; or at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20months.
 75. The method according to any preceding claim, wherein themean tumor volume in the subject after receiving at least 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 doses is lessthan the mean tumor volume of a control subject receiving an equivalentamount of trastuzumab.
 76. The method according to any preceding claim,wherein overall survival of the subject is significantly increased ascompared to a control subject receiving an equivalent amount of anon-specific control antibody or as compared to a control subject notreceiving treatment; or wherein the growth of tumor is significantlydecreased as compared to a control subject receiving an equivalentamount of a non-specific control antibody, as compared to a controlsubject receiving an equivalent amount of Herceptin, or as compared to acontrol subject not receiving treatment.
 77. The method of claim 76,wherein the significance is measured by a log rank test.
 78. The methodof claim 76, wherein the p value is less than 0.5, 0.01, or 0.001. 79.The method according to any preceding claim, wherein overall survival ofthe subject is more significantly increased as compared to a controlsubject receiving an equivalent amount of trastuzumab.
 80. The method ofclaim 79, wherein the antigen-binding construct p value is less than0.001 and wherein the trastuzumab p value is greater than 0.001.
 81. Themethod according to any preceding claim, wherein the p value of thesignificance of the increase relative to the control subject receivingan equivalent amount of a non-specific control antibody is less than thep value of an increase in survival of a second control receiving anequivalent amount of trastuzumab as compared to the control subjectreceiving an equivalent amount of a non-specific control antibody. 82.The method of claim 81, wherein the antigen-binding construct p value isless than 0.001 and wherein the trastuzumab p value is greater than0.001.
 83. The method according to any preceding claim, wherein overallsurvival of the subject after receiving a combination of theantigen-binding construct and an additional agent is significantlyincreased as compared to a control subject receiving an equivalentamount of trastuzumab alone.
 84. The method according to any precedingclaim, wherein overall survival of the subject is significantlyincreased as compared to a control subject receiving a lesser amount oftrastuzumab.